Inhaltsverzeichnis Glofitamab (COLUMVI®) in Kombination mit Gemcitabin und Oxaliplatin

STARGLO 3

Charakterisierung der Studienpopulationen 3

Center 3

Rando Factors (IxRS vs. eCRF) 5

Disposition (Study + Treatment) 9

Death 15

Demografie 17

Disease Characteristics (Medical History) 21

SAE between rando & Trt Start 29

FU OS (rKM) 31

FU EFS IRC (rKM) 33

FU Safety (Median) 35

Mortalität 37

Gesamtüberleben (DC 16.02.2024 und 29.03.2023) 37

Output TTE 37

KM Plot 41

Morbidität 45

Scheitern des kurativen Therapieansatzes 45

EFS IRC 45

Output TTE (DC 16.02.2024 und 29.03.2023) 45

KM Plot (DC 16.02.2024 und 29.03.2023) 49

Rate (DC 16.02.2024) 53

Art der Ereignisse (DC 16.02.2024) 55

EFS INV 57

Output TTE (DC 16.02.2024) 57

KM Plot (DC 16.02.2024) 59

Progressionsfreies Überleben 61

IRC (DC 16.02.2024 und 29.03.2023) 61

Output TTE 61

KM Plot 65

INV (DC 16.02.2024) 69

Output TTE 69

KM Plot 71

EORTC QLQ-C30 (Symptomskalen) (DC 16.02.2024) 73

Output TTE 73

Rücklaufquoten 89

MMRM 121

EQ-5D VAS (DC 16.02.2024) 137

Output TTE 137

Rücklaufquoten 139

MMRM 143

Gesundheitsbezogene Lebensqualität 145

EORTC QLQ-C30 (Funktionsskalen) (DC 16.02.2024) 145

Output TTE 145

Rücklaufquoten 157

MMRM 181

FACT-LymS (DC 16.02.2024) 193

Output TTE 193

Rücklaufquoten 195

MMRM 199

Verträglichkeit (DC 16.02.2024) 201

Generelle Verträglichkeit 201

Patienten mit AE 201

Patienten mit AE ≥ Grad 3 205

Patienten mit AE Grad 3 209

Patienten mit AE Grad 4 213

Patienten mit AE Grad 5 217

Patienten mit SAE 221

Patienten mit Behandlungsabbruch wegen AE 225
SOC/PT 229
Spezifische Verträglichkeit 1588
Glofitamab 1588
Patienten mit AESI 1588
Patienten mit AESI ≥ Grad 3 1624
Patienten mit SAESI 1660
Obinotuzumab 1696
Patienten mit AESI 1696
Patienten mit AESI ≥ Grad 3 1700
Patienten mit SAESI 1716
Glofitamab und Obinotuzumab 1732
Patienten mit AESI 1732
Patienten mit AESI ≥ Grad 3 1736
Patienten mit SAESI 1740
DILI 1744
STIAMP 1756
Outcome of Adverse Events 1768
AE 1768
AESI 1770

POPULATION: ITT Population (2L)
ENDPOINT: --
MODEL: descriptive
STUDY: GO41944
Number of Centers/Countries/Geographical Regions with <10, >=10 patients per arm

	Number in category						Patients randomized (4)					
	overall		with <10 patients per arm (1)		with >=10 patients per arm (2)		overall		with <10 patients per arm (1)		with >=10 patients per arm (2)	
	n	% (3)	n	% (3)	n	% (3)	n	% (5)	n	% (5)	n	% (5)
Center	50	100,0	50	100,0	0	0,0	172	100,0	172	100,0	0	0,0
Country	13	100,0	12	92,3	1	7,7	172	100,0	130	75,6	42	24,4
Geographical region	3	100,0	1	33,3	2	66,7	172	100,0	15	8,7	157	91,3

1: '<10 patients category' if at least one treatment arm has <10 patients.
2: '>=10 patients' category if all treatment arms have >=10 patients.
3: % of number of corresponding category compared to overall number
4: Number of patients randomized in the corresponding category (e.g .Number of patients randomized in centers with <10 pts per arm)
5: % of randomized patients compared to overall number of randomized patients (e.g . % of randomized patients in centers with <10 patients per arm compared to overall number of randomized patients)
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_center.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_center_ITT_2L_16FEB2024_41944.xls
03OCT2024 8:52

POPULATION: ITT Population (3L+)
ENDPOINT: --
MODEL: descriptive
STUDY: GO41944
Number of Centers/Countries/Geographical Regions with <10, >=10 patients per arm

	Number in category						Patients randomized (4)					
	overall		with <10 patients per arm (1)		with >=10 patients per arm (2)		overall		with <10 patients per arm (1)		with >=10 patients per arm (2)	
	n	% (3)	n	% (3)	n	% (3)	n	% (5)	n	% (5)	n	% (5)
Center	43	100,0	43	100,0	0	0,0	102	100,0	102	100,0	0	0,0
Country	13	100,0	12	92,3	1	7,7	102	100,0	64	62,7	38	37,3
Geographical region	3	100,0	2	66,7	1	33,3	102	100,0	39	38,2	63	61,8

1: '<10 patients category' if at least one treatment arm has <10 patients.
2: '>=10 patients' category if all treatment arms have >=10 patients.
3: % of number of corresponding category compared to overall number
4: Number of patients randomized in the corresponding category (e.g .Number of patients randomized in centers with <10 pts per arm)
5: % of randomized patients compared to overall number of randomized patients (e.g . % of randomized patients in centers with <10 patients per arm compared to overall number of randomized patients)
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_center.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_center_ITT_3Lp_16FEB2024_41944.xls
03OCT2024 8:56

POPULATION: ITT Population (2L)
ENDPOINT: --
MODEL: descriptive
STUDY: GO41944
Randomization Stratification Factors per arm

Stratification Factor: Number of previous lines of systemic therapy

	Glofitamab + GemOx (N=115)		Rituximab + GemOx (N=57)	
	eCRF data		eCRF data	
	1	Total	1	Total
IxRS data				
1	115 (100%)	115 (100%)	57 (100%)	57 (100%)
>=2	0	0	0	0
Total	115 (100%)	115 (100%)	57 (100%)	57 (100%)

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_rand.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_rand_ITT_2L_16FEB2024_41944.xls
16AUG2024 11:42

POPULATION: ITT Population (2L)
ENDPOINT: --
MODEL: descriptive
STUDY: GO41944
Randomization Stratification Factors per arm

Stratification Factor: Outcome of last systemic therapy

	Glofitamab + GemOx (N=115)			Rituximab + GemOx (N=57)		
	eCRF data			eCRF data		
	Refractory	Relapsed	Total	Refractory	Relapsed	Total
IxRS data						
Refractory	59 (51.3%)	1 (0.9%)	60 (52.2%)	29 (50.9%)	0	29 (50.9%)
Relapsed	4 (3.5%)	51 (44.3%)	55 (47.8%)	0	28 (49.1%)	28 (49.1%)
Total	63 (54.8%)	52 (45.2%)	115 (100%)	29 (50.9%)	28 (49.1%)	57 (100%)

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_rand.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_rand_ITT_2L_16FEB2024_41944.xls
16AUG2024 11:42

POPULATION: ITT Population (3L+)
ENDPOINT: --
MODEL: descriptive
STUDY: GO41944
Randomization Stratification Factors per arm

Stratification Factor: Number of previous lines of systemic therapy

	Glofitamab + GemOx (N=68)			Rituximab + GemOx (N=34)	
	eCRF data			eCRF data	
	1	>=2	Total	>=2	Total
IxRS data					
1	0	0	0	0	0
>=2	1 (1.5%)	67 (98.5%)	68 (100%)	34 (100%)	34 (100%)
Total	1 (1.5%)	67 (98.5%)	68 (100%)	34 (100%)	34 (100%)

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_rand.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_rand_ITT_3Lp_16FEB2024_41944.xls
16AUG2024 11:46

POPULATION: ITT Population (3L+)
ENDPOINT: --
MODEL: descriptive
STUDY: GO41944
Randomization Stratification Factors per arm

Stratification Factor: Outcome of last systemic therapy

	Glofitamab + GemOx (N=68)			Rituximab + GemOx (N=34)		
	eCRF data			eCRF data		
	Refractory	Relapsed	Total	Refractory	Relapsed	Total
IxRS data						
Refractory	51 (75.0%)	1 (1.5%)	52 (76.5%)	23 (67.6%)	2 (5.9%)	25 (73.5%)
Relapsed	3 (4.4%)	13 (19.1%)	16 (23.5%)	3 (8.8%)	6 (17.6%)	9 (26.5%)
Total	54 (79.4%)	14 (20.6%)	68 (100%)	26 (76.5%)	8 (23.5%)	34 (100%)

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_rand.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_rand_ITT_3Lp_16FEB2024_41944.xls
16AUG2024 11:46

POPULATION: ITT Population (2L)
ENDPOINT: --
MODEL: descriptive
STUDY: GO41944
Patients who Discontinued Study including Reason

	Glofitamab + GemOx (N=115)		Rituximab + GemOx (N=57)		All Patients (N=172)	
	n	%	n	%	n	%
All Patients	115	100,0	57	100,0	172	100,0
Received Treatment	112	97,4	55	96,5	167	97,1
On-study	64	55,7	22	38,6	86	50,0
Alive: In Follow-Up	63	54,8	22	38,6	85	49,4
Discontinued Study	51	44,3	35	61,4	86	50,0
Death	43	37,4	28	49,1	71	41,3
Lost to Follow-up	3	2,6	2	3,5	5	2,9
Withdrawal by Subject	5	4,3	5	8,8	10	5,8

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ds_st.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ds_st_ITT_2L_16FEB2024_41944.xls
07OCT2024 14:33

POPULATION: ITT Population (3L+)
ENDPOINT: --
MODEL: descriptive
STUDY: GO41944
Patients who Discontinued Study including Reason

	Glofitamab + GemOx (N=68)		Rituximab + GemOx (N=34)		All Patients (N=102)	
	n	%	n	%	n	%
All Patients	68	100,0	34	100,0	102	100,0
Received Treatment	68	100,0	33	97,1	101	99,0
On-study	22	32,4	6	17,6	28	27,5
Alive: In Follow-Up	22	32,4	6	17,6	28	27,5
Discontinued Study	46	67,6	28	82,4	74	72,5
Death	37	54,4	24	70,6	61	59,8
Lost to Follow-up	2	2,9	0	0,0	2	2,0
Physician Decision	0	0,0	1	2,9	1	1,0
Withdrawal by Subject	5	7,4	3	8,8	8	7,8
Other	2	2,9	0	0,0	2	2,0

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ds_st.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ds_st_ITT_3Lp_16FEB2024_41944.xls
07OCT2024 14:36

POPULATION: ITT Population (2L)
ENDPOINT: --
MODEL: descriptive
STUDY: GO41944
Patients who Discontinued Treatment including Reason

	Glofitamab + GemOx (N=115)	Rituximab + GemOx (N=57)	All Patients (N=172)
All patients	115 (100%)	57 (100%)	172 (100%)
Obinutuzumab pre-treatment Status			
Completed Treatment	108 (93.9%)		108 (62.8%)
Discontinued Treatment	7 (6.1%)		7 (4.1%)
Ongoing on Treatment	0		0
Obinutuzumab pre-treatment Discontinuation Reason			
Adverse Event	1 (0.9%)		1 (0.6%)
Death	3 (2.6%)		3 (1.7%)
Disease Relapse	1 (0.9%)		1 (0.6%)
Protocol Deviation	1 (0.9%)		1 (0.6%)
Withdrawal by Subject	1 (0.9%)		1 (0.6%)
Treatment Status			
Completed Treatment	52 (45.2%)	18 (31.6%)	70 (40.7%)
Discontinued Treatment	62 (53.9%)	39 (68.4%)	101 (58.7%)
Ongoing on Treatment	1 (0.9%)	0	1 (0.6%)
Treatment Discontinuation Reason			
Adverse Event	16 (13.9%)	6 (10.5%)	22 (12.8%)
Death	11 (9.6%)	0	11 (6.4%)
Lack of Efficacy	0	3 (5.3%)	3 (1.7%)
Lost to Follow-up	0	1 (1.8%)	1 (0.6%)
Physician Decision	4 (3.5%)	0	4 (2.3%)
Disease Relapse	25 (21.7%)	21 (36.8%)	46 (26.7%)
Protocol Deviation	1 (0.9%)	1 (1.8%)	2 (1.2%)
Symptomatic Deterioration	1 (0.9%)	3 (5.3%)	4 (2.3%)
Withdrawal by Subject	3 (2.6%)	4 (7.0%)	7 (4.1%)
Other	1 (0.9%)	0	1 (0.6%)

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ds_trt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ds_trt_ITT_2L_16FEB2024_41944.xls
23AUG2024 17:59

POPULATION: ITT Population (3L+)
ENDPOINT: --
MODEL: descriptive
STUDY: GO41944
Patients who Discontinued Treatment including Reason

	Glofitamab + GemOx (N=68)	Rituximab + GemOx (N=34)	All Patients (N=102)
All patients	68 (100%)	34 (100%)	102 (100%)
Obinutuzumab pre-treatment Status			
Completed Treatment	64 (94.1%)		64 (62.7%)
Discontinued Treatment	4 (5.9%)		4 (3.9%)
Ongoing on Treatment	0		0
Obinutuzumab pre-treatment Discontinuation Reason			
Adverse Event	2 (2.9%)		2 (2.0%)
Disease Relapse	1 (1.5%)		1 (1.0%)
Symptomatic Deterioration	1 (1.5%)		1 (1.0%)
Treatment Status			
Completed Treatment	24 (35.3%)	8 (23.5%)	32 (31.4%)
Discontinued Treatment	44 (64.7%)	26 (76.5%)	70 (68.6%)
Treatment Discontinuation Reason			
Adverse Event	12 (17.6%)	1 (2.9%)	13 (12.7%)
Death	4 (5.9%)	3 (8.8%)	7 (6.9%)
Lack of Efficacy	1 (1.5%)	1 (2.9%)	2 (2.0%)
Physician Decision	3 (4.4%)	0	3 (2.9%)
Disease Relapse	16 (23.5%)	17 (50.0%)	33 (32.4%)
Symptomatic Deterioration	3 (4.4%)	1 (2.9%)	4 (3.9%)
Withdrawal by Subject	4 (5.9%)	3 (8.8%)	7 (6.9%)
Other	1 (1.5%)	0	1 (1.0%)

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ds_trt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ds_trt_ITT_3Lp_16FEB2024_41944.xls
23AUG2024 18:03

POPULATION: Safety evaluable population (2L)
ENDPOINT: --
MODEL: descriptive
STUDY: GO41944
Number of Patients who Died including Primary Reason

		Glofitamab + GemOx (N=112)		Rituximab + GemOx (N=55)	
Subgroup	Categories	n	%	n	%
Reason of Death	All Deaths	42	37,5	27	49,1
	Adverse event	9	8,0	1	1,8
	Progressive disease	22	19,6	19	34,5
	Other	11	9,8	7	12,7

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_death.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_death_SE_2L_16FEB2024_41944.xls
13AUG2024 15:09

POPULATION: Safety evaluable population (3L+)
ENDPOINT: --
MODEL: descriptive
STUDY: GO41944
Number of Patients who Died including Primary Reason

		Glofitamab + GemOx (N=68)		Rituximab + GemOx (N=33)	
Subgroup	Categories	n	%	n	%
Reason of Death	All Deaths	37	54,4	24	72,7
	Adverse event	6	8,8	3	9,1
	Progressive disease	22	32,4	18	54,5
	Other	9	13,2	3	9,1

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_death.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_death_SE_3Lp_16FEB2024_41944.xls
13AUG2024 15:11

POPULATION: ITT Population (2L)
ENDPOINT: --
MODEL: descriptive
STUDY: GO41944
Summary of Demographic and Baseline Characteristics

	R-GemOx (N=57)	Glofit-GemOx (N=115)	All Intent-to-Treat Patients (N=172)
Age (yr)			
n	57	115	172
Mean (SD)	68.4 (11.6)	68.1 (11.6)	68.2 (11.6)
Median	70	71	70
Min - Max	28 - 84	24 - 88	24 - 88
Age Group			
n	57	115	172
<65	13 (22.8%)	29 (25.2%)	42 (24.4%)
>=65	44 (77.2%)	86 (74.8%)	130 (75.6%)
Sex			
n	57	115	172
Male	32 (56.1%)	61 (53.0%)	93 (54.1%)
Female	25 (43.9%)	54 (47.0%)	79 (45.9%)
Ethnicity			
n	57	115	172
Hispanic or Latino	4 (7.0%)	7 (6.1%)	11 (6.4%)
Not Hispanic or Latino	50 (87.7%)	96 (83.5%)	146 (84.9%)
Not Stated	2 (3.5%)	12 (10.4%)	14 (8.1%)
Unknown	1 (1.8%)	0	1 (0.6%)
Race			
n	57	115	172
Asian	30 (52.6%)	48 (41.7%)	78 (45.3%)
Black or African American	0	2 (1.7%)	2 (1.2%)
White	23 (40.4%)	53 (46.1%)	76 (44.2%)
Unknown	4 (7.0%)	12 (10.4%)	16 (9.3%)
Weight (kg)			
n	55	112	167

Mean (SD)	68.50 (16.37)	69.16 (15.97)	68.94 (16.05)
Median	64,5	66,43	66
Min - Max	41.6 - 110.0	44.0 - 136.0	41.6 - 136.0
Height (cm)			
n	55	112	167
Mean (SD)	165.13 (10.66)	164.01 (9.66)	164.38 (9.98)
Median	166,7	163,4	164
Min - Max	140.7 - 192.0	143.0 - 188.0	140.7 - 192.0
Body Mass Index (kg/m2) at Baseline			
n	55	112	167
Mean (SD)	24.95 (4.72)	25.66 (5.12)	25.43 (4.99)
Median	24,53	24,85	24,8
Min - Max	15.2 - 44.2	17.1 - 40.7	15.2 - 44.2
Body Surface Area (m2) at Baseline			
n	55	112	167
Mean (SD)	1.75 (0.24)	1.76 (0.23)	1.76 (0.23)
Median	1,72	1,72	1,72
Min - Max	1.3 - 2.3	1.3 - 2.7	1.3 - 2.7
ECOG Status at Baseline			
0	28 (50.9%)	45 (40.2%)	73 (43.7%)
1	20 (36.4%)	54 (48.2%)	74 (44.3%)
2	7 (12.7%)	13 (11.6%)	20 (12.0%)

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_demog.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_demog_ITT_2L_16FEB2024_41944.xls
05MAR2025 18:02

POPULATION: ITT Population (3L+)
ENDPOINT: --
MODEL: descriptive
STUDY: GO41944
Summary of Demographic and Baseline Characteristics

	R-GemOx (N=34)	Glofit-GemOx (N=68)	All Intent-to-Treat Patients (N=102)
Age (yr)			
n	34	68	102
Mean (SD)	56.0 (14.7)	61.6 (12.5)	59.7 (13.5)
Median	58,5	62	61
Min - Max	20 - 77	22 - 85	20 - 85
Age Group			
n	34	68	102
<65	22 (64.7%)	38 (55.9%)	60 (58.8%)
>=65	12 (35.3%)	30 (44.1%)	42 (41.2%)
Sex			
n	34	68	102
Male	21 (61.8%)	44 (64.7%)	65 (63.7%)
Female	13 (38.2%)	24 (35.3%)	37 (36.3%)
Ethnicity			
n	34	68	102
Hispanic or Latino	1 (2.9%)	4 (5.9%)	5 (4.9%)
Not Hispanic or Latino	32 (94.1%)	64 (94.1%)	96 (94.1%)
Not Stated	1 (2.9%)	0	1 (1.0%)
Race			
n	34	68	102
Asian	21 (61.8%)	38 (55.9%)	59 (57.8%)
Black or African American	1 (2.9%)	0	1 (1.0%)
White	10 (29.4%)	29 (42.6%)	39 (38.2%)
Unknown	2 (5.9%)	1 (1.5%)	3 (2.9%)
Weight (kg)			
n	33	68	101

Mean (SD)	67.58 (13.11)	69.99 (16.91)	69.21 (15.75)
Median	67,3	67,65	67,3
Min - Max	44.6 - 97.6	41.8 - 112.6	41.8 - 112.6
Height (cm)			
n	33	68	101
Mean (SD)	166.06 (9.64)	166.94 (9.59)	166.65 (9.56)
Median	165,7	166,05	165,7
Min - Max	147.2 - 181.6	145.0 - 195.0	145.0 - 195.0
Body Mass Index (kg/m2) at Baseline			
n	33	68	101
Mean (SD)	24.49 (4.33)	24.90 (4.79)	24.77 (4.63)
Median	23,27	23,47	23,44
Min - Max	17.7 - 38.1	16.5 - 45.7	16.5 - 45.7
Body Surface Area (m2) at Baseline			
n	33	67	100
Mean (SD)	1.75 (0.20)	1.78 (0.24)	1.77 (0.23)
Median	1,7	1,79	1,76
Min - Max	1.4 - 2.1	1.4 - 2.3	1.4 - 2.3
ECOG Status at Baseline			
0	16 (48.5%)	27 (39.7%)	43 (42.6%)
1	16 (48.5%)	35 (51.5%)	51 (50.5%)
2	1 (3.0%)	6 (8.8%)	7 (6.9%)

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_demog.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_demog_ITT_3Lp_16FEB2024_41944.xls
05MAR2025 18:08

POPULATION: ITT Population (2L)
ENDPOINT: --
MODEL: --
STUDY: GO41944
Summary of Disease Characteristics

	R-GemOx (N=57)	Glofit-GemOx (N=115)	All Intent-to-Treat Patients (N=172)
Number of previous lines of systemic therapy for DLBCL (IxRS)			
n	57	115	172
1	57 (100%)	115 (100%)	172 (100%)
Relapsed/refractory to last line of therapy (IxRS)			
n	57	115	172
Refractory	29 (50.9%)	60 (52.2%)	89 (51.7%)
Relapsed	28 (49.1%)	55 (47.8%)	83 (48.3%)
Relapse or Refractory to Any Prior Therapy			
n	57	115	172
Refractory	28 (49.1%)	67 (58.3%)	95 (55.2%)
Relapse (No Refractory)	29 (50.9%)	48 (41.7%)	77 (44.8%)
Relapse or Refractory to First Line of Prior Therapy			
n	57	115	172
Refractory	28 (49.1%)	67 (58.3%)	95 (55.2%)
Relapse	29 (50.9%)	48 (41.7%)	77 (44.8%)
Relapse or Refractory to Any Prior Platinum Therapy			
n	57	115	172
Platinum Responsive	0	1 (0.9%)	1 (0.6%)
No Prior Platinum	57 (100%)	114 (99.1%)	171 (99.4%)
Relapse or Refractory to Any Prior Anti-CD20 Therapy			
n	57	115	172
Refractory	28 (49.1%)	65 (56.5%)	93 (54.1%)
Relapse (No Refractory)	27 (47.4%)	48 (41.7%)	75 (43.6%)
Unknown	2 (3.5%)	2 (1.7%)	4 (2.3%)
Primary Refractory or Relapse within 12 months after Initial Diagnosis Date			

n	57	115	172
No	27 (47.4%)	45 (39.1%)	72 (41.9%)
Yes	30 (52.6%)	70 (60.9%)	100 (58.1%)
Primary Refractory or Relapse within 12 months after 1L Therapy			
n	57	115	172
No	21 (36.8%)	31 (27.0%)	52 (30.2%)
Yes	36 (63.2%)	84 (73.0%)	120 (69.8%)
Early relapse from ASCT (PD <= 12 months from completion)			
n	57	115	172
No prior ASCT	57 (100%)	115 (100%)	172 (100%)
Double refractory to any prior anti-CD20 and anthracycline based regimen			
n	57	115	172
Refractory	28 (49.1%)	62 (53.9%)	90 (52.3%)
Relapse (No Refractory)	26 (45.6%)	47 (40.9%)	73 (42.4%)
Unknown	3 (5.3%)	6 (5.2%)	9 (5.2%)
Cancer Histological subtype at Initial Diagnosis			
n	57	115	172
Non-GCB	5 (8.8%)	16 (13.9%)	21 (12.2%)
Unclassified	31 (54.4%)	54 (47.0%)	85 (49.4%)
GCB	17 (29.8%)	36 (31.3%)	53 (30.8%)
ABC	4 (7.0%)	9 (7.8%)	13 (7.6%)
Ann Arbor Staging at Study Entry			
n	57	115	172
Stage I	2 (3.5%)	15 (13.0%)	17 (9.9%)
Stage II	10 (17.5%)	25 (21.7%)	35 (20.3%)
Stage III	4 (7.0%)	16 (13.9%)	20 (11.6%)
Stage IV	41 (71.9%)	59 (51.3%)	100 (58.1%)
Prior autologous SCT			
n	57	115	172
No	57 (100%)	115 (100%)	172 (100%)
Primary Reason for SCT ineligibility			
n	57	115	172
AGE	22 (38.6%)	53 (46.1%)	75 (43.6%)
AGE >= 70 YEARS	12 (21.1%)	11 (9.6%)	23 (13.4%)
CO-MORBIDITY: CARDIAC DYSFUNCTION AND NON-INSULIN DEPENDENT DIABETES	1 (1.8%)	0	1 (0.6%)
CO-MORBIDITY: CARDIAC IMPAIRMENT (IMPAIRED LV FUNCTION)	0	1 (0.9%)	1 (0.6%)
CO-MORBIDITY: CARDIOMYOPATHY	0	1 (0.9%)	1 (0.6%)
CO-MORBIDITY: CONDITION AFTER GASTROINTESTINAL PERFORATION	0	1 (0.9%)	1 (0.6%)

CO-MORBIDITY: DEPRESSION	0	1 (0.9%)	1 (0.6%)
CO-MORBIDITY: HYPERTENSION, TYPE 2 DIABETES & HISTORY OF EMBOLIC STROKES.	0	1 (0.9%)	1 (0.6%)
CO-MORBIDITY: UNDERLYING LUNG DISEASE	0	1 (0.9%)	1 (0.6%)
INSUFFICIENT RESPONSE TO SALVAGE THERAPY	1 (1.8%)	3 (2.6%)	4 (2.3%)
OTHER: PATIENT HAD INSUFFICIENT RESPONSE TO PRE-TRANSPLANT CHEMOTHERAPY	1 (1.8%)	0	1 (0.6%)
OTHER: RISK OF MANY ADVERSE EVENTS	0	1 (0.9%)	1 (0.6%)
OTHER: THE PATIENT WAS FELT TO BE TOO CHEMO-REFRACTORY TO R-CHOP TO WARRANT FURTHER INTENSIVE CHEMOTHERAPY	1 (1.8%)	0	1 (0.6%)
PATIENT REFUSED TRANSPLANT	19 (33.3%)	39 (33.9%)	58 (33.7%)
PERFORMANCE STATUS	0	2 (1.7%)	2 (1.2%)
Double-Expressor			
n	57	115	172
No	41 (71.9%)	96 (83.5%)	137 (79.7%)
Yes	16 (28.1%)	19 (16.5%)	35 (20.3%)
Total number of risk factors for IPI			
n	57	115	172
NOT APPLICABLE	6 (10.5%)	8 (7.0%)	14 (8.1%)
0	1 (1.8%)	6 (5.2%)	7 (4.1%)
1	4 (7.0%)	17 (14.8%)	21 (12.2%)
2	12 (21.1%)	33 (28.7%)	45 (26.2%)
3	18 (31.6%)	23 (20.0%)	41 (23.8%)
4	13 (22.8%)	25 (21.7%)	38 (22.1%)
5	3 (5.3%)	3 (2.6%)	6 (3.5%)
Total number of risk factors for IPI (Derived)			
n	57	115	172
NOT APPLICABLE	2 (3.5%)	5 (4.3%)	7 (4.1%)
0	0	8 (7.0%)	8 (4.7%)
1	7 (12.3%)	21 (18.3%)	28 (16.3%)
2	17 (29.8%)	34 (29.6%)	51 (29.7%)
3	17 (29.8%)	24 (20.9%)	41 (23.8%)
4	12 (21.1%)	21 (18.3%)	33 (19.2%)
5	2 (3.5%)	2 (1.7%)	4 (2.3%)
Prior CAR-T therapy			
n	57	115	172
No	57 (100%)	115 (100%)	172 (100%)
Relapse or Refractory to Any Prior CAR-T Therapy			
n	57	115	172
Unknown	57 (100%)	115 (100%)	172 (100%)
Bulky Disease => 10cm			

n	57	115	172
No	46 (80.7%)	100 (87.0%)	146 (84.9%)
Yes	11 (19.3%)	15 (13.0%)	26 (15.1%)
Cell of Origin			
n	57	115	172
GCB	18 (31.6%)	44 (38.3%)	62 (36.0%)
Non-GCB (by IHC + Non GCB Unclassified)	30 (52.6%)	62 (53.9%)	92 (53.5%)
ABC	2 (3.5%)	2 (1.7%)	4 (2.3%)
Unknown	7 (12.3%)	7 (6.1%)	14 (8.1%)
Category Sum of Products of Diameters Value >=3000 - Investigator			
n	53	112	165
Baseline SPD < 3000	24 (42.1%)	65 (56.5%)	89 (51.7%)
Baseline SPD >= 3000	29 (50.9%)	47 (40.9%)	76 (44.2%)
Enrollment by geographic region			
n	57	115	172
Europe	18 (31.6%)	41 (35.7%)	59 (34.3%)
North America	6 (10.5%)	9 (7.8%)	15 (8.7%)
Rest of the World	33 (57.9%)	65 (56.5%)	98 (57.0%)
Anti-CD20 monoclonal antibody therapy			
n	57	115	172
No	2 (3.5%)	2 (1.7%)	4 (2.3%)
Yes	55 (96.5%)	113 (98.3%)	168 (97.7%)

Any missing/unknown values for histology at initial diagnosis will be imputed with histology at study entry.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_mh_char2.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_mh_char2_ITT_2L_16FEB2024_41944.xls
13MAR2025 14:14

POPULATION: ITT Population (3L+)
ENDPOINT: --
MODEL: --
STUDY: GO41944
Summary of Disease Characteristics

	R-GemOx (N=34)	Glofit-GemOx (N=68)	All Intent-to-Treat Patients (N=102)
Number of previous lines of systemic therapy for DLBCL (IxRS)			
n	34	68	102
>=2	34 (100%)	68 (100%)	102 (100%)
Relapsed/refractory to last line of therapy (IxRS)			
n	34	68	102
Refractory	25 (73.5%)	52 (76.5%)	77 (75.5%)
Relapsed	9 (26.5%)	16 (23.5%)	25 (24.5%)
Relapse or Refractory to Any Prior Therapy			
n	34	68	102
Refractory	30 (88.2%)	58 (85.3%)	88 (86.3%)
Relapse (No Refractory)	4 (11.8%)	10 (14.7%)	14 (13.7%)
Relapse or Refractory to First Line of Prior Therapy			
n	34	68	102
Refractory	19 (55.9%)	39 (57.4%)	58 (56.9%)
Relapse	15 (44.1%)	29 (42.6%)	44 (43.1%)
Relapse or Refractory to Any Prior Platinum Therapy			
n	34	68	102
Refractory	21 (61.8%)	32 (47.1%)	53 (52.0%)
Platinum Responsive	3 (8.8%)	10 (14.7%)	13 (12.7%)
No Prior Platinum	10 (29.4%)	26 (38.2%)	36 (35.3%)
Relapse or Refractory to Any Prior Anti-CD20 Therapy			
n	34	68	102
Refractory	27 (79.4%)	52 (76.5%)	79 (77.5%)
Relapse (No Refractory)	7 (20.6%)	16 (23.5%)	23 (22.5%)
Primary Refractory or Relapse within 12 months after Initial Diagnosis Date			

n	34	68	102
No	12 (35.3%)	26 (38.2%)	38 (37.3%)
Yes	22 (64.7%)	42 (61.8%)	64 (62.7%)
Primary Refractory or Relapse within 12 months after 1L Therapy			
n	34	68	102
No	7 (20.6%)	18 (26.5%)	25 (24.5%)
Yes	27 (79.4%)	50 (73.5%)	77 (75.5%)
Early relapse from ASCT (PD <= 12 months from completion)			
n	34	68	102
No	1 (2.9%)	4 (5.9%)	5 (4.9%)
Yes	2 (5.9%)	4 (5.9%)	6 (5.9%)
No prior ASCT	31 (91.2%)	60 (88.2%)	91 (89.2%)
Double refractory to any prior anti-CD20 and anthracycline based regimen			
n	34	68	102
Refractory	20 (58.8%)	42 (61.8%)	62 (60.8%)
Relapse (No Refractory)	14 (41.2%)	26 (38.2%)	40 (39.2%)
Cancer Histological subtype at Initial Diagnosis			
n	34	68	102
Non-GCB	5 (14.7%)	7 (10.3%)	12 (11.8%)
Unclassified	14 (41.2%)	41 (60.3%)	55 (53.9%)
GCB	12 (35.3%)	19 (27.9%)	31 (30.4%)
ABC	3 (8.8%)	1 (1.5%)	4 (3.9%)
Ann Arbor Staging at Study Entry			
n	33	68	101
Stage I	6 (17.6%)	6 (8.8%)	12 (11.8%)
Stage II	2 (5.9%)	14 (20.6%)	16 (15.7%)
Stage III	4 (11.8%)	9 (13.2%)	13 (12.7%)
Stage IV	21 (61.8%)	39 (57.4%)	60 (58.8%)
Prior autologous SCT			
n	34	68	102
No	31 (91.2%)	60 (88.2%)	91 (89.2%)
Yes	3 (8.8%)	8 (11.8%)	11 (10.8%)
Primary Reason for SCT ineligibility			
n	32	67	99
AGE	3 (8.8%)	10 (14.7%)	13 (12.7%)
AGE >= 70 YEARS	1 (2.9%)	4 (5.9%)	5 (4.9%)
CO-MORBIDITY: COMPLICATIONS DURING INDUCTION CHEMOTHERAPY	1 (2.9%)	0	1 (1.0%)
CO-MORBIDITY: DIABETES	1 (2.9%)	0	1 (1.0%)

CO-MORBIDITY: HYPERTENSION, DIABETES MELLITUS, ARRHYTHMIAS, SINUS NODE DISEASE WITH MAS SEIZURES.	1 (2.9%)	0	1 (1.0%)
CO-MORBIDITY: SEVERE PRIOR COVID INFECTION & PNEUMONITIS	0	1 (1.5%)	1 (1.0%)
FAILED PRIOR TRANSPLANT	4 (11.8%)	8 (11.8%)	12 (11.8%)
INSUFFICIENT RESPONSE TO SALVAGE THERAPY	9 (26.5%)	14 (20.6%)	23 (22.5%)
LACK OF ACCESS TO TRANSPLANT CENTER	0	2 (2.9%)	2 (2.0%)
OTHER: EXPECTED INSUFFICIENT RESPONSE	1 (2.9%)	0	1 (1.0%)
OTHER: NA AS >= 2 PRIOR LINES OF TREATMENT	0	1 (1.5%)	1 (1.0%)
OTHER: NON-CHEMOSENSITIVE DISEASE	0	1 (1.5%)	1 (1.0%)
PATIENT REFUSED TRANSPLANT	11 (32.4%)	26 (38.2%)	37 (36.3%)
Double-Expressor			
n	34	68	102
No	30 (88.2%)	57 (83.8%)	87 (85.3%)
Yes	4 (11.8%)	11 (16.2%)	15 (14.7%)
Total number of risk factors for IPI			
n	34	68	102
NOT APPLICABLE	2 (5.9%)	6 (8.8%)	8 (7.8%)
0	2 (5.9%)	9 (13.2%)	11 (10.8%)
1	6 (17.6%)	7 (10.3%)	13 (12.7%)
2	6 (17.6%)	17 (25.0%)	23 (22.5%)
3	11 (32.4%)	19 (27.9%)	30 (29.4%)
4	6 (17.6%)	7 (10.3%)	13 (12.7%)
5	1 (2.9%)	3 (4.4%)	4 (3.9%)
Total number of risk factors for IPI (Derived)			
n	34	68	102
NOT APPLICABLE	1 (2.9%)	1 (1.5%)	2 (2.0%)
0	3 (8.8%)	8 (11.8%)	11 (10.8%)
1	3 (8.8%)	11 (16.2%)	14 (13.7%)
2	11 (32.4%)	8 (11.8%)	19 (18.6%)
3	13 (38.2%)	25 (36.8%)	38 (37.3%)
4	2 (5.9%)	13 (19.1%)	15 (14.7%)
5	1 (2.9%)	2 (2.9%)	3 (2.9%)
Prior CAR-T therapy			
n	34	68	102
No	26 (76.5%)	55 (80.9%)	81 (79.4%)
Yes	8 (23.5%)	13 (19.1%)	21 (20.6%)
Relapse or Refractory to Any Prior CAR-T Therapy			
n	34	68	102
Refractory	6 (17.6%)	13 (19.1%)	19 (18.6%)
Relapse (No Refractory)	2 (5.9%)	0	2 (2.0%)

Unknown	26 (76.5%)	55 (80.9%)	81 (79.4%)
Bulky Disease => 10cm			
n	33	68	101
No	30 (88.2%)	60 (88.2%)	90 (88.2%)
Yes	3 (8.8%)	8 (11.8%)	11 (10.8%)
Cell of Origin			
n	34	68	102
GCB	11 (32.4%)	16 (23.5%)	27 (26.5%)
Non-GCB (by IHC + Non GCB Unclassified)	18 (52.9%)	37 (54.4%)	55 (53.9%)
ABC	0	2 (2.9%)	2 (2.0%)
Unknown	5 (14.7%)	13 (19.1%)	18 (17.6%)
Category Sum of Products of Diameters Value >=3000 - Investigator			
n	33	66	99
Baseline SPD < 3000	20 (58.8%)	37 (54.4%)	57 (55.9%)
Baseline SPD >= 3000	13 (38.2%)	29 (42.6%)	42 (41.2%)
Enrollment by geographic region			
n	34	68	102
Europe	8 (23.5%)	21 (30.9%)	29 (28.4%)
North America	4 (11.8%)	6 (8.8%)	10 (9.8%)
Rest of the World	22 (64.7%)	41 (60.3%)	63 (61.8%)
Anti-CD20 monoclonal antibody therapy			
n	34	68	102
Yes	34 (100%)	68 (100%)	102 (100%)

Any missing/unknown values for histology at initial diagnosis will be imputed with histology at study entry.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_mh_char2.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_mh_char2_ITT_3Lp_16FEB2024_41944.xls
13MAR2025 14:18

POPULATION: Safety evaluable population (2L)
MODEL: --
STUDY: GO41944
Number and Percentage of SAEs between randomization date and treatment start date

		Glofitamab + GemOx (N=112)			Rituximab + GemOx (N=55)		
		All SAEs	SAEs between randomization date and treatment start date		All SAEs	SAEs between randomization date and treatment start date	
Name	Level	n	n	%	n	n	%
All	n/a	140	0	0	24	0	0

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_num_sae.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_num_sae_SE_2L_16FEB2024_41944.xls
15AUG2024 15:39

POPULATION: Safety evaluable population (3L+)
MODEL: --
STUDY: GO41944
Number and Percentage of SAEs between randomization date and treatment start date

		Glofitamab + GemOx (N=68)			Rituximab + GemOx (N=33)		
		All SAEs	SAEs between randomization date and treatment start date		All SAEs	SAEs between randomization date and treatment start date	
Name	Level	n	n	%	n	n	%
All	n/a	75	0	0	11	0	0

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_num_sae.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_num_sae_SE_3Lp_16FEB2024_41944.xls
15AUG2024 15:41

POPULATION: ITT Population (2L)
ENDPOINT: Duration of Follow-up
MODEL: descriptive
STUDY: GO41944
Duration of Follow-up (reverse KM): Overall Survival

	Glofitamab + GemOx (N=115)						Rituximab + GemOx (N=57)					
	n	Median	25%-ile	75%-ile	Min	Max	n	Median	25%-ile	75%-ile	Min	Max
Duration of follow-up (months)	115	20,5	16,4	27,7	0	36	57	19,3	14,6	26,7	0	33

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_dur.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_dur_ITT_OS_2L_16FEB2024_41944.xls
16AUG2024 18:12

POPULATION: ITT Population (3L+)
ENDPOINT: Duration of Follow-up
MODEL: descriptive
STUDY: GO41944
Duration of Follow-up (reverse KM): Overall Survival

	Glofitamab + GemOx (N=68)						Rituximab + GemOx (N=34)					
	n	Median	25%-ile	75%-ile	Min	Max	n	Median	25%-ile	75%-ile	Min	Max
Duration of follow-up (months)	68	23,7	19,5	27,7	1	30	34	26,1	14,0	34,3	0	34

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_dur.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_dur_ITT_OS_3Lp_16FEB2024_41944.xls
16AUG2024 18:14

POPULATION: ITT Population (2L)
ENDPOINT: Duration of Follow-up
MODEL: descriptive
STUDY: GO41944
Duration of Follow-up (reverse KM): Event-free-survival (EoT)

	Glofitamab + GemOx (N=115)						Rituximab + GemOx (N=57)					
	n	Median	25%-ile	75%-ile	Min	Max	n	Median	25%-ile	75%-ile	Min	Max
Duration of follow-up (months)	115	17,0	12,0	23,1	0	33	57	16,5	6,3	17,3	0	27

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_dur.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_dur_ITT_EFSIRC_2L_16FEB2024_41944.xls
16AUG2024 18:18

POPULATION: ITT Population (3L+)
ENDPOINT: Duration of Follow-up
MODEL: descriptive
STUDY: GO41944
Duration of Follow-up (reverse KM): Event-free-survival (EoT)

	Glofitamab + GemOx (N=68)						Rituximab + GemOx (N=34)					
	n	Median	25%-ile	75%-ile	Min	Max	n	Median	25%-ile	75%-ile	Min	Max
Duration of follow-up (months)	68	21,2	11,1	23,0	0	27	34	10,7	9,7	12,7	0	27

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_dur.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_dur_ITT_EFSIRC_3Lp_16FEB2024_41944.xls
16AUG2024 18:19

POPULATION: Safety evaluable population (2L)
ENDPOINT: Duration of Follow-up
MODEL: descriptive
STUDY: GO41944
Duration of Follow-up (Median): Any AE

	Glofitamab + GemOx (N=112)								Rituximab + GemOx (N=55)							
	n	Mean	SD	Median	25%-ile	75%-ile	Minimum	Maximum	n	Mean	SD	Median	25%-ile	75%-ile	Minimum	Maximum
Duration of follow-up (months)	112	6,79	3,12	8,74	4,09	9,23	0,2	11,1	55	3,64	2,04	3,25	1,87	6,01	0,5	6,8

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_dur.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_dur_SE_DURFUPAE_2L_16FEB2024_41944.xls
19AUG2024 11:47

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Duration of Follow-up
MODEL: descriptive
STUDY: GO41944
Duration of Follow-up (Median): Any AE

	Glofitamab + GemOx (N=68)								Rituximab + GemOx (N=33)							
	n	Mean	SD	Median	25%-ile	75%-ile	Minimum	Maximum	n	Mean	SD	Median	25%-ile	75%-ile	Minimum	Maximum
Duration of follow-up (months)	68	5,94	3,35	6,60	2,48	8,80	0,5	11,1	33	3,18	2,08	2,56	1,51	5,36	0,7	7,2

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_dur.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_dur_SE_DURFUPAE_3Lp_16FEB2024_41944.xls
19AUG2024 11:49

POPULATION: ITT Population (2L)
ENDPOINT: Overall Survival
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=115)												Rituximab + GemOx (N=57)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	115	100,0	44	38,3	71	61,7	7,46	4,96	11,14	NE	20,37	NE	57	100,0	28	49,1	29	50,9	6,93	3,81	11,14	15,67	10,28	NE	0,0916	0,67	0,41	1,07	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_eff_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_eff_tte_ITT_str_OS_2L_16FEB2024_41944.xls
10DEC2024 20:03

POPULATION: ITT Population (2L)
ENDPOINT: Overall Survival
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=115)												Rituximab + GemOx (N=57)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	115	100,0	33	28,7	82	71,3	7,10	4,50	11,14	NE	NE	NE	57	100,0	20	35,1	37	64,9	6,47	3,55	8,28	14,42	7,46	NE	0,1515	0,66	0,38	1,17	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 29MAR2023

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_eff_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Interim_Analysis_2023/prod/output/t_eff_tte_ITT_str_OS_2L_29MAR2023_41944.xls
10DEC2024 20:50

POPULATION: ITT Population (3L+)
ENDPOINT: Overall Survival
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=68)												Rituximab + GemOx (N=34)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	68	100,0	36	52,9	32	47,1	5,09	3,25	10,68	18,27	11,50	NE	34	100,0	24	70,6	10	29,4	3,32	2,14	5,45	6,70	4,17	14,29	0,0270	0,56	0,33	0,94	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_eff_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_eff_tte_ITT_str_OS_3Lp_16FEB2024_41944.xls
10DEC2024 20:09

POPULATION: ITT Population (3L+)
ENDPOINT: Overall Survival
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=68)												Rituximab + GemOx (N=34)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	68	100,0	28	41,2	40	58,8	5,09	3,25	11,50	16,99	11,50	NE	34	100,0	20	58,8	14	41,2	3,32	1,91	5,62	6,70	4,17	13,54	0,0276	0,53	0,29	0,94	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 29MAR2023

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_eff_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Interim_Analysis_2023/prod/output/t_eff_tte_ITT_str_OS_3Lp_29MAR2023_41944.xls
10DEC2024 20:55

POPULATION: ITT Population (2L)
ENDPOINT: Overall Survival
STUDY: GO41944



Patients at risk																		
Rituximab + GemOx	57	53	42	39	35	32	29	25	20	17	11	8	6	6	4	2	1	NE
Glofitamab + GemOx	115	105	95	90	82	75	68	61	56	45	38	30	27	20	13	10	5	2
Patients censored																		
Rituximab + GemOx	0	3	6	7	7	7	8	9	12	14	19	21	23	23	25	27	28	NE
Glofitamab + GemOx	0	3	4	4	4	5	8	13	17	28	34	41	44	51	58	61	67	69

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_eff_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_eff_km_ITT_OS_2L_16FEB2024_41944.pdf
16AUG2024 17:35

POPULATION: ITT Population (2L)
ENDPOINT: Overall Survival
STUDY: GO41944



Patients at risk													
Rituximab + GemOx	57	50	35	30	21	11	7	7	4	4	1	NE	NE
Glofitamab + GemOx	115	97	82	69	53	39	31	23	14	10	6	2	1
Patients censored													
Rituximab + GemOx	0	6	13	16	21	28	31	31	33	33	36	NE	NE
Glofitamab + GemOx	0	11	17	25	36	45	52	59	68	72	76	80	81

Clinical cut-off: 29MAR2023

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_eff_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Interim_Analysis_2023/prod/output/g_eff_km_ITT_OS_2L_29MAR2023_41944.pdf
16AUG2024 18:20

POPULATION: ITT Population (3L+)
ENDPOINT: Overall Survival
STUDY: GO41944



Patients at risk																		
Rituximab + GemOx	34	28	21	16	13	13	11	9	6	6	5	5	4	4	1	1	1	1
Glofitamab + GemOx	68	61	51	45	43	41	36	30	29	26	23	20	13	9	6	1	NE	NE
Patients censored																		
Rituximab + GemOx	0	2	3	3	3	3	4	5	6	6	6	6	7	7	9	9	9	9
Glofitamab + GemOx	0	2	3	5	5	5	6	9	9	11	13	15	21	23	26	31	NE	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_eff_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_eff_km_ITT_OS_3Lp_16FEB2024_41944.pdf
16AUG2024 17:40

POPULATION: ITT Population (3L+)
ENDPOINT: Overall Survival
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	34	25	18	13	9	9	8	6	3	3	2	1
Glofitamab + GemOx	68	59	49	41	35	32	26	16	13	4	NE	NE
Patients censored												
Rituximab + GemOx	0	5	7	8	9	9	9	10	12	12	12	13
Glofitamab + GemOx	0	4	6	10	14	15	19	26	29	37	NE	NE

Clinical cut-off: 29MAR2023

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_eff_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Interim_Analysis_2023/prod/output/g_eff_km_ITT_OS_3Lp_29MAR2023_41944.pdf
16AUG2024 18:24

POPULATION: ITT Population (2L)
ENDPOINT: Event-free-Survival (EoT), IRC-Assessed
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=115)												Rituximab + GemOx (N=57)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	115	100,0	57	49,6	58	50,4	4,27	2,69	6,41	15,80	8,77	NE	57	100,0	41	71,9	16	28,1	2,17	1,41	2,99	5,06	2,99	6,11	<.0001	0,37	0,24	0,56	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_eff_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_eff_tte_ITT_str_EFSIRC_2L_16FEB2024_41944.xls
10DEC2024 20:21

POPULATION: ITT Population (2L)
ENDPOINT: Event-free-Survival (EoT), IRC-Assessed
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=115)												Rituximab + GemOx (N=57)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	115	100,0	39	33,9	76	66,1	4,04	2,69	6,05	12,06	6,70	NE	57	100,0	35	61,4	22	38,6	2,04	1,35	2,99	5,06	2,63	5,78	<.0001	0,34	0,21	0,54	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 29MAR2023

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_eff_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Interim_Analysis_2023/prod/output/t_eff_tte_ITT_str_EFSIRC_2L_29MAR2023_41944.xls
10DEC2024 21:03

POPULATION: ITT Population (3L+)
ENDPOINT: Event-free-Survival (EoT), IRC-Assessed
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=68)												Rituximab + GemOx (N=34)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	68	100,0	43	63,2	25	36,8	2,79	2,46	5,36	9,07	5,39	16,99	34	100,0	28	82,4	6	17,6	1,22	1,05	1,51	2,10	1,45	5,16	0,0003	0,41	0,25	0,67	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_eff_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_eff_tte_ITT_str_EFSIRC_3Lp_16FEB2024_41944.xls
10DEC2024 20:27

POPULATION: ITT Population (3L+)
ENDPOINT: Event-free-Survival (EoT), IRC-Assessed
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=68)												Rituximab + GemOx (N=34)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	68	100,0	35	51,5	33	48,5	3,09	2,50	5,36	9,17	5,36	16,99	34	100,0	23	67,6	11	32,4	1,25	1,05	1,81	2,53	1,45	4,50	0,0002	0,37	0,22	0,64	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 29MAR2023

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_eff_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Interim_Analysis_2023/prod/output/t_eff_tte_ITT_str_EFSIRC_3Lp_29MAR2023_41944.xls
10DEC2024 21:07

POPULATION: ITT Population (2L)
ENDPOINT: Event-free-Survival (EoT), IRC-Assessed
STUDY: GO41944



Patients at risk																	
Rituximab + GemOx	57	41	25	17	13	10	9	7	5	2	1	1	1	1	NE	NE	NE
Glofitamab + GemOx	115	99	83	74	62	49	46	38	32	25	24	13	12	10	2	2	2
Patients censored																	
Rituximab + GemOx	0	4	8	9	10	10	10	10	12	15	15	15	15	15	NE	NE	NE
Glofitamab + GemOx	0	3	6	7	10	16	18	24	29	36	37	46	47	48	56	56	56

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_eff_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_eff_km_ITT_EFSIRC_2L_16FEB2024_41944.pdf
16AUG2024 17:50

POPULATION: ITT Population (2L)
ENDPOINT: Event-free-Survival (EoT), IRC-Assessed
STUDY: GO41944



Patients at risk											
Rituximab + GemOx	57	35	22	13	8	2	2	1	1	NE	NE
Glofitamab + GemOx	115	82	62	43	32	21	18	11	6	3	2
Patients censored											
Rituximab + GemOx	0	11	13	15	16	20	20	21	21	NE	NE
Glofitamab + GemOx	0	22	31	42	47	56	59	65	71	73	74

Clinical cut-off: 29MAR2023

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_eff_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Interim_Analysis_2023/prod/output/g_eff_km_ITT_EFSIRC_2L_29MAR2023_41944.pdf
16AUG2024 18:32

POPULATION: ITT Population (3L+)
ENDPOINT: Event-free-Survival (EoT), IRC-Assessed
STUDY: GO41944



Patients at risk														
Rituximab + GemOx	34	17	11	7	6	4	2	1	1	1	1	1	1	1
Glofitamab + GemOx	68	55	38	34	31	26	22	21	18	16	13	7	4	3
Patients censored														
Rituximab + GemOx	0	1	2	2	2	4	5	6	6	6	6	6	6	6
Glofitamab + GemOx	0	3	7	7	7	8	11	11	12	13	15	20	22	22

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_eff_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_eff_km_ITT_EFSIRC_3Lp_16FEB2024_41944.pdf
16AUG2024 17:54

POPULATION: ITT Population (3L+)
ENDPOINT: Event-free-Survival (EoT), IRC-Assessed
STUDY: GO41944



Patients at risk										
Rituximab + GemOx	34	15	8	5	4	3	1	1	NE	NE
Glofitamab + GemOx	68	53	36	28	25	18	8	6	3	1
Patients censored										
Rituximab + GemOx	0	6	8	8	8	9	10	10	NE	NE
Glofitamab + GemOx	0	6	11	14	16	20	28	29	32	33

Clinical cut-off: 29MAR2023

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_eff_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Interim_Analysis_2023/prod/output/g_eff_km_ITT_EFSIRC_3Lp_29MAR2023_41944.pdf
16AUG2024 18:35

POPULATION: ITT Population (2L)
ENDPOINT: Event-free-Survival (EoT), IRC-Assessed,
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Dichotomous Analysis (Efficacy)

		Glofitamab + GemOx (N=115)				Rituximab + GemOx (N=57)				Glofitamab + GemOx vs. Rituximab + GemOx																Rituximab + GemOx vs. Glofitamab + GemOx			
		Patients		Patients with Event		Patients		Patients with Event		Odds Ratio					Absolute Risk Difference					Relative Risk							Relative Risk			
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Cochran-Mantel-Haenszel)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	115	100,0	57	49,6	57	100,0	41	71,9	0,34		Convergence criterion (GCONV=1E-8) satisfied.	0,17	0,70	-0,237		Algorithm converged.	-0,372	-0,101	0,695		Algorithm converged.	0,564	0,858	0,0030	1,438		Algorithm converged.	1,166	1,773

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_eff_resp_ITT_str_EFSIRC_2L_16FEB2024_41944.xls
03FEB2025 20:13

POPULATION: ITT Population (3L+)
ENDPOINT: Event-free-Survival (EoT), IRC-Assessed,
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Dichotomous Analysis (Efficacy)

		Glofitamab + GemOx (N=68)				Rituximab + GemOx (N=34)				Glofitamab + GemOx vs. Rituximab + GemOx																Rituximab + GemOx vs. Glofitamab + GemOx			
		Patients		Patients with Event		Patients		Patients with Event		Odds Ratio					Absolute Risk Difference				Relative Risk							Relative Risk			
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Cochran-Mantel-Haenszel)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	68	100,0	43	63,2	34	100,0	28	82,4	0,38		Convergence criterion (GCONV=1E-8) satisfied.	0,14	1,03	-0,190		Algorithm converged.	-0,363	-0,017	0,768		Algorithm converged.	0,603	0,978	0,0509	1,302		Algorithm converged.	1,023	1,658

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_eff_resp_ITT_str_EFSIRC_3Lp_16FEB2024_41944.xls
03FEB2025 20:19

POPULATION: ITT Population (2L)
ENDPOINT: Event-free-Survival (EoT), IRC-Assessed
STUDY: GO41944
Overview of EFS (EoT): first contributing event

	GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=115)		RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=57)	
	Patients		Patients	
Type of Event	Number of Patients with Event[1]	%	Number of Patients with Event[1]	%
EFS	57	49,6	41	71,9
Death	18	15,7	7	12,3
Progression/Relapse	34	29,6	26	45,6
Non-CR at EoT	5	4,3	8	14,0

[1] Number of Patients with this Event as "first contributing event"
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_efs_overview.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_efs_overview_ITT_EFSIRC_2L_16FEB2024_41944.xls
31MAR2025 14:32

POPULATION: ITT Population (3L+)
ENDPOINT: Event-free-Survival (EoT), IRC-Assessed
STUDY: GO41944
Overview of EFS (EoT): first contributing event

	GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)		RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=34)	
	Patients		Patients	
Type of Event	Number of Patients with Event[1]	%	Number of Patients with Event[1]	%
EFS	43	63,2	28	82,4
Death	13	19,1	4	11,8
Progression/Relapse	29	42,6	23	67,6
Non-CR at EoT	1	1,5	1	2,9

[1] Number of Patients with this Event as "first contributing event"
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_efs_overview.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_efs_overview_ITT_EFSIRC_3Lp_16FEB2024_41944.xls
31MAR2025 14:34

POPULATION: ITT Population (2L)
ENDPOINT: Event-free-Survival (EoT), INV-Assessed,
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Dichotomous Analysis (Efficacy)

		Glofitamab + GemOx (N=115)				Rituximab + GemOx (N=57)				Glofitamab + GemOx vs. Rituximab + GemOx																Rituximab + GemOx vs. Glofitamab + GemOx				
		Patients		Patients with Event		Patients		Patients with Event		Odds Ratio					Absolute Risk Difference				Relative Risk							Relative Risk				
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Cochran-Mantel-Haenszel)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	115	100,0	55	47,8	57	100,0	40	70,2	0,34		Convergence criterion (GCONV=1E-8) satisfied.	0,16	0,69	-0,237		Algorithm converged.	-0,372	-0,102	0,692		Algorithm converged.	0,560	0,857	0,0027	1,444		Algorithm converged.	1,168	1,787

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_eff_resp_ITT_str_EFSINV_2L_16FEB2024_41944.xls
03FEB2025 20:04

POPULATION: ITT Population (3L+)
ENDPOINT: Event-free-Survival (EoT), INV-Assessed,
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Dichotomous Analysis (Efficacy)

		Glofitamab + GemOx (N=68)				Rituximab + GemOx (N=34)				Glofitamab + GemOx vs. Rituximab + GemOx															Rituximab + GemOx vs. Glofitamab + GemOx				
		Patients		Patients with Event		Patients		Patients with Event		Odds Ratio					Absolute Risk Difference				Relative Risk						Relative Risk				
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Cochran-Mantel-Haenszel)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	68	100,0	42	61,8	34	100,0	28	82,4	0,35		Convergence criterion (GCONV=1E-8) satisfied.	0,13	0,96	-0,204		Algorithm converged.	-0,378	-0,030	0,751		Algorithm converged.	0,587	0,962	0,0373	1,331		Algorithm converged.	1,040	1,704

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_eff_resp_ITT_str_EFSINV_3Lp_16FEB2024_41944.xls
03FEB2025 20:10

POPULATION: ITT Population (2L)
ENDPOINT: Event-free-Survival (EoT), INV-Assessed
STUDY: GO41944



Patients at risk																	
Rituximab + GemOx	57	40	23	15	11	8	8	8	5	2	2	1	1	1	NE	NE	NE
Glofitamab + GemOx	115	99	85	76	65	53	47	39	33	25	24	13	12	10	2	2	2
Patients censored																	
Rituximab + GemOx	0	4	9	9	10	10	10	10	13	15	15	16	16	16	NE	NE	NE
Glofitamab + GemOx	0	2	4	7	10	15	18	24	29	37	38	47	48	50	58	58	58

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_eff_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_eff_km_ITT_EFSINV_2L_16FEB2024_41944.pdf
16AUG2024 17:42

POPULATION: ITT Population (3L+)
ENDPOINT: Event-free-Survival (EoT), INV-Assessed
STUDY: GO41944



Patients at risk														
Rituximab + GemOx	34	18	12	6	5	3	1	NE	NE	NE	NE	NE	NE	NE
Glofitamab + GemOx	68	55	39	35	34	29	23	22	18	16	13	7	4	3
Patients censored														
Rituximab + GemOx	0	1	2	2	2	4	5	NE	NE	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	2	6	6	6	7	10	10	12	13	15	20	23	23

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_eff_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_eff_km_ITT_EFSINV_3Lp_16FEB2024_41944.pdf
16AUG2024 17:47

POPULATION: ITT Population (2L)
ENDPOINT: Progression Free Survival by IRC - Censored Before NALT
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=115)												Rituximab + GemOx (N=57)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	115	100,0	51	44,3	64	55,7	4,96	2,92	6,70	20,37	9,20	NE	57	100,0	27	47,4	30	52,6	2,17	1,35	3,25	5,55	2,99	13,08	0,0002	0,41	0,25	0,67	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_eff_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_eff_tte_ITT_str_PFSPCON_2L_16FEB2024_41944.xls
10DEC2024 20:39

POPULATION: ITT Population (2L)
ENDPOINT: Progression Free Survival by IRC - Censored Before NALT
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=115)												Rituximab + GemOx (N=57)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	115	100,0	36	31,3	79	68,7	4,34	2,69	6,41	NE	6,83	NE	57	100,0	23	40,4	34	59,6	2,46	1,84	5,29	5,55	3,25	9,13	0,0011	0,41	0,23	0,71	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 29MAR2023

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_eff_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Interim_Analysis_2023/prod/output/t_eff_tte_ITT_str_PFSPCON_2L_29MAR2023_41944.xls
10DEC2024 21:15

POPULATION: ITT Population (3L+)
ENDPOINT: Progression Free Survival by IRC - Censored Before NALT
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=68)												Rituximab + GemOx (N=34)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	68	100,0	39	57,4	29	42,6	2,86	2,46	5,39	9,17	5,39	16,99	34	100,0	27	79,4	7	20,6	1,22	1,05	1,51	2,02	1,41	5,16	0,0002	0,39	0,24	0,66	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_eff_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_eff_tte_ITT_str_PFSPCON_3Lp_16FEB2024_41944.xls
10DEC2024 20:45

POPULATION: ITT Population (3L+)
ENDPOINT: Progression Free Survival by IRC - Censored Before NALT
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=68)												Rituximab + GemOx (N=34)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	68	100,0	32	47,1	36	52,9	3,25	2,50	5,39	9,30	5,39	16,99	34	100,0	21	61,8	13	38,2	1,22	1,05	1,51	2,17	1,41	2,79	<.0001	0,34	0,19	0,59	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 29MAR2023

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_eff_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Interim_Analysis_2023/prod/output/t_eff_tte_ITT_str_PFSPCON_3Lp_29MAR2023_41944.xls
10DEC2024 21:20

POPULATION: ITT Population (2L)
ENDPOINT: Progression Free Survival by IRC - Censored Before NALT
STUDY: GO41944



Patients at risk																		
Rituximab + GemOx	57	37	21	14	10	7	7	6	4	1	1	1	1	1	NE	NE	NE	NE
Glofitamab + GemOx	115	97	83	73	61	48	45	37	31	23	22	12	11	10	2	2	2	NE
Patients censored																		
Rituximab + GemOx	0	9	17	20	24	24	24	24	26	29	29	29	29	29	NE	NE	NE	NE
Glofitamab + GemOx	0	6	9	10	13	21	23	29	34	42	43	52	53	54	62	62	62	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_eff_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_eff_km_ITT_PFSPCON_2L_16FEB2024_41944.pdf
11DEC2024 17:56

POPULATION: ITT Population (2L)
ENDPOINT: Progression Free Survival by IRC - Censored Before NALT
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	57	33	21	11	8	2	2	1	1	NE	NE	NE
Glofitamab + GemOx	115	82	62	43	32	21	18	11	6	3	2	NE
Patients censored												
Rituximab + GemOx	0	17	21	25	28	32	32	33	33	NE	NE	NE
Glofitamab + GemOx	0	23	32	44	49	59	62	68	74	76	77	NE

Clinical cut-off: 29MAR2023

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_eff_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Interim_Analysis_2023/prod/output/g_eff_km_ITT_PFSPCON_2L_29MAR2023_41944.pdf
11DEC2024 17:54

POPULATION: ITT Population (3L+)
ENDPOINT: Progression Free Survival by IRC - Censored Before NALT
STUDY: GO41944



Patients at risk															
Rituximab + GemOx	34	16	10	8	6	4	2	1	1	1	1	1	1	1	NE
Glofitamab + GemOx	68	54	38	34	31	27	21	20	16	14	11	5	3	3	NE
Patients censored															
Rituximab + GemOx	0	2	3	3	3	5	6	7	7	7	7	7	7	7	NE
Glofitamab + GemOx	0	4	8	8	8	9	14	14	16	17	19	24	26	26	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_eff_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_eff_km_ITT_PFSPCON_3Lp_16FEB2024_41944.pdf
11DEC2024 18:00

POPULATION: ITT Population (3L+)
ENDPOINT: Progression Free Survival by IRC - Censored Before NALT
STUDY: GO41944



Patients at risk																				
Rituximab + GemOx	34	24	13	6	6	6	5	5	4	3	3	2	1	1	1	NE	NE	NE	NE	NE
Glofitamab + GemOx	68	60	51	42	35	35	27	25	24	24	17	11	8	7	6	6	3	1	1	NE
Patients censored																				
Rituximab + GemOx	0	8	8	10	10	10	10	10	10	11	11	12	12	12	12	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	7	8	12	14	14	17	18	19	19	23	28	31	32	32	32	35	36	36	NE

Clinical cut-off: 29MAR2023

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_eff_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Interim_Analysis_2023/prod/output/g_eff_km_ITT_PFSPCON_3Lp_29MAR2023_41944.pdf
11DEC2024 17:56

POPULATION: ITT Population (2L)
ENDPOINT: Progression Free Survival by Investigator - Censored Before NALT
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=115)												Rituximab + GemOx (N=57)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	115	100,0	51	44,3	64	55,7	4,73	2,79	6,83	24,64	9,56	NE	57	100,0	36	63,2	21	36,8	1,58	1,15	2,63	3,06	2,46	7,16	<.0001	0,30	0,19	0,47	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_eff_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_eff_tte_ITT_str_PFSPCN_2L_16FEB2024_41944.xls
10DEC2024 20:30

POPULATION: ITT Population (3L+)
ENDPOINT: Progression Free Survival by Investigator - Censored Before NALT
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=68)												Rituximab + GemOx (N=34)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	68	100,0	38	55,9	30	44,1	2,79	1,51	5,78	10,41	5,78	18,27	34	100,0	28	82,4	6	17,6	1,22	1,05	1,51	2,02	1,41	5,16	<.0001	0,36	0,21	0,60	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_eff_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_eff_tte_ITT_str_PFSPCN_3Lp_16FEB2024_41944.xls
10DEC2024 20:36

POPULATION: ITT Population (2L)
ENDPOINT: Progression Free Survival by Investigator - Censored Before NALT
STUDY: GO41944



Patients at risk																		
Rituximab + GemOx	57	37	20	14	11	8	8	7	5	2	2	1	1	1	NE	NE	NE	NE
Glofitamab + GemOx	115	98	84	75	63	51	47	39	33	25	24	14	12	10	2	2	2	NE
Patients censored																		
Rituximab + GemOx	0	6	11	13	15	15	15	15	17	19	19	20	20	20	NE	NE	NE	NE
Glofitamab + GemOx	0	4	7	9	12	19	22	28	33	41	42	51	53	54	62	62	62	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_eff_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_eff_km_ITT_PFSPCN_2L_16FEB2024_41944.pdf
11DEC2024 17:48

POPULATION: ITT Population (3L+)
ENDPOINT: Progression Free Survival by Investigator - Censored Before NALT
STUDY: GO41944



Patients at risk															
Rituximab + GemOx	34	16	11	8	6	4	2	1	1	1	1	1	1	1	NE
Glofitamab + GemOx	68	53	39	35	34	29	22	21	17	15	12	6	3	3	NE
Patients censored															
Rituximab + GemOx	0	2	2	2	2	4	5	6	6	6	6	6	6	6	NE
Glofitamab + GemOx	0	4	8	8	8	9	14	14	16	17	19	24	27	27	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_eff_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_eff_km_ITT_PFSPCN_3Lp_16FEB2024_41944.pdf
11DEC2024 17:54

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Appetite loss, Time to Deterioration (MID=10)
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=115)												Rituximab + GemOx (N=57)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	115	100,0	63	54,8	52	45,2	1,45	0,95	1,68	3,58	2,83	6,21	57	100,0	24	42,1	33	57,9	1,61	0,76	4,24	11,04	3,25	NE	0,2699	1,307	0,811	2,108	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_tte_ITT_str_QSAPMID_2L_16FEB2024_41944.xls
13DEC2024 14:36

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Appetite loss, Time to Deterioration (MID=10)
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=68)												Rituximab + GemOx (N=34)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	68	100,0	36	52,9	32	47,1	1,41	0,76	2,79	3,52	2,79	5,91	34	100,0	18	52,9	16	47,1	0,72	0,72	0,82	1,45	0,79	10,71	0,1899	0,676	0,376	1,217	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_tte_ITT_str_QSAPMID_3Lp_16FEB2024_41944.xls
13DEC2024 14:42

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Constipation, Time to Deterioration (MID=10)
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=115)												Rituximab + GemOx (N=57)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	115	100,0	50	43,5	65	56,5	2,10	1,41	3,02	16,46	4,50	NE	57	100,0	18	31,6	39	68,4	2,89	1,05	9,26	NE	6,37	NE	0,4816	1,217	0,704	2,102	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_tte_ITT_str_QSCOMID_2L_16FEB2024_41944.xls
13DEC2024 14:20

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Constipation, Time to Deterioration (MID=10)
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=68)												Rituximab + GemOx (N=34)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	68	100,0	27	39,7	41	60,3	4,21	1,08	6,90	12,22	5,59	21,16	34	100,0	10	29,4	24	70,6	2,99	0,82	20,70	14,13	4,24	NE	0,8956	0,952	0,457	1,984	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_tte_ITT_str_QSCOMID_3Lp_16FEB2024_41944.xls
13DEC2024 14:26

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Diarrhoea, Time to Deterioration (MID=10)
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=115)												Rituximab + GemOx (N=57)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	115	100,0	51	44,3	64	55,7	2,89	1,61	4,34	14,62	6,21	27,01	57	100,0	15	26,3	42	73,7	3,75	2,40	NE	NE	9,86	NE	0,1106	1,596	0,894	2,851	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_tte_ITT_str_QSDIMID_2L_16FEB2024_41944.xls
13DEC2024 14:13

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Diarrhoea, Time to Deterioration (MID=10)
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=68)												Rituximab + GemOx (N=34)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	68	100,0	27	39,7	41	60,3	4,21	1,54	5,82	9,92	5,59	NE	34	100,0	9	26,5	25	73,5	13,54	0,82	17,51	15,01	13,54	NE	0,7702	1,120	0,522	2,404	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_tte_ITT_str_QSDIMID_3Lp_16FEB2024_41944.xls
13DEC2024 14:18

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Dyspnoea, Time to Deterioration (MID=10)
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=115)												Rituximab + GemOx (N=57)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	115	100,0	45	39,1	70	60,9	1,54	0,95	6,11	15,47	7,23	NE	57	100,0	17	29,8	40	70,2	4,04	2,89	11,04	20,83	9,86	NE	0,3377	1,316	0,749	2,311	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_tte_ITT_str_QSDYMID_2L_16FEB2024_41944.xls
13DEC2024 14:05

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Dyspnoea, Time to Deterioration (MID=10)
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=68)												Rituximab + GemOx (N=34)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	68	100,0	28	41,2	40	58,8	1,48	1,02	11,63	15,41	9,07	21,06	34	100,0	14	41,2	20	58,8	2,83	0,79	4,30	4,30	2,99	17,51	0,3806	0,746	0,387	1,439	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_tte_ITT_str_QSDYMID_3Lp_16FEB2024_41944.xls
13DEC2024 14:10

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Fatigue, Time to Deterioration (MID=10)
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=115)												Rituximab + GemOx (N=57)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	115	100,0	72	62,6	43	37,4	0,76	0,76	1,08	1,64	1,45	4,27	57	100,0	34	59,6	23	40,4	0,82	0,76	0,95	1,48	0,92	9,26	0,8249	0,953	0,626	1,452	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_tte_ITT_str_QSFAMID_2L_16FEB2024_41944.xls
13DEC2024 13:49

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Fatigue, Time to Deterioration (MID=10)
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=68)												Rituximab + GemOx (N=34)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	68	100,0	41	60,3	27	39,7	0,76	0,76	1,08	1,91	1,08	4,63	34	100,0	19	55,9	15	44,1	0,76	0,72	1,18	1,41	0,79	6,80	0,5818	0,852	0,482	1,507	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_tte_ITT_str_QSFAMID_3Lp_16FEB2024_41944.xls
13DEC2024 13:54

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Nausea and vomiting, Time to Deterioration (MID=10)
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=115)												Rituximab + GemOx (N=57)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	115	100,0	62	53,9	53	46,1	1,45	1,41	1,68	3,12	2,79	6,21	57	100,0	25	43,9	32	56,1	1,02	0,79	2,40	7,85	1,97	NE	0,4145	1,216	0,760	1,945	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_tte_ITT_str_QSNVMID_2L_16FEB2024_41944.xls
13DEC2024 13:57

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Nausea and vomiting, Time to Deterioration (MID=10)
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=68)												Rituximab + GemOx (N=34)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	68	100,0	33	48,5	35	51,5	1,48	0,92	4,17	6,08	3,02	20,44	34	100,0	16	47,1	18	52,9	0,72	0,72	2,20	2,37	0,76	NE	0,3035	0,721	0,386	1,347	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_tte_ITT_str_QSNVMID_3Lp_16FEB2024_41944.xls
13DEC2024 14:02

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Pain, Time to Deterioration (MID=10)
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=115)												Rituximab + GemOx (N=57)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	115	100,0	41	35,7	74	64,3	3,09	1,51	11,01	NE	12,48	NE	57	100,0	27	47,4	30	52,6	1,61	0,76	3,25	7,85	2,76	18,53	0,0265	0,574	0,349	0,942	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_tte_ITT_str_QSPAMID_2L_16FEB2024_41944.xls
13DEC2024 14:44

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Pain, Time to Deterioration (MID=10)
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=68)												Rituximab + GemOx (N=34)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	68	100,0	26	38,2	42	61,8	1,45	0,79	5,59	10,48	5,16	NE	34	100,0	19	55,9	15	44,1	0,76	0,72	2,20	2,83	1,38	14,85	0,0587	0,562	0,308	1,029	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_tte_ITT_str_QSPAMID_3Lp_16FEB2024_41944.xls
13DEC2024 14:50

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Insomnia, Time to Deterioration (MID=10)
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=115)												Rituximab + GemOx (N=57)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	115	100,0	51	44,3	64	55,7	1,45	0,79	3,61	12,68	5,82	17,97	57	100,0	18	31,6	39	68,4	3,25	1,48	15,70	24,21	5,72	NE	0,2016	1,422	0,826	2,446	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_tte_ITT_str_QSSLMID_2L_16FEB2024_41944.xls
13DEC2024 13:41

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Insomnia, Time to Deterioration (MID=10)
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=68)												Rituximab + GemOx (N=34)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	68	100,0	27	39,7	41	60,3	1,91	0,99	5,59	12,85	4,44	NE	34	100,0	12	35,3	22	64,7	3,88	0,82	4,96	4,96	3,88	NE	0,5497	0,810	0,405	1,618	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_tte_ITT_str_QSSLMID_3Lp_16FEB2024_41944.xls
13DEC2024 13:46

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Appetite loss
MODEL: --
STUDY: GO41944
Compliance/Mean

		Glofitamab + GemOx (N=115)						Rituximab + GemOx (N=57)					
		Patients				Statistics		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)
All													
BASELINE	All	112	97,4	110	98,2	23,94	32,91	56	98,2	54	96,4	27,78	30,20
CYCLE 2 DAY 1	All	102	88,7	96	94,1	22,22	26,34	48	84,2	46	95,8	28,26	29,79
CYCLE 3 DAY 1	All	97	84,3	96	99,0	25,00	25,59	37	64,9	36	97,3	25,00	30,21
CYCLE 5 DAY 1	All	84	73,0	82	97,6	30,49	29,72	24	42,1	23	95,8	18,84	26,26
CYCLE 7 DAY 1	All	78	67,8	74	94,9	29,73	27,35	19	33,3	19	100,0	19,30	27,92
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	95	82,6	74	77,9	13,06	22,63	50	87,7	41	82,0	21,95	28,49
LONG TERM FOLLOW-UP MONTH 3	All	82	71,3	56	68,3	14,88	26,15	46	80,7	25	54,3	17,33	29,06
LONG TERM FOLLOW-UP MONTH 6	All	63	54,8	47	74,6	14,18	24,81	36	63,2	21	58,3	14,29	27,02
LONG TERM FOLLOW-UP MONTH 9	All	45	39,1	36	80,0	14,81	26,96	30	52,6	16	53,3	16,67	21,08
LONG TERM FOLLOW-UP MONTH 12	All	37	32,2	31	83,8	10,75	18,03	22	38,6	16	72,7	12,50	20,64
LONG TERM FOLLOW-UP MONTH 15	All	26	22,6	18	69,2	12,96	16,72	13	22,8	9	69,2	29,63	30,93
LONG TERM FOLLOW-UP MONTH 18	All	17	14,8	13	76,5	7,69	14,62	7	12,3	4	57,1	8,33	16,67
LONG TERM FOLLOW-UP MONTH 21	All	12	10,4	9	75,0	3,70	11,11	6	10,5	5	83,3	13,33	29,81
LONG TERM FOLLOW-UP MONTH 24	All	3	2,6	3	100,0	0,00	0,00	2	3,5	1	50,0	33,33	NE
LONG TERM FOLLOW-UP MONTH 27	All	1	0,9	1	100,0	0,00	NE	2	3,5	1	50,0	33,33	NE
LONG TERM FOLLOW-UP MONTH 30	All	1	0,9	1	100,0	0,00	NE	0	NE	0	NE	NE	NE

[1] in study: number of subjects in the ITT (or efficacy population) excluding subjects who died or withdrew their ICF before the visit had happened; % based on the ITT (or efficacy population)
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mean_ITT_QS028AP_2L_16FEB2024_41944.xls
07OCT2024 19:22

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Appetite loss
STUDY: GO41944
Line Plot of Mean by Visit



Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_pro_mean_ITT_QS028AP_2L_16FEB2024_41944.pdf
08OCT2024 21:58

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Appetite loss
MODEL: --
STUDY: GO41944
Compliance/Mean

		Glofitamab + GemOx (N=68)						Rituximab + GemOx (N=34)					
		Patients				Statistics		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)
All													
BASELINE	All	68	100,0	65	95,6	19,49	28,80	33	97,1	33	100,0	23,23	26,98
CYCLE 2 DAY 1	All	59	86,8	56	94,9	22,02	24,02	27	79,4	26	96,3	33,33	26,67
CYCLE 3 DAY 1	All	52	76,5	52	100,0	17,31	22,38	19	55,9	19	100,0	28,07	27,81
CYCLE 5 DAY 1	All	42	61,8	41	97,6	21,95	20,56	11	32,4	11	100,0	15,15	17,41
CYCLE 7 DAY 1	All	41	60,3	39	95,1	22,22	24,58	9	26,5	9	100,0	18,52	17,57
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	60	88,2	41	68,3	23,58	28,13	27	79,4	22	81,5	25,76	30,74
LONG TERM FOLLOW-UP MONTH 3	All	48	70,6	31	64,6	20,43	22,24	24	70,6	10	41,7	10,00	16,10
LONG TERM FOLLOW-UP MONTH 6	All	37	54,4	28	75,7	23,81	25,43	15	44,1	7	46,7	4,76	12,60
LONG TERM FOLLOW-UP MONTH 9	All	26	38,2	23	88,5	15,94	19,77	10	29,4	5	50,0	6,67	14,91
LONG TERM FOLLOW-UP MONTH 12	All	23	33,8	21	91,3	9,52	18,69	8	23,5	5	62,5	13,33	18,26
LONG TERM FOLLOW-UP MONTH 15	All	17	25,0	13	76,5	7,69	14,62	6	17,6	4	66,7	0,00	0,00
LONG TERM FOLLOW-UP MONTH 18	All	10	14,7	8	80,0	12,50	17,25	5	14,7	3	60,0	22,22	19,24
LONG TERM FOLLOW-UP MONTH 21	All	5	7,4	3	60,0	0,00	0,00	3	8,8	1	33,3	33,33	NE
LONG TERM FOLLOW-UP MONTH 24	All	1	1,5	1	100,0	0,00	NE	2	5,9	0	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 27	All	0	NE	0	NE	NE	NE	1	2,9	0	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 30	All	0	NE	0	NE	NE	NE	1	2,9	0	NE	NE	NE

[1] in study: number of subjects in the ITT (or efficacy population) excluding subjects who died or withdrew their ICF before the visit had happened; % based on the ITT (or efficacy population)
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mean_ITT_QS028AP_3Lp_16FEB2024_41944.xls
07OCT2024 19:25

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Appetite loss
STUDY: GO41944
Line Plot of Mean by Visit



Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_pro_mean_ITT_QS028AP_3Lp_16FEB2024_41944.pdf
08OCT2024 22:02

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Constipation
MODEL: --
STUDY: GO41944
Compliance/Mean

		Glofitamab + GemOx (N=115)						Rituximab + GemOx (N=57)					
		Patients				Statistics		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)
All													
BASELINE	All	112	97,4	110	98,2	19,09	27,63	56	98,2	54	96,4	17,90	29,47
CYCLE 2 DAY 1	All	102	88,7	96	94,1	18,75	28,54	48	84,2	46	95,8	17,39	26,05
CYCLE 3 DAY 1	All	97	84,3	96	99,0	16,32	23,69	37	64,9	36	97,3	16,67	27,02
CYCLE 5 DAY 1	All	84	73,0	82	97,6	13,01	22,68	24	42,1	23	95,8	7,25	22,38
CYCLE 7 DAY 1	All	78	67,8	74	94,9	15,32	20,78	19	33,3	19	100,0	10,53	22,37
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	95	82,6	74	77,9	11,71	20,96	50	87,7	41	82,0	10,57	20,33
LONG TERM FOLLOW-UP MONTH 3	All	82	71,3	56	68,3	11,90	19,52	46	80,7	25	54,3	10,67	20,91
LONG TERM FOLLOW-UP MONTH 6	All	63	54,8	47	74,6	9,93	22,96	36	63,2	21	58,3	6,35	22,65
LONG TERM FOLLOW-UP MONTH 9	All	45	39,1	36	80,0	12,04	18,09	30	52,6	16	53,3	14,58	20,97
LONG TERM FOLLOW-UP MONTH 12	All	37	32,2	31	83,8	10,75	24,93	22	38,6	16	72,7	6,25	13,44
LONG TERM FOLLOW-UP MONTH 15	All	26	22,6	18	69,2	20,37	28,33	13	22,8	9	69,2	14,81	24,22
LONG TERM FOLLOW-UP MONTH 18	All	17	14,8	13	76,5	10,26	21,01	7	12,3	4	57,1	0,00	0,00
LONG TERM FOLLOW-UP MONTH 21	All	12	10,4	10	83,3	13,33	23,31	6	10,5	5	83,3	0,00	0,00
LONG TERM FOLLOW-UP MONTH 24	All	3	2,6	3	100,0	0,00	0,00	2	3,5	1	50,0	0,00	NE
LONG TERM FOLLOW-UP MONTH 27	All	1	0,9	1	100,0	0,00	NE	2	3,5	1	50,0	0,00	NE
LONG TERM FOLLOW-UP MONTH 30	All	1	0,9	1	100,0	0,00	NE	0	NE	0	NE	NE	NE

[1] in study: number of subjects in the ITT (or efficacy population) excluding subjects who died or withdrew their ICF before the visit had happened; % based on the ITT (or efficacy population)
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mean_ITT_QS028CO_2L_16FEB2024_41944.xls
07OCT2024 19:10

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Constipation
STUDY: GO41944
Line Plot of Mean by Visit



Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_pro_mean_ITT_QS028CO_2L_16FEB2024_41944.pdf
08OCT2024 21:46

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Constipation
MODEL: --
STUDY: GO41944
Compliance/Mean

		Glofitamab + GemOx (N=68)						Rituximab + GemOx (N=34)					
		Patients				Statistics		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)
All													
BASELINE	All	68	100,0	65	95,6	16,41	25,09	33	97,1	33	100,0	22,22	24,53
CYCLE 2 DAY 1	All	59	86,8	56	94,9	19,05	28,33	27	79,4	26	96,3	21,79	29,73
CYCLE 3 DAY 1	All	52	76,5	52	100,0	11,54	22,76	19	55,9	19	100,0	17,54	28,04
CYCLE 5 DAY 1	All	42	61,8	41	97,6	17,07	25,95	11	32,4	11	100,0	3,03	10,05
CYCLE 7 DAY 1	All	41	60,3	39	95,1	20,51	30,22	9	26,5	9	100,0	11,11	16,67
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	60	88,2	41	68,3	15,45	22,48	27	79,4	22	81,5	16,67	24,67
LONG TERM FOLLOW-UP MONTH 3	All	48	70,6	31	64,6	16,13	22,56	24	70,6	10	41,7	6,67	14,05
LONG TERM FOLLOW-UP MONTH 6	All	37	54,4	28	75,7	11,90	18,62	15	44,1	7	46,7	0,00	0,00
LONG TERM FOLLOW-UP MONTH 9	All	26	38,2	23	88,5	8,70	14,97	10	29,4	5	50,0	6,67	14,91
LONG TERM FOLLOW-UP MONTH 12	All	23	33,8	21	91,3	11,11	21,94	8	23,5	5	62,5	6,67	14,91
LONG TERM FOLLOW-UP MONTH 15	All	17	25,0	13	76,5	7,69	14,62	6	17,6	4	66,7	16,67	19,24
LONG TERM FOLLOW-UP MONTH 18	All	10	14,7	8	80,0	4,17	11,79	5	14,7	3	60,0	0,00	0,00
LONG TERM FOLLOW-UP MONTH 21	All	5	7,4	3	60,0	0,00	0,00	3	8,8	1	33,3	0,00	NE
LONG TERM FOLLOW-UP MONTH 24	All	1	1,5	1	100,0	0,00	NE	2	5,9	0	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 27	All	0	NE	0	NE	NE	NE	1	2,9	0	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 30	All	0	NE	0	NE	NE	NE	1	2,9	0	NE	NE	NE

[1] in study: number of subjects in the ITT (or efficacy population) excluding subjects who died or withdrew their ICF before the visit had happened; % based on the ITT (or efficacy population)
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mean_ITT_QS028CO_3Lp_16FEB2024_41944.xls
07OCT2024 19:14

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Constipation
STUDY: GO41944
Line Plot of Mean by Visit



Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_pro_mean_ITT_QS028CO_3Lp_16FEB2024_41944.pdf
08OCT2024 21:51

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Diarrhoea
MODEL: --
STUDY: GO41944
Compliance/Mean

		Glofitamab + GemOx (N=115)						Rituximab + GemOx (N=57)					
		Patients				Statistics		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)
All													
BASELINE	All	112	97,4	110	98,2	10,91	19,74	56	98,2	54	96,4	19,14	28,67
CYCLE 2 DAY 1	All	102	88,7	96	94,1	9,03	19,63	48	84,2	46	95,8	13,04	21,63
CYCLE 3 DAY 1	All	97	84,3	96	99,0	12,50	25,71	37	64,9	36	97,3	9,26	18,87
CYCLE 5 DAY 1	All	84	73,0	83	98,8	13,25	23,25	24	42,1	23	95,8	7,25	14,06
CYCLE 7 DAY 1	All	78	67,8	74	94,9	16,22	25,43	19	33,3	19	100,0	17,54	23,22
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	95	82,6	74	77,9	5,86	13,91	50	87,7	41	82,0	12,20	20,76
LONG TERM FOLLOW-UP MONTH 3	All	82	71,3	56	68,3	5,36	16,55	46	80,7	25	54,3	16,00	27,42
LONG TERM FOLLOW-UP MONTH 6	All	63	54,8	47	74,6	7,09	13,79	36	63,2	21	58,3	7,94	17,97
LONG TERM FOLLOW-UP MONTH 9	All	45	39,1	36	80,0	2,78	9,34	30	52,6	16	53,3	2,08	8,33
LONG TERM FOLLOW-UP MONTH 12	All	37	32,2	31	83,8	3,23	10,02	22	38,6	16	72,7	4,17	11,39
LONG TERM FOLLOW-UP MONTH 15	All	26	22,6	18	69,2	3,70	10,78	13	22,8	9	69,2	3,70	11,11
LONG TERM FOLLOW-UP MONTH 18	All	17	14,8	13	76,5	2,56	9,24	7	12,3	4	57,1	16,67	19,24
LONG TERM FOLLOW-UP MONTH 21	All	12	10,4	10	83,3	3,33	10,54	6	10,5	5	83,3	13,33	18,26
LONG TERM FOLLOW-UP MONTH 24	All	3	2,6	3	100,0	0,00	0,00	2	3,5	1	50,0	66,67	NE
LONG TERM FOLLOW-UP MONTH 27	All	1	0,9	1	100,0	66,67	NE	2	3,5	1	50,0	33,33	NE
LONG TERM FOLLOW-UP MONTH 30	All	1	0,9	1	100,0	0,00	NE	0	NE	0	NE	NE	NE

[1] in study: number of subjects in the ITT (or efficacy population) excluding subjects who died or withdrew their ICF before the visit had happened; % based on the ITT (or efficacy population)
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mean_ITT_QS028DI_2L_16FEB2024_41944.xls
07OCT2024 19:04

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Diarrhoea
STUDY: GO41944
Line Plot of Mean by Visit



Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_pro_mean_ITT_QS028DI_2L_16FEB2024_41944.pdf
08OCT2024 21:40

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Diarrhoea
MODEL: --
STUDY: GO41944
Compliance/Mean

		Glofitamab + GemOx (N=68)						Rituximab + GemOx (N=34)					
		Patients				Statistics		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)
All													
BASELINE	All	68	100,0	65	95,6	7,69	19,34	33	97,1	33	100,0	6,06	13,06
CYCLE 2 DAY 1	All	59	86,8	55	93,2	9,09	19,73	27	79,4	26	96,3	8,97	17,78
CYCLE 3 DAY 1	All	52	76,5	52	100,0	7,05	19,06	19	55,9	19	100,0	5,26	12,49
CYCLE 5 DAY 1	All	42	61,8	41	97,6	5,69	14,72	11	32,4	10	90,9	3,33	10,54
CYCLE 7 DAY 1	All	41	60,3	39	95,1	11,97	19,48	9	26,5	9	100,0	3,70	11,11
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	60	88,2	41	68,3	10,57	20,33	27	79,4	22	81,5	9,09	23,42
LONG TERM FOLLOW-UP MONTH 3	All	48	70,6	31	64,6	9,68	23,08	24	70,6	10	41,7	0,00	0,00
LONG TERM FOLLOW-UP MONTH 6	All	37	54,4	28	75,7	10,71	24,09	15	44,1	7	46,7	0,00	0,00
LONG TERM FOLLOW-UP MONTH 9	All	26	38,2	23	88,5	2,90	9,60	10	29,4	5	50,0	0,00	0,00
LONG TERM FOLLOW-UP MONTH 12	All	23	33,8	21	91,3	6,35	22,65	8	23,5	5	62,5	33,33	23,57
LONG TERM FOLLOW-UP MONTH 15	All	17	25,0	13	76,5	0,00	0,00	6	17,6	4	66,7	8,33	16,67
LONG TERM FOLLOW-UP MONTH 18	All	10	14,7	8	80,0	4,17	11,79	5	14,7	3	60,0	11,11	19,24
LONG TERM FOLLOW-UP MONTH 21	All	5	7,4	3	60,0	0,00	0,00	3	8,8	1	33,3	0,00	NE
LONG TERM FOLLOW-UP MONTH 24	All	1	1,5	1	100,0	0,00	NE	2	5,9	0	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 27	All	0	NE	0	NE	NE	NE	1	2,9	0	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 30	All	0	NE	0	NE	NE	NE	1	2,9	0	NE	NE	NE

[1] in study: number of subjects in the ITT (or efficacy population) excluding subjects who died or withdrew their ICF before the visit had happened; % based on the ITT (or efficacy population)
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mean_ITT_QS028DI_3Lp_16FEB2024_41944.xls
07OCT2024 19:08

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Diarrhoea
STUDY: GO41944
Line Plot of Mean by Visit



Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_pro_mean_ITT_QS028DI_3Lp_16FEB2024_41944.pdf
08OCT2024 21:44

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Dyspnoea
MODEL: --
STUDY: GO41944
Compliance/Mean

		Glofitamab + GemOx (N=115)						Rituximab + GemOx (N=57)					
		Patients				Statistics		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)
All													
BASELINE	All	112	97,4	110	98,2	18,18	26,19	56	98,2	54	96,4	24,07	27,79
CYCLE 2 DAY 1	All	102	88,7	96	94,1	19,44	24,98	48	84,2	46	95,8	15,94	20,77
CYCLE 3 DAY 1	All	97	84,3	95	97,9	16,49	21,68	37	64,9	36	97,3	17,59	28,16
CYCLE 5 DAY 1	All	84	73,0	83	98,8	14,86	20,99	24	42,1	23	95,8	20,29	26,09
CYCLE 7 DAY 1	All	78	67,8	74	94,9	18,47	22,84	19	33,3	19	100,0	22,81	24,98
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	95	82,6	74	77,9	14,41	22,13	50	87,7	41	82,0	21,14	27,64
LONG TERM FOLLOW-UP MONTH 3	All	82	71,3	56	68,3	13,69	22,72	46	80,7	25	54,3	21,33	18,95
LONG TERM FOLLOW-UP MONTH 6	All	63	54,8	47	74,6	15,60	20,68	36	63,2	21	58,3	17,46	27,12
LONG TERM FOLLOW-UP MONTH 9	All	45	39,1	36	80,0	16,67	27,02	30	52,6	16	53,3	16,67	17,21
LONG TERM FOLLOW-UP MONTH 12	All	37	32,2	31	83,8	11,83	18,36	22	38,6	16	72,7	14,58	17,08
LONG TERM FOLLOW-UP MONTH 15	All	26	22,6	18	69,2	9,26	15,36	13	22,8	9	69,2	22,22	28,87
LONG TERM FOLLOW-UP MONTH 18	All	17	14,8	13	76,5	10,26	16,01	7	12,3	4	57,1	8,33	16,67
LONG TERM FOLLOW-UP MONTH 21	All	12	10,4	9	75,0	0,00	0,00	6	10,5	5	83,3	6,67	14,91
LONG TERM FOLLOW-UP MONTH 24	All	3	2,6	3	100,0	0,00	0,00	2	3,5	1	50,0	33,33	NE
LONG TERM FOLLOW-UP MONTH 27	All	1	0,9	1	100,0	0,00	NE	2	3,5	1	50,0	33,33	NE
LONG TERM FOLLOW-UP MONTH 30	All	1	0,9	1	100,0	33,33	NE	0	NE	0	NE	NE	NE

[1] in study: number of subjects in the ITT (or efficacy population) excluding subjects who died or withdrew their ICF before the visit had happened; % based on the ITT (or efficacy population)
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mean_ITT_QS028DY_2L_16FEB2024_41944.xls
07OCT2024 18:59

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Dyspnoea
STUDY: GO41944
Line Plot of Mean by Visit



Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_pro_mean_ITT_QS028DY_2L_16FEB2024_41944.pdf
08OCT2024 21:34

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Dyspnoea
MODEL: --
STUDY: GO41944
Compliance/Mean

		Glofitamab + GemOx (N=68)						Rituximab + GemOx (N=34)					
		Patients				Statistics		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)
All													
BASELINE	All	68	100,0	65	95,6	20,00	28,14	33	97,1	33	100,0	28,28	25,17
CYCLE 2 DAY 1	All	59	86,8	56	94,9	19,05	23,66	27	79,4	26	96,3	25,64	23,68
CYCLE 3 DAY 1	All	52	76,5	52	100,0	16,03	21,38	19	55,9	19	100,0	19,30	27,92
CYCLE 5 DAY 1	All	42	61,8	41	97,6	18,70	19,79	11	32,4	11	100,0	12,12	16,82
CYCLE 7 DAY 1	All	41	60,3	39	95,1	17,95	22,74	9	26,5	9	100,0	18,52	33,79
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	60	88,2	41	68,3	19,51	25,79	27	79,4	22	81,5	34,85	26,18
LONG TERM FOLLOW-UP MONTH 3	All	48	70,6	31	64,6	24,73	28,50	24	70,6	10	41,7	13,33	17,21
LONG TERM FOLLOW-UP MONTH 6	All	37	54,4	28	75,7	25,00	26,64	15	44,1	7	46,7	4,76	12,60
LONG TERM FOLLOW-UP MONTH 9	All	26	38,2	23	88,5	18,84	19,66	10	29,4	5	50,0	6,67	14,91
LONG TERM FOLLOW-UP MONTH 12	All	23	33,8	21	91,3	19,05	19,92	8	23,5	5	62,5	6,67	14,91
LONG TERM FOLLOW-UP MONTH 15	All	17	25,0	13	76,5	20,51	28,99	6	17,6	4	66,7	25,00	31,91
LONG TERM FOLLOW-UP MONTH 18	All	10	14,7	8	80,0	16,67	25,20	5	14,7	3	60,0	33,33	33,33
LONG TERM FOLLOW-UP MONTH 21	All	5	7,4	3	60,0	0,00	0,00	3	8,8	1	33,3	0,00	NE
LONG TERM FOLLOW-UP MONTH 24	All	1	1,5	1	100,0	0,00	NE	2	5,9	0	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 27	All	0	NE	0	NE	NE	NE	1	2,9	0	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 30	All	0	NE	0	NE	NE	NE	1	2,9	0	NE	NE	NE

[1] in study: number of subjects in the ITT (or efficacy population) excluding subjects who died or withdrew their ICF before the visit had happened; % based on the ITT (or efficacy population)
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mean_ITT_QS028DY_3Lp_16FEB2024_41944.xls
07OCT2024 19:02

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Dyspnoea
STUDY: GO41944
Line Plot of Mean by Visit



Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_pro_mean_ITT_QS028DY_3Lp_16FEB2024_41944.pdf
08OCT2024 21:38

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Fatigue
MODEL: --
STUDY: GO41944
Compliance/Mean

		Glofitamab + GemOx (N=115)						Rituximab + GemOx (N=57)					
		Patients				Statistics		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)
All													
BASELINE	All	112	97,4	110	98,2	32,53	23,97	56	98,2	54	96,4	31,28	20,48
CYCLE 2 DAY 1	All	102	88,7	96	94,1	35,19	21,00	48	84,2	46	95,8	37,20	24,25
CYCLE 3 DAY 1	All	97	84,3	96	99,0	33,68	20,04	37	64,9	36	97,3	32,72	26,82
CYCLE 5 DAY 1	All	84	73,0	83	98,8	35,07	22,05	24	42,1	23	95,8	27,05	22,43
CYCLE 7 DAY 1	All	78	67,8	74	94,9	34,08	19,41	19	33,3	19	100,0	26,32	22,59
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	95	82,6	74	77,9	25,23	18,96	50	87,7	41	82,0	34,42	27,53
LONG TERM FOLLOW-UP MONTH 3	All	82	71,3	56	68,3	26,59	21,47	46	80,7	25	54,3	33,33	25,66
LONG TERM FOLLOW-UP MONTH 6	All	63	54,8	47	74,6	25,77	20,34	36	63,2	21	58,3	26,46	22,90
LONG TERM FOLLOW-UP MONTH 9	All	45	39,1	36	80,0	25,31	25,56	30	52,6	16	53,3	29,17	19,40
LONG TERM FOLLOW-UP MONTH 12	All	37	32,2	31	83,8	21,51	16,46	22	38,6	16	72,7	19,44	16,48
LONG TERM FOLLOW-UP MONTH 15	All	26	22,6	18	69,2	26,23	15,92	13	22,8	9	69,2	32,10	24,50
LONG TERM FOLLOW-UP MONTH 18	All	17	14,8	13	76,5	17,95	13,25	7	12,3	4	57,1	33,33	15,71
LONG TERM FOLLOW-UP MONTH 21	All	12	10,4	9	75,0	16,05	12,56	6	10,5	5	83,3	20,00	9,30
LONG TERM FOLLOW-UP MONTH 24	All	3	2,6	3	100,0	18,52	16,97	2	3,5	1	50,0	44,44	NE
LONG TERM FOLLOW-UP MONTH 27	All	1	0,9	1	100,0	22,22	NE	2	3,5	1	50,0	33,33	NE
LONG TERM FOLLOW-UP MONTH 30	All	1	0,9	1	100,0	22,22	NE	0	NE	0	NE	NE	NE

[1] in study: number of subjects in the ITT (or efficacy population) excluding subjects who died or withdrew their ICF before the visit had happened; % based on the ITT (or efficacy population)
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mean_ITT_QS028FA_2L_16FEB2024_41944.xls
07OCT2024 18:49

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Fatigue
STUDY: GO41944
Line Plot of Mean by Visit



Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_pro_mean_ITT_QS028FA_2L_16FEB2024_41944.pdf
08OCT2024 21:22

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Fatigue
MODEL: --
STUDY: GO41944
Compliance/Mean

		Glofitamab + GemOx (N=68)						Rituximab + GemOx (N=34)					
		Patients				Statistics		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)
All													
BASELINE	All	68	100,0	65	95,6	33,76	27,33	33	97,1	33	100,0	33,67	22,48
CYCLE 2 DAY 1	All	59	86,8	56	94,9	34,03	20,87	27	79,4	26	96,3	41,03	21,03
CYCLE 3 DAY 1	All	52	76,5	52	100,0	30,56	21,54	19	55,9	19	100,0	35,67	28,83
CYCLE 5 DAY 1	All	42	61,8	41	97,6	31,44	20,62	11	32,4	11	100,0	19,70	19,14
CYCLE 7 DAY 1	All	41	60,3	39	95,1	33,33	20,23	9	26,5	9	100,0	25,93	20,79
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	60	88,2	41	68,3	35,77	23,77	27	79,4	22	81,5	39,90	24,88
LONG TERM FOLLOW-UP MONTH 3	All	48	70,6	31	64,6	34,77	26,56	24	70,6	10	41,7	21,11	21,24
LONG TERM FOLLOW-UP MONTH 6	All	37	54,4	28	75,7	33,33	27,38	15	44,1	7	46,7	15,87	16,80
LONG TERM FOLLOW-UP MONTH 9	All	26	38,2	23	88,5	26,57	20,58	10	29,4	5	50,0	22,22	23,57
LONG TERM FOLLOW-UP MONTH 12	All	23	33,8	21	91,3	28,57	23,98	8	23,5	5	62,5	31,11	19,88
LONG TERM FOLLOW-UP MONTH 15	All	17	25,0	13	76,5	17,09	17,92	6	17,6	4	66,7	13,89	10,64
LONG TERM FOLLOW-UP MONTH 18	All	10	14,7	8	80,0	27,78	19,70	5	14,7	3	60,0	40,74	12,83
LONG TERM FOLLOW-UP MONTH 21	All	5	7,4	3	60,0	11,11	19,24	3	8,8	1	33,3	22,22	NE
LONG TERM FOLLOW-UP MONTH 24	All	1	1,5	1	100,0	33,33	NE	2	5,9	0	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 27	All	0	NE	0	NE	NE	NE	1	2,9	0	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 30	All	0	NE	0	NE	NE	NE	1	2,9	0	NE	NE	NE

[1] in study: number of subjects in the ITT (or efficacy population) excluding subjects who died or withdrew their ICF before the visit had happened; % based on the ITT (or efficacy population)
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mean_ITT_QS028FA_3Lp_16FEB2024_41944.xls
07OCT2024 18:52

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Fatigue
STUDY: GO41944
Line Plot of Mean by Visit



Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_pro_mean_ITT_QS028FA_3Lp_16FEB2024_41944.pdf
08OCT2024 21:26

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Nausea and vomiting
MODEL: --
STUDY: GO41944
Compliance/Mean

		Glofitamab + GemOx (N=115)						Rituximab + GemOx (N=57)					
		Patients				Statistics		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)
All													
BASELINE	All	112	97,4	110	98,2	6,82	14,85	56	98,2	54	96,4	9,57	16,70
CYCLE 2 DAY 1	All	102	88,7	96	94,1	7,81	15,09	48	84,2	46	95,8	13,04	21,63
CYCLE 3 DAY 1	All	97	84,3	96	99,0	12,67	19,46	37	64,9	36	97,3	11,57	21,39
CYCLE 5 DAY 1	All	84	73,0	83	98,8	11,85	16,77	24	42,1	23	95,8	9,42	21,80
CYCLE 7 DAY 1	All	78	67,8	74	94,9	12,61	18,67	19	33,3	19	100,0	13,16	26,98
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	95	82,6	74	77,9	4,50	10,06	50	87,7	41	82,0	11,79	20,50
LONG TERM FOLLOW-UP MONTH 3	All	82	71,3	56	68,3	5,95	17,24	46	80,7	25	54,3	9,33	24,09
LONG TERM FOLLOW-UP MONTH 6	All	63	54,8	47	74,6	4,26	10,69	36	63,2	21	58,3	6,35	22,65
LONG TERM FOLLOW-UP MONTH 9	All	45	39,1	36	80,0	3,70	12,03	30	52,6	16	53,3	5,21	11,74
LONG TERM FOLLOW-UP MONTH 12	All	37	32,2	31	83,8	3,76	10,28	22	38,6	16	72,7	3,13	9,07
LONG TERM FOLLOW-UP MONTH 15	All	26	22,6	18	69,2	4,63	9,58	13	22,8	9	69,2	0,00	0,00
LONG TERM FOLLOW-UP MONTH 18	All	17	14,8	13	76,5	5,13	10,51	7	12,3	4	57,1	0,00	0,00
LONG TERM FOLLOW-UP MONTH 21	All	12	10,4	10	83,3	1,67	5,27	6	10,5	5	83,3	0,00	0,00
LONG TERM FOLLOW-UP MONTH 24	All	3	2,6	3	100,0	0,00	0,00	2	3,5	1	50,0	0,00	NE
LONG TERM FOLLOW-UP MONTH 27	All	1	0,9	1	100,0	0,00	NE	2	3,5	1	50,0	0,00	NE
LONG TERM FOLLOW-UP MONTH 30	All	1	0,9	1	100,0	0,00	NE	0	NE	0	NE	NE	NE

[1] in study: number of subjects in the ITT (or efficacy population) excluding subjects who died or withdrew their ICF before the visit had happened; % based on the ITT (or efficacy population)
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mean_ITT_QS028NV_2L_16FEB2024_41944.xls
07OCT2024 18:54

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Nausea and vomiting
STUDY: GO41944
Line Plot of Mean by Visit



Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_pro_mean_ITT_QS028NV_2L_16FEB2024_41944.pdf
08OCT2024 21:28

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Nausea and vomiting
MODEL: --
STUDY: GO41944
Compliance/Mean

		Glofitamab + GemOx (N=68)						Rituximab + GemOx (N=34)					
		Patients				Statistics		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)
All													
BASELINE	All	68	100,0	65	95,6	6,92	17,65	33	97,1	33	100,0	10,10	16,10
CYCLE 2 DAY 1	All	59	86,8	56	94,9	6,85	13,77	27	79,4	26	96,3	18,59	24,19
CYCLE 3 DAY 1	All	52	76,5	52	100,0	7,69	14,18	19	55,9	19	100,0	14,04	25,62
CYCLE 5 DAY 1	All	42	61,8	41	97,6	6,91	11,77	11	32,4	11	100,0	0,00	0,00
CYCLE 7 DAY 1	All	41	60,3	39	95,1	10,26	15,59	9	26,5	9	100,0	3,70	11,11
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	60	88,2	41	68,3	4,88	10,03	27	79,4	22	81,5	14,39	20,12
LONG TERM FOLLOW-UP MONTH 3	All	48	70,6	31	64,6	5,38	12,46	24	70,6	10	41,7	3,33	10,54
LONG TERM FOLLOW-UP MONTH 6	All	37	54,4	28	75,7	6,55	16,57	15	44,1	7	46,7	0,00	0,00
LONG TERM FOLLOW-UP MONTH 9	All	26	38,2	23	88,5	0,72	3,48	10	29,4	5	50,0	3,33	7,45
LONG TERM FOLLOW-UP MONTH 12	All	23	33,8	21	91,3	3,17	8,53	8	23,5	5	62,5	3,33	7,45
LONG TERM FOLLOW-UP MONTH 15	All	17	25,0	13	76,5	3,85	7,31	6	17,6	4	66,7	4,17	8,33
LONG TERM FOLLOW-UP MONTH 18	All	10	14,7	8	80,0	12,50	19,42	5	14,7	3	60,0	0,00	0,00
LONG TERM FOLLOW-UP MONTH 21	All	5	7,4	3	60,0	0,00	0,00	3	8,8	1	33,3	0,00	NE
LONG TERM FOLLOW-UP MONTH 24	All	1	1,5	1	100,0	0,00	NE	2	5,9	0	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 27	All	0	NE	0	NE	NE	NE	1	2,9	0	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 30	All	0	NE	0	NE	NE	NE	1	2,9	0	NE	NE	NE

[1] in study: number of subjects in the ITT (or efficacy population) excluding subjects who died or withdrew their ICF before the visit had happened; % based on the ITT (or efficacy population)
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mean_ITT_QS028NV_3Lp_16FEB2024_41944.xls
07OCT2024 18:57

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Nausea and vomiting
STUDY: GO41944
Line Plot of Mean by Visit



Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_pro_mean_ITT_QS028NV_3Lp_16FEB2024_41944.pdf
08OCT2024 21:32

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Pain
MODEL: --
STUDY: GO41944
Compliance/Mean

		Glofitamab + GemOx (N=115)						Rituximab + GemOx (N=57)					
		Patients				Statistics		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)
All													
BASELINE	All	112	97,4	110	98,2	30,30	26,05	56	98,2	54	96,4	30,86	25,98
CYCLE 2 DAY 1	All	102	88,7	96	94,1	19,97	24,62	48	84,2	46	95,8	21,38	26,68
CYCLE 3 DAY 1	All	97	84,3	96	99,0	13,37	18,98	37	64,9	36	97,3	18,52	24,16
CYCLE 5 DAY 1	All	84	73,0	83	98,8	13,05	21,31	24	42,1	23	95,8	14,49	23,73
CYCLE 7 DAY 1	All	78	67,8	74	94,9	11,71	18,66	19	33,3	19	100,0	11,40	20,83
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	95	82,6	74	77,9	13,51	16,24	50	87,7	41	82,0	29,67	29,93
LONG TERM FOLLOW-UP MONTH 3	All	82	71,3	56	68,3	16,67	22,47	46	80,7	25	54,3	16,67	24,53
LONG TERM FOLLOW-UP MONTH 6	All	63	54,8	47	74,6	15,25	24,53	36	63,2	21	58,3	11,90	24,23
LONG TERM FOLLOW-UP MONTH 9	All	45	39,1	36	80,0	16,20	20,50	30	52,6	16	53,3	13,54	22,13
LONG TERM FOLLOW-UP MONTH 12	All	37	32,2	31	83,8	12,37	17,73	22	38,6	16	72,7	13,54	18,48
LONG TERM FOLLOW-UP MONTH 15	All	26	22,6	18	69,2	17,59	20,19	13	22,8	9	69,2	24,07	22,22
LONG TERM FOLLOW-UP MONTH 18	All	17	14,8	13	76,5	7,69	12,94	7	12,3	4	57,1	8,33	9,62
LONG TERM FOLLOW-UP MONTH 21	All	12	10,4	10	83,3	1,67	5,27	6	10,5	5	83,3	3,33	7,45
LONG TERM FOLLOW-UP MONTH 24	All	3	2,6	3	100,0	0,00	0,00	2	3,5	1	50,0	0,00	NE
LONG TERM FOLLOW-UP MONTH 27	All	1	0,9	1	100,0	50,00	NE	2	3,5	1	50,0	16,67	NE
LONG TERM FOLLOW-UP MONTH 30	All	1	0,9	1	100,0	0,00	NE	0	NE	0	NE	NE	NE

[1] in study: number of subjects in the ITT (or efficacy population) excluding subjects who died or withdrew their ICF before the visit had happened; % based on the ITT (or efficacy population)
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mean_ITT_QS028PA_2L_16FEB2024_41944.xls
07OCT2024 19:27

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Pain
STUDY: GO41944
Line Plot of Mean by Visit



Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_pro_mean_ITT_QS028PA_2L_16FEB2024_41944.pdf
08OCT2024 22:04

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Pain
MODEL: --
STUDY: GO41944
Compliance/Mean

		Glofitamab + GemOx (N=68)						Rituximab + GemOx (N=34)					
		Patients				Statistics		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)
All													
BASELINE	All	68	100,0	65	95,6	24,10	27,49	33	97,1	33	100,0	29,29	30,91
CYCLE 2 DAY 1	All	59	86,8	56	94,9	17,86	25,00	27	79,4	26	96,3	28,21	24,39
CYCLE 3 DAY 1	All	52	76,5	52	100,0	15,38	22,35	19	55,9	19	100,0	16,67	27,22
CYCLE 5 DAY 1	All	42	61,8	41	97,6	12,60	16,15	11	32,4	11	100,0	7,58	17,26
CYCLE 7 DAY 1	All	41	60,3	39	95,1	13,25	15,38	9	26,5	9	100,0	9,26	22,22
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	60	88,2	41	68,3	20,33	23,43	27	79,4	22	81,5	25,00	29,43
LONG TERM FOLLOW-UP MONTH 3	All	48	70,6	31	64,6	11,83	15,63	24	70,6	10	41,7	16,67	17,57
LONG TERM FOLLOW-UP MONTH 6	All	37	54,4	28	75,7	20,24	28,09	15	44,1	7	46,7	14,29	11,50
LONG TERM FOLLOW-UP MONTH 9	All	26	38,2	23	88,5	10,14	16,47	10	29,4	5	50,0	23,33	19,00
LONG TERM FOLLOW-UP MONTH 12	All	23	33,8	21	91,3	15,87	22,65	8	23,5	5	62,5	23,33	27,89
LONG TERM FOLLOW-UP MONTH 15	All	17	25,0	13	76,5	7,69	12,94	6	17,6	4	66,7	20,83	20,97
LONG TERM FOLLOW-UP MONTH 18	All	10	14,7	8	80,0	12,50	17,25	5	14,7	3	60,0	22,22	25,46
LONG TERM FOLLOW-UP MONTH 21	All	5	7,4	3	60,0	0,00	0,00	3	8,8	1	33,3	0,00	NE
LONG TERM FOLLOW-UP MONTH 24	All	1	1,5	1	100,0	0,00	NE	2	5,9	0	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 27	All	0	NE	0	NE	NE	NE	1	2,9	0	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 30	All	0	NE	0	NE	NE	NE	1	2,9	0	NE	NE	NE

[1] in study: number of subjects in the ITT (or efficacy population) excluding subjects who died or withdrew their ICF before the visit had happened; % based on the ITT (or efficacy population)
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mean_ITT_QS028PA_3Lp_16FEB2024_41944.xls
07OCT2024 19:31

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Pain
STUDY: GO41944
Line Plot of Mean by Visit



Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_pro_mean_ITT_QS028PA_3Lp_16FEB2024_41944.pdf
08OCT2024 22:08

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Insomnia
MODEL: --
STUDY: GO41944
Compliance/Mean

		Glofitamab + GemOx (N=115)						Rituximab + GemOx (N=57)					
		Patients				Statistics		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)
All													
BASELINE	All	112	97,4	110	98,2	29,09	30,66	56	98,2	54	96,4	33,95	30,02
CYCLE 2 DAY 1	All	102	88,7	96	94,1	29,51	27,73	48	84,2	46	95,8	28,99	27,76
CYCLE 3 DAY 1	All	97	84,3	96	99,0	24,65	26,16	37	64,9	36	97,3	26,85	27,39
CYCLE 5 DAY 1	All	84	73,0	83	98,8	23,29	25,89	24	42,1	23	95,8	20,29	26,09
CYCLE 7 DAY 1	All	78	67,8	74	94,9	23,87	28,41	19	33,3	19	100,0	26,32	28,50
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	95	82,6	74	77,9	21,62	23,69	50	87,7	41	82,0	29,27	27,08
LONG TERM FOLLOW-UP MONTH 3	All	82	71,3	56	68,3	20,24	25,17	46	80,7	25	54,3	25,33	24,11
LONG TERM FOLLOW-UP MONTH 6	All	63	54,8	47	74,6	19,86	24,73	36	63,2	21	58,3	19,05	22,54
LONG TERM FOLLOW-UP MONTH 9	All	45	39,1	36	80,0	16,67	23,23	30	52,6	16	53,3	31,25	19,12
LONG TERM FOLLOW-UP MONTH 12	All	37	32,2	31	83,8	22,58	21,75	22	38,6	16	72,7	20,83	16,67
LONG TERM FOLLOW-UP MONTH 15	All	26	22,6	18	69,2	25,93	26,95	13	22,8	9	69,2	29,63	20,03
LONG TERM FOLLOW-UP MONTH 18	All	17	14,8	13	76,5	15,38	22,01	7	12,3	4	57,1	41,67	41,94
LONG TERM FOLLOW-UP MONTH 21	All	12	10,4	9	75,0	11,11	16,67	6	10,5	5	83,3	13,33	18,26
LONG TERM FOLLOW-UP MONTH 24	All	3	2,6	3	100,0	33,33	33,33	2	3,5	1	50,0	0,00	NE
LONG TERM FOLLOW-UP MONTH 27	All	1	0,9	1	100,0	0,00	NE	2	3,5	1	50,0	33,33	NE
LONG TERM FOLLOW-UP MONTH 30	All	1	0,9	1	100,0	33,33	NE	0	NE	0	NE	NE	NE

[1] in study: number of subjects in the ITT (or efficacy population) excluding subjects who died or withdrew their ICF before the visit had happened; % based on the ITT (or efficacy population)
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mean_ITT_QS028SL_2L_16FEB2024_41944.xls
07OCT2024 18:44

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Insomnia
STUDY: GO41944
Line Plot of Mean by Visit



Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_pro_mean_ITT_QS028SL_2L_16FEB2024_41944.pdf
08OCT2024 21:15

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Insomnia
MODEL: --
STUDY: GO41944
Compliance/Mean

		Glofitamab + GemOx (N=68)						Rituximab + GemOx (N=34)					
		Patients				Statistics		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)
All													
BASELINE	All	68	100,0	65	95,6	24,62	29,63	33	97,1	33	100,0	30,30	29,30
CYCLE 2 DAY 1	All	59	86,8	56	94,9	22,62	24,71	27	79,4	26	96,3	30,77	31,16
CYCLE 3 DAY 1	All	52	76,5	52	100,0	20,51	26,53	19	55,9	19	100,0	22,81	24,98
CYCLE 5 DAY 1	All	42	61,8	41	97,6	17,89	21,21	11	32,4	11	100,0	9,09	15,57
CYCLE 7 DAY 1	All	41	60,3	39	95,1	20,51	22,45	9	26,5	9	100,0	14,81	24,22
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	60	88,2	41	68,3	23,58	27,13	27	79,4	22	81,5	21,21	28,26
LONG TERM FOLLOW-UP MONTH 3	All	48	70,6	31	64,6	16,13	16,93	24	70,6	10	41,7	16,67	23,57
LONG TERM FOLLOW-UP MONTH 6	All	37	54,4	28	75,7	26,19	26,23	15	44,1	7	46,7	23,81	25,20
LONG TERM FOLLOW-UP MONTH 9	All	26	38,2	23	88,5	15,94	17,03	10	29,4	5	50,0	13,33	18,26
LONG TERM FOLLOW-UP MONTH 12	All	23	33,8	21	91,3	26,98	27,12	8	23,5	5	62,5	13,33	29,81
LONG TERM FOLLOW-UP MONTH 15	All	17	25,0	13	76,5	20,51	16,88	6	17,6	4	66,7	16,67	19,24
LONG TERM FOLLOW-UP MONTH 18	All	10	14,7	8	80,0	25,00	15,43	5	14,7	3	60,0	55,56	38,49
LONG TERM FOLLOW-UP MONTH 21	All	5	7,4	3	60,0	11,11	19,24	3	8,8	1	33,3	33,33	NE
LONG TERM FOLLOW-UP MONTH 24	All	1	1,5	1	100,0	33,33	NE	2	5,9	0	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 27	All	0	NE	0	NE	NE	NE	1	2,9	0	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 30	All	0	NE	0	NE	NE	NE	1	2,9	0	NE	NE	NE

[1] in study: number of subjects in the ITT (or efficacy population) excluding subjects who died or withdrew their ICF before the visit had happened; % based on the ITT (or efficacy population)
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mean_ITT_QS028SL_3Lp_16FEB2024_41944.xls
07OCT2024 18:47

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Insomnia
STUDY: GO41944
Line Plot of Mean by Visit



Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_pro_mean_ITT_QS028SL_3Lp_16FEB2024_41944.pdf
08OCT2024 21:19

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Appetite loss
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Change from Baseline (Analysis of MMRM)

EORTC QLQ-C30: Appetite loss

			Glofitamab + GemOx (N=115)					Rituximab + GemOx (N=57)					Difference between Treatments (Glofitamab + GemOx - Rituximab + GemOx)			
			N			Statistics		N			Statistics		Statistics			
Visit	Name	Level	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	LSMeans	SE (LSMeans)	95% CI (LL)	95% CI (UL)
BASELINE	All	n/a	110	110	110	NE	NE	54	54	54	NE	NE	NE	NE	NE	NE
CYCLE 2 DAY 1	All	n/a	100	100	95	-0,45	2,69	47	47	45	4,29	3,91	-4,74	4,74	-14,05	4,57
CYCLE 3 DAY 1	All	n/a	95	95	94	3,86	2,70	37	37	36	1,21	4,26	2,64	5,04	-7,25	12,54
CYCLE 5 DAY 1	All	n/a	83	83	82	8,60	2,85	24	24	23	-2,46	5,07	11,07	5,82	-0,35	22,48
CYCLE 7 DAY 1	All	n/a	77	77	74	7,91	2,96	19	19	19	-0,52	5,47	8,43	6,21	-3,77	20,63
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	n/a	92	92	72	-8,00	2,98	50	50	41	0,18	4,05	-8,18	5,03	-18,06	1,70
LONG TERM FOLLOW-UP MONTH 3	All	n/a	80	80	56	-3,99	3,29	45	45	25	-3,10	4,92	-0,88	5,91	-12,49	10,73
LONG TERM FOLLOW-UP MONTH 6	All	n/a	62	62	47	-4,44	3,52	36	36	21	-0,25	5,25	-4,18	6,32	-16,59	8,22
LONG TERM FOLLOW-UP MONTH 9	All	n/a	45	45	36	-4,39	3,91	30	30	16	-0,07	5,86	-4,33	7,05	-18,17	9,51
LONG TERM FOLLOW-UP MONTH 12	All	n/a	37	37	31	-5,94	4,16	22	22	16	-4,19	5,87	-1,75	7,19	-15,87	12,38
LONG TERM FOLLOW-UP MONTH 15	All	n/a	26	26	18	-3,31	5,25	13	13	9	15,70	7,49	-19,01	9,15	-36,97	-1,05
LONG TERM FOLLOW-UP MONTH 18	All	n/a	17	17	13	-7,57	6,08	7	7	4	-3,94	10,82	-3,63	12,41	-27,99	20,74
LONG TERM FOLLOW-UP MONTH 21	All	n/a	12	12	9	-6,41	7,21	6	6	5	-1,51	9,75	-4,90	12,13	-28,72	18,92
LONG TERM FOLLOW-UP MONTH 24	All	n/a	3	3	3	-8,08	12,24	2	2	1	18,50	21,07	-26,58	24,37	-74,42	21,26
LONG TERM FOLLOW-UP MONTH 27	All	n/a	1	1	1	-11,39	21,05	2	2	1	18,50	21,07	-29,89	29,78	-88,36	28,58
LONG TERM FOLLOW-UP MONTH 30	All	n/a	1	1	1	-11,39	21,05	0	0	0	NE	NE	NE	NE	NE	NE

[1] LSMeans of change from baseline to respective visit.
[2] Contrasts from MMRM. Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mmrm.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mmrm_ITT_str_QS028AP_2L_16FEB2024_41944.xls
17DEC2024 22:13

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Appetite loss
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Change from Baseline (Analysis of MMRM)

EORTC QLQ-C30: Appetite loss

			Glofitamab + GemOx (N=68)					Rituximab + GemOx (N=34)					Difference between Treatments (Glofitamab + GemOx - Rituximab + GemOx)			
			N			Statistics		N			Statistics		Statistics			
Visit	Name	Level	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	LSMeans	SE (LSMeans)	95% CI (LL)	95% CI (UL)
BASELINE	All	n/a	65	65	65	NE	NE	33	33	33	NE	NE	NE	NE	NE	NE
CYCLE 2 DAY 1	All	n/a	57	57	55	4,95	3,09	27	27	26	14,30	4,37	-9,35	5,21	-19,60	0,90
CYCLE 3 DAY 1	All	n/a	51	51	51	1,01	3,19	19	19	19	13,18	5,00	-12,17	5,82	-23,61	-0,73
CYCLE 5 DAY 1	All	n/a	41	41	40	6,55	3,50	11	11	11	7,79	6,35	-1,24	7,19	-15,39	12,90
CYCLE 7 DAY 1	All	n/a	40	40	38	6,03	3,56	9	9	9	12,32	6,95	-6,29	7,75	-21,54	8,96
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	n/a	57	57	40	5,06	3,52	27	27	22	5,77	4,73	-0,72	5,74	-12,01	10,58
LONG TERM FOLLOW-UP MONTH 3	All	n/a	47	47	30	3,90	3,95	24	24	10	2,54	6,67	1,36	7,67	-13,72	16,45
LONG TERM FOLLOW-UP MONTH 6	All	n/a	37	37	28	7,39	4,07	15	15	7	0,40	7,84	6,99	8,76	-10,25	24,22
LONG TERM FOLLOW-UP MONTH 9	All	n/a	25	25	23	1,97	4,41	10	10	5	3,16	9,16	-1,19	10,10	-21,06	18,68
LONG TERM FOLLOW-UP MONTH 12	All	n/a	23	23	21	-4,54	4,60	8	8	5	6,98	9,15	-11,52	10,19	-31,55	8,51
LONG TERM FOLLOW-UP MONTH 15	All	n/a	17	17	13	-3,75	5,69	6	6	4	-4,85	10,16	1,11	11,59	-21,68	23,89
LONG TERM FOLLOW-UP MONTH 18	All	n/a	10	10	8	-3,24	7,10	5	5	3	13,81	11,53	-17,05	13,50	-43,60	9,50
LONG TERM FOLLOW-UP MONTH 21	All	n/a	5	5	3	-8,23	11,39	3	3	1	20,97	19,62	-29,20	22,68	-73,79	15,39
LONG TERM FOLLOW-UP MONTH 24	All	n/a	1	1	1	-18,62	19,44	2	2	0	NE	NE	NE	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 27	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 30	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE

[1] LSMeans of change from baseline to respective visit.
[2] Contrasts from MMRM. Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mmrm.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mmrm_ITT_str_QS028AP_3Lp_16FEB2024_41944.xls
17DEC2024 22:19

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Constipation
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Change from Baseline (Analysis of MMRM)

EORTC QLQ-C30: Constipation

			Glofitamab + GemOx (N=115)					Rituximab + GemOx (N=57)					Difference between Treatments (Glofitamab + GemOx - Rituximab + GemOx)			
			N			Statistics		N			Statistics		Statistics			
Visit	Name	Level	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	LSMeans	SE (LSMeans)	95% CI (LL)	95% CI (UL)
BASELINE	All	n/a	110	110	110	NE	NE	54	54	54	NE	NE	NE	NE	NE	NE
CYCLE 2 DAY 1	All	n/a	100	100	95	1,62	2,23	47	47	45	-0,13	3,24	1,75	3,93	-5,96	9,47
CYCLE 3 DAY 1	All	n/a	95	95	94	0,02	2,24	37	37	36	0,25	3,55	-0,23	4,20	-8,47	8,01
CYCLE 5 DAY 1	All	n/a	83	83	82	-3,74	2,38	24	24	23	-6,47	4,30	2,73	4,91	-6,90	12,36
CYCLE 7 DAY 1	All	n/a	77	77	74	-1,85	2,48	19	19	19	-1,91	4,66	0,06	5,27	-10,29	10,41
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	n/a	92	92	72	-5,31	2,50	50	50	41	-5,09	3,37	-0,22	4,19	-8,45	8,01
LONG TERM FOLLOW-UP MONTH 3	All	n/a	80	80	56	-4,42	2,78	45	45	25	-3,59	4,15	-0,83	4,99	-10,63	8,97
LONG TERM FOLLOW-UP MONTH 6	All	n/a	62	62	47	-7,24	2,99	36	36	21	-3,79	4,46	-3,45	5,37	-13,99	7,08
LONG TERM FOLLOW-UP MONTH 9	All	n/a	45	45	36	-4,14	3,34	30	30	16	3,89	5,01	-8,04	6,03	-19,87	3,79
LONG TERM FOLLOW-UP MONTH 12	All	n/a	37	37	31	-4,99	3,57	22	22	16	-4,41	5,02	-0,58	6,16	-12,67	11,51
LONG TERM FOLLOW-UP MONTH 15	All	n/a	26	26	18	4,00	4,55	13	13	9	6,27	6,48	-2,27	7,92	-17,82	13,28
LONG TERM FOLLOW-UP MONTH 18	All	n/a	17	17	13	-6,03	5,30	7	7	4	-5,88	9,46	-0,15	10,84	-21,43	21,13
LONG TERM FOLLOW-UP MONTH 21	All	n/a	12	12	10	-4,95	6,00	6	6	5	-7,21	8,51	2,26	10,41	-18,18	22,69
LONG TERM FOLLOW-UP MONTH 24	All	n/a	3	3	3	-14,64	10,78	2	2	1	-8,71	18,54	-5,93	21,45	-48,04	36,18
LONG TERM FOLLOW-UP MONTH 27	All	n/a	1	1	1	-13,26	18,62	2	2	1	-8,71	18,54	-4,55	26,28	-56,15	47,05
LONG TERM FOLLOW-UP MONTH 30	All	n/a	1	1	1	-13,26	18,62	0	0	0	NE	NE	NE	NE	NE	NE

[1] LSMeans of change from baseline to respective visit.
[2] Contrasts from MMRM. Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mmrm.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mmrm_ITT_str_QS028CO_2L_16FEB2024_41944.xls
17DEC2024 21:53

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Constipation
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Change from Baseline (Analysis of MMRM)

EORTC QLQ-C30: Constipation

			Glofitamab + GemOx (N=68)					Rituximab + GemOx (N=34)					Difference between Treatments (Glofitamab + GemOx - Rituximab + GemOx)			
			N			Statistics		N			Statistics		Statistics			
Visit	Name	Level	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	LSMeans	SE (LSMeans)	95% CI (LL)	95% CI (UL)
BASELINE	All	n/a	65	65	65	NE	NE	33	33	33	NE	NE	NE	NE	NE	NE
CYCLE 2 DAY 1	All	n/a	57	57	55	3,95	3,16	27	27	26	3,52	4,47	0,43	5,31	-10,01	10,87
CYCLE 3 DAY 1	All	n/a	51	51	51	-4,32	3,26	19	19	19	2,70	5,05	-7,02	5,88	-18,58	4,53
CYCLE 5 DAY 1	All	n/a	41	41	40	1,20	3,55	11	11	11	-5,60	6,32	6,81	7,17	-7,30	20,91
CYCLE 7 DAY 1	All	n/a	40	40	38	4,28	3,61	9	9	9	3,31	6,88	0,97	7,70	-14,17	16,12
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	n/a	57	57	40	0,23	3,57	27	27	22	-0,23	4,79	0,46	5,80	-10,94	11,86
LONG TERM FOLLOW-UP MONTH 3	All	n/a	47	47	30	2,27	3,97	24	24	10	-0,14	6,64	2,40	7,64	-12,62	17,42
LONG TERM FOLLOW-UP MONTH 6	All	n/a	37	37	28	-2,54	4,08	15	15	7	-6,97	7,74	4,43	8,66	-12,61	21,47
LONG TERM FOLLOW-UP MONTH 9	All	n/a	25	25	23	-5,47	4,40	10	10	5	-2,28	9,00	-3,19	9,94	-22,74	16,36
LONG TERM FOLLOW-UP MONTH 12	All	n/a	23	23	21	-1,31	4,58	8	8	5	0,73	8,99	-2,04	10,02	-21,74	17,67
LONG TERM FOLLOW-UP MONTH 15	All	n/a	17	17	13	-1,79	5,60	6	6	4	9,71	9,96	-11,50	11,35	-33,82	10,83
LONG TERM FOLLOW-UP MONTH 18	All	n/a	10	10	8	-11,91	6,94	5	5	3	-2,19	11,23	-9,72	13,16	-35,59	16,15
LONG TERM FOLLOW-UP MONTH 21	All	n/a	5	5	3	-10,62	11,04	3	3	1	-1,85	18,99	-8,77	21,95	-51,94	34,40
LONG TERM FOLLOW-UP MONTH 24	All	n/a	1	1	1	-11,48	18,77	2	2	0	NE	NE	NE	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 27	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 30	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE

[1] LSMeans of change from baseline to respective visit.
[2] Contrasts from MMRM. Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mmrm.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mmrm_ITT_str_QS028CO_3Lp_16FEB2024_41944.xls
17DEC2024 21:59

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Diarrhoea
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Change from Baseline (Analysis of MMRM)

EORTC QLQ-C30: Diarrhoea

			Glofitamab + GemOx (N=115)					Rituximab + GemOx (N=57)					Difference between Treatments (Glofitamab + GemOx - Rituximab + GemOx)			
			N			Statistics		N			Statistics		Statistics			
Visit	Name	Level	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	LSMeans	SE (LSMeans)	95% CI (LL)	95% CI (UL)
BASELINE	All	n/a	110	110	110	NE	NE	54	54	54	NE	NE	NE	NE	NE	NE
CYCLE 2 DAY 1	All	n/a	100	100	95	-2,79	1,88	47	47	45	-2,84	2,74	0,05	3,33	-6,49	6,60
CYCLE 3 DAY 1	All	n/a	95	95	94	0,42	1,89	37	37	36	-5,27	3,02	5,69	3,57	-1,32	12,70
CYCLE 5 DAY 1	All	n/a	83	83	83	1,00	1,99	24	24	23	-6,44	3,66	7,43	4,17	-0,76	15,62
CYCLE 7 DAY 1	All	n/a	77	77	74	4,21	2,09	19	19	19	4,90	3,97	-0,69	4,49	-9,50	8,12
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	n/a	92	92	72	-5,15	2,11	50	50	41	-3,49	2,86	-1,66	3,57	-8,67	5,34
LONG TERM FOLLOW-UP MONTH 3	All	n/a	80	80	56	-5,19	2,35	45	45	25	0,21	3,53	-5,40	4,25	-13,75	2,95
LONG TERM FOLLOW-UP MONTH 6	All	n/a	62	62	47	-2,33	2,53	36	36	21	-4,51	3,80	2,18	4,57	-6,79	11,16
LONG TERM FOLLOW-UP MONTH 9	All	n/a	45	45	36	-6,14	2,85	30	30	16	-8,23	4,27	2,08	5,14	-8,02	12,18
LONG TERM FOLLOW-UP MONTH 12	All	n/a	37	37	31	-4,80	3,04	22	22	16	-9,07	4,28	4,27	5,26	-6,06	14,60
LONG TERM FOLLOW-UP MONTH 15	All	n/a	26	26	18	-2,64	3,89	13	13	9	-11,24	5,55	8,60	6,78	-4,71	21,92
LONG TERM FOLLOW-UP MONTH 18	All	n/a	17	17	13	-5,23	4,53	7	7	4	-5,36	8,11	0,13	9,30	-18,12	18,39
LONG TERM FOLLOW-UP MONTH 21	All	n/a	12	12	10	-4,56	5,13	6	6	5	-5,26	7,29	0,70	8,92	-16,82	18,21
LONG TERM FOLLOW-UP MONTH 24	All	n/a	3	3	3	-6,30	9,22	2	2	1	25,26	15,92	-31,56	18,41	-67,70	4,58
LONG TERM FOLLOW-UP MONTH 27	All	n/a	1	1	1	57,51	15,91	2	2	1	-8,07	15,92	65,58	22,50	21,40	109,76
LONG TERM FOLLOW-UP MONTH 30	All	n/a	1	1	1	-9,16	15,91	0	0	0	NE	NE	NE	NE	NE	NE

[1] LSMeans of change from baseline to respective visit.
[2] Contrasts from MMRM. Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mmrm.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mmrm_ITT_str_QS028DI_2L_16FEB2024_41944.xls
17DEC2024 21:43

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Diarrhoea
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Change from Baseline (Analysis of MMRM)

EORTC QLQ-C30: Diarrhoea

			Glofitamab + GemOx (N=68)					Rituximab + GemOx (N=34)					Difference between Treatments (Glofitamab + GemOx - Rituximab + GemOx)			
			N			Statistics		N			Statistics		Statistics			
Visit	Name	Level	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	LSMeans	SE (LSMeans)	95% CI (LL)	95% CI (UL)
BASELINE	All	n/a	65	65	65	NE	NE	33	33	33	NE	NE	NE	NE	NE	NE
CYCLE 2 DAY 1	All	n/a	57	57	54	2,20	2,33	27	27	26	2,39	3,32	-0,19	4,00	-8,06	7,68
CYCLE 3 DAY 1	All	n/a	51	51	51	0,41	2,39	19	19	19	-1,09	3,86	1,50	4,50	-7,35	10,36
CYCLE 5 DAY 1	All	n/a	41	41	40	0,17	2,67	11	11	10	-3,15	5,28	3,31	5,92	-8,32	14,95
CYCLE 7 DAY 1	All	n/a	40	40	38	6,74	2,74	9	9	9	-3,40	5,57	10,14	6,20	-2,05	22,32
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	n/a	57	57	40	2,29	2,70	27	27	22	1,37	3,61	0,92	4,44	-7,82	9,65
LONG TERM FOLLOW-UP MONTH 3	All	n/a	47	47	30	3,21	3,08	24	24	10	-4,18	5,31	7,39	6,11	-4,63	19,40
LONG TERM FOLLOW-UP MONTH 6	All	n/a	37	37	28	3,53	3,19	15	15	7	-4,45	6,33	7,98	7,06	-5,91	21,87
LONG TERM FOLLOW-UP MONTH 9	All	n/a	25	25	23	-3,17	3,50	10	10	5	-5,12	7,48	1,95	8,24	-14,25	18,14
LONG TERM FOLLOW-UP MONTH 12	All	n/a	23	23	21	-1,53	3,68	8	8	5	28,91	7,47	-30,43	8,31	-46,78	-14,08
LONG TERM FOLLOW-UP MONTH 15	All	n/a	17	17	13	-4,47	4,66	6	6	4	3,06	8,35	-7,53	9,53	-26,26	11,21
LONG TERM FOLLOW-UP MONTH 18	All	n/a	10	10	8	-4,08	5,90	5	5	3	5,35	9,61	-9,43	11,26	-31,58	12,72
LONG TERM FOLLOW-UP MONTH 21	All	n/a	5	5	3	-7,37	9,62	3	3	1	-1,04	16,61	-6,33	19,22	-44,12	31,47
LONG TERM FOLLOW-UP MONTH 24	All	n/a	1	1	1	-9,79	16,59	2	2	0	NE	NE	NE	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 27	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 30	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE

[1] LSMeans of change from baseline to respective visit.
[2] Contrasts from MMRM. Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mmrm.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mmrm_ITT_str_QS028DI_3Lp_16FEB2024_41944.xls
17DEC2024 21:50

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Dyspnoea
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Change from Baseline (Analysis of MMRM)

EORTC QLQ-C30: Dyspnoea

			Glofitamab + GemOx (N=115)					Rituximab + GemOx (N=57)					Difference between Treatments (Glofitamab + GemOx - Rituximab + GemOx)			
			N			Statistics		N			Statistics		Statistics			
Visit	Name	Level	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	LSMeans	SE (LSMeans)	95% CI (LL)	95% CI (UL)
BASELINE	All	n/a	110	110	110	NE	NE	54	54	54	NE	NE	NE	NE	NE	NE
CYCLE 2 DAY 1	All	n/a	100	100	95	0,64	2,12	47	47	45	-6,22	3,09	6,86	3,74	-0,49	14,21
CYCLE 3 DAY 1	All	n/a	95	95	93	-0,66	2,14	37	37	36	-2,19	3,36	1,53	3,99	-6,30	9,36
CYCLE 5 DAY 1	All	n/a	83	83	83	-3,19	2,24	24	24	23	-0,78	4,03	-2,41	4,61	-11,47	6,64
CYCLE 7 DAY 1	All	n/a	77	77	74	-0,43	2,34	19	19	19	-0,17	4,36	-0,26	4,94	-9,97	9,45
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	n/a	92	92	72	-3,25	2,36	50	50	41	0,85	3,20	-4,10	3,98	-11,90	3,71
LONG TERM FOLLOW-UP MONTH 3	All	n/a	80	80	56	-3,28	2,61	45	45	25	0,86	3,90	-4,14	4,70	-13,36	5,08
LONG TERM FOLLOW-UP MONTH 6	All	n/a	62	62	47	-2,07	2,80	36	36	21	1,05	4,18	-3,11	5,02	-12,98	6,75
LONG TERM FOLLOW-UP MONTH 9	All	n/a	45	45	36	0,55	3,12	30	30	16	-3,55	4,67	4,10	5,62	-6,94	15,13
LONG TERM FOLLOW-UP MONTH 12	All	n/a	37	37	31	-2,07	3,32	22	22	16	-2,26	4,68	0,19	5,74	-11,08	11,46
LONG TERM FOLLOW-UP MONTH 15	All	n/a	26	26	18	-5,61	4,21	13	13	9	7,11	6,00	-12,73	7,33	-27,12	1,66
LONG TERM FOLLOW-UP MONTH 18	All	n/a	17	17	13	-3,11	4,89	7	7	4	-8,42	8,70	5,31	9,98	-14,28	24,89
LONG TERM FOLLOW-UP MONTH 21	All	n/a	12	12	9	-10,04	5,80	6	6	5	-7,39	7,84	-2,65	9,75	-21,79	16,49
LONG TERM FOLLOW-UP MONTH 24	All	n/a	3	3	3	-13,21	9,87	2	2	1	7,35	16,99	-20,55	19,65	-59,12	18,02
LONG TERM FOLLOW-UP MONTH 27	All	n/a	1	1	1	-24,85	16,99	2	2	1	7,35	16,99	-32,20	24,03	-79,37	14,97
LONG TERM FOLLOW-UP MONTH 30	All	n/a	1	1	1	8,48	16,99	0	0	0	NE	NE	NE	NE	NE	NE

[1] LSMeans of change from baseline to respective visit.
[2] Contrasts from MMRM. Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mmrm.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mmrm_ITT_str_QS028DY_2L_16FEB2024_41944.xls
17DEC2024 21:31

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Dyspnoea
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Change from Baseline (Analysis of MMRM)

EORTC QLQ-C30: Dyspnoea

			Glofitamab + GemOx (N=68)					Rituximab + GemOx (N=34)					Difference between Treatments (Glofitamab + GemOx - Rituximab + GemOx)			
			N			Statistics		N			Statistics		Statistics			
Visit	Name	Level	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	LSMeans	SE (LSMeans)	95% CI (LL)	95% CI (UL)
BASELINE	All	n/a	65	65	65	NE	NE	33	33	33	NE	NE	NE	NE	NE	NE
CYCLE 2 DAY 1	All	n/a	57	57	55	3,60	2,86	27	27	26	2,48	4,09	1,12	4,87	-8,45	10,69
CYCLE 3 DAY 1	All	n/a	51	51	51	-0,02	2,95	19	19	19	1,60	4,62	-1,61	5,37	-12,17	8,94
CYCLE 5 DAY 1	All	n/a	41	41	40	2,03	3,23	11	11	11	1,41	5,80	0,62	6,58	-12,32	13,56
CYCLE 7 DAY 1	All	n/a	40	40	38	-0,75	3,29	9	9	9	9,35	6,33	-10,10	7,08	-24,01	3,82
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	n/a	57	57	40	3,05	3,24	27	27	22	14,05	4,40	-11,00	5,32	-21,46	-0,53
LONG TERM FOLLOW-UP MONTH 3	All	n/a	47	47	30	3,79	3,62	24	24	10	6,10	6,10	-2,30	7,01	-16,08	11,48
LONG TERM FOLLOW-UP MONTH 6	All	n/a	37	37	28	7,82	3,73	15	15	7	-1,17	7,13	8,99	7,98	-6,70	24,67
LONG TERM FOLLOW-UP MONTH 9	All	n/a	25	25	23	3,86	4,03	10	10	5	4,84	8,31	-0,98	9,17	-19,02	17,06
LONG TERM FOLLOW-UP MONTH 12	All	n/a	23	23	21	2,52	4,20	8	8	5	5,71	8,30	-3,19	9,25	-21,37	14,99
LONG TERM FOLLOW-UP MONTH 15	All	n/a	17	17	13	6,01	5,17	6	6	4	24,11	9,21	-18,10	10,50	-38,75	2,54
LONG TERM FOLLOW-UP MONTH 18	All	n/a	10	10	8	-4,10	6,42	5	5	3	33,21	10,41	-37,31	12,19	-61,28	-13,34
LONG TERM FOLLOW-UP MONTH 21	All	n/a	5	5	3	-8,19	10,25	3	3	1	-1,21	17,65	-6,98	20,40	-47,10	33,14
LONG TERM FOLLOW-UP MONTH 24	All	n/a	1	1	1	-22,47	17,47	2	2	0	NE	NE	NE	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 27	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 30	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE

[1] LSMeans of change from baseline to respective visit.
[2] Contrasts from MMRM. Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mmrm.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mmrm_ITT_str_QS028DY_3Lp_16FEB2024_41944.xls
17DEC2024 21:39

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Fatigue
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Change from Baseline (Analysis of MMRM)

EORTC QLQ-C30: Fatigue

			Glofitamab + GemOx (N=115)					Rituximab + GemOx (N=57)					Difference between Treatments (Glofitamab + GemOx - Rituximab + GemOx)			
			N			Statistics		N			Statistics		Statistics			
Visit	Name	Level	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	LSMeans	SE (LSMeans)	95% CI (LL)	95% CI (UL)
BASELINE	All	n/a	110	110	110	NE	NE	54	54	54	NE	NE	NE	NE	NE	NE
CYCLE 2 DAY 1	All	n/a	100	100	95	4,88	2,06	47	47	45	5,92	2,98	-1,05	3,62	-8,16	6,06
CYCLE 3 DAY 1	All	n/a	95	95	94	4,66	2,07	37	37	36	3,07	3,23	1,60	3,84	-5,94	9,13
CYCLE 5 DAY 1	All	n/a	83	83	83	5,00	2,17	24	24	23	-1,11	3,83	6,11	4,40	-2,53	14,75
CYCLE 7 DAY 1	All	n/a	77	77	74	3,68	2,25	19	19	19	-0,86	4,12	4,53	4,70	-4,68	13,75
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	n/a	92	92	72	-3,97	2,27	50	50	41	3,51	3,09	-7,48	3,83	-15,00	0,04
LONG TERM FOLLOW-UP MONTH 3	All	n/a	80	80	56	-1,90	2,49	45	45	25	4,88	3,72	-6,78	4,47	-15,56	2,00
LONG TERM FOLLOW-UP MONTH 6	All	n/a	62	62	47	-2,70	2,66	36	36	21	3,63	3,96	-6,33	4,77	-15,70	3,04
LONG TERM FOLLOW-UP MONTH 9	All	n/a	45	45	36	-1,83	2,95	30	30	16	4,96	4,41	-6,79	5,31	-17,21	3,63
LONG TERM FOLLOW-UP MONTH 12	All	n/a	37	37	31	-3,48	3,13	22	22	16	-3,21	4,42	-0,27	5,41	-10,90	10,35
LONG TERM FOLLOW-UP MONTH 15	All	n/a	26	26	18	0,68	3,94	13	13	9	9,38	5,61	-8,70	6,85	-22,15	4,76
LONG TERM FOLLOW-UP MONTH 18	All	n/a	17	17	13	-7,27	4,55	7	7	4	12,79	8,07	-20,06	9,27	-38,25	-1,87
LONG TERM FOLLOW-UP MONTH 21	All	n/a	12	12	9	-5,01	5,39	6	6	5	0,18	7,28	-5,19	9,06	-22,97	12,59
LONG TERM FOLLOW-UP MONTH 24	All	n/a	3	3	3	-3,28	9,12	2	2	1	14,60	15,68	-17,87	18,14	-53,48	17,73
LONG TERM FOLLOW-UP MONTH 27	All	n/a	1	1	1	-5,76	15,67	2	2	1	3,49	15,68	-9,24	22,16	-52,75	34,27
LONG TERM FOLLOW-UP MONTH 30	All	n/a	1	1	1	-5,76	15,67	0	0	0	NE	NE	NE	NE	NE	NE

[1] LSMeans of change from baseline to respective visit.
[2] Contrasts from MMRM. Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mmrm.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mmrm_ITT_str_QS028FA_2L_16FEB2024_41944.xls
17DEC2024 21:11

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Fatigue
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Change from Baseline (Analysis of MMRM)

EORTC QLQ-C30: Fatigue

			Glofitamab + GemOx (N=68)					Rituximab + GemOx (N=34)					Difference between Treatments (Glofitamab + GemOx - Rituximab + GemOx)			
			N			Statistics		N			Statistics		Statistics			
Visit	Name	Level	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	LSMeans	SE (LSMeans)	95% CI (LL)	95% CI (UL)
BASELINE	All	n/a	65	65	65	NE	NE	33	33	33	NE	NE	NE	NE	NE	NE
CYCLE 2 DAY 1	All	n/a	57	57	55	6,40	2,70	27	27	26	8,84	3,78	-2,44	4,49	-11,28	6,39
CYCLE 3 DAY 1	All	n/a	51	51	51	3,32	2,78	19	19	19	10,31	4,25	-6,99	4,95	-16,72	2,74
CYCLE 5 DAY 1	All	n/a	41	41	40	5,59	3,00	11	11	11	1,78	5,25	3,82	5,97	-7,92	15,55
CYCLE 7 DAY 1	All	n/a	40	40	38	6,72	3,05	9	9	9	8,49	5,69	-1,78	6,38	-14,33	10,78
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	n/a	57	57	40	6,22	3,02	27	27	22	11,43	4,03	-5,21	4,88	-14,81	4,39
LONG TERM FOLLOW-UP MONTH 3	All	n/a	47	47	30	6,11	3,33	24	24	10	9,47	5,50	-3,36	6,34	-15,82	9,11
LONG TERM FOLLOW-UP MONTH 6	All	n/a	37	37	28	7,54	3,41	15	15	7	2,97	6,38	4,57	7,15	-9,49	18,63
LONG TERM FOLLOW-UP MONTH 9	All	n/a	25	25	23	3,60	3,66	10	10	5	9,83	7,38	-6,22	8,16	-22,27	9,82
LONG TERM FOLLOW-UP MONTH 12	All	n/a	23	23	21	4,07	3,80	8	8	5	19,75	7,37	-15,67	8,22	-31,84	0,50
LONG TERM FOLLOW-UP MONTH 15	All	n/a	17	17	13	-4,11	4,61	6	6	4	0,35	8,14	-4,46	9,28	-22,72	13,80
LONG TERM FOLLOW-UP MONTH 18	All	n/a	10	10	8	0,44	5,67	5	5	3	26,84	9,15	-26,40	10,71	-47,46	-5,34
LONG TERM FOLLOW-UP MONTH 21	All	n/a	5	5	3	-3,34	8,94	3	3	1	19,56	15,36	-22,90	17,75	-57,80	12,01
LONG TERM FOLLOW-UP MONTH 24	All	n/a	1	1	1	4,63	15,15	2	2	0	NE	NE	NE	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 27	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 30	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE

[1] LSMeans of change from baseline to respective visit.
[2] Contrasts from MMRM. Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mmrm.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mmrm_ITT_str_QS028FA_3Lp_16FEB2024_41944.xls
17DEC2024 21:18

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Nausea and vomiting
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Change from Baseline (Analysis of MMRM)

EORTC QLQ-C30: Nausea and vomiting

			Glofitamab + GemOx (N=115)					Rituximab + GemOx (N=57)					Difference between Treatments (Glofitamab + GemOx - Rituximab + GemOx)			
			N			Statistics		N			Statistics		Statistics			
Visit	Name	Level	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	LSMeans	SE (LSMeans)	95% CI (LL)	95% CI (UL)
BASELINE	All	n/a	110	110	110	NE	NE	54	54	54	NE	NE	NE	NE	NE	NE
CYCLE 2 DAY 1	All	n/a	100	100	95	1,19	1,82	47	47	45	6,13	2,65	-4,94	3,21	-11,25	1,37
CYCLE 3 DAY 1	All	n/a	95	95	94	6,64	1,83	37	37	36	5,87	2,85	0,77	3,39	-5,88	7,43
CYCLE 5 DAY 1	All	n/a	83	83	83	5,81	1,91	24	24	23	2,84	3,36	2,97	3,87	-4,62	10,56
CYCLE 7 DAY 1	All	n/a	77	77	74	6,58	1,99	19	19	19	6,57	3,60	0,01	4,11	-8,06	8,09
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	n/a	92	92	72	-2,08	2,00	50	50	41	5,80	2,73	-7,87	3,39	-14,53	-1,22
LONG TERM FOLLOW-UP MONTH 3	All	n/a	80	80	56	0,76	2,18	45	45	25	1,99	3,26	-1,23	3,93	-8,94	6,49
LONG TERM FOLLOW-UP MONTH 6	All	n/a	62	62	47	-1,55	2,33	36	36	21	4,08	3,47	-5,62	4,18	-13,82	2,58
LONG TERM FOLLOW-UP MONTH 9	All	n/a	45	45	36	-2,38	2,57	30	30	16	2,72	3,84	-5,10	4,62	-14,18	3,98
LONG TERM FOLLOW-UP MONTH 12	All	n/a	37	37	31	-0,88	2,72	22	22	16	-0,68	3,85	-0,19	4,71	-9,45	9,06
LONG TERM FOLLOW-UP MONTH 15	All	n/a	26	26	18	0,17	3,40	13	13	9	-0,64	4,85	0,81	5,93	-10,82	12,45
LONG TERM FOLLOW-UP MONTH 18	All	n/a	17	17	13	1,95	3,92	7	7	4	-0,35	6,94	2,30	7,97	-13,34	17,95
LONG TERM FOLLOW-UP MONTH 21	All	n/a	12	12	10	-0,66	4,41	6	6	5	-3,51	6,27	2,86	7,67	-12,19	17,91
LONG TERM FOLLOW-UP MONTH 24	All	n/a	3	3	3	-1,15	7,81	2	2	1	-1,19	13,42	0,04	15,52	-30,44	30,52
LONG TERM FOLLOW-UP MONTH 27	All	n/a	1	1	1	-2,52	13,40	2	2	1	-1,19	13,42	-1,33	18,96	-38,56	35,90
LONG TERM FOLLOW-UP MONTH 30	All	n/a	1	1	1	-2,52	13,40	0	0	0	NE	NE	NE	NE	NE	NE

[1] LSMeans of change from baseline to respective visit.
[2] Contrasts from MMRM. Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mmrm.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mmrm_ITT_str_QS028NV_2L_16FEB2024_41944.xls
17DEC2024 21:21

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Nausea and vomiting
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Change from Baseline (Analysis of MMRM)

EORTC QLQ-C30: Nausea and vomiting

			Glofitamab + GemOx (N=68)					Rituximab + GemOx (N=34)					Difference between Treatments (Glofitamab + GemOx - Rituximab + GemOx)			
			N			Statistics		N			Statistics		Statistics			
Visit	Name	Level	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	LSMeans	SE (LSMeans)	95% CI (LL)	95% CI (UL)
BASELINE	All	n/a	65	65	65	NE	NE	33	33	33	NE	NE	NE	NE	NE	NE
CYCLE 2 DAY 1	All	n/a	57	57	55	1,28	2,04	27	27	26	11,05	2,90	-9,77	3,45	-16,56	-2,98
CYCLE 3 DAY 1	All	n/a	51	51	51	2,30	2,11	19	19	19	8,69	3,30	-6,38	3,84	-13,94	1,17
CYCLE 5 DAY 1	All	n/a	41	41	40	1,78	2,31	11	11	11	0,79	4,17	0,99	4,73	-8,31	10,29
CYCLE 7 DAY 1	All	n/a	40	40	38	4,99	2,35	9	9	9	6,36	4,56	-1,37	5,09	-11,38	8,65
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	n/a	57	57	40	-0,85	2,32	27	27	22	9,62	3,11	-10,47	3,79	-17,91	-3,02
LONG TERM FOLLOW-UP MONTH 3	All	n/a	47	47	30	0,21	2,60	24	24	10	5,46	4,39	-5,26	5,04	-15,17	4,66
LONG TERM FOLLOW-UP MONTH 6	All	n/a	37	37	28	0,85	2,68	15	15	7	2,80	5,14	-1,94	5,75	-13,25	9,36
LONG TERM FOLLOW-UP MONTH 9	All	n/a	25	25	23	-3,69	2,90	10	10	5	5,70	6,00	-9,39	6,62	-22,41	3,63
LONG TERM FOLLOW-UP MONTH 12	All	n/a	23	23	21	-1,53	3,02	8	8	5	5,68	5,99	-7,21	6,67	-20,34	5,91
LONG TERM FOLLOW-UP MONTH 15	All	n/a	17	17	13	0,67	3,73	6	6	4	6,15	6,65	-5,48	7,59	-20,40	9,44
LONG TERM FOLLOW-UP MONTH 18	All	n/a	10	10	8	5,56	4,65	5	5	3	2,88	7,53	2,68	8,82	-14,66	20,03
LONG TERM FOLLOW-UP MONTH 21	All	n/a	5	5	3	-0,38	7,43	3	3	1	3,80	12,80	-4,18	14,79	-33,27	24,91
LONG TERM FOLLOW-UP MONTH 24	All	n/a	1	1	1	-1,40	12,67	2	2	0	NE	NE	NE	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 27	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 30	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE

[1] LSMeans of change from baseline to respective visit.
[2] Contrasts from MMRM. Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mmrm.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mmrm_ITT_str_QS028NV_3Lp_16FEB2024_41944.xls
17DEC2024 21:28

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Pain
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Change from Baseline (Analysis of MMRM)

EORTC QLQ-C30: Pain

			Glofitamab + GemOx (N=115)					Rituximab + GemOx (N=57)					Difference between Treatments (Glofitamab + GemOx - Rituximab + GemOx)			
			N			Statistics		N			Statistics		Statistics			
Visit	Name	Level	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	LSMeans	SE (LSMeans)	95% CI (LL)	95% CI (UL)
BASELINE	All	n/a	110	110	110	NE	NE	54	54	54	NE	NE	NE	NE	NE	NE
CYCLE 2 DAY 1	All	n/a	100	100	95	-7,87	2,12	47	47	45	-7,10	3,08	-0,77	3,74	-8,11	6,57
CYCLE 3 DAY 1	All	n/a	95	95	94	-13,38	2,13	37	37	36	-6,90	3,34	-6,49	3,97	-14,27	1,30
CYCLE 5 DAY 1	All	n/a	83	83	83	-13,45	2,24	24	24	23	-8,66	3,97	-4,79	4,56	-13,73	4,15
CYCLE 7 DAY 1	All	n/a	77	77	74	-15,14	2,33	19	19	19	-10,79	4,28	-4,35	4,87	-13,91	5,20
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	n/a	92	92	72	-13,09	2,35	50	50	41	3,15	3,19	-16,24	3,96	-24,01	-8,47
LONG TERM FOLLOW-UP MONTH 3	All	n/a	80	80	56	-10,15	2,58	45	45	25	-7,22	3,85	-2,93	4,63	-12,02	6,17
LONG TERM FOLLOW-UP MONTH 6	All	n/a	62	62	47	-11,06	2,76	36	36	21	-7,07	4,11	-3,99	4,95	-13,71	5,72
LONG TERM FOLLOW-UP MONTH 9	All	n/a	45	45	36	-9,29	3,06	30	30	16	-4,11	4,58	-5,18	5,51	-15,99	5,63
LONG TERM FOLLOW-UP MONTH 12	All	n/a	37	37	31	-11,32	3,25	22	22	16	-6,37	4,58	-4,95	5,62	-15,98	6,08
LONG TERM FOLLOW-UP MONTH 15	All	n/a	26	26	18	-6,86	4,09	13	13	9	7,71	5,84	-14,57	7,13	-28,57	-0,58
LONG TERM FOLLOW-UP MONTH 18	All	n/a	17	17	13	-14,05	4,74	7	7	4	-7,50	8,41	-6,56	9,65	-25,50	12,39
LONG TERM FOLLOW-UP MONTH 21	All	n/a	12	12	10	-20,10	5,34	6	6	5	-11,44	7,59	-8,66	9,28	-26,87	9,56
LONG TERM FOLLOW-UP MONTH 24	All	n/a	3	3	3	-18,07	9,51	2	2	1	-16,20	16,36	-1,87	18,92	-39,01	35,27
LONG TERM FOLLOW-UP MONTH 27	All	n/a	1	1	1	23,78	16,35	2	2	1	0,47	16,36	23,32	23,12	-22,08	68,71
LONG TERM FOLLOW-UP MONTH 30	All	n/a	1	1	1	-26,22	16,35	0	0	0	NE	NE	NE	NE	NE	NE

[1] LSMeans of change from baseline to respective visit.
[2] Contrasts from MMRM. Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mmrm.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mmrm_ITT_str_QS028PA_2L_16FEB2024_41944.xls
17DEC2024 22:23

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Pain
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Change from Baseline (Analysis of MMRM)

EORTC QLQ-C30: Pain

			Glofitamab + GemOx (N=68)					Rituximab + GemOx (N=34)					Difference between Treatments (Glofitamab + GemOx - Rituximab + GemOx)			
			N			Statistics		N			Statistics		Statistics			
Visit	Name	Level	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	LSMeans	SE (LSMeans)	95% CI (LL)	95% CI (UL)
BASELINE	All	n/a	65	65	65	NE	NE	33	33	33	NE	NE	NE	NE	NE	NE
CYCLE 2 DAY 1	All	n/a	57	57	55	-3,48	2,91	27	27	26	2,66	4,06	-6,13	4,83	-15,63	3,37
CYCLE 3 DAY 1	All	n/a	51	51	51	-5,81	2,99	19	19	19	-1,27	4,56	-4,54	5,31	-14,98	5,89
CYCLE 5 DAY 1	All	n/a	41	41	40	-6,46	3,22	11	11	11	-2,15	5,60	-4,31	6,37	-16,84	8,22
CYCLE 7 DAY 1	All	n/a	40	40	38	-5,82	3,27	9	9	9	0,66	6,07	-6,47	6,80	-19,86	6,91
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	n/a	57	57	40	-0,78	3,24	27	27	22	1,57	4,34	-2,35	5,24	-12,66	7,96
LONG TERM FOLLOW-UP MONTH 3	All	n/a	47	47	30	-6,99	3,56	24	24	10	7,48	5,87	-14,46	6,76	-27,75	-1,17
LONG TERM FOLLOW-UP MONTH 6	All	n/a	37	37	28	2,70	3,65	15	15	7	6,58	6,78	-3,88	7,61	-18,84	11,08
LONG TERM FOLLOW-UP MONTH 9	All	n/a	25	25	23	-5,87	3,91	10	10	5	13,31	7,83	-19,17	8,67	-36,22	-2,12
LONG TERM FOLLOW-UP MONTH 12	All	n/a	23	23	21	0,33	4,06	8	8	5	15,67	7,82	-15,34	8,73	-32,52	1,84
LONG TERM FOLLOW-UP MONTH 15	All	n/a	17	17	13	-7,86	4,90	6	6	4	11,46	8,64	-19,32	9,85	-38,69	0,05
LONG TERM FOLLOW-UP MONTH 18	All	n/a	10	10	8	-5,41	6,01	5	5	3	14,46	9,69	-19,87	11,34	-42,17	2,43
LONG TERM FOLLOW-UP MONTH 21	All	n/a	5	5	3	-9,87	9,46	3	3	1	-0,79	16,23	-9,09	18,76	-45,97	27,80
LONG TERM FOLLOW-UP MONTH 24	All	n/a	1	1	1	-10,10	15,99	2	2	0	NE	NE	NE	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 27	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 30	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE

[1] LSMeans of change from baseline to respective visit.
[2] Contrasts from MMRM. Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mmrm.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mmrm_ITT_str_QS028PA_3Lp_16FEB2024_41944.xls
17DEC2024 22:29

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Insomnia
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Change from Baseline (Analysis of MMRM)

EORTC QLQ-C30: Insomnia

			Glofitamab + GemOx (N=115)					Rituximab + GemOx (N=57)					Difference between Treatments (Glofitamab + GemOx - Rituximab + GemOx)			
			N			Statistics		N			Statistics		Statistics			
Visit	Name	Level	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	LSMeans	SE (LSMeans)	95% CI (LL)	95% CI (UL)
BASELINE	All	n/a	110	110	110	NE	NE	54	54	54	NE	NE	NE	NE	NE	NE
CYCLE 2 DAY 1	All	n/a	100	100	95	1,03	2,40	47	47	45	-3,58	3,50	4,61	4,24	-3,72	12,95
CYCLE 3 DAY 1	All	n/a	95	95	94	-3,22	2,41	37	37	36	-2,93	3,82	-0,29	4,52	-9,17	8,60
CYCLE 5 DAY 1	All	n/a	83	83	83	-4,35	2,54	24	24	23	-10,06	4,62	5,72	5,27	-4,63	16,07
CYCLE 7 DAY 1	All	n/a	77	77	74	-5,03	2,66	19	19	19	-4,09	5,00	-0,93	5,66	-12,05	10,18
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	n/a	92	92	72	-5,71	2,69	50	50	41	-1,04	3,63	-4,67	4,52	-13,54	4,21
LONG TERM FOLLOW-UP MONTH 3	All	n/a	80	80	56	-6,27	2,98	45	45	25	-6,37	4,46	0,09	5,37	-10,44	10,63
LONG TERM FOLLOW-UP MONTH 6	All	n/a	62	62	47	-5,60	3,20	36	36	21	-6,21	4,78	0,61	5,76	-10,69	11,91
LONG TERM FOLLOW-UP MONTH 9	All	n/a	45	45	36	-9,30	3,58	30	30	16	2,66	5,37	-11,96	6,46	-24,64	0,72
LONG TERM FOLLOW-UP MONTH 12	All	n/a	37	37	31	-3,29	3,82	22	22	16	-6,51	5,38	3,23	6,60	-9,73	16,18
LONG TERM FOLLOW-UP MONTH 15	All	n/a	26	26	18	1,19	4,86	13	13	9	6,27	6,92	-5,08	8,46	-21,70	11,53
LONG TERM FOLLOW-UP MONTH 18	All	n/a	17	17	13	-8,19	5,65	7	7	4	20,00	10,08	-28,19	11,55	-50,87	-5,51
LONG TERM FOLLOW-UP MONTH 21	All	n/a	12	12	9	-10,45	6,72	6	6	5	-9,69	9,07	-0,76	11,29	-22,92	21,40
LONG TERM FOLLOW-UP MONTH 24	All	n/a	3	3	3	14,04	11,45	2	2	1	-38,74	19,73	52,77	22,82	7,98	97,56
LONG TERM FOLLOW-UP MONTH 27	All	n/a	1	1	1	-12,60	19,73	2	2	1	-5,40	19,73	-7,20	27,91	-61,99	47,59
LONG TERM FOLLOW-UP MONTH 30	All	n/a	1	1	1	20,73	19,73	0	0	0	NE	NE	NE	NE	NE	NE

[1] LSMeans of change from baseline to respective visit.
[2] Contrasts from MMRM. Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mmrm.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mmrm_ITT_str_QS028SL_2L_16FEB2024_41944.xls
17DEC2024 21:00

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Insomnia
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Change from Baseline (Analysis of MMRM)

EORTC QLQ-C30: Insomnia

			Glofitamab + GemOx (N=68)					Rituximab + GemOx (N=34)					Difference between Treatments (Glofitamab + GemOx - Rituximab + GemOx)			
			N			Statistics		N			Statistics		Statistics			
Visit	Name	Level	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	LSMeans	SE (LSMeans)	95% CI (LL)	95% CI (UL)
BASELINE	All	n/a	65	65	65	NE	NE	33	33	33	NE	NE	NE	NE	NE	NE
CYCLE 2 DAY 1	All	n/a	57	57	55	-1,37	3,39	27	27	26	1,99	4,74	-3,36	5,63	-14,42	7,70
CYCLE 3 DAY 1	All	n/a	51	51	51	-3,81	3,48	19	19	19	-0,02	5,27	-3,79	6,14	-15,86	8,28
CYCLE 5 DAY 1	All	n/a	41	41	40	-5,10	3,74	11	11	11	-5,95	6,42	0,86	7,31	-13,52	15,23
CYCLE 7 DAY 1	All	n/a	40	40	38	-2,40	3,79	9	9	9	-1,51	6,93	-0,89	7,79	-16,21	14,42
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	n/a	57	57	40	-1,14	3,75	27	27	22	-5,69	5,02	4,55	6,06	-7,37	16,46
LONG TERM FOLLOW-UP MONTH 3	All	n/a	47	47	30	-8,70	4,10	24	24	10	0,33	6,72	-9,03	7,74	-24,24	6,18
LONG TERM FOLLOW-UP MONTH 6	All	n/a	37	37	28	4,33	4,21	15	15	7	8,90	7,73	-4,56	8,68	-21,63	12,50
LONG TERM FOLLOW-UP MONTH 9	All	n/a	25	25	23	-4,50	4,49	10	10	5	0,24	8,90	-4,73	9,86	-24,12	14,65
LONG TERM FOLLOW-UP MONTH 12	All	n/a	23	23	21	5,59	4,65	8	8	5	2,85	8,89	2,74	9,93	-16,79	22,26
LONG TERM FOLLOW-UP MONTH 15	All	n/a	17	17	13	0,35	5,58	6	6	4	3,97	9,79	-3,63	11,17	-25,60	18,34
LONG TERM FOLLOW-UP MONTH 18	All	n/a	10	10	8	1,51	6,82	5	5	3	40,12	10,96	-38,61	12,83	-63,84	-13,38
LONG TERM FOLLOW-UP MONTH 21	All	n/a	5	5	3	-5,72	10,67	3	3	1	31,69	18,28	-37,41	21,13	-78,96	4,14
LONG TERM FOLLOW-UP MONTH 24	All	n/a	1	1	1	2,58	17,99	2	2	0	NE	NE	NE	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 27	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 30	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE

[1] LSMeans of change from baseline to respective visit.
[2] Contrasts from MMRM. Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mmrm.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mmrm_ITT_str_QS028SL_3Lp_16FEB2024_41944.xls
17DEC2024 21:07

POPULATION: ITT Population (2L)
ENDPOINT: EQ-5D-5L:EQ VAS Score, Time to Deterioration (MID=15)
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=115)												Rituximab + GemOx (N=57)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	115	100,0	37	32,2	78	67,8	4,17	1,54	8,54	NE	15,84	NE	57	100,0	22	38,6	35	61,4	1,48	0,79	6,60	15,70	5,62	NE	0,1126	0,651	0,382	1,110	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_tte_ITT_str_VASMID_2L_16FEB2024_41944.xls
13DEC2024 15:08

POPULATION: ITT Population (3L+)
ENDPOINT: EQ-5D-5L:EQ VAS Score, Time to Deterioration (MID=15)
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=68)												Rituximab + GemOx (N=34)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	68	100,0	24	35,3	44	64,7	4,30	2,60	10,48	16,16	7,00	NE	34	100,0	12	35,3	22	64,7	1,45	0,79	13,54	13,54	2,86	NE	0,2268	0,649	0,320	1,314	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_tte_ITT_str_VASMID_3Lp_16FEB2024_41944.xls
13DEC2024 15:13

POPULATION: ITT Population (2L)
ENDPOINT: EQ-5D-5L:EQ VAS Score
MODEL: --
STUDY: GO41944
Compliance/Mean

		Glofitamab + GemOx (N=115)						Rituximab + GemOx (N=57)					
		Patients				Statistics		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)
All													
BASELINE	All	112	97,4	109	97,3	70,64	18,12	56	98,2	54	96,4	70,17	18,58
CYCLE 2 DAY 1	All	102	88,7	95	93,1	71,81	18,76	48	84,2	46	95,8	70,50	17,99
CYCLE 3 DAY 1	All	97	84,3	96	99,0	74,30	16,72	37	64,9	36	97,3	74,75	18,01
CYCLE 5 DAY 1	All	84	73,0	82	97,6	74,04	14,83	24	42,1	23	95,8	75,65	20,24
CYCLE 7 DAY 1	All	78	67,8	74	94,9	74,55	15,55	19	33,3	19	100,0	73,84	20,73
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	95	82,6	73	76,8	77,44	16,64	50	87,7	41	82,0	70,56	18,54
LONG TERM FOLLOW-UP MONTH 3	All	82	71,3	54	65,9	78,02	17,69	46	80,7	25	54,3	67,12	25,07
LONG TERM FOLLOW-UP MONTH 6	All	63	54,8	46	73,0	76,00	17,20	36	63,2	21	58,3	78,33	13,26
LONG TERM FOLLOW-UP MONTH 9	All	45	39,1	36	80,0	76,50	16,90	30	52,6	16	53,3	73,50	12,81
LONG TERM FOLLOW-UP MONTH 12	All	37	32,2	30	81,1	81,70	12,79	22	38,6	16	72,7	76,63	12,64
LONG TERM FOLLOW-UP MONTH 15	All	26	22,6	17	65,4	75,06	13,81	13	22,8	9	69,2	68,89	19,81
LONG TERM FOLLOW-UP MONTH 18	All	17	14,8	13	76,5	80,00	14,14	7	12,3	4	57,1	76,25	14,36
LONG TERM FOLLOW-UP MONTH 21	All	12	10,4	9	75,0	76,11	12,44	6	10,5	5	83,3	71,00	13,42
LONG TERM FOLLOW-UP MONTH 24	All	3	2,6	3	100,0	86,67	7,64	2	3,5	1	50,0	55,00	NE
LONG TERM FOLLOW-UP MONTH 27	All	1	0,9	1	100,0	75,00	NE	2	3,5	1	50,0	65,00	NE
LONG TERM FOLLOW-UP MONTH 30	All	1	0,9	1	100,0	77,00	NE	0	NE	0	NE	NE	NE

[1] in study: number of subjects in the ITT (or efficacy population) excluding subjects who died or withdrew their ICF before the visit had happened; % based on the ITT (or efficacy population)
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mean_ITT_VAS_2L_16FEB2024_41944.xls
07OCT2024 19:45

POPULATION: ITT Population (3L+)
ENDPOINT: EQ-5D-5L:EQ VAS Score
MODEL: --
STUDY: GO41944
Compliance/Mean

		Glofitamab + GemOx (N=68)						Rituximab + GemOx (N=34)					
		Patients				Statistics		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)
All													
BASELINE	All	68	100,0	65	95,6	68,74	22,98	33	97,1	33	100,0	63,94	19,83
CYCLE 2 DAY 1	All	59	86,8	56	94,9	73,91	18,05	27	79,4	26	96,3	64,65	22,14
CYCLE 3 DAY 1	All	52	76,5	52	100,0	75,13	15,73	19	55,9	19	100,0	70,95	23,88
CYCLE 5 DAY 1	All	42	61,8	41	97,6	75,61	15,90	11	32,4	11	100,0	76,45	12,60
CYCLE 7 DAY 1	All	41	60,3	39	95,1	74,59	15,78	9	26,5	9	100,0	79,44	16,48
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	60	88,2	40	66,7	72,08	18,77	27	79,4	22	81,5	65,32	22,19
LONG TERM FOLLOW-UP MONTH 3	All	48	70,6	31	64,6	72,10	18,11	24	70,6	10	41,7	78,00	18,29
LONG TERM FOLLOW-UP MONTH 6	All	37	54,4	27	73,0	70,15	21,02	15	44,1	7	46,7	74,71	13,56
LONG TERM FOLLOW-UP MONTH 9	All	26	38,2	23	88,5	79,65	15,91	10	29,4	5	50,0	75,60	17,87
LONG TERM FOLLOW-UP MONTH 12	All	23	33,8	20	87,0	78,15	17,31	8	23,5	5	62,5	80,00	15,41
LONG TERM FOLLOW-UP MONTH 15	All	17	25,0	12	70,6	81,00	13,54	6	17,6	3	50,0	84,33	6,03
LONG TERM FOLLOW-UP MONTH 18	All	10	14,7	8	80,0	81,25	14,47	5	14,7	3	60,0	86,00	18,25
LONG TERM FOLLOW-UP MONTH 21	All	5	7,4	3	60,0	95,67	7,51	3	8,8	1	33,3	65,00	NE
LONG TERM FOLLOW-UP MONTH 24	All	1	1,5	1	100,0	85,00	NE	2	5,9	0	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 27	All	0	NE	0	NE	NE	NE	1	2,9	0	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 30	All	0	NE	0	NE	NE	NE	1	2,9	0	NE	NE	NE

[1] in study: number of subjects in the ITT (or efficacy population) excluding subjects who died or withdrew their ICF before the visit had happened; % based on the ITT (or efficacy population)
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mean_ITT_VAS_3Lp_16FEB2024_41944.xls
07OCT2024 19:49

POPULATION: ITT Population (2L)
ENDPOINT: EQ-5D-5L:EQ VAS Score
STUDY: GO41944
Line Plot of Mean by Visit



Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_pro_mean_ITT_VAS_2L_16FEB2024_41944.pdf
08OCT2024 22:29

POPULATION: ITT Population (3L+)
ENDPOINT: EQ-5D-5L:EQ VAS Score
STUDY: GO41944
Line Plot of Mean by Visit



Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_pro_mean_ITT_VAS_3Lp_16FEB2024_41944.pdf
08OCT2024 22:33

POPULATION: ITT Population (2L)
ENDPOINT: EQ-5D-5L:EQ VAS Score
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Change from Baseline (Analysis of MMRM)

EQ-5D-5L: EQ VAS Score

			Glofitamab + GemOx (N=115)					Rituximab + GemOx (N=57)					Difference between Treatments (Glofitamab + GemOx - Rituximab + GemOx)			
			N			Statistics		N			Statistics		Statistics			
Visit	Name	Level	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	LSMeans	SE (LSMeans)	95% CI (LL)	95% CI (UL)
BASELINE	All	n/a	109	109	109	NE	NE	54	54	54	NE	NE	NE	NE	NE	NE
CYCLE 2 DAY 1	All	n/a	99	99	94	-0,98	1,60	47	47	45	-1,84	2,31	0,86	2,81	-4,65	6,37
CYCLE 3 DAY 1	All	n/a	94	94	93	0,31	1,61	36	36	36	0,62	2,49	-0,31	2,97	-6,13	5,52
CYCLE 5 DAY 1	All	n/a	82	82	82	1,19	1,68	23	23	22	1,35	2,98	-0,16	3,42	-6,86	6,55
CYCLE 7 DAY 1	All	n/a	76	76	74	1,19	1,74	18	18	18	-0,09	3,20	1,28	3,64	-5,87	8,43
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	n/a	91	91	70	3,88	1,77	49	49	40	-1,89	2,40	5,76	2,98	-0,09	11,62
LONG TERM FOLLOW-UP MONTH 3	All	n/a	79	79	53	4,43	1,95	44	44	24	-4,83	2,89	9,27	3,48	2,43	16,11
LONG TERM FOLLOW-UP MONTH 6	All	n/a	61	61	45	2,14	2,07	35	35	20	0,38	3,08	1,77	3,71	-5,51	9,05
LONG TERM FOLLOW-UP MONTH 9	All	n/a	44	44	35	0,33	2,27	29	29	16	-3,69	3,35	4,02	4,05	-3,92	11,97
LONG TERM FOLLOW-UP MONTH 12	All	n/a	37	37	30	3,18	2,41	22	22	16	-0,15	3,36	3,33	4,13	-4,78	11,44
LONG TERM FOLLOW-UP MONTH 15	All	n/a	26	26	17	1,41	3,04	13	13	9	-7,55	4,23	8,96	5,21	-1,27	19,20
LONG TERM FOLLOW-UP MONTH 18	All	n/a	17	17	13	9,04	3,42	7	7	4	-0,57	6,05	9,61	6,95	-4,03	23,25
LONG TERM FOLLOW-UP MONTH 21	All	n/a	12	12	9	4,04	4,04	6	6	5	-5,26	5,46	9,31	6,79	-4,03	22,64
LONG TERM FOLLOW-UP MONTH 24	All	n/a	3	3	3	9,98	6,81	2	2	1	-8,09	11,69	18,07	13,53	-8,49	44,64
LONG TERM FOLLOW-UP MONTH 27	All	n/a	1	1	1	2,59	11,67	2	2	1	1,91	11,69	0,68	16,52	-31,76	33,11
LONG TERM FOLLOW-UP MONTH 30	All	n/a	1	1	1	4,59	11,67	0	0	0	NE	NE	NE	NE	NE	NE

[1] LSMeans of change from baseline to respective visit.
[2] Contrasts from MMRM. Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mmrm.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mmrm_ITT_str_VAS_2L_16FEB2024_41944.xls
17DEC2024 23:04

POPULATION: ITT Population (3L+)
ENDPOINT: EQ-5D-5L:EQ VAS Score
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Change from Baseline (Analysis of MMRM)

EQ-5D-5L: EQ VAS Score

			Glofitamab + GemOx (N=68)					Rituximab + GemOx (N=34)					Difference between Treatments (Glofitamab + GemOx - Rituximab + GemOx)			
			N			Statistics		N			Statistics		Statistics			
Visit	Name	Level	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	LSMeans	SE (LSMeans)	95% CI (LL)	95% CI (UL)
BASELINE	All	n/a	65	65	65	NE	NE	33	33	33	NE	NE	NE	NE	NE	NE
CYCLE 2 DAY 1	All	n/a	57	57	55	1,26	2,37	27	27	26	-4,91	3,27	6,17	3,87	-1,43	13,78
CYCLE 3 DAY 1	All	n/a	51	51	51	2,20	2,42	19	19	19	-4,25	3,56	6,44	4,15	-1,71	14,60
CYCLE 5 DAY 1	All	n/a	41	41	40	0,93	2,55	11	11	11	-6,89	4,18	7,82	4,78	-1,57	17,22
CYCLE 7 DAY 1	All	n/a	40	40	38	0,16	2,58	9	9	9	-4,59	4,46	4,75	5,04	-5,16	14,65
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	n/a	57	57	40	-1,39	2,56	27	27	22	-6,11	3,43	4,72	4,11	-3,35	12,80
LONG TERM FOLLOW-UP MONTH 3	All	n/a	47	47	30	-1,99	2,75	24	24	10	-5,30	4,35	3,31	5,02	-6,56	13,17
LONG TERM FOLLOW-UP MONTH 6	All	n/a	37	37	27	-5,99	2,83	15	15	7	-6,35	4,91	0,36	5,55	-10,56	11,27
LONG TERM FOLLOW-UP MONTH 9	All	n/a	25	25	23	2,25	2,95	10	10	5	-8,33	5,56	10,58	6,20	-1,61	22,76
LONG TERM FOLLOW-UP MONTH 12	All	n/a	23	23	20	0,70	3,08	8	8	5	-4,83	5,56	5,53	6,26	-6,78	17,83
LONG TERM FOLLOW-UP MONTH 15	All	n/a	17	17	12	0,96	3,65	6	6	3	-3,45	6,81	4,42	7,63	-10,59	19,43
LONG TERM FOLLOW-UP MONTH 18	All	n/a	10	10	8	3,88	4,24	5	5	3	-5,71	6,72	9,59	7,87	-5,89	25,07
LONG TERM FOLLOW-UP MONTH 21	All	n/a	5	5	3	7,15	6,45	3	3	1	-13,97	10,97	21,12	12,68	-3,81	46,06
LONG TERM FOLLOW-UP MONTH 24	All	n/a	1	1	1	2,90	10,73	2	2	0	NE	NE	NE	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 27	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 30	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE

[1] LSMeans of change from baseline to respective visit.
[2] Contrasts from MMRM. Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mmrm.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mmrm_ITT_str_VAS_3Lp_16FEB2024_41944.xls
17DEC2024 23:11

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Cognitive functioning, Time to Deterioration (MID=10)
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=115)											Rituximab + GemOx (N=57)											Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event					Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	115	100,0	59	51,3	56	48,7	1,51	0,95	3,02	6,97	3,61	18,96	57	100,0	24	42,1	33	57,9	1,45	0,79	4,27	9,26	2,79	NE	0,8428	1,050	0,650	1,694	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_tte_ITT_str_QSCFMID_2L_16FEB2024_41944.xls
13DEC2024 13:33

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Cognitive functioning, Time to Deterioration (MID=10)
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=68)												Rituximab + GemOx (N=34)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	68	100,0	30	44,1	38	55,9	2,79	1,45	3,32	7,79	3,32	NE	34	100,0	17	50,0	17	50,0	1,38	0,72	5,78	6,14	1,51	12,52	0,1639	0,651	0,354	1,196	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_tte_ITT_str_QSCFMID_3Lp_16FEB2024_41944.xls
13DEC2024 13:38

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Emotional functioning, Time to Deterioration (MID=10)
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=115)											Rituximab + GemOx (N=57)											Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	115	100,0	41	35,7	74	64,3	3,02	1,71	6,60	NE	7,72	NE	57	100,0	26	45,6	31	54,4	1,68	0,99	3,25	9,00	3,09	NE	0,0774	0,642	0,392	1,054	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_tte_ITT_str_QSEFMID_2L_16FEB2024_41944.xls
13DEC2024 13:17

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Emotional functioning, Time to Deterioration (MID=10)
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=68)												Rituximab + GemOx (N=34)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	68	100,0	30	44,1	38	55,9	2,60	1,41	5,16	11,63	4,70	20,11	34	100,0	18	52,9	16	47,1	0,99	0,72	2,37	2,99	1,45	12,02	0,0453	0,547	0,300	0,996	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_tte_ITT_str_QSEFMID_3Lp_16FEB2024_41944.xls
13DEC2024 13:22

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Physical functioning (revised), Time to Deterioration (MID=10)
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=115)												Rituximab + GemOx (N=57)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	115	100,0	56	48,7	59	51,3	1,35	0,82	1,68	10,15	4,17	24,21	57	100,0	28	49,1	29	50,9	1,48	0,76	6,47	9,26	4,63	11,04	0,6984	0,913	0,575	1,449	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_tte_ITT_str_QSPF2MID_2L_16FEB2024_41944.xls
13DEC2024 13:25

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Physical functioning (revised), Time to Deterioration (MID=10)
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=68)												Rituximab + GemOx (N=34)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	68	100,0	37	54,4	31	45,6	1,41	0,92	2,86	9,07	2,86	12,85	34	100,0	19	55,9	15	44,1	0,82	0,76	1,51	2,37	1,45	12,52	0,2276	0,704	0,397	1,248	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_tte_ITT_str_QSPF2MID_3Lp_16FEB2024_41944.xls
13DEC2024 13:30

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Global health status/QoL (revised), Time to Deterioration (MID=10)
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=115)												Rituximab + GemOx (N=57)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	115	100,0	59	51,3	56	48,7	1,54	1,41	2,89	4,40	3,45	15,84	57	100,0	29	50,9	28	49,1	1,68	0,92	2,89	6,60	2,76	9,86	0,5162	0,861	0,547	1,354	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_tte_ITT_str_QSQL2MID_2L_16FEB2024_41944.xls
13DEC2024 14:28

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Global health status/QoL (revised), Time to Deterioration (MID=10)
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=68)												Rituximab + GemOx (N=34)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	68	100,0	28	41,2	40	58,8	1,41	0,95	3,55	8,31	3,55	NE	34	100,0	15	44,1	19	55,9	1,41	0,82	2,92	4,24	1,45	NE	0,2411	0,681	0,357	1,299	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_tte_ITT_str_QSQL2MID_3Lp_16FEB2024_41944.xls
13DEC2024 14:34

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Role functioning (revised), Time to Deterioration (MID=10)
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=115)												Rituximab + GemOx (N=57)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	115	100,0	62	53,9	53	46,1	0,82	0,76	1,45	4,40	1,61	12,55	57	100,0	30	52,6	27	47,4	0,99	0,82	1,74	4,93	1,45	9,86	0,5156	0,861	0,549	1,351	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_tte_ITT_str_QSRF2MID_2L_16FEB2024_41944.xls
13DEC2024 13:09

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Role functioning (revised), Time to Deterioration (MID=10)
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=68)												Rituximab + GemOx (N=34)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	68	100,0	42	61,8	26	38,2	0,76	0,72	1,35	1,54	1,35	3,55	34	100,0	19	55,9	15	44,1	0,79	0,76	1,45	1,51	1,38	17,51	0,8845	1,042	0,593	1,832	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_tte_ITT_str_QSRF2MID_3Lp_16FEB2024_41944.xls
13DEC2024 13:14

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Social functioning, Time to Deterioration (MID=10)
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=115)												Rituximab + GemOx (N=57)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	115	100,0	65	56,5	50	43,5	1,08	0,82	1,45	3,06	1,58	7,59	57	100,0	32	56,1	25	43,9	0,92	0,79	1,48	2,27	1,41	8,64	0,5088	0,865	0,563	1,330	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_tte_ITT_str_QSSFMID_2L_16FEB2024_41944.xls
13DEC2024 13:00

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Social functioning, Time to Deterioration (MID=10)
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=68)												Rituximab + GemOx (N=34)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	68	100,0	27	39,7	41	60,3	1,45	1,08	2,86	11,63	2,86	NE	34	100,0	18	52,9	16	47,1	1,41	0,72	1,45	2,86	1,41	12,52	0,0677	0,564	0,303	1,050	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_tte_ITT_str_QSSFMID_3Lp_16FEB2024_41944.xls
13DEC2024 13:06

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Cognitive functioning
MODEL: --
STUDY: GO41944
Compliance/Mean

		Glofitamab + GemOx (N=115)						Rituximab + GemOx (N=57)					
		Patients				Statistics		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)
All													
BASELINE	All	112	97,4	110	98,2	84,09	20,98	56	98,2	54	96,4	79,01	20,27
CYCLE 2 DAY 1	All	102	88,7	96	94,1	82,99	20,23	48	84,2	46	95,8	81,16	20,97
CYCLE 3 DAY 1	All	97	84,3	96	99,0	84,90	18,59	37	64,9	36	97,3	81,02	18,32
CYCLE 5 DAY 1	All	84	73,0	83	98,8	85,54	17,22	24	42,1	23	95,8	86,23	15,61
CYCLE 7 DAY 1	All	78	67,8	74	94,9	83,33	17,66	19	33,3	19	100,0	79,82	22,62
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	95	82,6	74	77,9	84,91	17,70	50	87,7	41	82,0	84,15	16,22
LONG TERM FOLLOW-UP MONTH 3	All	82	71,3	56	68,3	84,52	19,55	46	80,7	25	54,3	84,00	14,01
LONG TERM FOLLOW-UP MONTH 6	All	63	54,8	47	74,6	85,11	19,11	36	63,2	21	58,3	85,71	21,27
LONG TERM FOLLOW-UP MONTH 9	All	45	39,1	36	80,0	87,04	19,56	30	52,6	16	53,3	88,54	13,22
LONG TERM FOLLOW-UP MONTH 12	All	37	32,2	31	83,8	89,78	13,39	22	38,6	16	72,7	87,50	11,39
LONG TERM FOLLOW-UP MONTH 15	All	26	22,6	18	69,2	89,81	14,16	13	22,8	9	69,2	87,04	18,22
LONG TERM FOLLOW-UP MONTH 18	All	17	14,8	13	76,5	91,03	12,94	7	12,3	4	57,1	83,33	13,61
LONG TERM FOLLOW-UP MONTH 21	All	12	10,4	10	83,3	91,67	14,16	6	10,5	5	83,3	93,33	9,13
LONG TERM FOLLOW-UP MONTH 24	All	3	2,6	3	100,0	100,00	0,00	2	3,5	1	50,0	83,33	NE
LONG TERM FOLLOW-UP MONTH 27	All	1	0,9	1	100,0	100,00	NE	2	3,5	1	50,0	66,67	NE
LONG TERM FOLLOW-UP MONTH 30	All	1	0,9	1	100,0	83,33	NE	0	NE	0	NE	NE	NE

[1] in study: number of subjects in the ITT (or efficacy population) excluding subjects who died or withdrew their ICF before the visit had happened; % based on the ITT (or efficacy population)
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mean_ITT_QS028CF_2L_16FEB2024_41944.xls
07OCT2024 18:38

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Cognitive functioning
STUDY: GO41944
Line Plot of Mean by Visit



Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_pro_mean_ITT_QS028CF_2L_16FEB2024_41944.pdf
08OCT2024 21:09

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Cognitive functioning
MODEL: --
STUDY: GO41944
Compliance/Mean

		Glofitamab + GemOx (N=68)						Rituximab + GemOx (N=34)					
		Patients				Statistics		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)
All													
BASELINE	All	68	100,0	65	95,6	82,56	20,71	33	97,1	33	100,0	83,84	16,92
CYCLE 2 DAY 1	All	59	86,8	56	94,9	85,12	18,72	27	79,4	26	96,3	82,69	19,14
CYCLE 3 DAY 1	All	52	76,5	52	100,0	89,74	13,67	19	55,9	19	100,0	83,33	18,43
CYCLE 5 DAY 1	All	42	61,8	41	97,6	84,96	19,65	11	32,4	10	90,9	91,67	14,16
CYCLE 7 DAY 1	All	41	60,3	39	95,1	83,76	19,30	9	26,5	9	100,0	94,44	11,79
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	60	88,2	41	68,3	81,71	17,00	27	79,4	22	81,5	78,79	22,53
LONG TERM FOLLOW-UP MONTH 3	All	48	70,6	31	64,6	83,87	14,58	24	70,6	10	41,7	93,33	11,65
LONG TERM FOLLOW-UP MONTH 6	All	37	54,4	28	75,7	80,95	16,17	15	44,1	7	46,7	95,24	8,13
LONG TERM FOLLOW-UP MONTH 9	All	26	38,2	23	88,5	82,61	18,45	10	29,4	5	50,0	86,67	13,94
LONG TERM FOLLOW-UP MONTH 12	All	23	33,8	21	91,3	85,71	15,17	8	23,5	5	62,5	80,00	13,94
LONG TERM FOLLOW-UP MONTH 15	All	17	25,0	13	76,5	79,49	20,59	6	17,6	4	66,7	87,50	15,96
LONG TERM FOLLOW-UP MONTH 18	All	10	14,7	8	80,0	81,25	20,77	5	14,7	3	60,0	83,33	16,67
LONG TERM FOLLOW-UP MONTH 21	All	5	7,4	3	60,0	100,00	0,00	3	8,8	1	33,3	83,33	NE
LONG TERM FOLLOW-UP MONTH 24	All	1	1,5	1	100,0	83,33	NE	2	5,9	0	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 27	All	0	NE	0	NE	NE	NE	1	2,9	0	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 30	All	0	NE	0	NE	NE	NE	1	2,9	0	NE	NE	NE

[1] in study: number of subjects in the ITT (or efficacy population) excluding subjects who died or withdrew their ICF before the visit had happened; % based on the ITT (or efficacy population)
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mean_ITT_QS028CF_3Lp_16FEB2024_41944.xls
07OCT2024 18:42

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Cognitive functioning
STUDY: GO41944
Line Plot of Mean by Visit



Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_pro_mean_ITT_QS028CF_3Lp_16FEB2024_41944.pdf
08OCT2024 21:13

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Emotional functioning
MODEL: --
STUDY: GO41944
Compliance/Mean

		Glofitamab + GemOx (N=115)						Rituximab + GemOx (N=57)					
		Patients				Statistics		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)
All													
BASELINE	All	112	97,4	110	98,2	76,52	17,46	56	98,2	54	96,4	75,93	23,33
CYCLE 2 DAY 1	All	102	88,7	96	94,1	80,15	15,73	48	84,2	46	95,8	78,44	19,45
CYCLE 3 DAY 1	All	97	84,3	96	99,0	83,71	17,42	37	64,9	36	97,3	79,86	19,04
CYCLE 5 DAY 1	All	84	73,0	83	98,8	83,13	19,30	24	42,1	23	95,8	84,06	16,46
CYCLE 7 DAY 1	All	78	67,8	74	94,9	82,09	19,39	19	33,3	19	100,0	77,19	21,84
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	95	82,6	74	77,9	82,66	19,74	50	87,7	41	82,0	75,00	23,50
LONG TERM FOLLOW-UP MONTH 3	All	82	71,3	56	68,3	83,04	20,78	46	80,7	25	54,3	78,67	24,19
LONG TERM FOLLOW-UP MONTH 6	All	63	54,8	47	74,6	83,87	21,10	36	63,2	21	58,3	82,14	23,61
LONG TERM FOLLOW-UP MONTH 9	All	45	39,1	36	80,0	84,72	18,74	30	52,6	16	53,3	85,42	16,80
LONG TERM FOLLOW-UP MONTH 12	All	37	32,2	31	83,8	86,02	15,87	22	38,6	16	72,7	88,54	14,55
LONG TERM FOLLOW-UP MONTH 15	All	26	22,6	18	69,2	86,11	13,10	13	22,8	9	69,2	90,74	11,37
LONG TERM FOLLOW-UP MONTH 18	All	17	14,8	13	76,5	87,18	10,55	7	12,3	4	57,1	93,75	12,50
LONG TERM FOLLOW-UP MONTH 21	All	12	10,4	10	83,3	93,06	8,71	6	10,5	5	83,3	90,00	13,69
LONG TERM FOLLOW-UP MONTH 24	All	3	2,6	3	100,0	80,56	33,68	2	3,5	1	50,0	100,00	NE
LONG TERM FOLLOW-UP MONTH 27	All	1	0,9	1	100,0	91,67	NE	2	3,5	1	50,0	91,67	NE
LONG TERM FOLLOW-UP MONTH 30	All	1	0,9	1	100,0	100,00	NE	0	NE	0	NE	NE	NE

[1] in study: number of subjects in the ITT (or efficacy population) excluding subjects who died or withdrew their ICF before the visit had happened; % based on the ITT (or efficacy population)
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mean_ITT_QS028EF_2L_16FEB2024_41944.xls
07OCT2024 18:28

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Emotional functioning
STUDY: GO41944
Line Plot of Mean by Visit



Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_pro_mean_ITT_QS028EF_2L_16FEB2024_41944.pdf
08OCT2024 20:57

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Emotional functioning
MODEL: --
STUDY: GO41944
Compliance/Mean

		Glofitamab + GemOx (N=68)						Rituximab + GemOx (N=34)					
		Patients				Statistics		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)
All													
BASELINE	All	68	100,0	65	95,6	80,38	19,68	33	97,1	33	100,0	79,55	19,44
CYCLE 2 DAY 1	All	59	86,8	56	94,9	82,44	18,65	27	79,4	26	96,3	75,00	21,47
CYCLE 3 DAY 1	All	52	76,5	52	100,0	85,74	13,74	19	55,9	19	100,0	79,82	23,62
CYCLE 5 DAY 1	All	42	61,8	41	97,6	83,54	16,40	11	32,4	10	90,9	85,83	21,17
CYCLE 7 DAY 1	All	41	60,3	39	95,1	82,69	18,47	9	26,5	9	100,0	84,26	22,61
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	60	88,2	41	68,3	78,66	18,92	27	79,4	22	81,5	73,86	27,37
LONG TERM FOLLOW-UP MONTH 3	All	48	70,6	31	64,6	80,65	19,65	24	70,6	10	41,7	88,33	13,72
LONG TERM FOLLOW-UP MONTH 6	All	37	54,4	28	75,7	78,57	21,92	15	44,1	7	46,7	85,71	10,45
LONG TERM FOLLOW-UP MONTH 9	All	26	38,2	23	88,5	84,78	14,14	10	29,4	5	50,0	80,00	16,24
LONG TERM FOLLOW-UP MONTH 12	All	23	33,8	21	91,3	84,92	15,51	8	23,5	5	62,5	85,00	13,69
LONG TERM FOLLOW-UP MONTH 15	All	17	25,0	13	76,5	84,62	15,90	6	17,6	4	66,7	85,42	12,50
LONG TERM FOLLOW-UP MONTH 18	All	10	14,7	8	80,0	73,96	19,13	5	14,7	3	60,0	88,89	9,62
LONG TERM FOLLOW-UP MONTH 21	All	5	7,4	3	60,0	88,89	19,24	3	8,8	1	33,3	83,33	NE
LONG TERM FOLLOW-UP MONTH 24	All	1	1,5	1	100,0	66,67	NE	2	5,9	0	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 27	All	0	NE	0	NE	NE	NE	1	2,9	0	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 30	All	0	NE	0	NE	NE	NE	1	2,9	0	NE	NE	NE

[1] in study: number of subjects in the ITT (or efficacy population) excluding subjects who died or withdrew their ICF before the visit had happened; % based on the ITT (or efficacy population)
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mean_ITT_QS028EF_3Lp_16FEB2024_41944.xls
07OCT2024 18:32

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Emotional functioning
STUDY: GO41944
Line Plot of Mean by Visit



Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_pro_mean_ITT_QS028EF_3Lp_16FEB2024_41944.pdf
08OCT2024 21:01

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Physical functioning (revised)
MODEL: --
STUDY: GO41944
Compliance/Mean

		Glofitamab + GemOx (N=115)						Rituximab + GemOx (N=57)					
		Patients				Statistics		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)
All													
BASELINE	All	112	97,4	110	98,2	76,85	19,98	56	98,2	54	96,4	76,67	19,11
CYCLE 2 DAY 1	All	102	88,7	96	94,1	74,93	20,45	48	84,2	46	95,8	74,20	19,96
CYCLE 3 DAY 1	All	97	84,3	96	99,0	78,06	16,44	37	64,9	36	97,3	76,30	18,06
CYCLE 5 DAY 1	All	84	73,0	83	98,8	75,80	18,31	24	42,1	23	95,8	77,39	22,18
CYCLE 7 DAY 1	All	78	67,8	74	94,9	77,03	17,10	19	33,3	19	100,0	79,30	18,71
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	95	82,6	74	77,9	82,52	15,12	50	87,7	41	82,0	73,33	20,49
LONG TERM FOLLOW-UP MONTH 3	All	82	71,3	56	68,3	80,74	20,03	46	80,7	25	54,3	77,60	15,97
LONG TERM FOLLOW-UP MONTH 6	All	63	54,8	47	74,6	83,55	14,30	36	63,2	21	58,3	80,32	21,24
LONG TERM FOLLOW-UP MONTH 9	All	45	39,1	36	80,0	85,00	15,56	30	52,6	16	53,3	81,67	18,30
LONG TERM FOLLOW-UP MONTH 12	All	37	32,2	31	83,8	85,16	16,03	22	38,6	16	72,7	83,75	13,10
LONG TERM FOLLOW-UP MONTH 15	All	26	22,6	18	69,2	82,59	14,31	13	22,8	9	69,2	77,04	22,64
LONG TERM FOLLOW-UP MONTH 18	All	17	14,8	13	76,5	86,03	13,19	7	12,3	4	57,1	83,33	11,55
LONG TERM FOLLOW-UP MONTH 21	All	12	10,4	10	83,3	88,67	11,35	6	10,5	5	83,3	85,33	5,58
LONG TERM FOLLOW-UP MONTH 24	All	3	2,6	3	100,0	93,33	6,67	2	3,5	1	50,0	66,67	NE
LONG TERM FOLLOW-UP MONTH 27	All	1	0,9	1	100,0	86,67	NE	2	3,5	1	50,0	60,00	NE
LONG TERM FOLLOW-UP MONTH 30	All	1	0,9	1	100,0	93,33	NE	0	NE	0	NE	NE	NE

[1] in study: number of subjects in the ITT (or efficacy population) excluding subjects who died or withdrew their ICF before the visit had happened; % based on the ITT (or efficacy population)
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mean_ITT_QS028PF2_2L_16FEB2024_41944.xls
07OCT2024 18:33

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Physical functioning (revised)
STUDY: GO41944
Line Plot of Mean by Visit



Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_pro_mean_ITT_QS028PF2_2L_16FEB2024_41944.pdf
08OCT2024 21:03

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Physical functioning (revised)
MODEL: --
STUDY: GO41944
Compliance/Mean

		Glofitamab + GemOx (N=68)						Rituximab + GemOx (N=34)					
		Patients				Statistics		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)
All													
BASELINE	All	68	100,0	65	95,6	78,05	20,23	33	97,1	33	100,0	76,57	18,34
CYCLE 2 DAY 1	All	59	86,8	56	94,9	77,14	20,77	27	79,4	26	96,3	78,21	11,86
CYCLE 3 DAY 1	All	52	76,5	52	100,0	81,41	17,38	19	55,9	19	100,0	75,70	26,11
CYCLE 5 DAY 1	All	42	61,8	41	97,6	81,30	15,93	11	32,4	11	100,0	85,45	9,34
CYCLE 7 DAY 1	All	41	60,3	39	95,1	79,15	18,55	9	26,5	9	100,0	88,15	10,42
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	60	88,2	41	68,3	74,96	24,30	27	79,4	22	81,5	71,82	18,96
LONG TERM FOLLOW-UP MONTH 3	All	48	70,6	31	64,6	75,48	22,67	24	70,6	10	41,7	85,33	12,88
LONG TERM FOLLOW-UP MONTH 6	All	37	54,4	28	75,7	79,76	21,12	15	44,1	7	46,7	83,81	11,45
LONG TERM FOLLOW-UP MONTH 9	All	26	38,2	23	88,5	83,19	17,85	10	29,4	5	50,0	66,67	21,60
LONG TERM FOLLOW-UP MONTH 12	All	23	33,8	21	91,3	79,37	16,45	8	23,5	5	62,5	84,00	10,11
LONG TERM FOLLOW-UP MONTH 15	All	17	25,0	13	76,5	87,18	10,70	6	17,6	4	66,7	80,00	12,17
LONG TERM FOLLOW-UP MONTH 18	All	10	14,7	8	80,0	80,83	17,97	5	14,7	3	60,0	64,44	10,18
LONG TERM FOLLOW-UP MONTH 21	All	5	7,4	3	60,0	95,56	7,70	3	8,8	1	33,3	73,33	NE
LONG TERM FOLLOW-UP MONTH 24	All	1	1,5	1	100,0	86,67	NE	2	5,9	0	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 27	All	0	NE	0	NE	NE	NE	1	2,9	0	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 30	All	0	NE	0	NE	NE	NE	1	2,9	0	NE	NE	NE

[1] in study: number of subjects in the ITT (or efficacy population) excluding subjects who died or withdrew their ICF before the visit had happened; % based on the ITT (or efficacy population)
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mean_ITT_QS028PF2_3Lp_16FEB2024_41944.xls
07OCT2024 18:37

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Physical functioning (revised)
STUDY: GO41944
Line Plot of Mean by Visit



Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_pro_mean_ITT_QS028PF2_3Lp_16FEB2024_41944.pdf
08OCT2024 21:07

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Global health status/QoL (revised)
MODEL: --
STUDY: GO41944
Compliance/Mean

		Glofitamab + GemOx (N=115)						Rituximab + GemOx (N=57)					
		Patients				Statistics		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)
All													
BASELINE	All	112	97,4	109	97,3	61,31	22,70	56	98,2	54	96,4	56,33	23,00
CYCLE 2 DAY 1	All	102	88,7	96	94,1	63,45	20,39	48	84,2	46	95,8	63,95	20,79
CYCLE 3 DAY 1	All	97	84,3	96	99,0	66,06	20,31	37	64,9	36	97,3	67,13	19,61
CYCLE 5 DAY 1	All	84	73,0	83	98,8	67,27	15,28	24	42,1	23	95,8	67,39	18,79
CYCLE 7 DAY 1	All	78	67,8	73	93,6	67,01	15,49	19	33,3	19	100,0	68,42	18,55
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	95	82,6	74	77,9	72,07	17,58	50	87,7	41	82,0	58,33	22,82
LONG TERM FOLLOW-UP MONTH 3	All	82	71,3	56	68,3	69,35	22,42	46	80,7	25	54,3	61,33	20,68
LONG TERM FOLLOW-UP MONTH 6	All	63	54,8	47	74,6	68,79	21,17	36	63,2	21	58,3	66,67	21,41
LONG TERM FOLLOW-UP MONTH 9	All	45	39,1	36	80,0	72,92	16,95	30	52,6	16	53,3	70,83	16,94
LONG TERM FOLLOW-UP MONTH 12	All	37	32,2	31	83,8	76,34	13,62	22	38,6	16	72,7	74,48	14,74
LONG TERM FOLLOW-UP MONTH 15	All	26	22,6	18	69,2	71,76	12,17	13	22,8	9	69,2	64,81	25,27
LONG TERM FOLLOW-UP MONTH 18	All	17	14,8	13	76,5	75,64	11,00	7	12,3	4	57,1	68,75	19,69
LONG TERM FOLLOW-UP MONTH 21	All	12	10,4	10	83,3	79,17	14,30	6	10,5	5	83,3	61,67	21,73
LONG TERM FOLLOW-UP MONTH 24	All	3	2,6	3	100,0	77,78	25,46	2	3,5	1	50,0	33,33	NE
LONG TERM FOLLOW-UP MONTH 27	All	1	0,9	1	100,0	75,00	NE	2	3,5	1	50,0	66,67	NE
LONG TERM FOLLOW-UP MONTH 30	All	1	0,9	1	100,0	66,67	NE	0	NE	0	NE	NE	NE

[1] in study: number of subjects in the ITT (or efficacy population) excluding subjects who died or withdrew their ICF before the visit had happened; % based on the ITT (or efficacy population)
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mean_ITT_QS028QL2_2L_16FEB2024_41944.xls
07OCT2024 19:16

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Global health status/QoL (revised)
STUDY: GO41944
Line Plot of Mean by Visit



Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_pro_mean_ITT_QS028QL2_2L_16FEB2024_41944.pdf
08OCT2024 21:53

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Global health status/QoL (revised)
MODEL: --
STUDY: GO41944
Compliance/Mean

		Glofitamab + GemOx (N=68)						Rituximab + GemOx (N=34)					
		Patients				Statistics		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)
All													
BASELINE	All	68	100,0	65	95,6	55,51	25,06	33	97,1	33	100,0	57,07	20,00
CYCLE 2 DAY 1	All	59	86,8	56	94,9	63,10	16,88	27	79,4	26	96,3	57,05	21,17
CYCLE 3 DAY 1	All	52	76,5	51	98,1	68,95	15,73	19	55,9	19	100,0	58,77	23,65
CYCLE 5 DAY 1	All	42	61,8	41	97,6	65,65	20,43	11	32,4	10	90,9	70,83	17,68
CYCLE 7 DAY 1	All	41	60,3	39	95,1	67,74	19,33	9	26,5	9	100,0	67,59	23,36
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	60	88,2	41	68,3	62,40	26,03	27	79,4	22	81,5	52,65	21,42
LONG TERM FOLLOW-UP MONTH 3	All	48	70,6	31	64,6	64,25	21,75	24	70,6	10	41,7	70,83	21,25
LONG TERM FOLLOW-UP MONTH 6	All	37	54,4	27	73,0	69,75	19,50	15	44,1	7	46,7	69,05	20,25
LONG TERM FOLLOW-UP MONTH 9	All	26	38,2	23	88,5	65,22	18,06	10	29,4	5	50,0	73,33	18,07
LONG TERM FOLLOW-UP MONTH 12	All	23	33,8	21	91,3	70,24	23,51	8	23,5	5	62,5	66,67	13,18
LONG TERM FOLLOW-UP MONTH 15	All	17	25,0	13	76,5	74,36	17,50	6	17,6	4	66,7	79,17	10,76
LONG TERM FOLLOW-UP MONTH 18	All	10	14,7	8	80,0	67,71	27,25	5	14,7	3	60,0	77,78	17,35
LONG TERM FOLLOW-UP MONTH 21	All	5	7,4	3	60,0	94,44	9,62	3	8,8	1	33,3	58,33	NE
LONG TERM FOLLOW-UP MONTH 24	All	1	1,5	1	100,0	83,33	NE	2	5,9	0	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 27	All	0	NE	0	NE	NE	NE	1	2,9	0	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 30	All	0	NE	0	NE	NE	NE	1	2,9	0	NE	NE	NE

[1] in study: number of subjects in the ITT (or efficacy population) excluding subjects who died or withdrew their ICF before the visit had happened; % based on the ITT (or efficacy population)
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mean_ITT_QS028QL2_3Lp_16FEB2024_41944.xls
07OCT2024 19:20

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Global health status/QoL (revised)
STUDY: GO41944
Line Plot of Mean by Visit



Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_pro_mean_ITT_QS028QL2_3Lp_16FEB2024_41944.pdf
08OCT2024 21:57

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Role functioning (revised)
MODEL: --
STUDY: GO41944
Compliance/Mean

		Glofitamab + GemOx (N=115)						Rituximab + GemOx (N=57)					
		Patients				Statistics		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)
All													
BASELINE	All	112	97,4	110	98,2	72,58	28,43	56	98,2	54	96,4	75,62	26,44
CYCLE 2 DAY 1	All	102	88,7	96	94,1	72,05	26,76	48	84,2	46	95,8	72,10	28,12
CYCLE 3 DAY 1	All	97	84,3	95	97,9	72,63	26,40	37	64,9	36	97,3	73,15	30,41
CYCLE 5 DAY 1	All	84	73,0	83	98,8	75,90	22,88	24	42,1	23	95,8	78,99	26,22
CYCLE 7 DAY 1	All	78	67,8	74	94,9	73,42	22,90	19	33,3	19	100,0	81,58	21,44
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	95	82,6	74	77,9	78,83	20,33	50	87,7	41	82,0	67,48	28,86
LONG TERM FOLLOW-UP MONTH 3	All	82	71,3	55	67,1	79,09	25,70	46	80,7	25	54,3	72,00	27,52
LONG TERM FOLLOW-UP MONTH 6	All	63	54,8	47	74,6	80,14	20,75	36	63,2	21	58,3	83,33	26,35
LONG TERM FOLLOW-UP MONTH 9	All	45	39,1	36	80,0	80,09	27,55	30	52,6	16	53,3	76,04	31,01
LONG TERM FOLLOW-UP MONTH 12	All	37	32,2	31	83,8	83,87	21,29	22	38,6	16	72,7	90,63	14,87
LONG TERM FOLLOW-UP MONTH 15	All	26	22,6	18	69,2	83,33	17,15	13	22,8	9	69,2	79,63	28,60
LONG TERM FOLLOW-UP MONTH 18	All	17	14,8	13	76,5	84,62	15,90	7	12,3	4	57,1	91,67	16,67
LONG TERM FOLLOW-UP MONTH 21	All	12	10,4	9	75,0	98,15	5,56	6	10,5	5	83,3	90,00	14,91
LONG TERM FOLLOW-UP MONTH 24	All	3	2,6	3	100,0	88,89	19,24	2	3,5	1	50,0	66,67	NE
LONG TERM FOLLOW-UP MONTH 27	All	1	0,9	1	100,0	100,00	NE	2	3,5	1	50,0	66,67	NE
LONG TERM FOLLOW-UP MONTH 30	All	1	0,9	1	100,0	100,00	NE	0	NE	0	NE	NE	NE

[1] in study: number of subjects in the ITT (or efficacy population) excluding subjects who died or withdrew their ICF before the visit had happened; % based on the ITT (or efficacy population)
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mean_ITT_QS028RF2_2L_16FEB2024_41944.xls
07OCT2024 18:23

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Role functioning (revised)
STUDY: GO41944
Line Plot of Mean by Visit



Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_pro_mean_ITT_QS028RF2_2L_16FEB2024_41944.pdf
08OCT2024 20:51

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Role functioning (revised)
MODEL: --
STUDY: GO41944
Compliance/Mean

		Glofitamab + GemOx (N=68)						Rituximab + GemOx (N=34)					
		Patients				Statistics		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)
All													
BASELINE	All	68	100,0	65	95,6	78,46	29,27	33	97,1	33	100,0	69,70	29,30
CYCLE 2 DAY 1	All	59	86,8	56	94,9	77,08	25,14	27	79,4	26	96,3	71,79	20,42
CYCLE 3 DAY 1	All	52	76,5	52	100,0	79,81	20,44	19	55,9	19	100,0	72,81	32,02
CYCLE 5 DAY 1	All	42	61,8	41	97,6	77,24	24,37	11	32,4	11	100,0	75,76	29,22
CYCLE 7 DAY 1	All	41	60,3	39	95,1	79,06	24,70	9	26,5	9	100,0	72,22	30,05
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	60	88,2	41	68,3	71,95	30,60	27	79,4	22	81,5	59,85	31,56
LONG TERM FOLLOW-UP MONTH 3	All	48	70,6	31	64,6	77,42	23,78	24	70,6	10	41,7	85,00	18,34
LONG TERM FOLLOW-UP MONTH 6	All	37	54,4	28	75,7	75,00	27,78	15	44,1	7	46,7	73,81	38,32
LONG TERM FOLLOW-UP MONTH 9	All	26	38,2	23	88,5	79,71	23,00	10	29,4	5	50,0	76,67	19,00
LONG TERM FOLLOW-UP MONTH 12	All	23	33,8	21	91,3	78,57	20,51	8	23,5	5	62,5	76,67	14,91
LONG TERM FOLLOW-UP MONTH 15	All	17	25,0	13	76,5	87,18	28,99	6	17,6	4	66,7	95,83	8,33
LONG TERM FOLLOW-UP MONTH 18	All	10	14,7	8	80,0	83,33	19,92	5	14,7	3	60,0	72,22	25,46
LONG TERM FOLLOW-UP MONTH 21	All	5	7,4	3	60,0	100,00	0,00	3	8,8	1	33,3	100,00	NE
LONG TERM FOLLOW-UP MONTH 24	All	1	1,5	1	100,0	100,00	NE	2	5,9	0	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 27	All	0	NE	0	NE	NE	NE	1	2,9	0	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 30	All	0	NE	0	NE	NE	NE	1	2,9	0	NE	NE	NE

[1] in study: number of subjects in the ITT (or efficacy population) excluding subjects who died or withdrew their ICF before the visit had happened; % based on the ITT (or efficacy population)
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mean_ITT_QS028RF2_3Lp_16FEB2024_41944.xls
07OCT2024 18:27

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Role functioning (revised)
STUDY: GO41944
Line Plot of Mean by Visit



Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_pro_mean_ITT_QS028RF2_3Lp_16FEB2024_41944.pdf
08OCT2024 20:55

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Social functioning
MODEL: --
STUDY: GO41944
Compliance/Mean

		Glofitamab + GemOx (N=115)						Rituximab + GemOx (N=57)					
		Patients				Statistics		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)
All													
BASELINE	All	112	97,4	110	98,2	73,64	25,88	56	98,2	54	96,4	74,69	23,73
CYCLE 2 DAY 1	All	102	88,7	96	94,1	71,88	26,08	48	84,2	46	95,8	66,30	26,64
CYCLE 3 DAY 1	All	97	84,3	96	99,0	71,88	26,64	37	64,9	36	97,3	69,91	25,45
CYCLE 5 DAY 1	All	84	73,0	83	98,8	72,69	25,84	24	42,1	23	95,8	80,43	21,70
CYCLE 7 DAY 1	All	78	67,8	74	94,9	73,65	22,58	19	33,3	19	100,0	80,70	22,40
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	95	82,6	74	77,9	80,41	21,96	50	87,7	41	82,0	66,67	26,61
LONG TERM FOLLOW-UP MONTH 3	All	82	71,3	56	68,3	80,95	20,70	46	80,7	25	54,3	72,00	28,35
LONG TERM FOLLOW-UP MONTH 6	All	63	54,8	47	74,6	82,27	23,67	36	63,2	21	58,3	80,95	28,03
LONG TERM FOLLOW-UP MONTH 9	All	45	39,1	36	80,0	85,19	23,16	30	52,6	16	53,3	81,25	25,00
LONG TERM FOLLOW-UP MONTH 12	All	37	32,2	31	83,8	88,71	16,88	22	38,6	16	72,7	94,79	11,74
LONG TERM FOLLOW-UP MONTH 15	All	26	22,6	18	69,2	85,19	18,86	13	22,8	9	69,2	81,48	33,79
LONG TERM FOLLOW-UP MONTH 18	All	17	14,8	13	76,5	89,74	16,01	7	12,3	4	57,1	95,83	8,33
LONG TERM FOLLOW-UP MONTH 21	All	12	10,4	10	83,3	95,00	11,25	6	10,5	5	83,3	90,00	14,91
LONG TERM FOLLOW-UP MONTH 24	All	3	2,6	3	100,0	100,00	0,00	2	3,5	1	50,0	83,33	NE
LONG TERM FOLLOW-UP MONTH 27	All	1	0,9	1	100,0	100,00	NE	2	3,5	1	50,0	66,67	NE
LONG TERM FOLLOW-UP MONTH 30	All	1	0,9	1	100,0	100,00	NE	0	NE	0	NE	NE	NE

[1] in study: number of subjects in the ITT (or efficacy population) excluding subjects who died or withdrew their ICF before the visit had happened; % based on the ITT (or efficacy population)
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mean_ITT_QS028SF_2L_16FEB2024_41944.xls
07OCT2024 18:18

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Social functioning
STUDY: GO41944
Line Plot of Mean by Visit



Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_pro_mean_ITT_QS028SF_2L_16FEB2024_41944.pdf
08OCT2024 20:44

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Social functioning
MODEL: --
STUDY: GO41944
Compliance/Mean

		Glofitamab + GemOx (N=68)						Rituximab + GemOx (N=34)					
		Patients				Statistics		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)
All													
BASELINE	All	68	100,0	65	95,6	69,49	29,98	33	97,1	33	100,0	70,20	21,55
CYCLE 2 DAY 1	All	59	86,8	56	94,9	74,40	23,56	27	79,4	26	96,3	73,08	25,42
CYCLE 3 DAY 1	All	52	76,5	52	100,0	74,68	23,68	19	55,9	19	100,0	66,67	34,25
CYCLE 5 DAY 1	All	42	61,8	41	97,6	74,80	25,85	11	32,4	10	90,9	78,33	33,38
CYCLE 7 DAY 1	All	41	60,3	39	95,1	76,07	24,42	9	26,5	9	100,0	85,19	26,93
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	60	88,2	41	68,3	73,17	29,32	27	79,4	22	81,5	72,73	30,67
LONG TERM FOLLOW-UP MONTH 3	All	48	70,6	31	64,6	76,34	23,87	24	70,6	10	41,7	78,33	27,27
LONG TERM FOLLOW-UP MONTH 6	All	37	54,4	28	75,7	75,00	23,35	15	44,1	7	46,7	71,43	40,50
LONG TERM FOLLOW-UP MONTH 9	All	26	38,2	23	88,5	77,54	21,68	10	29,4	5	50,0	83,33	16,67
LONG TERM FOLLOW-UP MONTH 12	All	23	33,8	21	91,3	77,78	14,27	8	23,5	5	62,5	80,00	18,26
LONG TERM FOLLOW-UP MONTH 15	All	17	25,0	13	76,5	74,36	22,17	6	17,6	4	66,7	91,67	16,67
LONG TERM FOLLOW-UP MONTH 18	All	10	14,7	8	80,0	79,17	17,25	5	14,7	3	60,0	94,44	9,62
LONG TERM FOLLOW-UP MONTH 21	All	5	7,4	3	60,0	94,44	9,62	3	8,8	1	33,3	100,00	NE
LONG TERM FOLLOW-UP MONTH 24	All	1	1,5	1	100,0	100,00	NE	2	5,9	0	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 27	All	0	NE	0	NE	NE	NE	1	2,9	0	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 30	All	0	NE	0	NE	NE	NE	1	2,9	0	NE	NE	NE

[1] in study: number of subjects in the ITT (or efficacy population) excluding subjects who died or withdrew their ICF before the visit had happened; % based on the ITT (or efficacy population)
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mean_ITT_QS028SF_3Lp_16FEB2024_41944.xls
07OCT2024 18:22

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Social functioning
STUDY: GO41944
Line Plot of Mean by Visit



Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_pro_mean_ITT_QS028SF_3Lp_16FEB2024_41944.pdf
08OCT2024 20:48

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Cognitive functioning
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Change from Baseline (Analysis of MMRM)

EORTC QLQ-C30: Cognitive functioning

			Glofitamab + GemOx (N=115)					Rituximab + GemOx (N=57)					Difference between Treatments (Glofitamab + GemOx - Rituximab + GemOx)			
			N			Statistics		N			Statistics		Statistics			
Visit	Name	Level	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	LSMeans	SE (LSMeans)	95% CI (LL)	95% CI (UL)
BASELINE	All	n/a	110	110	110	NE	NE	54	54	54	NE	NE	NE	NE	NE	NE
CYCLE 2 DAY 1	All	n/a	100	100	95	-1,15	1,71	47	47	45	-0,58	2,48	-0,58	3,01	-6,49	5,34
CYCLE 3 DAY 1	All	n/a	95	95	94	-0,17	1,71	37	37	36	-2,20	2,67	2,02	3,18	-4,21	8,26
CYCLE 5 DAY 1	All	n/a	83	83	83	0,38	1,79	24	24	23	3,54	3,14	-3,16	3,61	-10,25	3,94
CYCLE 7 DAY 1	All	n/a	77	77	74	-1,57	1,86	19	19	19	-3,06	3,36	1,48	3,84	-6,06	9,02
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	n/a	92	92	72	-1,67	1,87	50	50	41	1,90	2,56	-3,56	3,17	-9,80	2,67
LONG TERM FOLLOW-UP MONTH 3	All	n/a	80	80	56	-1,45	2,04	45	45	25	0,41	3,05	-1,86	3,67	-9,07	5,35
LONG TERM FOLLOW-UP MONTH 6	All	n/a	62	62	47	-0,75	2,17	36	36	21	-1,31	3,24	0,56	3,90	-7,09	8,22
LONG TERM FOLLOW-UP MONTH 9	All	n/a	45	45	36	-0,42	2,40	30	30	16	1,42	3,59	-1,84	4,32	-10,31	6,64
LONG TERM FOLLOW-UP MONTH 12	All	n/a	37	37	31	0,63	2,54	22	22	16	0,07	3,59	0,56	4,40	-8,08	9,20
LONG TERM FOLLOW-UP MONTH 15	All	n/a	26	26	18	-0,23	3,17	13	13	9	-1,83	4,52	1,61	5,53	-9,24	12,46
LONG TERM FOLLOW-UP MONTH 18	All	n/a	17	17	13	0,47	3,65	7	7	4	-8,54	6,46	9,02	7,42	-5,56	23,59
LONG TERM FOLLOW-UP MONTH 21	All	n/a	12	12	10	-0,99	4,11	6	6	5	1,55	5,84	-2,54	7,14	-16,56	11,48
LONG TERM FOLLOW-UP MONTH 24	All	n/a	3	3	3	3,36	7,26	2	2	1	4,67	12,49	-1,31	14,45	-29,69	27,06
LONG TERM FOLLOW-UP MONTH 27	All	n/a	1	1	1	5,49	12,47	2	2	1	-11,99	12,49	17,49	17,65	-17,17	52,14
LONG TERM FOLLOW-UP MONTH 30	All	n/a	1	1	1	-11,18	12,47	0	0	0	NE	NE	NE	NE	NE	NE

[1] LSMeans of change from baseline to respective visit.
[2] Contrasts from MMRM. Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mmrm.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mmrm_ITT_str_QS028CF_2L_16FEB2024_41944.xls
17DEC2024 20:50

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Cognitive functioning
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Change from Baseline (Analysis of MMRM)

EORTC QLQ-C30: Cognitive functioning

			Glofitamab + GemOx (N=68)					Rituximab + GemOx (N=34)					Difference between Treatments (Glofitamab + GemOx - Rituximab + GemOx)			
			N			Statistics		N			Statistics		Statistics			
Visit	Name	Level	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	LSMeans	SE (LSMeans)	95% CI (LL)	95% CI (UL)
BASELINE	All	n/a	65	65	65	NE	NE	33	33	33	NE	NE	NE	NE	NE	NE
CYCLE 2 DAY 1	All	n/a	57	57	55	2,00	2,37	27	27	26	-0,31	3,32	2,30	3,96	-5,48	10,09
CYCLE 3 DAY 1	All	n/a	51	51	51	6,08	2,44	19	19	19	-3,73	3,76	9,81	4,38	1,20	18,43
CYCLE 5 DAY 1	All	n/a	41	41	40	1,31	2,65	11	11	10	1,44	4,85	-0,13	5,47	-10,89	10,63
CYCLE 7 DAY 1	All	n/a	40	40	38	0,18	2,69	9	9	9	2,72	5,08	-2,54	5,69	-13,72	8,65
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	n/a	57	57	40	-0,95	2,66	27	27	22	-5,71	3,56	4,76	4,32	-3,73	13,25
LONG TERM FOLLOW-UP MONTH 3	All	n/a	47	47	30	1,31	2,94	24	24	10	-1,26	4,91	2,57	5,65	-8,53	13,67
LONG TERM FOLLOW-UP MONTH 6	All	n/a	37	37	28	-1,11	3,02	15	15	7	1,26	5,70	-2,38	6,38	-14,93	10,18
LONG TERM FOLLOW-UP MONTH 9	All	n/a	25	25	23	-0,45	3,25	10	10	5	-7,31	6,60	6,86	7,30	-7,49	21,21
LONG TERM FOLLOW-UP MONTH 12	All	n/a	23	23	21	4,43	3,38	8	8	5	-13,54	6,59	17,97	7,35	3,51	32,43
LONG TERM FOLLOW-UP MONTH 15	All	n/a	17	17	13	-3,93	4,11	6	6	4	-5,47	7,29	1,54	8,31	-14,81	17,88
LONG TERM FOLLOW-UP MONTH 18	All	n/a	10	10	8	2,33	5,07	5	5	3	-11,15	8,20	13,48	9,60	-5,40	32,37
LONG TERM FOLLOW-UP MONTH 21	All	n/a	5	5	3	14,21	8,03	3	3	1	-12,47	13,81	26,68	15,95	-4,70	58,05
LONG TERM FOLLOW-UP MONTH 24	All	n/a	1	1	1	2,67	13,63	2	2	0	NE	NE	NE	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 27	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 30	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE

[1] LSMeans of change from baseline to respective visit.
[2] Contrasts from MMRM. Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mmrm.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mmrm_ITT_str_QS028CF_3Lp_16FEB2024_41944.xls
17DEC2024 20:57

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Emotional functioning
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Change from Baseline (Analysis of MMRM)

EORTC QLQ-C30: Emotional functioning

			Glofitamab + GemOx (N=115)					Rituximab + GemOx (N=57)					Difference between Treatments (Glofitamab + GemOx - Rituximab + GemOx)			
			N			Statistics		N			Statistics		Statistics			
Visit	Name	Level	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	LSMeans	SE (LSMeans)	95% CI (LL)	95% CI (UL)
BASELINE	All	n/a	110	110	110	NE	NE	54	54	54	NE	NE	NE	NE	NE	NE
CYCLE 2 DAY 1	All	n/a	100	100	95	2,95	1,68	47	47	45	2,00	2,44	0,95	2,96	-4,86	6,76
CYCLE 3 DAY 1	All	n/a	95	95	94	6,19	1,69	37	37	36	1,89	2,64	4,30	3,14	-1,86	10,46
CYCLE 5 DAY 1	All	n/a	83	83	83	5,82	1,77	24	24	23	4,87	3,14	0,95	3,60	-6,12	8,03
CYCLE 7 DAY 1	All	n/a	77	77	74	4,61	1,84	19	19	19	-2,16	3,38	6,76	3,85	-0,79	14,32
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	n/a	92	92	72	5,16	1,86	50	50	41	-0,81	2,52	5,97	3,13	-0,18	12,12
LONG TERM FOLLOW-UP MONTH 3	All	n/a	80	80	56	5,12	2,04	45	45	25	-0,13	3,04	5,25	3,66	-1,94	12,45
LONG TERM FOLLOW-UP MONTH 6	All	n/a	62	62	47	6,03	2,18	36	36	21	0,06	3,25	5,97	3,91	-1,71	13,65
LONG TERM FOLLOW-UP MONTH 9	All	n/a	45	45	36	6,74	2,42	30	30	16	2,96	3,62	3,78	4,35	-4,76	12,32
LONG TERM FOLLOW-UP MONTH 12	All	n/a	37	37	31	5,66	2,57	22	22	16	6,48	3,62	-0,83	4,44	-9,54	7,89
LONG TERM FOLLOW-UP MONTH 15	All	n/a	26	26	18	6,21	3,23	13	13	9	5,70	4,61	0,51	5,63	-10,53	11,56
LONG TERM FOLLOW-UP MONTH 18	All	n/a	17	17	13	7,54	3,74	7	7	4	13,77	6,63	-6,23	7,61	-21,18	8,72
LONG TERM FOLLOW-UP MONTH 21	All	n/a	12	12	10	12,11	4,21	6	6	5	8,93	5,98	3,18	7,32	-11,19	17,55
LONG TERM FOLLOW-UP MONTH 24	All	n/a	3	3	3	6,16	7,50	2	2	1	24,49	12,89	-18,34	14,91	-47,61	10,94
LONG TERM FOLLOW-UP MONTH 27	All	n/a	1	1	1	11,17	12,88	2	2	1	16,16	12,89	-4,99	18,23	-40,77	30,80
LONG TERM FOLLOW-UP MONTH 30	All	n/a	1	1	1	19,51	12,88	0	0	0	NE	NE	NE	NE	NE	NE

[1] LSMeans of change from baseline to respective visit.
[2] Contrasts from MMRM. Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mmrm.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mmrm_ITT_str_QS028EF_2L_16FEB2024_41944.xls
17DEC2024 20:31

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Emotional functioning
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Change from Baseline (Analysis of MMRM)

EORTC QLQ-C30: Emotional functioning

			Glofitamab + GemOx (N=68)					Rituximab + GemOx (N=34)					Difference between Treatments (Glofitamab + GemOx - Rituximab + GemOx)			
			N			Statistics		N			Statistics		Statistics			
Visit	Name	Level	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	LSMeans	SE (LSMeans)	95% CI (LL)	95% CI (UL)
BASELINE	All	n/a	65	65	65	NE	NE	33	33	33	NE	NE	NE	NE	NE	NE
CYCLE 2 DAY 1	All	n/a	57	57	55	1,27	2,34	27	27	26	-4,27	3,26	5,54	3,87	-2,07	13,14
CYCLE 3 DAY 1	All	n/a	51	51	51	3,83	2,40	19	19	19	-4,05	3,66	7,88	4,25	-0,49	16,24
CYCLE 5 DAY 1	All	n/a	41	41	40	0,05	2,59	11	11	10	-2,40	4,66	2,44	5,26	-7,90	12,78
CYCLE 7 DAY 1	All	n/a	40	40	38	-1,09	2,63	9	9	9	-3,54	4,86	2,46	5,45	-8,26	13,18
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	n/a	57	57	40	-3,06	2,60	27	27	22	-6,16	3,47	3,10	4,20	-5,16	11,35
LONG TERM FOLLOW-UP MONTH 3	All	n/a	47	47	30	-1,90	2,86	24	24	10	-4,26	4,70	2,36	5,41	-8,29	13,01
LONG TERM FOLLOW-UP MONTH 6	All	n/a	37	37	28	-4,57	2,93	15	15	7	-6,42	5,44	1,85	6,10	-10,14	13,84
LONG TERM FOLLOW-UP MONTH 9	All	n/a	25	25	23	1,27	3,14	10	10	5	-11,93	6,28	13,19	6,95	-0,47	26,86
LONG TERM FOLLOW-UP MONTH 12	All	n/a	23	23	21	0,57	3,25	8	8	5	-5,50	6,27	6,07	7,00	-7,70	19,83
LONG TERM FOLLOW-UP MONTH 15	All	n/a	17	17	13	-0,41	3,93	6	6	4	-4,39	6,92	3,97	7,89	-11,54	19,49
LONG TERM FOLLOW-UP MONTH 18	All	n/a	10	10	8	-9,19	4,82	5	5	3	-4,89	7,76	-4,30	9,09	-22,17	13,57
LONG TERM FOLLOW-UP MONTH 21	All	n/a	5	5	3	0,41	7,58	3	3	1	-9,93	13,00	10,34	15,03	-19,21	39,90
LONG TERM FOLLOW-UP MONTH 24	All	n/a	1	1	1	-7,66	12,81	2	2	0	NE	NE	NE	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 27	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 30	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE

[1] LSMeans of change from baseline to respective visit.
[2] Contrasts from MMRM. Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mmrm.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mmrm_ITT_str_QS028EF_3Lp_16FEB2024_41944.xls
17DEC2024 20:37

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Physical functioning (revised)
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Change from Baseline (Analysis of MMRM)

EORTC QLQ-C30: Physical functioning (revised)

			Glofitamab + GemOx (N=115)					Rituximab + GemOx (N=57)					Difference between Treatments (Glofitamab + GemOx - Rituximab + GemOx)			
			N			Statistics		N			Statistics		Statistics			
Visit	Name	Level	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	LSMeans	SE (LSMeans)	95% CI (LL)	95% CI (UL)
BASELINE	All	n/a	110	110	110	NE	NE	54	54	54	NE	NE	NE	NE	NE	NE
CYCLE 2 DAY 1	All	n/a	100	100	95	-3,69	1,63	47	47	45	-3,26	2,35	-0,43	2,85	-6,03	5,17
CYCLE 3 DAY 1	All	n/a	95	95	94	-1,95	1,63	37	37	36	-2,64	2,52	0,68	3,00	-5,20	6,57
CYCLE 5 DAY 1	All	n/a	83	83	83	-2,96	1,70	24	24	23	-3,23	2,92	0,27	3,37	-6,35	6,88
CYCLE 7 DAY 1	All	n/a	77	77	74	-2,10	1,75	19	19	19	-1,93	3,11	-0,17	3,56	-7,16	6,83
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	n/a	92	92	72	2,62	1,77	50	50	41	-5,19	2,42	7,81	2,99	1,94	13,69
LONG TERM FOLLOW-UP MONTH 3	All	n/a	80	80	56	0,28	1,91	45	45	25	-4,00	2,84	4,28	3,42	-2,43	10,99
LONG TERM FOLLOW-UP MONTH 6	All	n/a	62	62	47	2,25	2,02	36	36	21	-5,23	3,00	7,48	3,62	0,39	14,58
LONG TERM FOLLOW-UP MONTH 9	All	n/a	45	45	36	1,67	2,21	30	30	16	-2,70	3,30	4,37	3,97	-3,43	12,17
LONG TERM FOLLOW-UP MONTH 12	All	n/a	37	37	31	-0,48	2,34	22	22	16	-1,79	3,30	1,31	4,05	-6,64	9,25
LONG TERM FOLLOW-UP MONTH 15	All	n/a	26	26	18	-2,13	2,88	13	13	9	-8,34	4,12	6,21	5,03	-3,66	16,08
LONG TERM FOLLOW-UP MONTH 18	All	n/a	17	17	13	0,62	3,31	7	7	4	-3,55	5,82	4,17	6,69	-8,97	17,31
LONG TERM FOLLOW-UP MONTH 21	All	n/a	12	12	10	3,40	3,71	6	6	5	-0,86	5,27	4,26	6,44	-8,39	16,91
LONG TERM FOLLOW-UP MONTH 24	All	n/a	3	3	3	6,77	6,50	2	2	1	-12,17	11,16	18,95	12,92	-6,41	44,31
LONG TERM FOLLOW-UP MONTH 27	All	n/a	1	1	1	0,37	11,13	2	2	1	-18,84	11,16	19,21	15,76	-11,73	50,15
LONG TERM FOLLOW-UP MONTH 30	All	n/a	1	1	1	7,04	11,13	0	0	0	NE	NE	NE	NE	NE	NE

[1] LSMeans of change from baseline to respective visit.
[2] Contrasts from MMRM. Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mmrm.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mmrm_ITT_str_QS028PF2_2L_16FEB2024_41944.xls
17DEC2024 20:40

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Physical functioning (revised)
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Change from Baseline (Analysis of MMRM)

EORTC QLQ-C30: Physical functioning (revised)

			Glofitamab + GemOx (N=68)					Rituximab + GemOx (N=34)					Difference between Treatments (Glofitamab + GemOx - Rituximab + GemOx)			
			N			Statistics		N			Statistics		Statistics			
Visit	Name	Level	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	LSMeans	SE (LSMeans)	95% CI (LL)	95% CI (UL)
BASELINE	All	n/a	65	65	65	NE	NE	33	33	33	NE	NE	NE	NE	NE	NE
CYCLE 2 DAY 1	All	n/a	57	57	55	-4,52	2,46	27	27	26	-0,82	3,39	-3,71	4,02	-11,62	4,20
CYCLE 3 DAY 1	All	n/a	51	51	51	-0,84	2,52	19	19	19	-7,21	3,74	6,36	4,36	-2,21	14,94
CYCLE 5 DAY 1	All	n/a	41	41	40	-2,16	2,68	11	11	11	-4,07	4,46	1,91	5,10	-8,11	11,94
CYCLE 7 DAY 1	All	n/a	40	40	38	-4,06	2,71	9	9	9	-2,60	4,79	-1,46	5,40	-12,08	9,16
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	n/a	57	57	40	-5,04	2,69	27	27	22	-9,34	3,58	4,30	4,31	-4,17	12,77
LONG TERM FOLLOW-UP MONTH 3	All	n/a	47	47	30	-6,16	2,91	24	24	10	-6,86	4,66	0,70	5,37	-9,87	11,27
LONG TERM FOLLOW-UP MONTH 6	All	n/a	37	37	28	-4,89	2,97	15	15	7	-7,73	5,30	2,84	5,97	-8,90	14,59
LONG TERM FOLLOW-UP MONTH 9	All	n/a	25	25	23	-2,64	3,15	10	10	5	-28,03	6,05	25,39	6,73	12,16	38,63
LONG TERM FOLLOW-UP MONTH 12	All	n/a	23	23	21	-6,53	3,24	8	8	5	-9,99	6,05	3,46	6,77	-9,86	16,79
LONG TERM FOLLOW-UP MONTH 15	All	n/a	17	17	13	-0,01	3,83	6	6	4	-14,58	6,63	14,56	7,58	-0,34	29,46
LONG TERM FOLLOW-UP MONTH 18	All	n/a	10	10	8	-4,36	4,63	5	5	3	-26,37	7,38	22,01	8,64	5,02	39,00
LONG TERM FOLLOW-UP MONTH 21	All	n/a	5	5	3	1,35	7,13	3	3	1	-18,32	12,17	19,67	14,06	-7,99	47,33
LONG TERM FOLLOW-UP MONTH 24	All	n/a	1	1	1	-1,18	11,94	2	2	0	NE	NE	NE	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 27	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 30	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE

[1] LSMeans of change from baseline to respective visit.
[2] Contrasts from MMRM. Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mmrm.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mmrm_ITT_str_QS028PF2_3Lp_16FEB2024_41944.xls
17DEC2024 20:47

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Global health status/QoL (revised)
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Change from Baseline (Analysis of MMRM)

EORTC QLQ-C30: Global health status/QoL (revised)

			Glofitamab + GemOx (N=115)					Rituximab + GemOx (N=57)					Difference between Treatments (Glofitamab + GemOx - Rituximab + GemOx)			
			N			Statistics		N			Statistics		Statistics			
Visit	Name	Level	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	LSMeans	SE (LSMeans)	95% CI (LL)	95% CI (UL)
BASELINE	All	n/a	109	109	109	NE	NE	54	54	54	NE	NE	NE	NE	NE	NE
CYCLE 2 DAY 1	All	n/a	99	99	94	1,58	1,81	47	47	45	2,96	2,62	-1,38	3,19	-7,64	4,88
CYCLE 3 DAY 1	All	n/a	94	94	93	2,85	1,82	37	37	36	4,46	2,89	-1,61	3,42	-8,32	5,10
CYCLE 5 DAY 1	All	n/a	82	82	82	4,69	1,93	24	24	23	4,33	3,53	0,36	4,02	-7,53	8,26
CYCLE 7 DAY 1	All	n/a	76	76	72	4,27	2,04	19	19	19	4,82	3,84	-0,55	4,34	-9,08	7,97
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	n/a	91	91	71	9,79	2,05	50	50	41	-2,60	2,73	12,39	3,41	5,68	19,09
LONG TERM FOLLOW-UP MONTH 3	All	n/a	79	79	55	5,35	2,29	45	45	25	-0,38	3,40	5,73	4,10	-2,32	13,77
LONG TERM FOLLOW-UP MONTH 6	All	n/a	61	61	46	5,38	2,48	36	36	21	0,74	3,66	4,64	4,42	-4,04	13,32
LONG TERM FOLLOW-UP MONTH 9	All	n/a	44	44	35	7,00	2,79	30	30	16	4,67	4,14	2,33	4,99	-7,47	12,13
LONG TERM FOLLOW-UP MONTH 12	All	n/a	36	36	31	10,76	2,95	22	22	16	8,60	4,14	2,16	5,09	-7,83	12,16
LONG TERM FOLLOW-UP MONTH 15	All	n/a	25	25	17	5,87	3,90	13	13	9	0,71	5,39	5,16	6,65	-7,90	18,22
LONG TERM FOLLOW-UP MONTH 18	All	n/a	16	16	12	12,23	4,60	7	7	4	4,58	7,92	7,65	9,15	-10,32	25,62
LONG TERM FOLLOW-UP MONTH 21	All	n/a	11	11	9	14,19	5,28	6	6	5	-2,54	7,11	16,73	8,86	-0,65	34,12
LONG TERM FOLLOW-UP MONTH 24	All	n/a	3	3	3	11,85	9,04	2	2	1	-22,20	15,58	34,05	18,01	-1,31	69,41
LONG TERM FOLLOW-UP MONTH 27	All	n/a	1	1	1	16,52	15,60	2	2	1	11,13	15,58	5,38	22,04	-37,90	48,66
LONG TERM FOLLOW-UP MONTH 30	All	n/a	1	1	1	8,18	15,60	0	0	0	NE	NE	NE	NE	NE	NE

[1] LSMeans of change from baseline to respective visit.
[2] Contrasts from MMRM. Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mmrm.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mmrm_ITT_str_QS028QL2_2L_16FEB2024_41944.xls
17DEC2024 22:03

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Global health status/QoL (revised)
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Change from Baseline (Analysis of MMRM)

EORTC QLQ-C30: Global health status/QoL (revised)

			Glofitamab + GemOx (N=68)					Rituximab + GemOx (N=34)					Difference between Treatments (Glofitamab + GemOx - Rituximab + GemOx)			
			N			Statistics		N			Statistics		Statistics			
Visit	Name	Level	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	LSMeans	SE (LSMeans)	95% CI (LL)	95% CI (UL)
BASELINE	All	n/a	65	65	65	NE	NE	33	33	33	NE	NE	NE	NE	NE	NE
CYCLE 2 DAY 1	All	n/a	57	57	55	0,98	2,70	27	27	26	-4,33	3,76	5,31	4,47	-3,47	14,10
CYCLE 3 DAY 1	All	n/a	51	51	50	6,09	2,79	19	19	19	-7,96	4,24	14,05	4,95	4,32	23,77
CYCLE 5 DAY 1	All	n/a	41	41	40	2,05	3,00	11	11	10	-3,99	5,46	6,04	6,16	-6,08	18,15
CYCLE 7 DAY 1	All	n/a	40	40	38	4,97	3,05	9	9	9	-8,22	5,71	13,19	6,40	0,61	25,78
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	n/a	57	57	40	0,28	3,01	27	27	22	-10,38	4,02	10,66	4,87	1,09	20,23
LONG TERM FOLLOW-UP MONTH 3	All	n/a	47	47	30	0,89	3,33	24	24	10	-1,83	5,52	2,71	6,35	-9,77	15,20
LONG TERM FOLLOW-UP MONTH 6	All	n/a	37	37	27	4,08	3,46	15	15	7	-2,93	6,40	7,00	7,20	-7,15	21,16
LONG TERM FOLLOW-UP MONTH 9	All	n/a	25	25	23	-0,22	3,67	10	10	5	-1,17	7,42	0,96	8,20	-15,18	17,09
LONG TERM FOLLOW-UP MONTH 12	All	n/a	23	23	21	4,27	3,81	8	8	5	-7,59	7,41	11,86	8,27	-4,40	28,11
LONG TERM FOLLOW-UP MONTH 15	All	n/a	17	17	13	5,64	4,63	6	6	4	3,87	8,19	1,76	9,34	-16,61	20,14
LONG TERM FOLLOW-UP MONTH 18	All	n/a	10	10	8	0,85	5,71	5	5	3	-3,06	9,22	3,91	10,79	-17,32	25,13
LONG TERM FOLLOW-UP MONTH 21	All	n/a	5	5	3	13,97	9,03	3	3	1	-11,78	15,51	25,75	17,92	-9,50	61,00
LONG TERM FOLLOW-UP MONTH 24	All	n/a	1	1	1	17,55	15,31	2	2	0	NE	NE	NE	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 27	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 30	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE

[1] LSMeans of change from baseline to respective visit.
[2] Contrasts from MMRM. Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mmrm.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mmrm_ITT_str_QS028QL2_3Lp_16FEB2024_41944.xls
17DEC2024 22:10

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Role functioning (revised)
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Change from Baseline (Analysis of MMRM)

EORTC QLQ-C30: Role functioning (revised)

			Glofitamab + GemOx (N=115)					Rituximab + GemOx (N=57)					Difference between Treatments (Glofitamab + GemOx - Rituximab + GemOx)			
			N			Statistics		N			Statistics		Statistics			
Visit	Name	Level	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	LSMeans	SE (LSMeans)	95% CI (LL)	95% CI (UL)
BASELINE	All	n/a	110	110	110	NE	NE	54	54	54	NE	NE	NE	NE	NE	NE
CYCLE 2 DAY 1	All	n/a	100	100	95	-3,57	2,35	47	47	45	-2,97	3,40	-0,61	4,13	-8,72	7,51
CYCLE 3 DAY 1	All	n/a	95	95	93	-4,74	2,37	37	37	36	-5,08	3,68	0,34	4,38	-8,26	8,94
CYCLE 5 DAY 1	All	n/a	83	83	83	0,80	2,48	24	24	23	-0,48	4,36	1,28	5,01	-8,55	11,11
CYCLE 7 DAY 1	All	n/a	77	77	74	-2,07	2,57	19	19	19	2,48	4,69	-4,55	5,34	-15,03	5,94
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	n/a	92	92	72	2,47	2,59	50	50	41	-8,35	3,52	10,82	4,37	2,24	19,40
LONG TERM FOLLOW-UP MONTH 3	All	n/a	80	80	55	2,69	2,86	45	45	25	-7,43	4,23	10,13	5,10	0,11	20,14
LONG TERM FOLLOW-UP MONTH 6	All	n/a	62	62	47	2,20	3,03	36	36	21	-2,02	4,51	4,22	5,43	-6,44	14,88
LONG TERM FOLLOW-UP MONTH 9	All	n/a	45	45	36	0,21	3,35	30	30	16	-6,39	5,01	6,60	6,03	-5,23	18,43
LONG TERM FOLLOW-UP MONTH 12	All	n/a	37	37	31	2,83	3,56	22	22	16	3,55	5,01	-0,72	6,15	-12,79	11,35
LONG TERM FOLLOW-UP MONTH 15	All	n/a	26	26	18	0,49	4,46	13	13	9	-7,66	6,36	8,15	7,77	-7,10	23,40
LONG TERM FOLLOW-UP MONTH 18	All	n/a	17	17	13	0,44	5,15	7	7	4	0,82	9,14	-0,38	10,49	-20,97	20,21
LONG TERM FOLLOW-UP MONTH 21	All	n/a	12	12	9	9,42	6,10	6	6	5	-2,64	8,25	12,06	10,25	-8,07	32,20
LONG TERM FOLLOW-UP MONTH 24	All	n/a	3	3	3	-2,92	10,31	2	2	1	-1,93	17,72	-0,99	20,50	-41,24	39,26
LONG TERM FOLLOW-UP MONTH 27	All	n/a	1	1	1	13,67	17,71	2	2	1	-1,93	17,72	15,60	25,05	-33,58	64,79
LONG TERM FOLLOW-UP MONTH 30	All	n/a	1	1	1	13,67	17,71	0	0	0	NE	NE	NE	NE	NE	NE

[1] LSMeans of change from baseline to respective visit.
[2] Contrasts from MMRM. Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mmrm.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mmrm_ITT_str_QS028RF2_2L_16FEB2024_41944.xls
17DEC2024 20:19

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Role functioning (revised)
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Change from Baseline (Analysis of MMRM)

EORTC QLQ-C30: Role functioning (revised)

			Glofitamab + GemOx (N=68)					Rituximab + GemOx (N=34)					Difference between Treatments (Glofitamab + GemOx - Rituximab + GemOx)			
			N			Statistics		N			Statistics		Statistics			
Visit	Name	Level	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	LSMeans	SE (LSMeans)	95% CI (LL)	95% CI (UL)
BASELINE	All	n/a	65	65	65	NE	NE	33	33	33	NE	NE	NE	NE	NE	NE
CYCLE 2 DAY 1	All	n/a	57	57	55	-7,89	3,36	27	27	26	-4,95	4,79	-2,95	5,65	-14,06	8,17
CYCLE 3 DAY 1	All	n/a	51	51	51	-5,91	3,46	19	19	19	-9,02	5,35	3,12	6,19	-9,06	15,29
CYCLE 5 DAY 1	All	n/a	41	41	40	-9,58	3,73	11	11	11	-10,90	6,57	1,32	7,45	-13,33	15,97
CYCLE 7 DAY 1	All	n/a	40	40	38	-7,88	3,79	9	9	9	-15,96	7,10	8,09	7,95	-7,54	23,72
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	n/a	57	57	40	-11,75	3,75	27	27	22	-19,27	5,10	7,52	6,11	-4,50	19,54
LONG TERM FOLLOW-UP MONTH 3	All	n/a	47	47	30	-7,08	4,13	24	24	10	-9,89	6,86	2,81	7,88	-12,68	18,31
LONG TERM FOLLOW-UP MONTH 6	All	n/a	37	37	28	-13,62	4,24	15	15	7	-18,21	7,95	4,59	8,90	-12,91	22,09
LONG TERM FOLLOW-UP MONTH 9	All	n/a	25	25	23	-9,78	4,55	10	10	5	-19,47	9,18	9,69	10,15	-10,27	29,65
LONG TERM FOLLOW-UP MONTH 12	All	n/a	23	23	21	-11,28	4,72	8	8	5	-20,51	9,17	9,23	10,22	-10,88	29,33
LONG TERM FOLLOW-UP MONTH 15	All	n/a	17	17	13	-4,20	5,72	6	6	4	1,63	10,13	-5,82	11,54	-28,52	16,88
LONG TERM FOLLOW-UP MONTH 18	All	n/a	10	10	8	-6,64	7,03	5	5	3	-26,66	11,35	20,02	13,28	-6,10	46,15
LONG TERM FOLLOW-UP MONTH 21	All	n/a	5	5	3	0,45	11,08	3	3	1	-9,05	19,03	9,49	21,99	-33,76	52,75
LONG TERM FOLLOW-UP MONTH 24	All	n/a	1	1	1	5,92	18,76	2	2	0	NE	NE	NE	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 27	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 30	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE

[1] LSMeans of change from baseline to respective visit.
[2] Contrasts from MMRM. Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mmrm.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mmrm_ITT_str_QS028RF2_3Lp_16FEB2024_41944.xls
17DEC2024 20:27

POPULATION: ITT Population (2L)
ENDPOINT: EORTC QLQ-C30: Social functioning
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Change from Baseline (Analysis of MMRM)

EORTC QLQ-C30: Social functioning

			Glofitamab + GemOx (N=115)					Rituximab + GemOx (N=57)					Difference between Treatments (Glofitamab + GemOx - Rituximab + GemOx)			
			N			Statistics		N			Statistics		Statistics			
Visit	Name	Level	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	LSMeans	SE (LSMeans)	95% CI (LL)	95% CI (UL)
BASELINE	All	n/a	110	110	110	NE	NE	54	54	54	NE	NE	NE	NE	NE	NE
CYCLE 2 DAY 1	All	n/a	100	100	95	-3,08	2,28	47	47	45	-7,89	3,29	4,80	4,00	-3,05	12,66
CYCLE 3 DAY 1	All	n/a	95	95	94	-4,59	2,29	37	37	36	-6,58	3,60	1,99	4,26	-6,38	10,36
CYCLE 5 DAY 1	All	n/a	83	83	83	-3,47	2,40	24	24	23	1,62	4,32	-5,08	4,94	-14,79	4,62
CYCLE 7 DAY 1	All	n/a	77	77	74	-2,93	2,51	19	19	19	1,45	4,67	-4,38	5,30	-14,79	6,02
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	n/a	92	92	72	2,14	2,53	50	50	41	-8,48	3,42	10,62	4,26	2,26	18,97
LONG TERM FOLLOW-UP MONTH 3	All	n/a	80	80	56	1,62	2,80	45	45	25	-6,67	4,18	8,29	5,03	-1,58	18,17
LONG TERM FOLLOW-UP MONTH 6	All	n/a	62	62	47	3,40	3,00	36	36	21	-0,08	4,48	3,48	5,39	-7,11	14,07
LONG TERM FOLLOW-UP MONTH 9	All	n/a	45	45	36	5,15	3,35	30	30	16	-2,34	5,02	7,49	6,03	-4,35	19,34
LONG TERM FOLLOW-UP MONTH 12	All	n/a	37	37	31	8,06	3,57	22	22	16	8,91	5,02	-0,85	6,16	-12,95	11,24
LONG TERM FOLLOW-UP MONTH 15	All	n/a	26	26	18	3,84	4,53	13	13	9	-3,07	6,45	6,91	7,88	-8,56	22,38
LONG TERM FOLLOW-UP MONTH 18	All	n/a	17	17	13	5,55	5,26	7	7	4	10,97	9,36	-5,42	10,74	-26,49	15,66
LONG TERM FOLLOW-UP MONTH 21	All	n/a	12	12	10	11,90	5,94	6	6	5	2,99	8,43	8,91	10,31	-11,34	29,16
LONG TERM FOLLOW-UP MONTH 24	All	n/a	3	3	3	19,07	10,62	2	2	1	4,52	18,30	14,55	21,16	-26,98	56,09
LONG TERM FOLLOW-UP MONTH 27	All	n/a	1	1	1	30,22	18,30	2	2	1	-12,15	18,30	42,37	25,87	-8,43	93,16
LONG TERM FOLLOW-UP MONTH 30	All	n/a	1	1	1	30,22	18,30	0	0	0	NE	NE	NE	NE	NE	NE

[1] LSMeans of change from baseline to respective visit.
[2] Contrasts from MMRM. Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mmrm.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mmrm_ITT_str_QS028SF_2L_16FEB2024_41944.xls
17DEC2024 20:08

POPULATION: ITT Population (3L+)
ENDPOINT: EORTC QLQ-C30: Social functioning
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Change from Baseline (Analysis of MMRM)

EORTC QLQ-C30: Social functioning

			Glofitamab + GemOx (N=68)					Rituximab + GemOx (N=34)					Difference between Treatments (Glofitamab + GemOx - Rituximab + GemOx)			
			N			Statistics		N			Statistics		Statistics			
Visit	Name	Level	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	LSMeans	SE (LSMeans)	95% CI (LL)	95% CI (UL)
BASELINE	All	n/a	65	65	65	NE	NE	33	33	33	NE	NE	NE	NE	NE	NE
CYCLE 2 DAY 1	All	n/a	57	57	55	0,03	3,46	27	27	26	1,56	4,80	-1,53	5,70	-12,74	9,69
CYCLE 3 DAY 1	All	n/a	51	51	51	-0,46	3,55	19	19	19	-7,85	5,35	7,39	6,23	-4,86	19,64
CYCLE 5 DAY 1	All	n/a	41	41	40	-1,46	3,80	11	11	10	-7,15	6,73	5,69	7,61	-9,27	20,65
CYCLE 7 DAY 1	All	n/a	40	40	38	-0,11	3,86	9	9	9	1,06	7,01	-1,17	7,88	-16,66	14,32
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	n/a	57	57	40	-0,16	3,82	27	27	22	-2,46	5,10	2,30	6,15	-9,80	14,39
LONG TERM FOLLOW-UP MONTH 3	All	n/a	47	47	30	3,11	4,17	24	24	10	-7,88	6,80	10,99	7,83	-4,40	26,38
LONG TERM FOLLOW-UP MONTH 6	All	n/a	37	37	28	-1,19	4,27	15	15	7	-11,69	7,81	10,49	8,77	-6,75	27,74
LONG TERM FOLLOW-UP MONTH 9	All	n/a	25	25	23	0,07	4,55	10	10	5	-5,85	8,97	5,93	9,95	-13,63	25,49
LONG TERM FOLLOW-UP MONTH 12	All	n/a	23	23	21	0,90	4,71	8	8	5	-9,35	8,96	10,25	10,02	-9,45	29,94
LONG TERM FOLLOW-UP MONTH 15	All	n/a	17	17	13	-4,95	5,63	6	6	4	4,78	9,87	-9,73	11,26	-31,87	12,41
LONG TERM FOLLOW-UP MONTH 18	All	n/a	10	10	8	2,87	6,87	5	5	3	-1,32	11,03	4,19	12,91	-21,20	29,58
LONG TERM FOLLOW-UP MONTH 21	All	n/a	5	5	3	18,99	10,72	3	3	1	0,79	18,36	18,20	21,22	-23,53	59,92
LONG TERM FOLLOW-UP MONTH 24	All	n/a	1	1	1	43,05	18,06	2	2	0	NE	NE	NE	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 27	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 30	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE

[1] LSMeans of change from baseline to respective visit.
[2] Contrasts from MMRM. Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mmrm.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mmrm_ITT_str_QS028SF_3Lp_16FEB2024_41944.xls
17DEC2024 20:15

POPULATION: ITT Population (2L)
ENDPOINT: FACT-LYMV4: Subscale Score, Time to Deterioration (MID=9)
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=115)												Rituximab + GemOx (N=57)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	115	100,0	30	26,1	85	73,9	6,60	3,09	15,80	NE	NE	NE	57	100,0	15	26,3	42	73,7	3,75	1,48	NE	NE	15,67	NE	0,6686	0,873	0,468	1,628	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_tte_ITT_str_LYMMID_2L_16FEB2024_41944.xls
13DEC2024 15:01

POPULATION: ITT Population (3L+)
ENDPOINT: FACT-LYMV4: Subscale Score, Time to Deterioration (MID=9)
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Time to Event Analysis (Efficacy)

		Glofitamab + GemOx (N=68)												Rituximab + GemOx (N=34)												Glofitamab + GemOx vs. Rituximab + GemOx				
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio			
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
All	n/a	68	100,0	23	33,8	45	66,2	6,21	2,60	17,35	17,77	15,24	NE	34	100,0	7	20,6	27	79,4	12,52	4,47	17,68	17,68	12,52	NE	0,9959	1,002	0,419	2,396	

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_tte_ITT_str_LYMMID_3Lp_16FEB2024_41944.xls
13DEC2024 15:06

POPULATION: ITT Population (2L)
ENDPOINT: FACT-Lym LymS (reverse scored)
MODEL: --
STUDY: GO41944
Compliance/Mean

		Glofitamab + GemOx (N=115)						Rituximab + GemOx (N=57)					
		Patients				Statistics		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)
All													
BASELINE	All	112	97,4	110	98,2	45,41	10,56	56	98,2	53	94,6	44,44	10,47
CYCLE 2 DAY 1	All	102	88,7	96	94,1	47,38	8,68	48	84,2	45	93,8	45,53	10,76
CYCLE 3 DAY 1	All	97	84,3	96	99,0	48,83	9,56	37	64,9	36	97,3	46,92	12,00
CYCLE 5 DAY 1	All	84	73,0	83	98,8	48,79	8,91	24	42,1	23	95,8	51,17	7,60
CYCLE 7 DAY 1	All	78	67,8	74	94,9	48,66	8,56	19	33,3	19	100,0	48,84	10,78
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	95	82,6	74	77,9	49,67	8,62	50	87,7	41	82,0	45,37	10,93
LONG TERM FOLLOW-UP MONTH 3	All	82	71,3	56	68,3	51,05	8,66	46	80,7	25	54,3	48,68	9,95
LONG TERM FOLLOW-UP MONTH 6	All	63	54,8	47	74,6	50,13	9,91	36	63,2	21	58,3	51,05	11,61
LONG TERM FOLLOW-UP MONTH 9	All	45	39,1	36	80,0	51,94	7,75	30	52,6	16	53,3	49,44	8,52
LONG TERM FOLLOW-UP MONTH 12	All	37	32,2	31	83,8	52,24	6,93	22	38,6	16	72,7	53,50	5,76
LONG TERM FOLLOW-UP MONTH 15	All	26	22,6	18	69,2	51,57	6,70	13	22,8	9	69,2	50,22	9,90
LONG TERM FOLLOW-UP MONTH 18	All	17	14,8	13	76,5	53,43	5,41	7	12,3	4	57,1	53,25	7,41
LONG TERM FOLLOW-UP MONTH 21	All	12	10,4	9	75,0	54,84	6,53	6	10,5	5	83,3	52,80	5,22
LONG TERM FOLLOW-UP MONTH 24	All	3	2,6	3	100,0	55,67	5,13	2	3,5	1	50,0	53,00	NE
LONG TERM FOLLOW-UP MONTH 27	All	1	0,9	1	100,0	56,00	NE	2	3,5	1	50,0	51,00	NE
LONG TERM FOLLOW-UP MONTH 30	All	1	0,9	1	100,0	55,00	NE	0	NE	0	NE	NE	NE

[1] in study: number of subjects in the ITT (or efficacy population) excluding subjects who died or withdrew their ICF before the visit had happened; % based on the ITT (or efficacy population)
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mean_ITT_LYMREV_2L_16FEB2024_41944.xls
07OCT2024 19:50

POPULATION: ITT Population (3L+)
ENDPOINT: FACT-Lym LymS (reverse scored)
MODEL: --
STUDY: GO41944
Compliance/Mean

		Glofitamab + GemOx (N=68)						Rituximab + GemOx (N=34)					
		Patients				Statistics		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)	in study[1]	%	with value[1]	%	Mean[2]	SD(Mean)
All													
BASELINE	All	68	100,0	65	95,6	45,32	10,74	33	97,1	33	100,0	43,03	10,47
CYCLE 2 DAY 1	All	59	86,8	56	94,9	47,02	8,69	27	79,4	26	96,3	43,65	10,49
CYCLE 3 DAY 1	All	52	76,5	52	100,0	49,96	7,46	19	55,9	19	100,0	46,00	10,29
CYCLE 5 DAY 1	All	42	61,8	41	97,6	49,95	7,05	11	32,4	11	100,0	50,82	10,18
CYCLE 7 DAY 1	All	41	60,3	39	95,1	49,72	8,38	9	26,5	9	100,0	51,78	10,07
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	60	88,2	41	68,3	47,17	8,56	27	79,4	22	81,5	44,68	11,73
LONG TERM FOLLOW-UP MONTH 3	All	48	70,6	31	64,6	47,26	8,93	24	70,6	10	41,7	52,60	5,99
LONG TERM FOLLOW-UP MONTH 6	All	37	54,4	28	75,7	45,96	10,56	15	44,1	7	46,7	52,71	4,15
LONG TERM FOLLOW-UP MONTH 9	All	26	38,2	23	88,5	50,70	7,66	10	29,4	5	50,0	52,00	5,79
LONG TERM FOLLOW-UP MONTH 12	All	23	33,8	21	91,3	47,71	9,81	8	23,5	5	62,5	49,80	6,83
LONG TERM FOLLOW-UP MONTH 15	All	17	25,0	12	70,6	48,67	9,35	6	17,6	4	66,7	51,00	3,92
LONG TERM FOLLOW-UP MONTH 18	All	10	14,7	8	80,0	48,00	9,01	5	14,7	3	60,0	50,67	2,52
LONG TERM FOLLOW-UP MONTH 21	All	5	7,4	3	60,0	57,00	5,20	3	8,8	1	33,3	55,00	NE
LONG TERM FOLLOW-UP MONTH 24	All	1	1,5	1	100,0	51,00	NE	2	5,9	0	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 27	All	0	NE	0	NE	NE	NE	1	2,9	0	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 30	All	0	NE	0	NE	NE	NE	1	2,9	0	NE	NE	NE

[1] in study: number of subjects in the ITT (or efficacy population) excluding subjects who died or withdrew their ICF before the visit had happened; % based on the ITT (or efficacy population)
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mean_ITT_LYMREV_3Lp_16FEB2024_41944.xls
07OCT2024 19:54

POPULATION: ITT Population (2L)
ENDPOINT: FACT-Lym LymS (reverse scored)
STUDY: GO41944
Line Plot of Mean by Visit



Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_pro_mean_ITT_LYMREV_2L_16FEB2024_41944.pdf
08OCT2024 22:17

POPULATION: ITT Population (3L+)
ENDPOINT: FACT-Lym LymS (reverse scored)
STUDY: GO41944
Line Plot of Mean by Visit



Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_pro_mean.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_pro_mean_ITT_LYMREV_3Lp_16FEB2024_41944.pdf
08OCT2024 22:21

POPULATION: ITT Population (2L)
ENDPOINT: FACT-LYMV4: Subscale Score
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Change from Baseline (Analysis of MMRM)

FACT-LYMV4: Subscale Score

			Glofitamab + GemOx (N=115)					Rituximab + GemOx (N=57)					Difference between Treatments (Glofitamab + GemOx - Rituximab + GemOx)			
			N			Statistics		N			Statistics		Statistics			
Visit	Name	Level	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	LSMeans	SE (LSMeans)	95% CI (LL)	95% CI (UL)
BASELINE	All	n/a	110	110	110	NE	NE	53	53	53	NE	NE	NE	NE	NE	NE
CYCLE 2 DAY 1	All	n/a	100	100	95	-1,19	0,82	46	46	44	-0,54	1,20	-0,65	1,45	-3,51	2,20
CYCLE 3 DAY 1	All	n/a	95	95	94	-2,08	0,82	36	36	35	0,23	1,29	-2,32	1,53	-5,33	0,69
CYCLE 5 DAY 1	All	n/a	83	83	83	-2,05	0,86	24	24	23	-4,30	1,50	2,25	1,73	-1,15	5,65
CYCLE 7 DAY 1	All	n/a	77	77	74	-1,98	0,89	19	19	19	-1,77	1,61	-0,21	1,84	-3,82	3,40
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	n/a	92	92	72	-2,67	0,90	49	49	40	0,09	1,24	-2,76	1,53	-5,76	0,25
LONG TERM FOLLOW-UP MONTH 3	All	n/a	80	80	56	-3,77	0,98	44	44	25	-2,09	1,46	-1,68	1,76	-5,13	1,77
LONG TERM FOLLOW-UP MONTH 6	All	n/a	62	62	47	-2,84	1,04	36	36	21	-2,25	1,55	-0,59	1,86	-4,25	3,07
LONG TERM FOLLOW-UP MONTH 9	All	n/a	45	45	36	-4,51	1,14	30	30	16	0,18	1,71	-4,70	2,06	-8,74	-0,65
LONG TERM FOLLOW-UP MONTH 12	All	n/a	37	37	31	-3,74	1,21	22	22	16	-3,11	1,71	-0,63	2,10	-4,75	3,49
LONG TERM FOLLOW-UP MONTH 15	All	n/a	26	26	18	-3,05	1,51	13	13	9	0,64	2,16	-3,70	2,63	-8,86	1,47
LONG TERM FOLLOW-UP MONTH 18	All	n/a	17	17	13	-4,74	1,74	7	7	4	-0,94	3,07	-3,80	3,53	-10,73	3,12
LONG TERM FOLLOW-UP MONTH 21	All	n/a	12	12	9	-5,65	2,05	6	6	5	-0,58	2,78	-5,06	3,45	-11,84	1,71
LONG TERM FOLLOW-UP MONTH 24	All	n/a	3	3	3	-6,63	3,45	2	2	1	-4,13	5,93	-2,50	6,86	-15,96	10,97
LONG TERM FOLLOW-UP MONTH 27	All	n/a	1	1	1	-8,51	5,91	2	2	1	-2,13	5,93	-6,38	8,37	-22,82	10,05
LONG TERM FOLLOW-UP MONTH 30	All	n/a	1	1	1	-7,51	5,91	0	0	0	NE	NE	NE	NE	NE	NE

[1] LSMeans of change from baseline to respective visit.
[2] Contrasts from MMRM. Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mmrm.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mmrm_ITT_str_LYM_2L_16FEB2024_41944.xls
17DEC2024 22:42

POPULATION: ITT Population (3L+)
ENDPOINT: FACT-LYMV4: Subscale Score
MODEL: Stratified Analysis by Outcome of last sytemic therapy (relapsed vs refractory)
STUDY: GO41944
Change from Baseline (Analysis of MMRM)

FACT-LYMV4: Subscale Score

			Glofitamab + GemOx (N=68)					Rituximab + GemOx (N=34)					Difference between Treatments (Glofitamab + GemOx - Rituximab + GemOx)			
			N			Statistics		N			Statistics		Statistics			
Visit	Name	Level	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	With baseline value	With baseline value and at least one post-baseline value[1]	With baseline value and a value at respective visit	LSMeans[2]	SE (LSMeans)	LSMeans	SE (LSMeans)	95% CI (LL)	95% CI (UL)
BASELINE	All	n/a	65	65	65	NE	NE	33	33	33	NE	NE	NE	NE	NE	NE
CYCLE 2 DAY 1	All	n/a	57	57	55	-1,71	1,10	27	27	26	-0,33	1,55	-1,38	1,84	-4,99	2,24
CYCLE 3 DAY 1	All	n/a	51	51	51	-4,39	1,13	19	19	19	-0,35	1,74	-4,03	2,02	-8,01	-0,06
CYCLE 5 DAY 1	All	n/a	41	41	40	-3,59	1,22	11	11	11	-1,68	2,14	-1,91	2,43	-6,69	2,87
CYCLE 7 DAY 1	All	n/a	40	40	38	-3,39	1,24	9	9	9	-1,52	2,32	-1,86	2,60	-6,97	3,25
TREATMENT COMPLETION / EARLY DISCONTINUATION	All	n/a	57	57	40	-2,01	1,23	27	27	22	0,61	1,65	-2,63	1,99	-6,55	1,29
LONG TERM FOLLOW-UP MONTH 3	All	n/a	47	47	30	-1,93	1,36	24	24	10	-0,67	2,24	-1,26	2,58	-6,33	3,81
LONG TERM FOLLOW-UP MONTH 6	All	n/a	37	37	28	-0,09	1,39	15	15	7	-0,99	2,59	0,90	2,91	-4,82	6,62
LONG TERM FOLLOW-UP MONTH 9	All	n/a	25	25	23	-4,23	1,49	10	10	5	0,04	3,00	-4,28	3,32	-10,80	2,25
LONG TERM FOLLOW-UP MONTH 12	All	n/a	23	23	21	-1,67	1,55	8	8	5	2,77	2,99	-4,44	3,34	-11,01	2,14
LONG TERM FOLLOW-UP MONTH 15	All	n/a	17	17	12	-0,78	1,94	6	6	4	1,08	3,31	-1,87	3,80	-9,35	5,62
LONG TERM FOLLOW-UP MONTH 18	All	n/a	10	10	8	-2,90	2,30	5	5	3	2,61	3,71	-5,51	4,35	-14,06	3,04
LONG TERM FOLLOW-UP MONTH 21	All	n/a	5	5	3	-7,30	3,63	3	3	1	-0,50	6,23	-6,80	7,20	-20,97	7,37
LONG TERM FOLLOW-UP MONTH 24	All	n/a	1	1	1	-7,31	6,15	2	2	0	NE	NE	NE	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 27	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE
LONG TERM FOLLOW-UP MONTH 30	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE

[1] LSMeans of change from baseline to respective visit.
[2] Contrasts from MMRM. Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_pro_mmrm.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_pro_mmrm_ITT_str_LYM_3Lp_16FEB2024_41944.xls
17DEC2024 22:49

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	112	100,0	0	0	55	100,0	54	98,2	1	1,8	0,9225	1,02	0,70	1,48

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AE_2L_16FEB2024_41944.xls
06DEC2024 11:48

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	68	100,0	0	0	33	100,0	30	90,9	3	9,1	0,4883	1,20	0,72	2,00

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AE_3Lp_16FEB2024_41944.xls
06DEC2024 11:54

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk						
Rituximab + GemOx	55	2	1	NE	NE	NE
Glofitamab + GemOx	112	6	5	1	1	1
Patients censored						
Rituximab + GemOx	0	1	1	NE	NE	NE
Glofitamab + GemOx	0	0	0	0	0	0

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AE_2L_16FEB2024_41944.pdf
24AUG2024 7:10

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk							
Rituximab + GemOx	33	3	1	1	1	1	1
Glofitamab + GemOx	68	1	NE	NE	NE	NE	NE
Patients censored							
Rituximab + GemOx	0	0	2	2	2	2	2
Glofitamab + GemOx	0	0	NE	NE	NE	NE	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 7:14

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	85	75,9	27	24,1	55	100,0	23	41,8	32	58,2	0,0049	1,95	1,21	3,12

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AEGE3_2L_16FEB2024_41944.xls
06DEC2024 11:56

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	55	80,9	13	19,1	33	100,0	13	39,4	20	60,6	0,0019	2,62	1,40	4,89

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AEGE3_3Lp_16FEB2024_41944.xls
06DEC2024 12:01

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk											
Rituximab + GemOx	55	41	30	18	12	11	10	NE	NE	NE	NE
Glofitamab + GemOx	112	55	47	42	38	34	28	21	18	6	3
Patients censored											
Rituximab + GemOx	0	1	9	14	20	21	22	NE	NE	NE	NE
Glofitamab + GemOx	0	0	2	2	3	3	4	9	10	22	25

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 7:17

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk										
Rituximab + GemOx	33	21	9	6	6	6	4	1	NE	NE
Glofitamab + GemOx	68	25	20	16	11	10	8	7	6	3
Patients censored										
Rituximab + GemOx	0	2	12	14	14	14	16	19	NE	NE
Glofitamab + GemOx	0	0	3	3	4	4	6	6	7	10

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 7:22

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	76	67,9	36	32,1	55	100,0	22	40,0	33	60,0	0,0244	1,73	1,07	2,81

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AEGR3_2L_16FEB2024_41944.xls
06DEC2024 12:03

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	50	73,5	18	26,5	33	100,0	10	30,3	23	69,7	0,0033	2,74	1,37	5,50

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AEGR3_3Lp_16FEB2024_41944.xls
06DEC2024 12:08

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk											
Rituximab + GemOx	55	41	30	18	12	11	10	NE	NE	NE	NE
Glofitamab + GemOx	112	60	51	46	42	37	33	26	22	9	4
Patients censored											
Rituximab + GemOx	0	2	10	15	21	22	23	NE	NE	NE	NE
Glofitamab + GemOx	0	0	4	4	6	7	8	13	15	28	33

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 7:24

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk										
Rituximab + GemOx	33	23	10	7	6	6	4	1	NE	NE
Glofitamab + GemOx	68	30	25	20	17	14	12	9	8	3
Patients censored										
Rituximab + GemOx	0	2	14	16	17	17	19	22	NE	NE
Glofitamab + GemOx	0	0	4	5	6	6	8	9	10	15

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AEGR3_3Lp_16FEB2024_41944.pdf
24AUG2024 7:29

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	25	22,3	87	77,7	55	100,0	6	10,9	49	89,1	0,2661	1,67	0,67	4,15

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AEGR4_2L_16FEB2024_41944.xls
06DEC2024 12:10

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	27	39,7	41	60,3	33	100,0	5	15,2	28	84,8	0,0514	2,54	0,96	6,69

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AEGR4_3Lp_16FEB2024_41944.xls
06DEC2024 12:15

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	48	38	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	96	87	84	77	69	65	52	50	31	6	1
Patients censored												
Rituximab + GemOx	0	1	11	19	28	31	33	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	1	9	11	17	24	26	36	37	56	81	86

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AEGR4_2L_16FEB2024_41944.pdf
24AUG2024 7:32

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	27	15	11	8	8	6	1	NE	NE	NE	NE
Glofitamab + GemOx	68	48	39	35	28	27	23	19	18	8	1	1
Patients censored												
Rituximab + GemOx	0	2	14	17	20	20	22	27	NE	NE	NE	NE
Glofitamab + GemOx	0	1	9	11	16	16	20	22	23	33	40	40

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AEGR4_3Lp_16FEB2024_41944.pdf
24AUG2024 7:36

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	9	8,0	103	92,0	55	100,0	1	1,8	54	98,2	0,2439	3,23	0,40	26,00

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AEGR5_2L_16FEB2024_41944.xls
06DEC2024 12:17

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	6	8,8	62	91,2	33	100,0	3	9,1	30	90,9	0,5095	0,62	0,15	2,59

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AEGR5_3Lp_16FEB2024_41944.xls
06DEC2024 12:22

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	97	93	84	78	74	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	2	10	13	21	27	30	39	42	64	96	102

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AEGR5_2L_16FEB2024_41944.pdf
24AUG2024 7:39

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	31	17	14	9	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	53	50	42	42	36	31	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	14	17	21	21	23	29	NE	NE	NE	NE
Glofitamab + GemOx	0	2	12	14	21	21	27	32	33	47	58	61

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AEGR5_3Lp_16FEB2024_41944.pdf
24AUG2024 7:43

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	62	55,4	50	44,6	55	100,0	12	21,8	43	78,2	0,0035	2,47	1,32	4,63

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_SAE_2L_16FEB2024_41944.xls
06DEC2024 12:24

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	36	52,9	32	47,1	33	100,0	3	9,1	30	90,9	0,0008	5,94	1,82	19,41

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_SAE_3Lp_16FEB2024_41944.xls
06DEC2024 12:28

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk											
Rituximab + GemOx	55	46	35	25	17	15	13	NE	NE	NE	NE
Glofitamab + GemOx	112	70	64	58	49	48	45	37	36	21	4
Patients censored											
Rituximab + GemOx	0	2	11	19	26	28	30	NE	NE	NE	NE
Glofitamab + GemOx	0	0	3	4	11	11	11	16	16	30	47

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 7:45

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk											
Rituximab + GemOx	33	29	16	13	9	9	7	1	NE	NE	NE
Glofitamab + GemOx	68	45	38	33	27	27	24	19	17	9	1
Patients censored											
Rituximab + GemOx	0	2	14	17	21	21	23	29	NE	NE	NE
Glofitamab + GemOx	0	0	4	4	9	9	11	14	15	23	31

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_SAE_3Lp_16FEB2024_41944.pdf
24AUG2024 7:50

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event leading to treatment discontinuation
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	30	26,8	82	73,2	55	100,0	7	12,7	48	87,3	0,5508	1,29	0,55	3,03

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_DAE_2L_16FEB2024_41944.xls
06DEC2024 12:31

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event leading to treatment discontinuation
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	18	26,5	50	73,5	33	100,0	4	12,1	29	87,9	0,5210	1,43	0,47	4,35

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_DAE_3Lp_16FEB2024_41944.xls
06DEC2024 12:36

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event leading to treatment discontinuation
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	51	39	29	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	101	93	89	79	73	65	58	54	35	6	1
Patients censored												
Rituximab + GemOx	0	3	14	22	29	30	32	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	1	6	8	16	21	24	28	30	48	76	81

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_DAE_2L_16FEB2024_41944.pdf
24AUG2024 7:52

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event leading to treatment discontinuation
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk											
Rituximab + GemOx	33	31	17	14	9	8	7	1	NE	NE	NE
Glofitamab + GemOx	68	63	51	48	40	37	33	29	27	14	3
Patients censored											
Rituximab + GemOx	0	2	14	17	21	21	22	28	NE	NE	NE
Glofitamab + GemOx	0	1	8	10	17	17	20	23	24	37	48

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_DAE_3Lp_16FEB2024_41944.pdf
24AUG2024 7:56

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

All

			GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx				
			Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio			
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
Blood and lymphatic system disorders		n/a	112	100,0	59	52,7	53	47,3	55	100,0	19	34,5	36	65,5	0,0723	1,609	0,953	2,716	
Blood and lymphatic system disorders	Anaemia	n/a	112	100,0	41	36,6	71	63,4	55	100,0	12	21,8	43	78,2	0,1283	1,643	0,861	3,137	
Blood and lymphatic system disorders	Cytopenia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Blood and lymphatic system disorders	Febrile neutropenia	n/a	112	100,0	2	1,8	110	98,2	55	100,0	1	1,8	54	98,2	0,9690	0,953	0,086	10,510	
Blood and lymphatic system disorders	Haemolysis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4795	>1000.000	0,000	NE	
Blood and lymphatic system disorders	Hypoglobulinaemia	n/a	112	100,0	2	1,8	110	98,2	55	100,0	1	1,8	54	98,2	0,5069	0,403	0,025	6,490	
Blood and lymphatic system disorders	Leukocytosis	n/a	112	100,0	6	5,4	106	94,6	55	100,0	1	1,8	54	98,2	0,2820	3,021	0,363	25,115	
Blood and lymphatic system disorders	Lymph node pain	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Blood and lymphatic system disorders	Lymphopenia	n/a	112	100,0	3	2,7	109	97,3	55	100,0	1	1,8	54	98,2	0,7284	1,491	0,154	14,461	
Blood and lymphatic system disorders	Microcytic anaemia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6242	>1000.000	0,000	NE	
Blood and lymphatic system disorders	Myelosuppression	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1536	0,000	0,000	NE	
Blood and lymphatic system disorders	Neutropenia	n/a	112	100,0	16	14,3	96	85,7	55	100,0	4	7,3	51	92,7	0,8577	1,110	0,356	3,460	
Blood and lymphatic system disorders	Thrombocytopenia	n/a	112	100,0	15	13,4	97	86,6	55	100,0	7	12,7	48	87,3	0,8978	0,942	0,378	2,346	
Cardiac disorders		n/a	112	100,0	13	11,6	99	88,4	55	100,0	4	7,3	51	92,7	0,6083	1,341	0,435	4,136	
Cardiac disorders	Atrial fibrillation	n/a	112	100,0	6	5,4	106	94,6	55	100,0	0	0,0	55	100,0	0,1190	>1000.000	0,000	NE	
Cardiac disorders	Atrial flutter	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4969	>1000.000	0,000	NE	
Cardiac disorders	Cardiac failure	n/a	112	100,0	3	2,7	109	97,3	55	100,0	1	1,8	54	98,2	0,9161	1,130	0,115	11,078	
Cardiac disorders	Cardiac failure congestive	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,8124	>1000.000	0,000	NE	
Cardiac disorders	Chronic left ventricular failure	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5961	>1000.000	0,000	NE	
Cardiac disorders	Mitral valve incompetence	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Cardiac disorders	Myocardial infarction	n/a	112	100,0	1	0,9	111	99,1	55	100,0	1	1,8	54	98,2	0,6123	0,496	0,031	7,923	
Cardiac disorders	Palpitations	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3646	>1000.000	0,000	NE	
Cardiac disorders	Sinus tachycardia	n/a	112	100,0	0	0,0	112	100,0	55	100,0	2	3,6	53	96,4	0,0242	0,000	0,000	NE	
Cardiac disorders	Ventricular extrasystoles	n/a	112	100,0	0	0,0	112	100,0	55	100,0	2	3,6	53	96,4	0,0407	0,000	0,000	NE	
Ear and labyrinth disorders		n/a	112	100,0	5	4,5	107	95,5	55	100,0	1	1,8	54	98,2	0,4963	2,078	0,241	17,897	
Ear and labyrinth disorders	Deafness	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5658	>1000.000	0,000	NE	
Ear and labyrinth disorders	Ear pain	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5961	>1000.000	0,000	NE	
Ear and labyrinth disorders	Presbyacusis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4878	>1000.000	0,000	NE	
Ear and labyrinth disorders	Tinnitus	n/a	112	100,0	1	0,9	111	99,1	55	100,0	1	1,8	54	98,2	0,5973	0,482	0,030	7,700	
Ear and labyrinth disorders	Vertigo	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4948	>1000.000	0,000	NE	
Endocrine disorders		n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3512	>1000.000	0,000	NE	
Endocrine disorders	Adrenal insufficiency	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	

Endocrine disorders	Graves' disease	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5403	>1000.000	0,000	NE
Eye disorders		n/a	112	100,0	6	5,4	106	94,6	55	100,0	2	3,6	53	96,4	0,9695	1,032	0,199	5,368
Eye disorders	Diabetic retinopathy	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5952	>1000.000	0,000	NE
Eye disorders	Dry eye	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE
Eye disorders	Eye swelling	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5045	>1000.000	0,000	NE
Eye disorders	Eyelid oedema	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE
Eye disorders	Vision blurred	n/a	112	100,0	1	0,9	111	99,1	55	100,0	1	1,8	54	98,2	0,5630	0,451	0,028	7,208
Eye disorders	Visual impairment	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,0483	0,000	0,000	NE
Eye disorders	Vitritis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	NE	NE	NE	NE
Gastrointestinal disorders		n/a	112	100,0	82	73,2	30	26,8	55	100,0	39	70,9	16	29,1	0,9225	0,981	0,662	1,453
Gastrointestinal disorders	Abdominal discomfort	n/a	112	100,0	3	2,7	109	97,3	55	100,0	0	0,0	55	100,0	0,2257	>1000.000	0,000	NE
Gastrointestinal disorders	Abdominal distension	n/a	112	100,0	2	1,8	110	98,2	55	100,0	2	3,6	53	96,4	0,2952	0,363	0,050	2,618
Gastrointestinal disorders	Abdominal pain	n/a	112	100,0	9	8,0	103	92,0	55	100,0	1	1,8	54	98,2	0,1687	3,861	0,487	30,644
Gastrointestinal disorders	Abdominal pain upper	n/a	112	100,0	9	8,0	103	92,0	55	100,0	1	1,8	54	98,2	0,1310	4,317	0,545	34,211
Gastrointestinal disorders	Abdominal tenderness	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5260	>1000.000	0,000	NE
Gastrointestinal disorders	Anal incontinence	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6106	>1000.000	0,000	NE
Gastrointestinal disorders	Ascites	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	1,0000	NE	NE	NE
Gastrointestinal disorders	Colitis ischaemic	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,5997	>1000.000	0,000	NE
Gastrointestinal disorders	Constipation	n/a	112	100,0	28	25,0	84	75,0	55	100,0	9	16,4	46	83,6	0,2773	1,515	0,712	3,222
Gastrointestinal disorders	Diarrhoea	n/a	112	100,0	42	37,5	70	62,5	55	100,0	19	34,5	36	65,5	0,5439	0,843	0,485	1,464
Gastrointestinal disorders	Dry mouth	n/a	112	100,0	4	3,6	108	96,4	55	100,0	0	0,0	55	100,0	0,1898	>1000.000	0,000	NE
Gastrointestinal disorders	Duodenal ulcer	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,0977	0,000	0,000	NE
Gastrointestinal disorders	Dyspepsia	n/a	112	100,0	4	3,6	108	96,4	55	100,0	0	0,0	55	100,0	0,1755	>1000.000	0,000	NE
Gastrointestinal disorders	Enterocolitis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6287	>1000.000	0,000	NE
Gastrointestinal disorders	Gastritis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6109	>1000.000	0,000	NE
Gastrointestinal disorders	Gastrooesophageal reflux disease	n/a	112	100,0	4	3,6	108	96,4	55	100,0	1	1,8	54	98,2	0,6426	1,674	0,185	15,121
Gastrointestinal disorders	Gingival pain	n/a	112	100,0	1	0,9	111	99,1	55	100,0	1	1,8	54	98,2	0,4916	0,390	0,024	6,307
Gastrointestinal disorders	Gingival swelling	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4927	>1000.000	0,000	NE
Gastrointestinal disorders	Haemorrhoidal haemorrhage	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6171	>1000.000	0,000	NE
Gastrointestinal disorders	Haemorrhoids	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3218	>1000.000	0,000	NE
Gastrointestinal disorders	Intestinal obstruction	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5403	>1000.000	0,000	NE
Gastrointestinal disorders	Large intestine perforation	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE
Gastrointestinal disorders	Lip swelling	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1554	0,000	0,000	NE
Gastrointestinal disorders	Mouth haemorrhage	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE
Gastrointestinal disorders	Mouth ulceration	n/a	112	100,0	6	5,4	106	94,6	55	100,0	0	0,0	55	100,0	0,1024	>1000.000	0,000	NE
Gastrointestinal disorders	Nausea	n/a	112	100,0	49	43,8	63	56,3	55	100,0	21	38,2	34	61,8	0,7905	1,073	0,638	1,804
Gastrointestinal disorders	Odynophagia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5424	>1000.000	0,000	NE
Gastrointestinal disorders	Oesophageal spasm	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5424	>1000.000	0,000	NE
Gastrointestinal disorders	Oral mucosa haematoma	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE
Gastrointestinal disorders	Oral pain	n/a	112	100,0	2	1,8	110	98,2	55	100,0	1	1,8	54	98,2	0,8796	0,831	0,075	9,205
Gastrointestinal disorders	Pancreatitis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5952	>1000.000	0,000	NE
Gastrointestinal disorders	Pancreatitis acute	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE
Gastrointestinal disorders	Stomatitis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4900	>1000.000	0,000	NE
Gastrointestinal disorders	Toothache	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6150	>1000.000	0,000	NE
Gastrointestinal disorders	Upper gastrointestinal haemorrhage	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1554	0,000	0,000	NE
Gastrointestinal disorders	Vomiting	n/a	112	100,0	26	23,2	86	76,8	55	100,0	9	16,4	46	83,6	0,4131	1,373	0,640	2,945
General disorders and administration site conditions		n/a	112	100,0	68	60,7	44	39,3	55	100,0	27	49,1	28	50,9	0,5757	1,138	0,723	1,792
General disorders and administration site conditions	Administration site extravasation	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4795	>1000.000	0,000	NE
General disorders and administration site conditions	Asthenia	n/a	112	100,0	18	16,1	94	83,9	55	100,0	5	9,1	50	90,9	0,5304	1,380	0,503	3,787
General disorders and administration site conditions	Chest discomfort	n/a	112	100,0	2	1,8	110	98,2	55	100,0	1	1,8	54	98,2	0,8575	0,801	0,071	9,059
General disorders and administration site conditions	Chest pain	n/a	112	100,0	4	3,6	108	96,4	55	100,0	1	1,8	54	98,2	0,8609	1,226	0,126	11,967

General disorders and administration site conditions	Chills	n/a	112	100,0	4	3,6	108	96,4	55	100,0	0	0,0	55	100,0	0,1763	>1000.000	0,000	NE	
General disorders and administration site conditions	Face oedema	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,0481	0,000	0,000	NE	
General disorders and administration site conditions	Facial pain	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
General disorders and administration site conditions	Fatigue	n/a	112	100,0	23	20,5	89	79,5	55	100,0	11	20,0	44	80,0	0,9116	0,960	0,466	1,978	
General disorders and administration site conditions	General physical health deterioration	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1554	0,000	0,000	NE	
General disorders and administration site conditions	Injection site pain	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3871	>1000.000	0,000	NE	
General disorders and administration site conditions	Injection site reaction	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1317	0,000	0,000	NE	
General disorders and administration site conditions	Localised oedema	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1573	0,000	0,000	NE	
General disorders and administration site conditions	Malaise	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4878	>1000.000	0,000	NE	
General disorders and administration site conditions	Multiple organ dysfunction syndrome	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4969	>1000.000	0,000	NE	
General disorders and administration site conditions	Non-cardiac chest pain	n/a	112	100,0	0	0,0	112	100,0	55	100,0	2	3,6	53	96,4	0,0439	0,000	0,000	NE	
General disorders and administration site conditions	Oedema	n/a	112	100,0	1	0,9	111	99,1	55	100,0	1	1,8	54	98,2	0,1536	0,000	0,000	NE	
General disorders and administration site conditions	Oedema peripheral	n/a	112	100,0	9	8,0	103	92,0	55	100,0	5	9,1	50	90,9	0,4129	0,631	0,208	1,916	
General disorders and administration site conditions	Pain	n/a	112	100,0	3	2,7	109	97,3	55	100,0	1	1,8	54	98,2	0,8301	1,281	0,133	12,361	
General disorders and administration site conditions	Pyrexia	n/a	112	100,0	32	28,6	80	71,4	55	100,0	2	3,6	53	96,4	0,0024	6,814	1,625	28,575	
General disorders and administration site conditions	Swelling face	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Hepatobiliary disorders		n/a	112	100,0	7	6,3	105	93,8	55	100,0	2	3,6	53	96,4	0,7314	1,325	0,265	6,632	
Hepatobiliary disorders	Biliary colic	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Hepatobiliary disorders	Cholecystitis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,8638	>1000.000	0,000	NE	
Hepatobiliary disorders	Cholelithiasis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	1	1,8	54	98,2	0,1171	0,073	0,002	3,002	
Hepatobiliary disorders	Cholestasis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	
Hepatobiliary disorders	Congestive hepatopathy	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6310	>1000.000	0,000	NE	
Hepatobiliary disorders	Hepatic cytolysis	n/a	112	100,0	2	1,8	110	98,2	55	100,0	1	1,8	54	98,2	0,9857	0,978	0,089	10,789	
Hepatobiliary disorders	Hepatotoxicity	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	NE	NE	NE	NE	
Hepatobiliary disorders	Hyperbilirubinaemia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Hepatobiliary disorders	Liver disorder	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4878	>1000.000	0,000	NE	
Immune system disorders		n/a	112	100,0	51	45,5	61	54,5	55	100,0	1	1,8	54	98,2	<.0001	32,272	4,444	234,377	
Immune system disorders	Cytokine release syndrome	n/a	112	100,0	51	45,5	61	54,5	55	100,0	0	0,0	55	100,0	<.0001	>1000.000	0,000	NE	
Immune system disorders	Drug hypersensitivity	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1536	0,000	0,000	NE	
Immune system disorders	Hypersensitivity	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	
Infections and infestations		n/a	112	100,0	71	63,4	41	36,6	55	100,0	21	38,2	34	61,8	0,4216	1,226	0,745	2,018	
Infections and infestations	Bacteraemia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	1	1,8	54	98,2	0,5319	0,423	0,026	6,818	
Infections and infestations	Biliary tract infection	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	

Infections and infestations	Bronchitis	n/a	112	100,0	4	3,6	108	96,4	55	100,0	0	0,0	55	100,0	0,2798	>1000.000	0,000	NE	
Infections and infestations	COVID-19	n/a	112	100,0	18	16,1	94	83,9	55	100,0	6	10,9	49	89,1	0,5962	0,768	0,288	2,047	
Infections and infestations	COVID-19 pneumonia	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,6192	>1000.000	0,000	NE	
Infections and infestations	Candida infection	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Infections and infestations	Cellulitis	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3834	>1000.000	0,000	NE	
Infections and infestations	Cellulitis of male external genital organ	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5077	>1000.000	0,000	NE	
Infections and infestations	Citrobacter infection	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4990	>1000.000	0,000	NE	
Infections and infestations	Cystitis	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,5952	>1000.000	0,000	NE	
Infections and infestations	Cytomegalovirus infection reactivation	n/a	112	100,0	7	6,3	105	93,8	55	100,0	1	1,8	54	98,2	0,2405	3,271	0,402	26,620	
Infections and infestations	Cytomegalovirus viraemia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	1,0000	NE	NE	NE	
Infections and infestations	Device related infection	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4878	>1000.000	0,000	NE	
Infections and infestations	Ear, nose and throat infection	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,0598	0,000	0,000	NE	
Infections and infestations	Enterococcal sepsis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6287	>1000.000	0,000	NE	
Infections and infestations	Escherichia bacteraemia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	NE	NE	NE	NE	
Infections and infestations	Escherichia infection	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1495	0,000	0,000	NE	
Infections and infestations	Escherichia pyelonephritis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4857	>1000.000	0,000	NE	
Infections and infestations	Eye infection	n/a	112	100,0	1	0,9	111	99,1	55	100,0	1	1,8	54	98,2	0,6147	0,498	0,031	7,958	
Infections and infestations	Folliculitis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4900	>1000.000	0,000	NE	
Infections and infestations	Gastroenteritis	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3723	>1000.000	0,000	NE	
Infections and infestations	Hepatitis B reactivation	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	1,0000	NE	NE	NE	
Infections and infestations	Herpes virus infection	n/a	112	100,0	2	1,8	110	98,2	55	100,0	1	1,8	54	98,2	0,1573	0,000	0,000	NE	
Infections and infestations	Herpes zoster	n/a	112	100,0	4	3,6	108	96,4	55	100,0	0	0,0	55	100,0	0,5721	>1000.000	0,000	NE	
Infections and infestations	Infection	n/a	112	100,0	0	0,0	112	100,0	55	100,0	2	3,6	53	96,4	0,0308	0,000	0,000	NE	
Infections and infestations	Influenza	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,6171	>1000.000	0,000	NE	
Infections and infestations	Infusion site cellulitis	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1573	0,000	0,000	NE	
Infections and infestations	Listeriosis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4857	>1000.000	0,000	NE	
Infections and infestations	Lower respiratory tract infection	n/a	112	100,0	6	5,4	106	94,6	55	100,0	1	1,8	54	98,2	0,7565	1,413	0,157	12,690	
Infections and infestations	Meningitis aseptic	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Infections and infestations	Nasopharyngitis	n/a	112	100,0	2	1,8	110	98,2	55	100,0	1	1,8	54	98,2	0,4388	0,351	0,022	5,622	
Infections and infestations	Onychomycosis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	1	1,8	54	98,2	0,2932	0,253	0,016	4,041	
Infections and infestations	Oral candidiasis	n/a	112	100,0	3	2,7	109	97,3	55	100,0	2	3,6	53	96,4	0,5509	0,581	0,095	3,537	
Infections and infestations	Orchitis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6109	>1000.000	0,000	NE	
Infections and infestations	Otitis media	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,0493	0,000	0,000	NE	
Infections and infestations	Paronychia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Infections and infestations	Pneumocystis jirovecii pneumonia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	1,0000	NE	NE	NE	
Infections and infestations	Pneumonia	n/a	112	100,0	18	16,1	94	83,9	55	100,0	2	3,6	53	96,4	0,1742	2,693	0,609	11,912	
Infections and infestations	Pneumonia bacterial	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1007	0,000	0,000	NE	

Infections and infestations	Pneumonia pneumococcal	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	1,0000	NE	NE	NE	
Infections and infestations	Respiratory tract infection	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6310	>1000.000	0,000	NE	
Infections and infestations	Respiratory tract infection bacterial	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,8336	>1000.000	0,000	NE	
Infections and infestations	Rhinitis	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1341	0,000	0,000	NE	
Infections and infestations	Rhinovirus infection	n/a	112	100,0	1	0,9	111	99,1	55	100,0	1	1,8	54	98,2	0,4155	0,325	0,019	5,528	
Infections and infestations	Sepsis	n/a	112	100,0	3	2,7	109	97,3	55	100,0	0	0,0	55	100,0	0,3571	>1000.000	0,000	NE	
Infections and infestations	Septic shock	n/a	112	100,0	2	1,8	110	98,2	55	100,0	1	1,8	54	98,2	0,9901	0,985	0,089	10,862	
Infections and infestations	Sinusitis	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,4074	>1000.000	0,000	NE	
Infections and infestations	Skin infection	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3693	>1000.000	0,000	NE	
Infections and infestations	Splenic abscess	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,0718	0,000	0,000	NE	
Infections and infestations	Streptococcal sepsis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	
Infections and infestations	Upper respiratory tract infection	n/a	112	100,0	10	8,9	102	91,1	55	100,0	1	1,8	54	98,2	0,2599	3,113	0,388	24,951	
Infections and infestations	Ureteritis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6242	>1000.000	0,000	NE	
Infections and infestations	Urinary tract infection	n/a	112	100,0	5	4,5	107	95,5	55	100,0	3	5,5	52	94,5	0,3202	0,471	0,103	2,147	
Infections and infestations	Urosepsis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5403	>1000.000	0,000	NE	
Infections and infestations	Viraemia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4795	>1000.000	0,000	NE	
Infections and infestations	Vulvovaginitis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6242	>1000.000	0,000	NE	
Injury, poisoning and procedural complications		n/a	112	100,0	33	29,5	79	70,5	55	100,0	9	16,4	46	83,6	0,1341	1,775	0,830	3,795	
Injury, poisoning and procedural complications	Contusion	n/a	112	100,0	1	0,9	111	99,1	55	100,0	1	1,8	54	98,2	0,5770	0,463	0,029	7,417	
Injury, poisoning and procedural complications	Fall	n/a	112	100,0	8	7,1	104	92,9	55	100,0	0	0,0	55	100,0	0,1080	>1000.000	0,000	NE	
Injury, poisoning and procedural complications	Femur fracture	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5403	>1000.000	0,000	NE	
Injury, poisoning and procedural complications	Hip fracture	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,8371	>1000.000	0,000	NE	
Injury, poisoning and procedural complications	Infusion related reaction	n/a	112	100,0	19	17,0	93	83,0	55	100,0	7	12,7	48	87,3	0,4883	1,377	0,555	3,413	
Injury, poisoning and procedural complications	Product storage error	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3202	>1000.000	0,000	NE	
Injury, poisoning and procedural complications	Road traffic accident	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5403	>1000.000	0,000	NE	
Injury, poisoning and procedural complications	Skin laceration	n/a	112	100,0	2	1,8	110	98,2	55	100,0	1	1,8	54	98,2	0,5576	0,466	0,034	6,302	
Injury, poisoning and procedural complications	Splenic rupture	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Injury, poisoning and procedural complications	Subdural haematoma	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5518	>1000.000	0,000	NE	
Injury, poisoning and procedural complications	Tibia fracture	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5403	>1000.000	0,000	NE	
Injury, poisoning and procedural complications	Tracheal haemorrhage	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Injury, poisoning and procedural complications	Vascular access site erythema	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	
Injury, poisoning and procedural complications	Vascular access site pain	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5721	>1000.000	0,000	NE	
Injury, poisoning and procedural complications	Vulvovaginal injury	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	NE	NE	NE	NE	
Injury, poisoning and procedural complications	Wound complication	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1536	0,000	0,000	NE	
Investigations		n/a	112	100,0	75	67,0	37	33,0	55	100,0	30	54,5	25	45,5	0,3369	1,243	0,797	1,940	
Investigations	Activated partial thromboplastin time shortened	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	

Investigations	Alanine aminotransferase abnormal	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	
Investigations	Alanine aminotransferase increased	n/a	112	100,0	35	31,3	77	68,8	55	100,0	14	25,5	41	74,5	0,6321	1,166	0,622	2,183	
Investigations	Alpha hydroxybutyrate dehydrogenase increased	n/a	112	100,0	2	1,8	110	98,2	55	100,0	1	1,8	54	98,2	0,5414	0,432	0,027	6,911	
Investigations	Amylase increased	n/a	112	100,0	1	0,9	111	99,1	55	100,0	3	5,5	52	94,5	0,0050	0,000	0,000	NE	
Investigations	Aspartate aminotransferase abnormal	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	
Investigations	Aspartate aminotransferase increased	n/a	112	100,0	33	29,5	79	70,5	55	100,0	11	20,0	44	80,0	0,3144	1,422	0,714	2,835	
Investigations	B-lymphocyte count decreased	n/a	112	100,0	2	1,8	110	98,2	55	100,0	1	1,8	54	98,2	0,6176	0,520	0,038	7,034	
Investigations	Blood albumin decreased	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3202	>1000.000	0,000	NE	
Investigations	Blood alkaline phosphatase abnormal	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	
Investigations	Blood alkaline phosphatase increased	n/a	112	100,0	19	17,0	93	83,0	55	100,0	11	20,0	44	80,0	0,5308	0,787	0,371	1,668	
Investigations	Blood bilirubin increased	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3513	>1000.000	0,000	NE	
Investigations	Blood cholesterol increased	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4878	>1000.000	0,000	NE	
Investigations	Blood creatine increased	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4795	>1000.000	0,000	NE	
Investigations	Blood creatinine decreased	n/a	112	100,0	1	0,9	111	99,1	55	100,0	1	1,8	54	98,2	0,6051	0,489	0,031	7,815	
Investigations	Blood creatinine increased	n/a	112	100,0	2	1,8	110	98,2	55	100,0	1	1,8	54	98,2	0,8681	0,815	0,072	9,194	
Investigations	Blood fibrinogen decreased	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	
Investigations	Blood fibrinogen increased	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1536	0,000	0,000	NE	
Investigations	Blood immunoglobulin A decreased	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5596	>1000.000	0,000	NE	
Investigations	Blood immunoglobulin M decreased	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5596	>1000.000	0,000	NE	
Investigations	Blood lactate dehydrogenase increased	n/a	112	100,0	12	10,7	100	89,3	55	100,0	4	7,3	51	92,7	0,6445	1,306	0,419	4,076	
Investigations	Blood magnesium decreased	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3184	>1000.000	0,000	NE	
Investigations	Blood thyroid stimulating hormone decreased	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4795	>1000.000	0,000	NE	
Investigations	Body temperature increased	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5208	>1000.000	0,000	NE	
Investigations	C-reactive protein increased	n/a	112	100,0	8	7,1	104	92,9	55	100,0	4	7,3	51	92,7	0,9043	0,929	0,279	3,094	
Investigations	CD19 lymphocytes decreased	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	
Investigations	Carbon dioxide decreased	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1536	0,000	0,000	NE	
Investigations	Cytomegalovirus test positive	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Investigations	Electrocardiogram PR prolongation	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6128	>1000.000	0,000	NE	
Investigations	Electrocardiogram ST-T change	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1273	0,000	0,000	NE	
Investigations	Eosinophil count increased	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4969	>1000.000	0,000	NE	
Investigations	Fibrin D dimer increased	n/a	112	100,0	4	3,6	108	96,4	55	100,0	0	0,0	55	100,0	0,2206	>1000.000	0,000	NE	
Investigations	Gamma-glutamyltransferase abnormal	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	
Investigations	Gamma-glutamyltransferase increased	n/a	112	100,0	13	11,6	99	88,4	55	100,0	6	10,9	49	89,1	0,7759	0,867	0,326	2,310	
Investigations	Globulins decreased	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6109	>1000.000	0,000	NE	

Investigations	Heart rate increased	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Investigations	Human rhinovirus test positive	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5952	>1000.000	0,000	NE	
Investigations	Interleukin level increased	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Investigations	Light chain analysis decreased	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5596	>1000.000	0,000	NE	
Investigations	Lipase increased	n/a	112	100,0	2	1,8	110	98,2	55	100,0	4	7,3	51	92,7	0,0309	0,181	0,032	1,019	
Investigations	Liver function test abnormal	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3600	>1000.000	0,000	NE	
Investigations	Lymphocyte count decreased	n/a	112	100,0	15	13,4	97	86,6	55	100,0	10	18,2	45	81,8	0,2433	0,614	0,268	1,404	
Investigations	Magnetic resonance imaging abnormal	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5497	>1000.000	0,000	NE	
Investigations	Natural killer cell count decreased	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3614	>1000.000	0,000	NE	
Investigations	Natural killer cell count increased	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	
Investigations	Neutrophil count decreased	n/a	112	100,0	26	23,2	86	76,8	55	100,0	14	25,5	41	74,5	0,2334	0,667	0,341	1,304	
Investigations	Neutrophil count increased	n/a	112	100,0	3	2,7	109	97,3	55	100,0	0	0,0	55	100,0	0,2641	>1000.000	0,000	NE	
Investigations	Oxygen saturation decreased	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5952	>1000.000	0,000	NE	
Investigations	Platelet count decreased	n/a	112	100,0	34	30,4	78	69,6	55	100,0	16	29,1	39	70,9	0,9235	0,970	0,528	1,785	
Investigations	Platelet count increased	n/a	112	100,0	1	0,9	111	99,1	55	100,0	2	3,6	53	96,4	0,1849	0,225	0,020	2,505	
Investigations	Procalcitonin increased	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Investigations	Protein total decreased	n/a	112	100,0	3	2,7	109	97,3	55	100,0	0	0,0	55	100,0	0,3679	>1000.000	0,000	NE	
Investigations	SARS-CoV-2 test positive	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Investigations	Serum ferritin increased	n/a	112	100,0	18	16,1	94	83,9	55	100,0	5	9,1	50	90,9	0,2301	1,832	0,672	4,994	
Investigations	T-lymphocyte count decreased	n/a	112	100,0	1	0,9	111	99,1	55	100,0	1	1,8	54	98,2	0,5587	0,447	0,028	7,164	
Investigations	T-lymphocyte count increased	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	
Investigations	Transaminases increased	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4878	>1000.000	0,000	NE	
Investigations	Urine output decreased	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1536	0,000	0,000	NE	
Investigations	Weight decreased	n/a	112	100,0	10	8,9	102	91,1	55	100,0	2	3,6	53	96,4	0,4270	1,841	0,399	8,489	
Investigations	Weight increased	n/a	112	100,0	1	0,9	111	99,1	55	100,0	1	1,8	54	98,2	0,4783	0,381	0,024	6,096	
Investigations	White blood cell count decreased	n/a	112	100,0	15	13,4	97	86,6	55	100,0	10	18,2	45	81,8	0,2819	0,639	0,280	1,454	
Investigations	White blood cell count increased	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1554	0,000	0,000	NE	
Metabolism and nutrition disorders		n/a	112	100,0	62	55,4	50	44,6	55	100,0	26	47,3	29	52,7	0,8971	1,031	0,648	1,640	
Metabolism and nutrition disorders	Decreased appetite	n/a	112	100,0	31	27,7	81	72,3	55	100,0	16	29,1	39	70,9	0,4489	0,791	0,431	1,453	
Metabolism and nutrition disorders	Dehydration	n/a	112	100,0	5	4,5	107	95,5	55	100,0	0	0,0	55	100,0	0,1371	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Diabetic metabolic decompensation	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Electrolyte imbalance	n/a	112	100,0	4	3,6	108	96,4	55	100,0	0	0,0	55	100,0	0,1890	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Folate deficiency	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6331	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Hypercalcaemia	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3623	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Hypercholesterolaemia	n/a	112	100,0	7	6,3	105	93,8	55	100,0	3	5,5	52	94,5	0,9364	1,057	0,271	4,118	
Metabolism and nutrition disorders	Hyperglycaemia	n/a	112	100,0	4	3,6	108	96,4	55	100,0	1	1,8	54	98,2	0,7448	1,453	0,151	13,968	
Metabolism and nutrition disorders	Hyperkalaemia	n/a	112	100,0	3	2,7	109	97,3	55	100,0	1	1,8	54	98,2	0,7852	1,369	0,142	13,229	
Metabolism and nutrition disorders	Hyperlipidaemia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	1,0000	NE	NE	NE	
Metabolism and nutrition disorders	Hyperphosphataemia	n/a	112	100,0	4	3,6	108	96,4	55	100,0	0	0,0	55	100,0	0,1559	>1000.000	0,000	NE	

Metabolism and nutrition disorders	Hypertriglyceridaemia	n/a	112	100,0	7	6,3	105	93,8	55	100,0	2	3,6	53	96,4	0,5632	1,585	0,328	7,669	
Metabolism and nutrition disorders	Hyperuricaemia	n/a	112	100,0	6	5,4	106	94,6	55	100,0	5	9,1	50	90,9	0,1317	0,394	0,113	1,380	
Metabolism and nutrition disorders	Hypervolaemia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4948	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Hypoalbuminaemia	n/a	112	100,0	5	4,5	107	95,5	55	100,0	3	5,5	52	94,5	0,6339	0,706	0,167	2,982	
Metabolism and nutrition disorders	Hypocalcaemia	n/a	112	100,0	8	7,1	104	92,9	55	100,0	4	7,3	51	92,7	0,7136	0,798	0,238	2,671	
Metabolism and nutrition disorders	Hypochloraemia	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3513	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Hypoglycaemia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Hypokalaemia	n/a	112	100,0	16	14,3	96	85,7	55	100,0	4	7,3	51	92,7	0,3445	1,698	0,560	5,151	
Metabolism and nutrition disorders	Hypomagnesaemia	n/a	112	100,0	8	7,1	104	92,9	55	100,0	7	12,7	48	87,3	0,0953	0,418	0,146	1,202	
Metabolism and nutrition disorders	Hyponatraemia	n/a	112	100,0	9	8,0	103	92,0	55	100,0	3	5,5	52	94,5	0,7561	1,235	0,326	4,681	
Metabolism and nutrition disorders	Hypophosphataemia	n/a	112	100,0	4	3,6	108	96,4	55	100,0	1	1,8	54	98,2	0,7416	1,460	0,152	14,035	
Metabolism and nutrition disorders	Hypoproteinaemia	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,4771	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Iron deficiency	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	1,0000	NE	NE	NE	
Metabolism and nutrition disorders	Malnutrition	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Tumour lysis syndrome	n/a	112	100,0	2	1,8	110	98,2	55	100,0	3	5,5	52	94,5	0,1871	0,319	0,053	1,911	
Metabolism and nutrition disorders	Vitamin D deficiency	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4878	>1000.000	0,000	NE	
Musculoskeletal and connective tissue disorders		n/a	112	100,0	26	23,2	86	76,8	55	100,0	12	21,8	43	78,2	0,7200	0,881	0,442	1,758	
Musculoskeletal and connective tissue disorders	Arthralgia	n/a	112	100,0	10	8,9	102	91,1	55	100,0	1	1,8	54	98,2	0,1496	4,070	0,515	32,162	
Musculoskeletal and connective tissue disorders	Back pain	n/a	112	100,0	3	2,7	109	97,3	55	100,0	5	9,1	50	90,9	0,0369	0,240	0,056	1,022	
Musculoskeletal and connective tissue disorders	Bone pain	n/a	112	100,0	4	3,6	108	96,4	55	100,0	1	1,8	54	98,2	0,6234	1,723	0,191	15,539	
Musculoskeletal and connective tissue disorders	Groin pain	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,4072	>1000.000	0,000	NE	
Musculoskeletal and connective tissue disorders	Joint swelling	n/a	112	100,0	1	0,9	111	99,1	55	100,0	1	1,8	54	98,2	0,5520	0,441	0,027	7,078	
Musculoskeletal and connective tissue disorders	Muscle spasms	n/a	112	100,0	0	0,0	112	100,0	55	100,0	2	3,6	53	96,4	0,0426	0,000	0,000	NE	
Musculoskeletal and connective tissue disorders	Muscular weakness	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3829	>1000.000	0,000	NE	
Musculoskeletal and connective tissue disorders	Musculoskeletal chest pain	n/a	112	100,0	3	2,7	109	97,3	55	100,0	3	5,5	52	94,5	0,2116	0,372	0,074	1,867	
Musculoskeletal and connective tissue disorders	Musculoskeletal pain	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4969	>1000.000	0,000	NE	
Musculoskeletal and connective tissue disorders	Musculoskeletal stiffness	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5952	>1000.000	0,000	NE	
Musculoskeletal and connective tissue disorders	Myalgia	n/a	112	100,0	3	2,7	109	97,3	55	100,0	0	0,0	55	100,0	0,2228	>1000.000	0,000	NE	
Musculoskeletal and connective tissue disorders	Neck pain	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5120	>1000.000	0,000	NE	
Musculoskeletal and connective tissue disorders	Pain in extremity	n/a	112	100,0	5	4,5	107	95,5	55	100,0	3	5,5	52	94,5	0,6958	0,752	0,179	3,160	

Musculoskeletal and connective tissue disorders	Pain in jaw	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1536	0,000	0,000	NE	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		n/a	112	100,0	4	3,6	108	96,4	55	100,0	1	1,8	54	98,2	0,6089	1,764	0,195	15,956	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6128	>1000.000	0,000	NE	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Tumour pain	n/a	112	100,0	3	2,7	109	97,3	55	100,0	1	1,8	54	98,2	0,7356	1,474	0,153	14,208	
Nervous system disorders		n/a	112	100,0	54	48,2	58	51,8	55	100,0	19	34,5	36	65,5	0,4701	1,217	0,714	2,075	
Nervous system disorders	Ageusia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	1	1,8	54	98,2	0,6028	0,487	0,030	7,780	
Nervous system disorders	Balance disorder	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6150	>1000.000	0,000	NE	
Nervous system disorders	Cognitive disorder	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Nervous system disorders	Dizziness	n/a	112	100,0	7	6,3	105	93,8	55	100,0	3	5,5	52	94,5	0,9673	0,971	0,243	3,888	
Nervous system disorders	Dysaesthesia	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3206	>1000.000	0,000	NE	
Nervous system disorders	Dysgeusia	n/a	112	100,0	8	7,1	104	92,9	55	100,0	2	3,6	53	96,4	0,5316	1,636	0,345	7,761	
Nervous system disorders	Extrapyramidal disorder	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6310	>1000.000	0,000	NE	
Nervous system disorders	Headache	n/a	112	100,0	9	8,0	103	92,0	55	100,0	5	9,1	50	90,9	0,7508	0,838	0,280	2,505	
Nervous system disorders	Hypoaesthesia	n/a	112	100,0	3	2,7	109	97,3	55	100,0	3	5,5	52	94,5	0,1691	0,337	0,067	1,706	
Nervous system disorders	Immune effector cell-associated neurotoxicity syndrome	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Nervous system disorders	Lethargy	n/a	112	100,0	2	1,8	110	98,2	55	100,0	2	3,6	53	96,4	0,2438	0,294	0,034	2,569	
Nervous system disorders	Memory impairment	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Nervous system disorders	Metabolic encephalopathy	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6109	>1000.000	0,000	NE	
Nervous system disorders	Myoclonus	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6265	>1000.000	0,000	NE	
Nervous system disorders	Neuropathy peripheral	n/a	112	100,0	18	16,1	94	83,9	55	100,0	4	7,3	51	92,7	0,3024	1,774	0,588	5,354	
Nervous system disorders	Paraesthesia	n/a	112	100,0	5	4,5	107	95,5	55	100,0	3	5,5	52	94,5	0,6888	0,746	0,177	3,150	
Nervous system disorders	Peripheral motor neuropathy	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5403	>1000.000	0,000	NE	
Nervous system disorders	Peripheral sensory neuropathy	n/a	112	100,0	17	15,2	95	84,8	55	100,0	6	10,9	49	89,1	0,9581	1,026	0,396	2,660	
Nervous system disorders	Polyneuropathy	n/a	112	100,0	1	0,9	111	99,1	55	100,0	3	5,5	52	94,5	0,0049	0,055	0,005	0,680	
Nervous system disorders	Syncope	n/a	112	100,0	5	4,5	107	95,5	55	100,0	0	0,0	55	100,0	0,1721	>1000.000	0,000	NE	
Nervous system disorders	Taste disorder	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5045	>1000.000	0,000	NE	
Nervous system disorders	Tremor	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	
Psychiatric disorders		n/a	112	100,0	26	23,2	86	76,8	55	100,0	7	12,7	48	87,3	0,3438	1,505	0,642	3,527	
Psychiatric disorders	Affective disorder	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5596	>1000.000	0,000	NE	
Psychiatric disorders	Anxiety	n/a	112	100,0	3	2,7	109	97,3	55	100,0	1	1,8	54	98,2	0,7511	1,440	0,149	13,887	
Psychiatric disorders	Bradyphrenia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5071	>1000.000	0,000	NE	
Psychiatric disorders	Confusional state	n/a	112	100,0	1	0,9	111	99,1	55	100,0	1	1,8	54	98,2	0,1148	0,000	0,000	NE	
Psychiatric disorders	Delirium	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,4717	>1000.000	0,000	NE	
Psychiatric disorders	Depression	n/a	112	100,0	4	3,6	108	96,4	55	100,0	0	0,0	55	100,0	0,2255	>1000.000	0,000	NE	
Psychiatric disorders	Initial insomnia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	
Psychiatric disorders	Insomnia	n/a	112	100,0	13	11,6	99	88,4	55	100,0	5	9,1	50	90,9	0,9307	1,048	0,363	3,024	
Psychiatric disorders	Libido decreased	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4878	>1000.000	0,000	NE	
Psychiatric disorders	Mood altered	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5952	>1000.000	0,000	NE	
Renal and urinary disorders		n/a	112	100,0	10	8,9	102	91,1	55	100,0	3	5,5	52	94,5	0,8059	1,181	0,313	4,458	
Renal and urinary disorders	Acute kidney injury	n/a	112	100,0	4	3,6	108	96,4	55	100,0	1	1,8	54	98,2	0,7330	1,479	0,154	14,215	
Renal and urinary disorders	Bladder perforation	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5077	>1000.000	0,000	NE	
Renal and urinary disorders	Dysuria	n/a	112	100,0	1	0,9	111	99,1	55	100,0	1	1,8	54	98,2	0,4083	0,324	0,020	5,360	
Renal and urinary disorders	Haematuria	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1554	0,000	0,000	NE	
Renal and urinary disorders	Nocturia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4878	>1000.000	0,000	NE	
Renal and urinary disorders	Pollakiuria	n/a	112	100,0	1	0,9	111	99,1	55	100,0	1	1,8	54	98,2	0,6065	0,489	0,030	7,889	

Renal and urinary disorders	Renal ischaemia	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1554	0,000	0,000	NE	
Renal and urinary disorders	Urinary incontinence	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,5835	>1000.000	0,000	NE	
Renal and urinary disorders	Urinary tract pain	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4878	>1000.000	0,000	NE	
Reproductive system and breast disorders		n/a	112	100,0	3	2,7	109	97,3	55	100,0	2	3,6	53	96,4	0,6209	0,636	0,104	3,880	
Reproductive system and breast disorders	Benign prostatic hyperplasia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6331	>1000.000	0,000	NE	
Reproductive system and breast disorders	Pelvic pain	n/a	112	100,0	0	0,0	112	100,0	55	100,0	2	3,6	53	96,4	0,0436	0,000	0,000	NE	
Reproductive system and breast disorders	Prostatic haemorrhage	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4878	>1000.000	0,000	NE	
Reproductive system and breast disorders	Prostatism	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders		n/a	112	100,0	29	25,9	83	74,1	55	100,0	11	20,0	44	80,0	0,8803	1,056	0,521	2,138	
Respiratory, thoracic and mediastinal disorders	Acute respiratory distress syndrome	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6109	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1554	0,000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Asphyxia	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1007	0,000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Aspiration	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4948	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Asthma	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6106	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Bronchospasm	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1554	0,000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Cough	n/a	112	100,0	9	8,0	103	92,0	55	100,0	3	5,5	52	94,5	0,7986	1,186	0,319	4,416	
Respiratory, thoracic and mediastinal disorders	Dysphonia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Dyspnoea	n/a	112	100,0	6	5,4	106	94,6	55	100,0	1	1,8	54	98,2	0,4033	2,409	0,287	20,232	
Respiratory, thoracic and mediastinal disorders	Dyspnoea exertional	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3195	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Epistaxis	n/a	112	100,0	2	1,8	110	98,2	55	100,0	2	3,6	53	96,4	0,3458	0,401	0,056	2,863	
Respiratory, thoracic and mediastinal disorders	Hiccups	n/a	112	100,0	2	1,8	110	98,2	55	100,0	1	1,8	54	98,2	0,7875	0,718	0,064	8,063	
Respiratory, thoracic and mediastinal disorders	Hypoxia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	1	1,8	54	98,2	0,6065	0,489	0,030	7,889	
Respiratory, thoracic and mediastinal disorders	Lower respiratory tract congestion	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4795	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain	n/a	112	100,0	2	1,8	110	98,2	55	100,0	1	1,8	54	98,2	0,7930	0,724	0,064	8,154	
Respiratory, thoracic and mediastinal disorders	Pleural effusion	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,5869	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Pneumonitis	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,6242	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Productive cough	n/a	112	100,0	3	2,7	109	97,3	55	100,0	2	3,6	53	96,4	0,3644	0,414	0,058	2,964	
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	n/a	112	100,0	1	0,9	111	99,1	55	100,0	1	1,8	54	98,2	0,3620	0,294	0,018	4,800	
Respiratory, thoracic and mediastinal disorders	Pulmonary hypertension	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1573	0,000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Rhinalgia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4878	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Rhinorrhoea	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3621	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Sneezing	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Tachypnoea	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Upper-airway cough syndrome	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4948	>1000.000	0,000	NE	
Skin and subcutaneous tissue disorders		n/a	112	100,0	38	33,9	74	66,1	55	100,0	12	21,8	43	78,2	0,5549	1,219	0,631	2,358	

Skin and subcutaneous tissue disorders	Alopecia	n/a	112	100,0	0	0,0	112	100,0	55	100,0	3	5,5	52	94,5	0,0043	0,000	0,000	NE	
Skin and subcutaneous tissue disorders	Drug eruption	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	
Skin and subcutaneous tissue disorders	Dry skin	n/a	112	100,0	2	1,8	110	98,2	55	100,0	1	1,8	54	98,2	0,4139	0,332	0,021	5,338	
Skin and subcutaneous tissue disorders	Eczema	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6340	>1000.000	0,000	NE	
Skin and subcutaneous tissue disorders	Erythema	n/a	112	100,0	7	6,3	105	93,8	55	100,0	0	0,0	55	100,0	0,1771	>1000.000	0,000	NE	
Skin and subcutaneous tissue disorders	Erythema multiforme	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1317	0,000	0,000	NE	
Skin and subcutaneous tissue disorders	Hyperkeratosis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5260	>1000.000	0,000	NE	
Skin and subcutaneous tissue disorders	Nail dystrophy	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,8336	>1000.000	0,000	NE	
Skin and subcutaneous tissue disorders	Night sweats	n/a	112	100,0	3	2,7	109	97,3	55	100,0	0	0,0	55	100,0	0,3006	>1000.000	0,000	NE	
Skin and subcutaneous tissue disorders	Onychoclasis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5403	>1000.000	0,000	NE	
Skin and subcutaneous tissue disorders	Pruritus	n/a	112	100,0	11	9,8	101	90,2	55	100,0	3	5,5	52	94,5	0,4946	1,558	0,432	5,621	
Skin and subcutaneous tissue disorders	Rash	n/a	112	100,0	15	13,4	97	86,6	55	100,0	5	9,1	50	90,9	0,4869	1,431	0,518	3,948	
Skin and subcutaneous tissue disorders	Rash erythematous	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4878	>1000.000	0,000	NE	
Skin and subcutaneous tissue disorders	Rash maculo-papular	n/a	112	100,0	2	1,8	110	98,2	55	100,0	2	3,6	53	96,4	0,3489	0,400	0,055	2,905	
Skin and subcutaneous tissue disorders	Rash pruritic	n/a	112	100,0	1	0,9	111	99,1	55	100,0	1	1,8	54	98,2	0,4371	0,343	0,021	5,738	
Skin and subcutaneous tissue disorders	Urticaria	n/a	112	100,0	2	1,8	110	98,2	55	100,0	1	1,8	54	98,2	0,9042	0,863	0,078	9,591	
Vascular disorders		n/a	112	100,0	23	20,5	89	79,5	55	100,0	7	12,7	48	87,3	0,2773	1,594	0,682	3,730	
Vascular disorders	Deep vein thrombosis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4969	>1000.000	0,000	NE	
Vascular disorders	Embolism	n/a	112	100,0	3	2,7	109	97,3	55	100,0	0	0,0	55	100,0	0,2550	>1000.000	0,000	NE	
Vascular disorders	Flushing	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3853	>1000.000	0,000	NE	
Vascular disorders	Hypertension	n/a	112	100,0	1	0,9	111	99,1	55	100,0	2	3,6	53	96,4	0,1270	0,181	0,016	2,086	
Vascular disorders	Hypotension	n/a	112	100,0	8	7,1	104	92,9	55	100,0	1	1,8	54	98,2	0,1607	3,964	0,495	31,716	
Vascular disorders	Orthostatic hypotension	n/a	112	100,0	3	2,7	109	97,3	55	100,0	0	0,0	55	100,0	0,2707	>1000.000	0,000	NE	
Vascular disorders	Phlebitis	n/a	112	100,0	4	3,6	108	96,4	55	100,0	0	0,0	55	100,0	0,1805	>1000.000	0,000	NE	
Vascular disorders	Superficial vein thrombosis	n/a	112	100,0	4	3,6	108	96,4	55	100,0	1	1,8	54	98,2	0,5317	1,985	0,222	17,761	
Vascular disorders	Thrombophlebitis	n/a	112	100,0	3	2,7	109	97,3	55	100,0	0	0,0	55	100,0	0,2290	>1000.000	0,000	NE	
Vascular disorders	Vasculitis	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1495	0,000	0,000	NE	
Vascular disorders	Vein disorder	n/a	112	100,0	1	0,9	111	99,1	55	100,0	2	3,6	53	96,4	0,2137	0,245	0,022	2,707	

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte_soc.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_soc_SE_AE_2L_16FEB2024_41944.xls
28FEB2025 12:13

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

All

			GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
			Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
Blood and lymphatic system disorders		n/a	68	100,0	43	63,2	25	36,8	33	100,0	15	45,5	18	54,5	0,2738	1,401	0,764	2,568
Blood and lymphatic system disorders	Anaemia	n/a	68	100,0	32	47,1	36	52,9	33	100,0	7	21,2	26	78,8	0,0482	2,259	0,985	5,179
Blood and lymphatic system disorders	Febrile neutropenia	n/a	68	100,0	4	5,9	64	94,1	33	100,0	0	0,0	33	100,0	0,1621	>1000.000	0,000	NE
Blood and lymphatic system disorders	Leukocytosis	n/a	68	100,0	3	4,4	65	95,6	33	100,0	6	18,2	27	81,8	0,0180	0,215	0,053	0,868
Blood and lymphatic system disorders	Leukopenia	n/a	68	100,0	2	2,9	66	97,1	33	100,0	1	3,0	32	97,0	0,9869	0,980	0,088	10,897
Blood and lymphatic system disorders	Lymphopenia	n/a	68	100,0	4	5,9	64	94,1	33	100,0	0	0,0	33	100,0	0,2578	>1000.000	0,000	NE
Blood and lymphatic system disorders	Myelosuppression	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE
Blood and lymphatic system disorders	Neutropenia	n/a	68	100,0	13	19,1	55	80,9	33	100,0	5	15,2	28	84,8	0,6436	0,777	0,266	2,268
Blood and lymphatic system disorders	Neutrophilia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5289	>1000.000	0,000	NE
Blood and lymphatic system disorders	Thrombocytopenia	n/a	68	100,0	12	17,6	56	82,4	33	100,0	8	24,2	25	75,8	0,3730	0,663	0,266	1,648
Cardiac disorders		n/a	68	100,0	6	8,8	62	91,2	33	100,0	2	6,1	31	93,9	0,6988	1,371	0,275	6,840
Cardiac disorders	Angina pectoris	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE
Cardiac disorders	Arrhythmia	n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0,0	33	100,0	0,3309	>1000.000	0,000	NE
Cardiac disorders	Atrial fibrillation	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4931	>1000.000	0,000	NE
Cardiac disorders	Cardiac arrest	n/a	68	100,0	1	1,5	67	98,5	33	100,0	1	3,0	32	97,0	0,4358	0,345	0,021	5,664
Cardiac disorders	Cardiac failure	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE
Cardiac disorders	Cardiac failure congestive	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE
Cardiac disorders	Coronary artery stenosis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE
Cardiac disorders	Palpitations	n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,1512	0,000	0,000	NE
Cardiac disorders	Tachycardia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE
Ear and labyrinth disorders		n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0,0	33	100,0	0,3746	>1000.000	0,000	NE
Ear and labyrinth disorders	Deafness	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5839	>1000.000	0,000	NE
Ear and labyrinth disorders	Tinnitus	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE
Eye disorders		n/a	68	100,0	5	7,4	63	92,6	33	100,0	0	0,0	33	100,0	0,1536	>1000.000	0,000	NE
Eye disorders	Eye irritation	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE
Eye disorders	Eye pain	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE
Eye disorders	Lacrimation increased	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5115	>1000.000	0,000	NE
Eye disorders	Necrotising retinitis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5973	>1000.000	0,000	NE
Eye disorders	Retinal haemorrhage	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5439	>1000.000	0,000	NE
Eye disorders	Uveitis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	NE	NE	NE	NE
Eye disorders	Vitreous floaters	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6434	>1000.000	0,000	NE
Gastrointestinal disorders		n/a	68	100,0	43	63,2	25	36,8	33	100,0	20	60,6	13	39,4	0,4715	0,818	0,473	1,414
Gastrointestinal disorders	Abdominal discomfort	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,8597	>1000.000	0,000	NE
Gastrointestinal disorders	Abdominal distension	n/a	68	100,0	3	4,4	65	95,6	33	100,0	0	0,0	33	100,0	0,3451	>1000.000	0,000	NE
Gastrointestinal disorders	Abdominal pain	n/a	68	100,0	8	11,8	60	88,2	33	100,0	1	3,0	32	97,0	0,2165	3,444	0,427	27,749
Gastrointestinal disorders	Abdominal pain lower	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4828	>1000.000	0,000	NE
Gastrointestinal disorders	Abdominal pain upper	n/a	68	100,0	4	5,9	64	94,1	33	100,0	1	3,0	32	97,0	0,7793	1,369	0,150	12,462

Gastrointestinal disorders	Anal haemorrhage	n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,0771	0,000	0,000	NE	
Gastrointestinal disorders	Ascites	n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0,0	33	100,0	0,3765	>1000.000	0,000	NE	
Gastrointestinal disorders	Colitis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6256	>1000.000	0,000	NE	
Gastrointestinal disorders	Constipation	n/a	68	100,0	6	8,8	62	91,2	33	100,0	5	15,2	28	84,8	0,2377	0,491	0,147	1,636	
Gastrointestinal disorders	Diarrhoea	n/a	68	100,0	20	29,4	48	70,6	33	100,0	5	15,2	28	84,8	0,2664	1,736	0,648	4,648	
Gastrointestinal disorders	Dry mouth	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4828	>1000.000	0,000	NE	
Gastrointestinal disorders	Dyspepsia	n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0,0	33	100,0	0,3949	>1000.000	0,000	NE	
Gastrointestinal disorders	Dysphagia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4931	>1000.000	0,000	NE	
Gastrointestinal disorders	Enteritis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6256	>1000.000	0,000	NE	
Gastrointestinal disorders	Gastric ulcer	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	NE	NE	NE	NE	
Gastrointestinal disorders	Gastrointestinal pain	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5675	>1000.000	0,000	NE	
Gastrointestinal disorders	Gastrooesophageal reflux disease	n/a	68	100,0	0	0,0	68	100,0	33	100,0	2	6,1	31	93,9	0,0413	0,000	0,000	NE	
Gastrointestinal disorders	Gingival bleeding	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4931	>1000.000	0,000	NE	
Gastrointestinal disorders	Gingival pain	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4931	>1000.000	0,000	NE	
Gastrointestinal disorders	Nausea	n/a	68	100,0	22	32,4	46	67,6	33	100,0	14	42,4	19	57,6	0,0786	0,543	0,273	1,082	
Gastrointestinal disorders	Pancreatitis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Gastrointestinal disorders	Paraesthesia oral	n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,1512	0,000	0,000	NE	
Gastrointestinal disorders	Proctalgia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Gastrointestinal disorders	Rectal haemorrhage	n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,1512	0,000	0,000	NE	
Gastrointestinal disorders	Stomatitis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	1	3,0	32	97,0	0,5933	0,478	0,030	7,641	
Gastrointestinal disorders	Tongue ulceration	n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,1512	0,000	0,000	NE	
Gastrointestinal disorders	Tooth loss	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6256	>1000.000	0,000	NE	
Gastrointestinal disorders	Vomiting	n/a	68	100,0	15	22,1	53	77,9	33	100,0	10	30,3	23	69,7	0,2115	0,600	0,267	1,348	
General disorders and administration site conditions		n/a	68	100,0	36	52,9	32	47,1	33	100,0	12	36,4	21	63,6	0,2554	1,467	0,755	2,852	
General disorders and administration site conditions	Asthenia	n/a	68	100,0	6	8,8	62	91,2	33	100,0	2	6,1	31	93,9	0,7132	1,351	0,270	6,750	
General disorders and administration site conditions	Chest discomfort	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6256	>1000.000	0,000	NE	
General disorders and administration site conditions	Chest pain	n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0,0	33	100,0	0,3227	>1000.000	0,000	NE	
General disorders and administration site conditions	Cyst	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6547	>1000.000	0,000	NE	
General disorders and administration site conditions	Extravasation	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6256	>1000.000	0,000	NE	
General disorders and administration site conditions	Fatigue	n/a	68	100,0	16	23,5	52	76,5	33	100,0	8	24,2	25	75,8	0,7456	0,868	0,367	2,048	
General disorders and administration site conditions	General physical health deterioration	n/a	68	100,0	3	4,4	65	95,6	33	100,0	0	0,0	33	100,0	0,2581	>1000.000	0,000	NE	
General disorders and administration site conditions	Influenza like illness	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	NE	NE	NE	NE	
General disorders and administration site conditions	Infusion site erythema	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4862	>1000.000	0,000	NE	
General disorders and administration site conditions	Infusion site extravasation	n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,0507	0,000	0,000	NE	
General disorders and administration site conditions	Injection site pain	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6434	>1000.000	0,000	NE	
General disorders and administration site conditions	Localised oedema	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
General disorders and administration site conditions	Malaise	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
General disorders and administration site conditions	Multiple organ dysfunction syndrome	n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,1445	0,000	0,000	NE	

General disorders and administration site conditions	Non-cardiac chest pain	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
General disorders and administration site conditions	Oedema	n/a	68	100,0	3	4,4	65	95,6	33	100,0	0	0,0	33	100,0	0,2237	>1000.000	0,000	NE	
General disorders and administration site conditions	Oedema peripheral	n/a	68	100,0	3	4,4	65	95,6	33	100,0	0	0,0	33	100,0	0,2293	>1000.000	0,000	NE	
General disorders and administration site conditions	Pain	n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0,0	33	100,0	0,3221	>1000.000	0,000	NE	
General disorders and administration site conditions	Peripheral swelling	n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0,0	33	100,0	0,3877	>1000.000	0,000	NE	
General disorders and administration site conditions	Pyrexia	n/a	68	100,0	10	14,7	58	85,3	33	100,0	3	9,1	30	90,9	0,5112	1,537	0,422	5,599	
General disorders and administration site conditions	Systemic inflammatory response syndrome	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Hepatobiliary disorders		n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0,0	33	100,0	0,3683	>1000.000	0,000	NE	
Hepatobiliary disorders	Hypertransaminasaemia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Hepatobiliary disorders	Ocular icterus	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5716	>1000.000	0,000	NE	
Immune system disorders		n/a	68	100,0	26	38,2	42	61,8	33	100,0	0	0,0	33	100,0	0,0002	>1000.000	0,000	NE	
Immune system disorders	Cytokine release syndrome	n/a	68	100,0	25	36,8	43	63,2	33	100,0	0	0,0	33	100,0	0,0002	>1000.000	0,000	NE	
Immune system disorders	Hypogammaglobulinaemia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,8111	>1000.000	0,000	NE	
Infections and infestations		n/a	68	100,0	32	47,1	36	52,9	33	100,0	5	15,2	28	84,8	0,0755	2,326	0,893	6,061	
Infections and infestations	Acinetobacter bacteraemia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6088	>1000.000	0,000	NE	
Infections and infestations	COVID-19	n/a	68	100,0	12	17,6	56	82,4	33	100,0	2	6,1	31	93,9	0,4971	1,700	0,361	7,994	
Infections and infestations	COVID-19 pneumonia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5754	>1000.000	0,000	NE	
Infections and infestations	Cellulitis	n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0,0	33	100,0	0,3682	>1000.000	0,000	NE	
Infections and infestations	Clostridial infection	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Infections and infestations	Clostridium difficile infection	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Infections and infestations	Cytomegalovirus infection	n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0,0	33	100,0	0,4138	>1000.000	0,000	NE	
Infections and infestations	Gingivitis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Infections and infestations	H1N1 influenza	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6592	>1000.000	0,000	NE	
Infections and infestations	Hepatitis B	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6434	>1000.000	0,000	NE	
Infections and infestations	Hepatitis B reactivation	n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0,0	33	100,0	0,4854	>1000.000	0,000	NE	
Infections and infestations	Herpes virus infection	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5973	>1000.000	0,000	NE	
Infections and infestations	Herpes zoster	n/a	68	100,0	3	4,4	65	95,6	33	100,0	0	0,0	33	100,0	NE	NE	NE	NE	
Infections and infestations	Klebsiella bacteraemia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5973	>1000.000	0,000	NE	
Infections and infestations	Lower respiratory tract infection	n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0,0	33	100,0	0,5081	>1000.000	0,000	NE	
Infections and infestations	Nasopharyngitis	n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0,0	33	100,0	0,6434	>1000.000	0,000	NE	
Infections and infestations	Neutropenic sepsis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5754	>1000.000	0,000	NE	
Infections and infestations	Oral candidiasis	n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,0803	0,000	0,000	NE	
Infections and infestations	Paronychia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5716	>1000.000	0,000	NE	
Infections and infestations	Periodontitis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4795	>1000.000	0,000	NE	

Infections and infestations	Pharyngitis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Infections and infestations	Pneumonia	n/a	68	100,0	5	7,4	63	92,6	33	100,0	2	6,1	31	93,9	0,5208	0,567	0,098	3,272	
Infections and infestations	Respiratory tract infection	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5289	>1000.000	0,000	NE	
Infections and infestations	Sepsis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Infections and infestations	Sinusitis	n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0,0	33	100,0	0,4033	>1000.000	0,000	NE	
Infections and infestations	Soft tissue infection	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6256	>1000.000	0,000	NE	
Infections and infestations	Upper respiratory tract infection	n/a	68	100,0	6	8,8	62	91,2	33	100,0	1	3,0	32	97,0	0,6172	1,718	0,200	14,726	
Infections and infestations	Urinary tract infection	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6088	>1000.000	0,000	NE	
Injury, poisoning and procedural complications		n/a	68	100,0	12	17,6	56	82,4	33	100,0	3	9,1	30	90,9	0,2950	1,954	0,545	7,004	
Injury, poisoning and procedural complications	Contusion	n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0,0	33	100,0	0,3347	>1000.000	0,000	NE	
Injury, poisoning and procedural complications	Fall	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4931	>1000.000	0,000	NE	
Injury, poisoning and procedural complications	Femur fracture	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4795	>1000.000	0,000	NE	
Injury, poisoning and procedural complications	Infusion related reaction	n/a	68	100,0	6	8,8	62	91,2	33	100,0	3	9,1	30	90,9	0,9276	0,937	0,228	3,850	
Injury, poisoning and procedural complications	Product storage error	n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0,0	33	100,0	0,3299	>1000.000	0,000	NE	
Investigations		n/a	68	100,0	47	69,1	21	30,9	33	100,0	18	54,5	15	45,5	0,0461	1,794	1,004	3,205	
Investigations	Alanine aminotransferase increased	n/a	68	100,0	22	32,4	46	67,6	33	100,0	5	15,2	28	84,8	0,1241	2,119	0,796	5,640	
Investigations	Amylase increased	n/a	68	100,0	4	5,9	64	94,1	33	100,0	0	0,0	33	100,0	0,2202	>1000.000	0,000	NE	
Investigations	Aspartate aminotransferase increased	n/a	68	100,0	26	38,2	42	61,8	33	100,0	6	18,2	27	81,8	0,1013	2,079	0,850	5,085	
Investigations	B-lymphocyte count decreased	n/a	68	100,0	3	4,4	65	95,6	33	100,0	0	0,0	33	100,0	0,2237	>1000.000	0,000	NE	
Investigations	Bilirubin conjugated increased	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4931	>1000.000	0,000	NE	
Investigations	Blood alkaline phosphatase increased	n/a	68	100,0	13	19,1	55	80,9	33	100,0	5	15,2	28	84,8	0,8774	1,086	0,383	3,079	
Investigations	Blood bilirubin increased	n/a	68	100,0	3	4,4	65	95,6	33	100,0	1	3,0	32	97,0	0,7605	1,419	0,148	13,645	
Investigations	Blood cholesterol increased	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Investigations	Blood creatinine increased	n/a	68	100,0	1	1,5	67	98,5	33	100,0	1	3,0	32	97,0	0,4939	0,392	0,024	6,333	
Investigations	Blood fibrinogen decreased	n/a	68	100,0	4	5,9	64	94,1	33	100,0	0	0,0	33	100,0	0,2318	>1000.000	0,000	NE	
Investigations	Blood glucose increased	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6256	>1000.000	0,000	NE	
Investigations	Blood immunoglobulin G decreased	n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	<.0001	0,000	0,000	NE	
Investigations	Blood immunoglobulin M decreased	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	NE	NE	NE	NE	
Investigations	Blood lactate dehydrogenase increased	n/a	68	100,0	8	11,8	60	88,2	33	100,0	0	0,0	33	100,0	0,0721	>1000.000	0,000	NE	
Investigations	C-reactive protein increased	n/a	68	100,0	10	14,7	58	85,3	33	100,0	2	6,1	31	93,9	0,3988	1,920	0,411	8,973	
Investigations	Fibrin D dimer increased	n/a	68	100,0	2	2,9	66	97,1	33	100,0	2	6,1	31	93,9	0,4647	0,489	0,069	3,470	
Investigations	Gamma-glutamyltransferase increased	n/a	68	100,0	12	17,6	56	82,4	33	100,0	4	12,1	29	87,9	0,6538	1,297	0,414	4,063	
Investigations	Globulins decreased	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Investigations	Hepatic enzyme increased	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4795	>1000.000	0,000	NE	
Investigations	Hepatitis B surface antigen positive	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5973	>1000.000	0,000	NE	

Investigations	Interferon gamma level increased	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Investigations	Interleukin level increased	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Investigations	Intraocular pressure increased	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5439	>1000.000	0,000	NE	
Investigations	Laboratory test abnormal	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Investigations	Lipase increased	n/a	68	100,0	6	8,8	62	91,2	33	100,0	0	0,0	33	100,0	0,1147	>1000.000	0,000	NE	
Investigations	Liver function test abnormal	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Investigations	Lymphocyte count decreased	n/a	68	100,0	22	32,4	46	67,6	33	100,0	2	6,1	31	93,9	0,0056	6,083	1,422	26,026	
Investigations	Lymphocyte count increased	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	NE	NE	NE	NE	
Investigations	Natural killer cell count decreased	n/a	68	100,0	5	7,4	63	92,6	33	100,0	0	0,0	33	100,0	0,2187	>1000.000	0,000	NE	
Investigations	Neutrophil count decreased	n/a	68	100,0	25	36,8	43	63,2	33	100,0	4	12,1	29	87,9	0,0474	2,815	0,969	8,180	
Investigations	Neutrophil count increased	n/a	68	100,0	3	4,4	65	95,6	33	100,0	1	3,0	32	97,0	0,8175	1,305	0,135	12,620	
Investigations	Platelet count decreased	n/a	68	100,0	32	47,1	36	52,9	33	100,0	11	33,3	22	66,7	0,1945	1,599	0,783	3,267	
Investigations	Platelet count increased	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4795	>1000.000	0,000	NE	
Investigations	Procalcitonin increased	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Investigations	Protein total decreased	n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0,0	33	100,0	0,3622	>1000.000	0,000	NE	
Investigations	Serum ferritin increased	n/a	68	100,0	11	16,2	57	83,8	33	100,0	5	15,2	28	84,8	0,8459	1,112	0,380	3,257	
Investigations	T-lymphocyte count decreased	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Investigations	T-lymphocyte count increased	n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0,0	33	100,0	0,3227	>1000.000	0,000	NE	
Investigations	Urinary occult blood positive	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6434	>1000.000	0,000	NE	
Investigations	Weight decreased	n/a	68	100,0	7	10,3	61	89,7	33	100,0	3	9,1	30	90,9	0,7705	0,816	0,208	3,200	
Investigations	White blood cell count decreased	n/a	68	100,0	22	32,4	46	67,6	33	100,0	2	6,1	31	93,9	0,0093	5,584	1,301	23,972	
Investigations	White blood cell count increased	n/a	68	100,0	4	5,9	64	94,1	33	100,0	0	0,0	33	100,0	0,1753	>1000.000	0,000	NE	
Metabolism and nutrition disorders		n/a	68	100,0	42	61,8	26	38,2	33	100,0	15	45,5	18	54,5	0,2455	1,423	0,782	2,591	
Metabolism and nutrition disorders	Decreased appetite	n/a	68	100,0	19	27,9	49	72,1	33	100,0	8	24,2	25	75,8	0,9947	1,003	0,435	2,310	
Metabolism and nutrition disorders	Electrolyte imbalance	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6256	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Hypercalcaemia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5675	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Hypercholesterolaemia	n/a	68	100,0	9	13,2	59	86,8	33	100,0	3	9,1	30	90,9	0,7413	1,247	0,335	4,637	
Metabolism and nutrition disorders	Hyperglycaemia	n/a	68	100,0	10	14,7	58	85,3	33	100,0	4	12,1	29	87,9	0,9017	1,076	0,335	3,457	
Metabolism and nutrition disorders	Hyperkalaemia	n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0,0	33	100,0	0,4581	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Hypermagnesaemia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	1	3,0	32	97,0	0,4511	0,360	0,022	5,772	
Metabolism and nutrition disorders	Hyperphosphataemia	n/a	68	100,0	6	8,8	62	91,2	33	100,0	3	9,1	30	90,9	0,7931	0,830	0,206	3,341	
Metabolism and nutrition disorders	Hypertriglyceridaemia	n/a	68	100,0	10	14,7	58	85,3	33	100,0	3	9,1	30	90,9	0,5059	1,547	0,423	5,652	
Metabolism and nutrition disorders	Hyperuricaemia	n/a	68	100,0	8	11,8	60	88,2	33	100,0	1	3,0	32	97,0	0,2821	2,988	0,368	24,246	
Metabolism and nutrition disorders	Hypoalbuminaemia	n/a	68	100,0	6	8,8	62	91,2	33	100,0	3	9,1	30	90,9	0,7657	0,808	0,198	3,298	
Metabolism and nutrition disorders	Hypocalcaemia	n/a	68	100,0	3	4,4	65	95,6	33	100,0	1	3,0	32	97,0	0,7440	1,455	0,151	13,982	
Metabolism and nutrition disorders	Hypoglycaemia	n/a	68	100,0	2	2,9	66	97,1	33	100,0	1	3,0	32	97,0	0,6850	0,608	0,054	6,892	
Metabolism and nutrition disorders	Hypokalaemia	n/a	68	100,0	17	25,0	51	75,0	33	100,0	2	6,1	31	93,9	0,0431	4,053	0,934	17,593	
Metabolism and nutrition disorders	Hypomagnesaemia	n/a	68	100,0	5	7,4	63	92,6	33	100,0	3	9,1	30	90,9	0,5538	0,643	0,147	2,805	

Metabolism and nutrition disorders	Hyponatraemia	n/a	68	100,0	10	14,7	58	85,3	33	100,0	2	6,1	31	93,9	0,4642	1,765	0,378	8,244	
Metabolism and nutrition disorders	Hypophosphataemia	n/a	68	100,0	6	8,8	62	91,2	33	100,0	1	3,0	32	97,0	0,2893	2,992	0,357	25,110	
Metabolism and nutrition disorders	Hypoproteinaemia	n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0,0	33	100,0	0,3385	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Malnutrition	n/a	68	100,0	1	1,5	67	98,5	33	100,0	1	3,0	32	97,0	0,6092	0,493	0,031	7,876	
Metabolism and nutrition disorders	Steroid diabetes	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Tumour lysis syndrome	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Musculoskeletal and connective tissue disorders		n/a	68	100,0	10	14,7	58	85,3	33	100,0	5	15,2	28	84,8	0,6933	0,805	0,272	2,376	
Musculoskeletal and connective tissue disorders	Arthralgia	n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0,0	33	100,0	0,3663	>1000.000	0,000	NE	
Musculoskeletal and connective tissue disorders	Back pain	n/a	68	100,0	3	4,4	65	95,6	33	100,0	3	9,1	30	90,9	0,2548	0,405	0,081	2,022	
Musculoskeletal and connective tissue disorders	Bone pain	n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,1245	0,000	0,000	NE	
Musculoskeletal and connective tissue disorders	Groin pain	n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,1512	0,000	0,000	NE	
Musculoskeletal and connective tissue disorders	Intervertebral disc degeneration	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5009	>1000.000	0,000	NE	
Musculoskeletal and connective tissue disorders	Muscle atrophy	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5967	>1000.000	0,000	NE	
Musculoskeletal and connective tissue disorders	Muscular weakness	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4931	>1000.000	0,000	NE	
Musculoskeletal and connective tissue disorders	Myalgia	n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,1445	0,000	0,000	NE	
Musculoskeletal and connective tissue disorders	Pain in extremity	n/a	68	100,0	4	5,9	64	94,1	33	100,0	1	3,0	32	97,0	0,6588	1,632	0,181	14,690	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		n/a	68	100,0	4	5,9	64	94,1	33	100,0	0	0,0	33	100,0	0,1946	>1000.000	0,000	NE	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5973	>1000.000	0,000	NE	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Tumour flare	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Tumour pain	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Tumour ulceration	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5151	>1000.000	0,000	NE	
Nervous system disorders		n/a	68	100,0	28	41,2	40	58,8	33	100,0	7	21,2	26	78,8	0,2998	1,555	0,670	3,608	
Nervous system disorders	Brain fog	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Nervous system disorders	Cerebral haemorrhage	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6101	>1000.000	0,000	NE	
Nervous system disorders	Dizziness	n/a	68	100,0	5	7,4	63	92,6	33	100,0	0	0,0	33	100,0	0,1571	>1000.000	0,000	NE	
Nervous system disorders	Dysgeusia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4931	>1000.000	0,000	NE	
Nervous system disorders	Headache	n/a	68	100,0	6	8,8	62	91,2	33	100,0	2	6,1	31	93,9	0,7715	1,268	0,254	6,327	
Nervous system disorders	Hypoaesthesia	n/a	68	100,0	5	7,4	63	92,6	33	100,0	0	0,0	33	100,0	0,2866	>1000.000	0,000	NE	
Nervous system disorders	Hypotonia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Nervous system disorders	Loss of consciousness	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4795	>1000.000	0,000	NE	
Nervous system disorders	Neuropathy peripheral	n/a	68	100,0	2	2,9	66	97,1	33	100,0	2	6,1	31	93,9	0,4389	0,470	0,066	3,334	
Nervous system disorders	Paraesthesia	n/a	68	100,0	4	5,9	64	94,1	33	100,0	2	6,1	31	93,9	0,7736	0,777	0,139	4,344	
Nervous system disorders	Peripheral motor neuropathy	n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,1512	0,000	0,000	NE	

Nervous system disorders	Peripheral sensory neuropathy	n/a	68	100,0	10	14,7	58	85,3	33	100,0	2	6,1	31	93,9	0,5413	1,611	0,344	7,542	
Nervous system disorders	Peroneal nerve palsy	n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,1512	0,000	0,000	NE	
Nervous system disorders	Polyneuropathy	n/a	68	100,0	3	4,4	65	95,6	33	100,0	0	0,0	33	100,0	0,4313	>1000.000	0,000	NE	
Nervous system disorders	Taste disorder	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4931	>1000.000	0,000	NE	
Product issues		n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0,0	33	100,0	0,3621	>1000.000	0,000	NE	
Product issues	Device breakage	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4795	>1000.000	0,000	NE	
Product issues	Device occlusion	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5675	>1000.000	0,000	NE	
Psychiatric disorders		n/a	68	100,0	12	17,6	56	82,4	33	100,0	4	12,1	29	87,9	0,6585	1,292	0,413	4,043	
Psychiatric disorders	Anxiety	n/a	68	100,0	1	1,5	67	98,5	33	100,0	1	3,0	32	97,0	0,5210	0,415	0,026	6,640	
Psychiatric disorders	Confusional state	n/a	68	100,0	3	4,4	65	95,6	33	100,0	0	0,0	33	100,0	0,2217	>1000.000	0,000	NE	
Psychiatric disorders	Delirium	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6256	>1000.000	0,000	NE	
Psychiatric disorders	Depression	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5501	>1000.000	0,000	NE	
Psychiatric disorders	Insomnia	n/a	68	100,0	8	11,8	60	88,2	33	100,0	4	12,1	29	87,9	0,7244	0,805	0,240	2,702	
Psychiatric disorders	Panic attack	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6256	>1000.000	0,000	NE	
Psychiatric disorders	Restlessness	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Renal and urinary disorders		n/a	68	100,0	4	5,9	64	94,1	33	100,0	0	0,0	33	100,0	0,2474	>1000.000	0,000	NE	
Renal and urinary disorders	Haematuria	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5675	>1000.000	0,000	NE	
Renal and urinary disorders	Nocturia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,8111	>1000.000	0,000	NE	
Renal and urinary disorders	Renal failure	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4931	>1000.000	0,000	NE	
Renal and urinary disorders	Urinary retention	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Reproductive system and breast disorders		n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Reproductive system and breast disorders	Benign prostatic hyperplasia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders		n/a	68	100,0	18	26,5	50	73,5	33	100,0	6	18,2	27	81,8	0,6658	1,231	0,479	3,160	
Respiratory, thoracic and mediastinal disorders	Cough	n/a	68	100,0	3	4,4	65	95,6	33	100,0	0	0,0	33	100,0	0,2353	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Dysphonia	n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,1512	0,000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Dyspnoea	n/a	68	100,0	9	13,2	59	86,8	33	100,0	1	3,0	32	97,0	0,2720	3,066	0,374	25,125	
Respiratory, thoracic and mediastinal disorders	Dyspnoea exertional	n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,1445	0,000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Epistaxis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Haemoptysis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6256	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Hiccups	n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0,0	33	100,0	0,3221	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Hypoxia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Nasal congestion	n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,1277	0,000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain	n/a	68	100,0	0	0,0	68	100,0	33	100,0	2	6,1	31	93,9	0,0353	0,000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Pleural effusion	n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,1512	0,000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Pneumonitis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Pneumothorax	n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,0507	0,000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Productive cough	n/a	68	100,0	3	4,4	65	95,6	33	100,0	2	6,1	31	93,9	0,6117	0,630	0,104	3,808	
Respiratory, thoracic and mediastinal disorders	Respiratory disorder	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,8055	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Rhinorrhoea	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5289	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,0679	0,000	0,000	NE	

Skin and subcutaneous tissue disorders		n/a	68	100,0	16	23,5	52	76,5	33	100,0	4	12,1	29	87,9	0,2334	1,930	0,642	5,798	
Skin and subcutaneous tissue disorders	Alopecia	n/a	68	100,0	3	4,4	65	95,6	33	100,0	0	0,0	33	100,0	0,2649	>1000.000	0,000	NE	
Skin and subcutaneous tissue disorders	Dry skin	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4931	>1000.000	0,000	NE	
Skin and subcutaneous tissue disorders	Erythema	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Skin and subcutaneous tissue disorders	Pruritus	n/a	68	100,0	4	5,9	64	94,1	33	100,0	2	6,1	31	93,9	0,8256	0,825	0,148	4,594	
Skin and subcutaneous tissue disorders	Rash	n/a	68	100,0	8	11,8	60	88,2	33	100,0	1	3,0	32	97,0	0,1750	3,818	0,476	30,652	
Skin and subcutaneous tissue disorders	Rash pruritic	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Skin and subcutaneous tissue disorders	Urticaria	n/a	68	100,0	1	1,5	67	98,5	33	100,0	1	3,0	32	97,0	0,4111	0,322	0,019	5,464	
Vascular disorders		n/a	68	100,0	12	17,6	56	82,4	33	100,0	3	9,1	30	90,9	0,5597	1,463	0,404	5,301	
Vascular disorders	Deep vein thrombosis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Vascular disorders	Haematoma	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5637	>1000.000	0,000	NE	
Vascular disorders	Hot flush	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6434	>1000.000	0,000	NE	
Vascular disorders	Hypertension	n/a	68	100,0	3	4,4	65	95,6	33	100,0	2	6,1	31	93,9	0,3447	0,397	0,055	2,883	
Vascular disorders	Hypotension	n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0,0	33	100,0	0,4051	>1000.000	0,000	NE	
Vascular disorders	Lymphoedema	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Vascular disorders	Orthostatic hypotension	n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,1374	0,000	0,000	NE	
Vascular disorders	Phlebitis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Vascular disorders	Superficial vein thrombosis	n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0,0	33	100,0	0,3268	>1000.000	0,000	NE	
Vascular disorders	Thrombophlebitis	n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,1512	0,000	0,000	NE	
Vascular disorders	Thrombosis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5002	>1000.000	0,000	NE	

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte_soc.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_soc_SE_AE_3Lp_16FEB2024_41944.xls
28FEB2025 12:20

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, All



Patients at risk											
Rituximab + GemOx	55	41	30	21	14	13	10	NE	NE	NE	NE
Glofitamab + GemOx	112	66	56	51	42	36	32	26	24	13	4
Patients censored											
Rituximab + GemOx	0	2	11	16	23	24	26	NE	NE	NE	NE
Glofitamab + GemOx	0	3	10	12	16	18	21	27	29	40	49

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Anaemia



Patients at risk											
Rituximab + GemOx	55	46	32	23	16	15	13	NE	NE	NE	NE
Glofitamab + GemOx	112	82	70	65	57	50	46	40	38	24	6
Patients censored											
Rituximab + GemOx	0	3	14	20	27	28	30	NE	NE	NE	NE
Glofitamab + GemOx	0	3	10	13	18	22	25	31	33	47	65

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Cytopenia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	6	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Febrile neutropenia



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	96	93	84	77	74	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	45	48	71	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Haemolysis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Hypoglobulinaemia



Patients at risk											
Rituximab + GemOx	55	52	39	29	20	17	15	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	64	61	38	6
Patients censored											
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Leukocytosis



Patients at risk												
Rituximab + GemOx	55	51	38	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	102	91	88	81	74	71	62	59	37	7	1
Patients censored												
Rituximab + GemOx	0	3	16	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	25	32	35	44	47	69	99	105

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Lymph node pain



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Lymphopenia



Patients at risk												
Rituximab + GemOx	55	51	38	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	105	94	92	84	77	74	64	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	17	25	32	35	45	47	70	102	108

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Microcytic anaemia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	74	64	61	38	6	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Myelosuppression



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	2	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Neutropenia



Patients at risk												
Rituximab + GemOx	55	51	38	28	19	17	14	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	104	92	87	78	70	65	52	48	30	6	1
Patients censored												
Rituximab + GemOx	0	3	16	24	33	35	37	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	32	35	45	48	66	90	95

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Thrombocytopenia



Patients at risk												
Rituximab + GemOx	55	47	37	27	19	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	98	87	84	74	69	65	54	52	33	7	1
Patients censored												
Rituximab + GemOx	0	3	13	21	29	31	33	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	13	16	25	30	33	43	45	64	90	96

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, All



Patients at risk												
Rituximab + GemOx	55	50	37	28	19	16	14	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	104	91	87	76	68	65	56	53	34	6	1
Patients censored												
Rituximab + GemOx	0	3	15	23	32	35	37	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	13	16	25	32	34	43	46	65	93	98

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Atrial fibrillation



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	94	91	82	75	70	60	57	36	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	70	99	105

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Atrial flutter



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	64	61	38	6	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Cardiac failure



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	83	75	73	63	60	38	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	36	46	49	71	102	108

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Cardiac failure congestive



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Chronic left ventricular failure



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Mitral valve incompetence



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Myocardial infarction



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Palpitations



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	92	83	76	73	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	49	71	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Sinus tachycardia



Patients at risk												
Rituximab + GemOx	55	52	38	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Ventricular extrasystoles



Patients at risk												
Rituximab + GemOx	55	51	37	28	19	16	14	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Ear and labyrinth disorders, All



Patients at risk												
Rituximab + GemOx	55	51	38	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	95	91	81	74	71	61	58	37	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	70	100	106

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Ear and labyrinth disorders, Deafness



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Ear and labyrinth disorders, Ear pain



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Ear and labyrinth disorders, Presbyacusis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Ear and labyrinth disorders, Tinnitus



Patients at risk												
Rituximab + GemOx	55	51	38	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Ear and labyrinth disorders, Vertigo



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Endocrine disorders, All



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	35	45	48	71	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Endocrine disorders, Adrenal insufficiency



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Endocrine disorders, Graves' disease



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Eye disorders, All



Patients at risk																		
Rituximab + GemOx	55	52	38	29	21	17	15	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	93	90	80	73	70	61	58	37	8	2	1	1	1	1	1	1
Patients censored																		
Rituximab + GemOx	0	3	16	25	33	36	38	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	49	70	99	105	106	106	106	106	106	106

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Eye disorders, Diabetic retinopathy



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	84	77	74	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Eye disorders, Dry eye



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Eye disorders, Eye swelling



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Eye disorders, Eyelid oedema



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Eye disorders, Vision blurred



Patients at risk												
Rituximab + GemOx	55	52	38	29	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Eye disorders, Visual impairment



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Eye disorders, Vitritis



Patients at risk																		
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	40	8	2	1	1	1	1	1	1
Patients censored																		
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110	111	111	111	111	111	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, All



Patients at risk											
Rituximab + GemOx	55	24	14	11	4	2	2	NE	NE	NE	NE
Glofitamab + GemOx	112	44	33	28	21	18	18	15	14	9	3
Patients censored											
Rituximab + GemOx	0	1	7	8	13	14	14	NE	NE	NE	NE
Glofitamab + GemOx	0	1	7	7	11	14	14	16	17	21	27

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Abdominal discomfort



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	105	94	91	82	75	72	62	59	37	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	102	108

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Abdominal distension



Patients at risk												
Rituximab + GemOx	55	52	39	29	20	16	14	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	97	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	71	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Abdominal pain



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	104	94	90	81	73	70	60	58	36	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	13	16	23	30	33	43	45	67	96	102

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Abdominal pain upper



Patients at risk												
Rituximab + GemOx	55	51	38	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	100	91	88	80	73	69	59	56	35	6	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	13	16	24	31	34	44	47	68	97	102

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Abdominal tenderness



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Anal incontinence



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Ascites



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Colitis ischaemic



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	36	46	49	72	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Constipation



Patients at risk												
Rituximab + GemOx	55	48	33	25	16	13	12	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	89	74	72	65	56	55	47	44	28	6	1
Patients censored												
Rituximab + GemOx	0	2	15	22	30	33	34	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	12	14	21	28	29	37	40	56	78	83

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Diarrhoea



Patients at risk												
Rituximab + GemOx	55	38	26	20	12	10	9	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	86	73	62	51	46	43	37	35	24	4	1
Patients censored												
Rituximab + GemOx	0	2	13	18	25	27	28	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	12	15	23	27	29	34	36	46	66	69

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Dry mouth



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	95	92	83	75	73	63	60	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	35	45	48	70	101	107

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Duodenal ulcer



Patients at risk												
Rituximab + GemOx	55	52	39	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Dyspepsia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	105	94	90	82	75	72	62	59	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	33	36	46	49	70	101	107

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Enterocolitis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	74	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Gastritis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	84	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Gastrooesophageal reflux disease



Patients at risk												
Rituximab + GemOx	55	52	39	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	94	91	81	75	72	62	59	37	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	71	101	107

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Gingival pain



Patients at risk												
Rituximab + GemOx	55	52	39	29	20	17	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Gingival swelling



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Haemorrhoidal haemorrhage



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	77	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Haemorrhoids



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	95	92	83	76	73	63	60	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	71	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Intestinal obstruction



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Large intestine perforation



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Lip swelling



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Mouth haemorrhage



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Mouth ulceration



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	105	92	89	79	72	69	60	57	35	6	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	49	71	100	105

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Nausea



Patients at risk											
Rituximab + GemOx	55	34	25	19	12	9	9	NE	NE	NE	NE
Glofitamab + GemOx	112	68	55	52	43	38	37	31	28	21	4
Patients censored											
Rituximab + GemOx	0	3	11	17	23	25	25	NE	NE	NE	NE
Glofitamab + GemOx	0	4	13	14	21	26	26	32	35	42	59

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Odynophagia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Oesophageal spasm



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	74	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Oral mucosa haematoma



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Oral pain



Patients at risk												
Rituximab + GemOx	55	52	39	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	92	83	76	73	63	60	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Pancreatitis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	84	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Pancreatitis acute



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Stomatitis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Toothache



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Upper gastrointestinal haemorrhage



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Vomiting



Patients at risk											
Rituximab + GemOx	55	44	31	23	14	11	11	NE	NE	NE	NE
Glofitamab + GemOx	112	90	74	72	63	56	54	47	44	28	4
Patients censored											
Rituximab + GemOx	0	3	16	24	32	35	35	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	15	23	30	32	39	42	58	82

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, All



Patients at risk											
Rituximab + GemOx	55	34	20	12	10	10	10	NE	NE	NE	NE
Glofitamab + GemOx	112	65	50	42	35	30	27	22	21	12	3
Patients censored											
Rituximab + GemOx	0	3	12	17	18	18	18	NE	NE	NE	NE
Glofitamab + GemOx	0	3	10	11	15	18	20	25	26	33	41

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Administration site extravasation



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Asthenia



Patients at risk												
Rituximab + GemOx	55	49	34	26	18	16	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	101	87	84	75	66	62	55	52	31	5	1
Patients censored												
Rituximab + GemOx	0	3	16	24	32	34	34	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	16	25	31	34	41	44	63	89	93

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Chest discomfort



Patients at risk												
Rituximab + GemOx	55	51	38	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	83	76	73	63	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	49	71	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Chest pain



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	95	92	83	76	72	61	58	37	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	71	101	107

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Chills



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	105	94	90	81	75	72	62	59	37	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	71	101	107

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Face oedema



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Facial pain



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Fatigue



Patients at risk												
Rituximab + GemOx	55	46	32	21	16	15	13	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	90	79	73	65	60	57	48	45	30	6	1
Patients censored												
Rituximab + GemOx	0	3	15	24	28	29	31	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	25	30	32	41	44	59	83	88

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, General physical health deterioration



Patients at risk												
Rituximab + GemOx	55	51	38	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Injection site pain



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	83	76	73	63	60	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	71	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Injection site reaction



Patients at risk												
Rituximab + GemOx	55	52	38	29	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Localised oedema



Patients at risk												
Rituximab + GemOx	55	51	38	29	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Malaise



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Multiple organ dysfunction syndrome



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Non-cardiac chest pain



Patients at risk												
Rituximab + GemOx	55	50	38	29	20	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	35	37	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Oedema



Patients at risk											
Rituximab + GemOx	55	51	38	29	20	17	15	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	6
Patients censored											
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Oedema peripheral



Patients at risk												
Rituximab + GemOx	55	49	38	30	21	18	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	94	89	79	71	68	59	57	37	7	1
Patients censored												
Rituximab + GemOx	0	3	14	21	30	33	35	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	44	46	66	96	102

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Pain



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	16	24	31	34	44	47	70	102	108

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Pyrexia



Patients at risk												
Rituximab + GemOx	55	50	38	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	96	81	74	65	59	56	46	44	23	5	1
Patients censored												
Rituximab + GemOx	0	3	15	23	32	35	37	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	12	14	20	25	27	35	37	57	75	79

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Swelling face



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Hepatobiliary disorders, All



Patients at risk												
Rituximab + GemOx	55	51	38	28	19	16	14	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	103	92	91	82	75	72	61	58	36	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	16	25	32	34	44	47	69	98	104

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Hepatobiliary disorders, Biliary colic



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Hepatobiliary disorders, Cholecystitis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Hepatobiliary disorders, Cholelithiasis



Patients at risk												
Rituximab + GemOx	55	52	39	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Hepatobiliary disorders, Cholestasis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Hepatobiliary disorders, Congestive hepatopathy



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Hepatobiliary disorders, Hepatic cytolysis



Patients at risk												
Rituximab + GemOx	55	51	38	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	95	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	17	26	33	36	46	49	71	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Hepatobiliary disorders, Hepatotoxicity



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Hepatobiliary disorders, Hyperbilirubinaemia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Hepatobiliary disorders, Liver disorder



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Immune system disorders, All



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	62	54	52	48	45	43	34	34	22	4	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	2	9	11	15	18	19	27	27	39	57	60

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Immune system disorders, Cytokine release syndrome



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	62	54	52	48	45	43	34	34	22	4	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	2	9	11	15	18	19	27	27	39	57	60

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Immune system disorders, Drug hypersensitivity



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Immune system disorders, Hypersensitivity



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, All



Patients at risk											
Rituximab + GemOx	55	43	32	23	16	12	10	NE	NE	NE	NE
Glofitamab + GemOx	112	89	76	61	48	44	38	31	25	11	1
Patients censored											
Rituximab + GemOx	0	2	9	15	20	22	24	NE	NE	NE	NE
Glofitamab + GemOx	0	1	5	7	13	14	15	17	19	31	40

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Bacteraemia



Patients at risk												
Rituximab + GemOx	55	51	38	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Biliary tract infection



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Bronchitis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	82	76	73	62	59	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	70	101	107

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, COVID-19



Patients at risk												
Rituximab + GemOx	55	50	38	29	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	104	95	91	81	75	71	63	60	38	4	1
Patients censored												
Rituximab + GemOx	0	3	14	22	29	31	33	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	12	14	23	26	29	34	36	58	90	93

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, COVID-19 pneumonia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	84	78	75	65	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	72	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Candida infection



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Cellulitis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	83	76	73	63	60	37	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Cellulitis of male external genital organ



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Citrobacter infection



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Cystitis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	84	77	74	64	60	37	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Cytomegalovirus infection reactivation



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	105	91	88	79	72	69	59	56	33	5	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	17	26	33	36	46	49	72	100	104

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Cytomegalovirus viraemia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Device related infection



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Ear, nose and throat infection



Patients at risk												
Rituximab + GemOx	55	52	39	30	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Enterococcal sepsis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Escherichia bacteraemia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Escherichia infection



Patients at risk												
Rituximab + GemOx	55	52	38	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Escherichia pyelonephritis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Eye infection



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	2	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Folliculitis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Gastroenteritis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	92	83	76	73	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	49	72	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Hepatitis B reactivation



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Herpes virus infection



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	37	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Herpes zoster



Patients at risk											
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	84	77	74	65	61	38	7
Patients censored											
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	49	71	102

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Infection



Patients at risk												
Rituximab + GemOx	55	51	39	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Influenza



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	77	74	64	60	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Infusion site cellulitis



Patients at risk												
Rituximab + GemOx	55	51	38	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Listeriosis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Lower respiratory tract infection



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	77	73	62	58	35	6	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	32	35	45	48	71	100	105

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Meningitis aseptic



Patients at risk													
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	97	94	85	78	75	65	62	40	8	2	1
Patients censored													
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	71	103	109	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Nasopharyngitis



Patients at risk												
Rituximab + GemOx	55	52	39	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	74	63	60	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Onychomycosis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Oral candidiasis



Patients at risk												
Rituximab + GemOx	55	51	38	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	82	75	73	63	60	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	23	32	35	37	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	36	46	49	70	102	108

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Orchitis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Otitis media



Patients at risk												
Rituximab + GemOx	55	52	39	30	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Paronychia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Pneumocystis jirovecii pneumonia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Pneumonia



Patients at risk											
Rituximab + GemOx	55	51	38	29	20	17	15	NE	NE	NE	NE
Glofitamab + GemOx	112	103	95	87	78	72	68	58	54	32	7
Patients censored											
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE
Glofitamab + GemOx	0	4	12	15	23	28	31	38	41	63	88

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Pneumonia bacterial



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Pneumonia pneumococcal



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Respiratory tract infection



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	74	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Respiratory tract infection bacterial



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Rhinitis



Patients at risk												
Rituximab + GemOx	55	52	38	29	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Rhinovirus infection



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Sepsis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	32	35	45	48	71	102	108

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Septic shock



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	16	25	32	35	45	48	71	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Sinusitis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	83	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	72	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Skin infection



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	83	77	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	35	45	48	71	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Splenic abscess



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Streptococcal sepsis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Upper respiratory tract infection



Patients at risk												
Rituximab + GemOx	55	52	39	29	20	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	105	93	89	79	73	69	58	54	33	6	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	35	45	48	69	96	101

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Ureteritis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Urinary tract infection



Patients at risk												
Rituximab + GemOx	55	51	38	28	21	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	95	92	83	76	73	62	59	37	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	32	35	37	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	35	45	48	70	100	106

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Urosepsis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Viraemia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	6	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Vulvovaginitis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, All



Patients at risk											
Rituximab + GemOx	55	45	34	25	18	15	14	NE	NE	NE	NE
Glofitamab + GemOx	112	86	76	70	60	53	51	42	40	25	3
Patients censored											
Rituximab + GemOx	0	2	13	21	28	31	32	NE	NE	NE	NE
Glofitamab + GemOx	0	3	11	14	22	28	29	37	39	54	76

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Contusion



Patients at risk												
Rituximab + GemOx	55	51	38	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	64	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Fall



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	95	90	80	73	70	59	56	35	6	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	35	45	48	69	98	103

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Femur fracture



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	74	64	61	38	6	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Hip fracture



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Infusion related reaction



Patients at risk											
Rituximab + GemOx	55	47	35	25	18	15	14	NE	NE	NE	NE
Glofitamab + GemOx	112	90	81	78	69	62	60	52	49	31	5
Patients censored											
Rituximab + GemOx	0	2	14	23	30	33	34	NE	NE	NE	NE
Glofitamab + GemOx	0	3	12	15	24	31	33	41	44	62	88

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Product storage error



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	95	92	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	33	36	46	49	72	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Road traffic accident



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	74	64	61	38	6	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Skin laceration



Patients at risk												
Rituximab + GemOx	55	51	38	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	84	77	74	63	60	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Splenic rupture



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Subdural haematoma



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Tibia fracture



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	74	64	61	38	6	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Tracheal haemorrhage



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Vascular access site erythema



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Vascular access site pain



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Vulvovaginal injury



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Wound complication



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Investigations, All



Patients at risk											
Rituximab + GemOx	55	27	19	15	10	8	8	NE	NE	NE	NE
Glofitamab + GemOx	112	53	44	35	28	25	23	18	18	9	1
Patients censored											
Rituximab + GemOx	0	1	8	11	16	17	17	NE	NE	NE	NE
Glofitamab + GemOx	0	3	8	8	12	14	15	19	19	28	36

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Activated partial thromboplastin time shortened



Patients at risk											
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	6
Patients censored											
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Alanine aminotransferase abnormal



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Alanine aminotransferase increased



Patients at risk											
Rituximab + GemOx	55	42	30	22	16	13	12	NE	NE	NE	NE
Glofitamab + GemOx	112	82	73	67	60	54	49	41	40	25	3
Patients censored											
Rituximab + GemOx	0	3	12	20	26	28	29	NE	NE	NE	NE
Glofitamab + GemOx	0	4	12	14	20	25	28	36	37	52	74

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Alpha hydroxybutyrate dehydrogenase increased



Patients at risk												
Rituximab + GemOx	55	52	38	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	64	60	37	6	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Amylase increased



Patients at risk												
Rituximab + GemOx	55	51	37	29	20	16	14	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Aspartate aminotransferase abnormal



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Aspartate aminotransferase increased



Patients at risk											
Rituximab + GemOx	55	44	31	23	17	14	13	NE	NE	NE	NE
Glofitamab + GemOx	112	85	77	68	62	55	52	44	43	27	3
Patients censored											
Rituximab + GemOx	0	3	14	22	28	30	31	NE	NE	NE	NE
Glofitamab + GemOx	0	4	11	13	19	24	27	35	36	52	76

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, B-lymphocyte count decreased



Patients at risk												
Rituximab + GemOx	55	52	38	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	49	72	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Blood albumin decreased



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	96	93	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	25	32	35	45	48	71	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Blood alkaline phosphatase abnormal



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Blood alkaline phosphatase increased



Patients at risk											
Rituximab + GemOx	55	44	32	25	17	15	14	NE	NE	NE	NE
Glofitamab + GemOx	112	93	81	78	72	66	63	55	53	33	4
Patients censored											
Rituximab + GemOx	0	2	13	20	28	29	30	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	17	23	28	31	38	40	60	89

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Blood bilirubin increased



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	17	26	33	36	46	49	72	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Blood cholesterol increased



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Blood creatine increased



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Blood creatinine decreased



Patients at risk												
Rituximab + GemOx	55	51	38	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Blood creatinine increased



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	95	92	83	76	73	64	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	48	71	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Blood fibrinogen decreased



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Blood fibrinogen increased



Patients at risk												
Rituximab + GemOx	55	51	38	29	20	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Blood immunoglobulin A decreased



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Blood immunoglobulin M decreased



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Blood lactate dehydrogenase increased



Patients at risk											
Rituximab + GemOx	55	50	36	27	18	15	14	NE	NE	NE	NE
Glofitamab + GemOx	112	102	89	82	74	68	65	56	54	32	4
Patients censored											
Rituximab + GemOx	0	3	16	25	34	36	37	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	32	35	44	46	68	96

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Blood magnesium decreased



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	95	92	83	76	73	63	60	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Blood thyroid stimulating hormone decreased



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Body temperature increased



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, C-reactive protein increased



Patients at risk												
Rituximab + GemOx	55	50	37	28	19	17	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	101	91	88	81	74	71	62	59	37	7	1
Patients censored												
Rituximab + GemOx	0	3	15	23	32	34	35	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	16	23	30	33	42	45	67	97	103

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, CD19 lymphocytes decreased



Patients at risk											
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	6
Patients censored											
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Carbon dioxide decreased



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	2	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Cytomegalovirus test positive



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Electrocardiogram PR prolongation



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Electrocardiogram ST-T change



Patients at risk												
Rituximab + GemOx	55	52	38	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Eosinophil count increased



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Fibrin D dimer increased



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	105	94	91	83	76	73	65	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	33	36	44	47	70	101	107

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Gamma-glutamyltransferase abnormal



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Gamma-glutamyltransferase increased



Patients at risk											
Rituximab + GemOx	55	47	36	27	17	15	14	NE	NE	NE	NE
Glofitamab + GemOx	112	102	89	86	78	71	65	57	55	32	3
Patients censored											
Rituximab + GemOx	0	3	14	23	32	34	35	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	17	24	31	34	42	44	67	96

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Globulins decreased



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Heart rate increased



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Human rhinovirus test positive



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Interleukin level increased



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Light chain analysis decreased



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Lipase increased



Patients at risk												
Rituximab + GemOx	55	49	35	28	19	16	14	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	77	73	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	23	32	35	37	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	45	48	71	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Liver function test abnormal



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	92	83	76	73	63	60	37	6	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Lymphocyte count decreased



Patients at risk											
Rituximab + GemOx	55	44	32	26	18	14	13	NE	NE	NE	NE
Glofitamab + GemOx	112	96	85	81	75	68	65	57	54	32	6
Patients censored											
Rituximab + GemOx	0	3	14	20	28	31	32	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	24	31	34	41	43	65	91

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Magnetic resonance imaging abnormal



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Natural killer cell count decreased



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	92	84	77	74	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	33	36	45	48	71	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Natural killer cell count increased



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Neutrophil count decreased



Patients at risk											
Rituximab + GemOx	55	47	34	23	14	12	12	NE	NE	NE	NE
Glofitamab + GemOx	112	95	82	77	70	61	57	46	45	24	4
Patients censored											
Rituximab + GemOx	0	1	13	20	27	29	29	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	24	29	32	40	41	62	82

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Neutrophil count increased



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	95	92	84	76	73	63	60	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	33	36	46	49	71	102	108

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Oxygen saturation decreased



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	84	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Platelet count decreased



Patients at risk											
Rituximab + GemOx	55	43	34	24	17	13	11	NE	NE	NE	NE
Glofitamab + GemOx	112	80	71	67	61	57	54	48	47	25	4
Patients censored											
Rituximab + GemOx	0	1	10	18	24	27	28	NE	NE	NE	NE
Glofitamab + GemOx	0	4	12	14	19	23	25	31	32	53	74

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Platelet count increased



Patients at risk												
Rituximab + GemOx	55	51	38	28	19	16	14	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Procalcitonin increased



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Protein total decreased



Patients at risk											
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	92	84	77	74	64	61	37	6
Patients censored											
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	33	36	46	49	72	103

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, SARS-CoV-2 test positive



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Serum ferritin increased



Patients at risk											
Rituximab + GemOx	55	48	35	25	16	13	12	NE	NE	NE	NE
Glofitamab + GemOx	112	92	80	77	71	65	62	55	53	31	4
Patients censored											
Rituximab + GemOx	0	3	16	25	34	37	38	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	17	23	29	32	39	41	63	90

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, T-lymphocyte count decreased



Patients at risk												
Rituximab + GemOx	55	52	38	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, T-lymphocyte count increased



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Transaminases increased



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Urine output decreased



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Weight decreased



Patients at risk											
Rituximab + GemOx	55	51	38	28	19	16	14	NE	NE	NE	NE
Glofitamab + GemOx	112	106	93	91	82	74	69	59	56	37	6
Patients censored											
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	15	24	30	33	43	46	65	96

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Weight increased



Patients at risk												
Rituximab + GemOx	55	52	38	29	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, White blood cell count decreased



Patients at risk											
Rituximab + GemOx	55	48	35	24	17	15	14	NE	NE	NE	NE
Glofitamab + GemOx	112	96	85	83	74	68	65	56	54	32	6
Patients censored											
Rituximab + GemOx	0	1	13	21	28	30	31	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	16	24	30	33	42	43	65	91

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, White blood cell count increased



Patients at risk												
Rituximab + GemOx	55	51	38	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, All



Patients at risk											
Rituximab + GemOx	55	32	25	19	12	8	8	NE	NE	NE	NE
Glofitamab + GemOx	112	64	56	51	42	40	35	30	30	18	3
Patients censored											
Rituximab + GemOx	0	2	8	12	19	21	21	NE	NE	NE	NE
Glofitamab + GemOx	0	2	7	9	13	14	15	20	20	32	47

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Decreased appetite



Patients at risk												
Rituximab + GemOx	55	41	29	22	15	12	12	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	92	80	72	60	56	52	45	44	29	6	1
Patients censored												
Rituximab + GemOx	0	3	12	17	24	27	27	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	13	16	23	26	29	36	37	52	75	80

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Dehydration



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	104	94	91	82	76	73	63	60	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	32	34	44	47	68	100	106

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Diabetic metabolic decompensation



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Electrolyte imbalance



Patients at risk											
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE
Glofitamab + GemOx	112	105	95	92	83	76	73	63	60	37	6
Patients censored											
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	32	35	45	48	71	102

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Folate deficiency



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	79	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypercalcaemia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	97	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	71	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypercholesterolaemia



Patients at risk												
Rituximab + GemOx	55	50	36	28	19	16	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	103	92	88	80	73	70	61	58	36	7	1
Patients censored												
Rituximab + GemOx	0	3	16	24	33	36	37	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	25	32	35	44	47	69	98	104

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hyperglycaemia



Patients at risk											
Rituximab + GemOx	55	51	38	30	21	18	16	NE	NE	NE	NE
Glofitamab + GemOx	112	107	95	92	83	76	73	63	59	36	6
Patients censored											
Rituximab + GemOx	0	3	16	24	33	36	38	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	72	102

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hyperkalaemia



Patients at risk												
Rituximab + GemOx	55	51	38	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	92	83	76	73	63	60	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	70	102	108

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hyperlipidaemia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hyperphosphataemia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	104	93	90	82	75	72	63	60	37	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	33	36	45	48	71	101	107

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypertriglyceridaemia



Patients at risk												
Rituximab + GemOx	55	51	38	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	103	91	88	80	72	69	60	58	36	7	1
Patients censored												
Rituximab + GemOx	0	3	16	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	33	36	45	47	69	98	104

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hyperuricaemia



Patients at risk											
Rituximab + GemOx	55	51	39	28	19	16	14	NE	NE	NE	NE
Glofitamab + GemOx	112	104	93	90	82	75	72	63	59	37	6
Patients censored											
Rituximab + GemOx	0	3	15	23	32	34	36	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	32	35	44	47	69	100

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypervolaemia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypoalbuminaemia



Patients at risk												
Rituximab + GemOx	55	50	37	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	95	91	84	77	73	63	60	37	7	1
Patients censored												
Rituximab + GemOx	0	3	15	23	32	35	37	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	24	31	34	44	47	70	100	106

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypocalcaemia



Patients at risk												
Rituximab + GemOx	55	49	36	29	20	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	105	94	89	81	72	69	59	56	34	6	1
Patients censored												
Rituximab + GemOx	0	2	15	22	31	33	35	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	17	25	32	35	45	48	70	98	103

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypochloraemia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	17	25	32	35	45	48	71	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypoglycaemia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypokalaemia



Patients at risk											
Rituximab + GemOx	55	49	36	28	19	17	15	NE	NE	NE	NE
Glofitamab + GemOx	112	98	89	85	78	72	67	57	55	31	5
Patients censored											
Rituximab + GemOx	0	3	15	23	32	34	36	NE	NE	NE	NE
Glofitamab + GemOx	0	3	12	14	21	27	30	40	42	65	91

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypomagnesaemia



Patients at risk												
Rituximab + GemOx	55	48	35	28	19	16	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	103	91	88	79	72	70	60	57	34	6	1
Patients censored												
Rituximab + GemOx	0	3	15	21	30	32	33	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	35	45	48	70	98	103

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hyponatraemia



Patients at risk												
Rituximab + GemOx	55	51	38	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	104	92	88	82	75	72	63	59	37	7	1
Patients censored												
Rituximab + GemOx	0	2	14	22	31	34	36	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	16	22	29	32	41	44	66	96	102

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypophosphataemia



Patients at risk												
Rituximab + GemOx	55	51	38	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	95	92	83	76	73	63	59	37	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	71	101	107

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypoproteinaemia



Patients at risk											
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	84	76	73	63	60	37	6
Patients censored											
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Iron deficiency



Patients at risk											
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	60	37	6
Patients censored											
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Malnutrition



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Tumour lysis syndrome



Patients at risk												
Rituximab + GemOx	55	49	38	29	20	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	14	23	32	34	36	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	13	16	25	32	35	45	48	71	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Vitamin D deficiency



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Musculoskeletal and connective tissue disorders, All



Patients at risk												
Rituximab + GemOx	55	43	31	24	18	14	13	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	94	79	73	65	57	55	45	44	28	7	1
Patients censored												
Rituximab + GemOx	0	3	14	21	26	29	30	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	23	30	32	41	42	58	79	85

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Musculoskeletal and connective tissue disorders, Arthralgia



Patients at risk												
Rituximab + GemOx	55	51	38	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	103	91	86	79	72	68	58	56	35	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	25	32	35	44	46	67	95	101

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Musculoskeletal and connective tissue disorders, Back pain



Patients at risk												
Rituximab + GemOx	55	48	36	27	21	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	95	92	84	76	73	63	60	38	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	30	33	35	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	33	36	46	49	71	102	108

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Musculoskeletal and connective tissue disorders, Bone pain



Patients at risk												
Rituximab + GemOx	55	51	38	29	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	94	91	82	74	71	61	58	37	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	71	101	107

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Musculoskeletal and connective tissue disorders, Groin pain



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	63	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	49	71	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Musculoskeletal and connective tissue disorders, Joint swelling



Patients at risk												
Rituximab + GemOx	55	51	38	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Musculoskeletal and connective tissue disorders, Muscle spasms



Patients at risk												
Rituximab + GemOx	55	50	38	29	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	32	35	37	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Musculoskeletal and connective tissue disorders, Muscular weakness



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	97	94	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Musculoskeletal and connective tissue disorders, Musculoskeletal chest pain



Patients at risk												
Rituximab + GemOx	55	51	37	28	20	17	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	92	82	75	72	62	59	37	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	32	35	36	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	102	108

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Musculoskeletal and connective tissue disorders, Musculoskeletal pain



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Musculoskeletal and connective tissue disorders, Musculoskeletal stiffness



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	84	77	74	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Musculoskeletal and connective tissue disorders, Myalgia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	105	94	91	83	76	73	63	60	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	33	36	46	49	71	102	108

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Musculoskeletal and connective tissue disorders, Neck pain



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Musculoskeletal and connective tissue disorders, Pain in extremity



Patients at risk												
Rituximab + GemOx	55	50	37	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	105	93	90	80	73	71	61	59	37	7	1
Patients censored												
Rituximab + GemOx	0	3	15	22	31	34	36	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	36	46	48	70	100	106

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Musculoskeletal and connective tissue disorders, Pain in jaw



Patients at risk												
Rituximab + GemOx	55	51	38	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Neoplasms benign, malignant and unspecified (incl cysts and polyps), All



Patients at risk												
Rituximab + GemOx	55	51	38	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	105	96	93	84	76	73	63	60	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	13	16	25	32	35	45	48	69	101	107

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Neoplasms benign, malignant and unspecified (incl cysts and polyps), Squamous cell carcinoma



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Neoplasms benign, malignant and unspecified (incl cysts and polyps), Tumour pain



Patients at risk												
Rituximab + GemOx	55	51	38	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	105	96	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	13	16	25	32	35	45	48	70	102	108

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, All



Patients at risk											
Rituximab + GemOx	55	38	26	17	10	8	7	NE	NE	NE	NE
Glofitamab + GemOx	112	75	59	51	45	40	34	25	23	15	3
Patients censored											
Rituximab + GemOx	0	3	14	21	27	28	29	NE	NE	NE	NE
Glofitamab + GemOx	0	3	13	15	21	25	27	34	36	43	55

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Ageusia



Patients at risk												
Rituximab + GemOx	55	51	38	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Balance disorder



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Cognitive disorder



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Dizziness



Patients at risk											
Rituximab + GemOx	55	50	36	27	20	17	15	NE	NE	NE	NE
Glofitamab + GemOx	112	103	91	88	79	72	69	58	55	34	5
Patients censored											
Rituximab + GemOx	0	3	16	25	32	35	37	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	71	100

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Dysaesthesia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	95	92	83	76	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	36	46	49	71	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Dysgeusia



Patients at risk												
Rituximab + GemOx	55	52	39	29	21	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	104	92	87	78	73	69	60	57	37	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	32	35	44	47	67	97	103

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Extrapyramidal disorder



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Headache



Patients at risk												
Rituximab + GemOx	55	49	36	27	18	15	14	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	102	90	86	78	71	68	58	55	36	7	1
Patients censored												
Rituximab + GemOx	0	3	15	23	32	35	36	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	25	32	35	45	48	67	96	102

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Hypoaesthesia



Patients at risk												
Rituximab + GemOx	55	51	38	28	18	15	14	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	92	83	76	72	62	59	37	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	102	108

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Immune effector cell-associated neurotoxicity syndrome



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Lethargy



Patients at risk												
Rituximab + GemOx	55	50	37	28	19	16	14	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	63	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	49	72	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Memory impairment



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Metabolic encephalopathy



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	84	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Myoclonus



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Neuropathy peripheral



Patients at risk											
Rituximab + GemOx	55	50	35	26	18	15	13	NE	NE	NE	NE
Glofitamab + GemOx	112	99	84	81	75	68	65	53	50	32	5
Patients censored											
Rituximab + GemOx	0	3	16	25	33	36	38	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	17	23	29	32	42	44	62	89

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Paraesthesia



Patients at risk												
Rituximab + GemOx	55	50	37	28	20	17	14	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	103	92	89	80	73	70	61	58	37	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	49	70	100	106

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Peripheral motor neuropathy



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Peripheral sensory neuropathy



Patients at risk												
Rituximab + GemOx	55	46	34	27	18	16	14	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	103	89	82	73	66	62	53	50	31	6	1
Patients censored												
Rituximab + GemOx	0	3	15	22	31	33	35	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	35	44	47	64	89	94

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Polyneuropathy



Patients at risk												
Rituximab + GemOx	55	51	38	28	19	16	14	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Syncope



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	91	82	75	72	63	60	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	32	35	44	47	69	100	106

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Taste disorder



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Tremor



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Psychiatric disorders, All



Patients at risk												
Rituximab + GemOx	55	49	34	26	20	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	95	81	78	69	61	57	51	46	30	4	1
Patients censored												
Rituximab + GemOx	0	2	15	22	28	30	32	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	13	15	24	30	33	38	41	57	83	86

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Psychiatric disorders, Affective disorder



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Psychiatric disorders, Anxiety



Patients at risk												
Rituximab + GemOx	55	52	38	29	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	95	92	83	76	73	63	60	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	71	102	108

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Psychiatric disorders, Bradyphrenia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Psychiatric disorders, Confusional state



Patients at risk												
Rituximab + GemOx	55	52	39	29	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Psychiatric disorders, Delirium



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	49	72	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Psychiatric disorders, Depression



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	96	93	84	77	73	63	60	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	32	35	45	48	70	101	107

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Psychiatric disorders, Initial insomnia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Psychiatric disorders, Insomnia



Patients at risk												
Rituximab + GemOx	55	49	35	28	20	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	101	87	84	75	67	64	57	52	33	4	1
Patients censored												
Rituximab + GemOx	0	2	15	22	30	32	34	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	44	47	66	95	98

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Psychiatric disorders, Libido decreased



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Psychiatric disorders, Mood altered



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Renal and urinary disorders, All



Patients at risk												
Rituximab + GemOx	55	50	37	29	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	103	93	90	81	73	69	59	56	35	7	1
Patients censored												
Rituximab + GemOx	0	3	15	23	31	34	36	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	13	16	25	32	35	44	47	67	95	101

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Renal and urinary disorders, Acute kidney injury



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	13	16	25	32	35	45	48	70	101	107

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Renal and urinary disorders, Bladder perforation



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Renal and urinary disorders, Dysuria



Patients at risk												
Rituximab + GemOx	55	52	38	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Renal and urinary disorders, Haematuria



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Renal and urinary disorders, Nocturia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Renal and urinary disorders, Pollakiuria



Patients at risk												
Rituximab + GemOx	55	51	38	29	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Renal and urinary disorders, Renal ischaemia



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Renal and urinary disorders, Urinary incontinence



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	77	74	63	60	37	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Renal and urinary disorders, Urinary tract pain



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Reproductive system and breast disorders, All



Patients at risk												
Rituximab + GemOx	55	50	38	29	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	96	93	84	78	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	32	35	37	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	32	35	45	48	70	102	108

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Reproductive system and breast disorders, Benign prostatic hyperplasia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	79	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Reproductive system and breast disorders, Pelvic pain



Patients at risk												
Rituximab + GemOx	55	50	38	29	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	32	35	37	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Reproductive system and breast disorders, Prostatic haemorrhage



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Reproductive system and breast disorders, Prostatism



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, All



Patients at risk												
Rituximab + GemOx	55	45	35	25	17	13	11	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	94	82	74	65	59	56	48	46	28	7	1
Patients censored												
Rituximab + GemOx	0	3	13	20	28	31	33	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	13	16	23	28	29	36	38	55	76	82

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Acute respiratory distress syndrome



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	84	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Acute respiratory failure



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Asphyxia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Aspiration



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Asthma



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Bronchospasm



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Chronic obstructive pulmonary disease



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Cough



Patients at risk												
Rituximab + GemOx	55	49	36	28	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	93	89	79	72	68	59	56	34	7	1
Patients censored												
Rituximab + GemOx	0	3	16	24	32	35	37	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	32	35	44	47	69	96	102

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Dysphonia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Dyspnoea



Patients at risk												
Rituximab + GemOx	55	52	39	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	104	94	91	81	74	71	61	58	35	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	35	45	48	71	99	105

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Dyspnoea exertional



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	95	92	83	76	73	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	49	72	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Epistaxis



Patients at risk												
Rituximab + GemOx	55	51	37	28	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	92	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	33	36	46	49	71	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Hiccups



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	92	83	76	73	63	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	49	72	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Hypoxia



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Lower respiratory tract congestion



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Oropharyngeal pain



Patients at risk												
Rituximab + GemOx	55	51	38	29	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	83	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	72	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Pleural effusion



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	77	74	63	60	37	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Pneumonitis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	74	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	49	71	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Productive cough



Patients at risk																		
Rituximab + GemOx	55	52	39	29	20	17	15	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	95	92	84	77	74	65	62	40	8	2	1	1	1	1	1	1
Patients censored																		
Rituximab + GemOx	0	3	16	24	33	36	38	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	33	36	45	48	70	102	108	109	109	109	109	109	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Pulmonary embolism



Patients at risk												
Rituximab + GemOx	55	52	39	29	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Pulmonary hypertension



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Rhinalgia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Rhinorrhoea



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	92	83	76	74	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	36	45	48	71	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Sneezing



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Tachypnoea



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Upper-airway cough syndrome



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Skin and subcutaneous tissue disorders, All



Patients at risk												
Rituximab + GemOx	55	45	30	21	15	12	10	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	87	75	68	61	56	50	42	40	26	7	1
Patients censored												
Rituximab + GemOx	0	3	15	23	29	31	33	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	13	15	21	25	28	33	35	48	67	73

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Skin and subcutaneous tissue disorders, Alopecia



Patients at risk												
Rituximab + GemOx	55	51	37	28	20	16	14	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Skin and subcutaneous tissue disorders, Drug eruption



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Skin and subcutaneous tissue disorders, Dry skin



Patients at risk												
Rituximab + GemOx	55	52	39	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	84	77	74	64	61	37	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Skin and subcutaneous tissue disorders, Eczema



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Skin and subcutaneous tissue disorders, Erythema



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	94	91	83	76	72	60	57	37	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	33	36	45	48	68	98	104

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Skin and subcutaneous tissue disorders, Erythema multiforme



Patients at risk												
Rituximab + GemOx	55	52	38	29	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Skin and subcutaneous tissue disorders, Hyperkeratosis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Skin and subcutaneous tissue disorders, Nail dystrophy



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Skin and subcutaneous tissue disorders, Night sweats



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	95	92	83	76	73	63	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	48	71	102	108

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Skin and subcutaneous tissue disorders, Onychoclasis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Skin and subcutaneous tissue disorders, Pruritus



Patients at risk												
Rituximab + GemOx	55	50	36	28	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	101	92	87	79	71	67	59	56	35	7	1
Patients censored												
Rituximab + GemOx	0	3	16	24	32	35	37	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	13	16	24	31	34	42	45	66	94	100

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Skin and subcutaneous tissue disorders, Rash



Patients at risk												
Rituximab + GemOx	55	51	34	26	18	16	14	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	97	86	83	75	69	65	56	54	34	7	1
Patients censored												
Rituximab + GemOx	0	3	16	24	32	34	36	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	13	15	23	29	32	41	43	63	90	96

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Skin and subcutaneous tissue disorders, Rash erythematous



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Skin and subcutaneous tissue disorders, Rash maculo-papular



Patients at risk												
Rituximab + GemOx	55	51	38	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	95	92	83	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	72	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Skin and subcutaneous tissue disorders, Rash pruritic



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Skin and subcutaneous tissue disorders, Urticaria



Patients at risk												
Rituximab + GemOx	55	51	38	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	92	83	76	73	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	49	71	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, All



Patients at risk												
Rituximab + GemOx	55	45	36	27	18	15	13	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	92	78	75	67	61	61	52	50	33	6	1
Patients censored												
Rituximab + GemOx	0	3	12	21	30	33	35	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	13	16	22	28	28	37	39	56	83	88

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, Deep vein thrombosis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, Embolism



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	95	91	83	77	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	32	34	44	47	70	102	108

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, Flushing



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	76	73	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	49	72	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, Hypertension



Patients at risk												
Rituximab + GemOx	55	50	37	28	19	16	14	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, Hypotension



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	101	89	86	78	72	71	61	58	38	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	32	33	43	46	66	97	103

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, Orthostatic hypotension



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	83	76	73	63	60	37	6	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	103	108

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, Phlebitis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	94	91	82	75	72	62	59	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	33	36	46	49	70	101	107

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, Superficial vein thrombosis



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	104	93	90	81	74	71	61	59	37	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	49	71	101	107

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, Thrombophlebitis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	94	91	83	76	73	63	60	37	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	33	36	46	49	72	102	108

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, Vasculitis



Patients at risk												
Rituximab + GemOx	55	51	38	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, Vein disorder



Patients at risk												
Rituximab + GemOx	55	50	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	14	23	32	35	37	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_2L_16FEB2024_41944.pdf
23AUG2024 23:40

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, All



Patients at risk										
Rituximab + GemOx	33	17	9	7	6	6	5	NE	NE	NE
Glofitamab + GemOx	68	33	25	23	19	19	16	14	14	3
Patients censored										
Rituximab + GemOx	0	1	9	11	12	12	13	NE	NE	NE
Glofitamab + GemOx	0	1	5	6	8	8	11	12	12	22

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Anaemia



Patients at risk											
Rituximab + GemOx	33	25	13	11	7	7	5	NE	NE	NE	NE
Glofitamab + GemOx	68	42	33	30	26	26	22	18	18	5	1
Patients censored											
Rituximab + GemOx	0	1	13	15	19	19	21	NE	NE	NE	NE
Glofitamab + GemOx	0	2	8	9	12	12	16	19	19	31	35

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Febrile neutropenia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	63	53	49	41	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	1	11	15	23	23	28	33	34	49	60	63

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Leukocytosis



Patients at risk												
Rituximab + GemOx	33	27	16	13	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	64	51	47	39	39	33	28	27	12	4	1
Patients censored												
Rituximab + GemOx	0	1	12	14	17	18	20	26	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	61	64

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Leukopenia



Patients at risk												
Rituximab + GemOx	33	30	16	13	9	8	6	1	NE	NE	NE	NE
Glofitamab + GemOx	68	64	52	49	41	41	35	30	29	14	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	25	25	31	36	37	52	63	65

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Lymphopenia



Patients at risk											
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE
Glofitamab + GemOx	68	64	52	48	39	39	34	29	28	13	2
Patients censored											
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	51	62

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Myelosuppression



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Neutropenia



Patients at risk											
Rituximab + GemOx	33	26	12	9	7	7	5	NE	NE	NE	NE
Glofitamab + GemOx	68	62	50	46	35	33	29	27	26	12	1
Patients censored											
Rituximab + GemOx	0	2	16	19	21	21	23	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	16	24	24	28	29	29	43	54

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Neutrophilia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	53	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Thrombocytopenia



Patients at risk												
Rituximab + GemOx	33	25	12	8	6	6	5	NE	NE	NE	NE	NE
Glofitamab + GemOx	68	57	45	43	35	35	31	29	28	14	3	1
Patients censored												
Rituximab + GemOx	0	2	14	17	19	19	20	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	1	12	14	21	21	25	27	28	42	53	55

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, All



Patients at risk											
Rituximab + GemOx	33	30	16	13	9	9	7	1	NE	NE	NE
Glofitamab + GemOx	68	63	53	49	41	41	35	30	29	14	3
Patients censored											
Rituximab + GemOx	0	2	16	19	22	22	24	30	NE	NE	NE
Glofitamab + GemOx	0	1	9	13	21	21	27	32	33	48	59

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Angina pectoris



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	1	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Arrhythmia



Patients at risk											
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	14	3
Patients censored											
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Atrial fibrillation



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Cardiac arrest



Patients at risk												
Rituximab + GemOx	33	31	17	14	9	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Cardiac failure



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Cardiac failure congestive



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Coronary artery stenosis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Palpitations



Patients at risk												
Rituximab + GemOx	33	30	16	13	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	22	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Tachycardia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	1	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Ear and labyrinth disorders, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	48	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	51	62	65

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Ear and labyrinth disorders, Deafness



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Ear and labyrinth disorders, Tinnitus



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Eye disorders, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	64	50	46	39	38	32	27	26	14	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	49	60	62

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Eye disorders, Eye irritation



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Eye disorders, Eye pain



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Eye disorders, Lacrimation increased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	53	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Eye disorders, Necrotising retinitis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	41	41	35	30	29	14	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Eye disorders, Retinal haemorrhage



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	53	49	41	41	35	30	29	14	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Eye disorders, Uveitis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	14	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Eye disorders, Vitreous floaters



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, All



Patients at risk											
Rituximab + GemOx	33	14	7	4	3	3	2	NE	NE	NE	NE
Glofitamab + GemOx	68	33	25	24	17	16	14	13	12	6	2
Patients censored											
Rituximab + GemOx	0	1	8	10	10	10	11	NE	NE	NE	NE
Glofitamab + GemOx	0	1	6	7	9	9	11	12	13	19	23

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Abdominal discomfort



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Abdominal distension



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	53	49	41	41	35	31	29	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	35	36	51	61	64

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Abdominal pain



Patients at risk												
Rituximab + GemOx	33	30	16	13	9	8	6	1	NE	NE	NE	NE
Glofitamab + GemOx	68	60	49	46	40	39	32	27	26	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	16	22	22	28	33	34	45	56	59

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Abdominal pain lower



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Abdominal pain upper



Patients at risk												
Rituximab + GemOx	33	31	17	14	9	8	6	NE	NE	NE	NE	NE
Glofitamab + GemOx	68	64	52	48	39	38	33	29	28	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	35	36	50	60	63

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Anal haemorrhage



Patients at risk												
Rituximab + GemOx	33	31	17	13	9	8	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Ascites



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	16	24	24	30	35	36	51	62	65

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Colitis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Constipation



Patients at risk												
Rituximab + GemOx	33	26	14	11	8	7	5	1	NE	NE	NE	NE
Glofitamab + GemOx	68	62	51	46	38	37	32	28	27	14	4	1
Patients censored												
Rituximab + GemOx	0	2	14	17	20	21	23	27	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	30	34	35	48	58	61

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Diarrhoea



Patients at risk											
Rituximab + GemOx	33	27	13	10	7	6	5	1	NE	NE	NE
Glofitamab + GemOx	68	55	41	37	30	30	26	24	23	10	3
Patients censored											
Rituximab + GemOx	0	2	16	19	22	22	23	27	NE	NE	NE
Glofitamab + GemOx	0	1	11	13	18	18	22	24	25	38	45

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Dry mouth



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Dyspepsia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	40	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	30	35	36	51	62	65

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Dysphagia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Enteritis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Gastric ulcer



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	37	32	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Gastrointestinal pain



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	49	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Gastrooesophageal reflux disease



Patients at risk												
Rituximab + GemOx	33	29	15	12	8	8	6	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	23	25	30	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Gingival bleeding



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Gingival pain



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Nausea



Patients at risk												
Rituximab + GemOx	33	19	9	6	4	4	3	1	NE	NE	NE	NE
Glofitamab + GemOx	68	53	39	35	27	26	23	20	19	9	3	1
Patients censored												
Rituximab + GemOx	0	1	11	13	15	15	16	18	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	16	21	21	23	26	27	37	43	45

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Pancreatitis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Paraesthesia oral



Patients at risk												
Rituximab + GemOx	33	30	16	13	9	8	6	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Proctalgia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Rectal haemorrhage



Patients at risk												
Rituximab + GemOx	33	30	16	13	9	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Stomatitis



Patients at risk												
Rituximab + GemOx	33	30	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	15	18	22	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Tongue ulceration



Patients at risk												
Rituximab + GemOx	33	30	16	13	9	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Tooth loss



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	41	35	30	29	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Vomiting



Patients at risk											
Rituximab + GemOx	33	22	13	9	6	6	5	1	NE	NE	NE
Glofitamab + GemOx	68	56	41	38	32	32	28	24	23	11	3
Patients censored											
Rituximab + GemOx	0	2	11	14	17	17	18	22	NE	NE	NE
Glofitamab + GemOx	0	2	14	16	21	21	25	29	30	42	50

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, All



Patients at risk												
Rituximab + GemOx	33	23	8	6	4	4	3	1	NE	NE	NE	NE
Glofitamab + GemOx	68	35	29	26	21	21	19	17	17	8	3	1
Patients censored												
Rituximab + GemOx	0	2	13	15	17	17	18	20	NE	NE	NE	NE
Glofitamab + GemOx	0	2	7	8	11	11	13	15	15	24	29	31

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Asthenia



Patients at risk												
Rituximab + GemOx	33	30	16	13	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	61	50	47	39	39	34	29	29	14	3	1
Patients censored												
Rituximab + GemOx	0	2	15	18	21	22	24	30	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	16	23	23	28	33	33	48	59	61

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Chest discomfort



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Chest pain



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	64	53	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	51	62	65

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Cyst



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Extravasation



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	41	35	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Fatigue



Patients at risk												
Rituximab + GemOx	33	25	10	7	4	4	3	1	NE	NE	NE	NE
Glofitamab + GemOx	68	52	42	38	30	30	26	23	22	10	4	1
Patients censored												
Rituximab + GemOx	0	2	15	18	21	21	22	24	NE	NE	NE	NE
Glofitamab + GemOx	0	2	12	15	22	22	26	29	30	42	48	51

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, General physical health deterioration



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	15	23	23	29	34	35	50	61	64

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Influenza like illness



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	29	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Infusion site erythema



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Infusion site extravasation



Patients at risk												
Rituximab + GemOx	33	31	17	14	9	8	6	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Injection site pain



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Localised oedema



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Malaise



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Multiple organ dysfunction syndrome



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	15	18	22	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Non-cardiac chest pain



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Oedema



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	63	52	48	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	24	24	30	35	36	50	61	64

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Oedema peripheral



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	64	53	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	12	15	23	23	29	34	35	50	61	64

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Pain



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	64	52	48	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	51	62	65

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Peripheral swelling



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	51	62	65

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Pyrexia



Patients at risk												
Rituximab + GemOx	33	30	16	14	9	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	58	47	43	36	36	32	28	27	14	4	1
Patients censored												
Rituximab + GemOx	0	2	15	17	21	21	23	29	NE	NE	NE	NE
Glofitamab + GemOx	0	2	12	15	22	22	26	30	31	44	54	57

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Systemic inflammatory response syndrome



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Hepatobiliary disorders, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	48	40	40	34	29	28	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	51	62	65

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Hepatobiliary disorders, Hypertransaminasaemia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Hepatobiliary disorders, Ocular icterus



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Immune system disorders, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	46	34	31	26	26	22	18	17	7	2	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	1	11	13	18	18	21	24	25	35	40	41

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Immune system disorders, Cytokine release syndrome



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	46	34	31	26	26	22	19	18	8	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	1	11	13	18	18	21	24	25	35	40	42

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Immune system disorders, Hypogammaglobulinaemia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	30	29	14	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, All



Patients at risk										
Rituximab + GemOx	33	31	17	12	8	8	6	1	NE	NE
Glofitamab + GemOx	68	56	46	40	27	23	21	18	16	7
Patients censored										
Rituximab + GemOx	0	2	13	16	20	20	22	27	NE	NE
Glofitamab + GemOx	0	1	8	10	18	18	20	21	21	29

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Acinetobacter bacteraemia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	41	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, COVID-19



Patients at risk											
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE
Glofitamab + GemOx	68	64	51	49	41	40	35	30	27	14	3
Patients censored											
Rituximab + GemOx	0	2	14	17	21	22	24	30	NE	NE	NE
Glofitamab + GemOx	0	1	11	13	21	21	25	29	30	43	54

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, COVID-19 pneumonia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	55	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Cellulitis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	49	41	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	1	13	17	25	25	30	35	36	51	62	65

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Clostridial infection



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Clostridium difficile infection



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Cytomegalovirus infection



Patients at risk											
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE
Glofitamab + GemOx	68	66	53	49	41	40	35	30	29	14	3
Patients censored											
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	52	63

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Gingivitis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, H1N1 influenza



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Hepatitis B



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Hepatitis B reactivation



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	41	41	35	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	35	36	51	62	65

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Herpes virus infection



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	41	41	35	30	29	14	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Herpes zoster



Patients at risk											
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	29	14	4
Patients censored											
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	62

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Klebsiella bacteraemia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	41	41	35	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Lower respiratory tract infection



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	51	62	65

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Nasopharyngitis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	41	35	30	28	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	62	65

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Neutropenic sepsis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	55	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Oral candidiasis



Patients at risk												
Rituximab + GemOx	33	31	17	13	9	8	6	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Paronychia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	49	41	41	35	30	29	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Periodontitis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Pharyngitis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Pneumonia



Patients at risk											
Rituximab + GemOx	33	31	17	13	9	9	7	1	NE	NE	NE
Glofitamab + GemOx	68	65	54	48	40	40	34	28	27	14	3
Patients censored											
Rituximab + GemOx	0	2	15	18	22	22	24	30	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	49	60

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Respiratory tract infection



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	53	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Sepsis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Sinusitis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	53	49	40	40	34	29	28	13	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	63	65

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Soft tissue infection



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	41	35	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Upper respiratory tract infection



Patients at risk											
Rituximab + GemOx	33	31	17	14	10	8	6	1	NE	NE	NE
Glofitamab + GemOx	68	65	52	47	38	37	32	26	26	12	2
Patients censored											
Rituximab + GemOx	0	2	16	19	23	24	26	31	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	36	50	60

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Urinary tract infection



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	41	41	35	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, All



Patients at risk												
Rituximab + GemOx	33	29	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	56	44	40	34	34	30	26	25	13	4	1
Patients censored												
Rituximab + GemOx	0	1	13	16	20	21	23	29	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	16	22	22	26	30	31	43	52	55

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Contusion



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	52	48	40	40	35	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	35	36	51	62	65

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Fall



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Femur fracture



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Infusion related reaction



Patients at risk												
Rituximab + GemOx	33	29	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	61	49	44	37	37	32	27	26	13	4	1
Patients censored												
Rituximab + GemOx	0	1	13	16	20	21	23	29	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	30	35	36	49	58	61

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Product storage error



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	64	52	48	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	51	62	65

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Investigations, All



Patients at risk											
Rituximab + GemOx	33	15	9	7	5	3	2	NE	NE	NE	NE
Glofitamab + GemOx	68	21	12	10	9	9	7	7	6	1	1
Patients censored											
Rituximab + GemOx	0	1	7	9	11	12	13	NE	NE	NE	NE
Glofitamab + GemOx	0	2	9	11	12	12	14	14	15	20	20

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Alanine aminotransferase increased



Patients at risk											
Rituximab + GemOx	33	26	13	10	6	5	3	NE	NE	NE	NE
Glofitamab + GemOx	68	48	36	31	25	24	20	18	17	6	1
Patients censored											
Rituximab + GemOx	0	2	15	18	22	23	25	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	22	22	26	28	29	40	45

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Amylase increased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	64	52	47	39	38	32	27	26	13	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	51	61	63

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Aspartate aminotransferase increased



Patients at risk											
Rituximab + GemOx	33	28	14	10	7	5	3	NE	NE	NE	NE
Glofitamab + GemOx	68	51	33	29	25	23	20	18	17	7	1
Patients censored											
Rituximab + GemOx	0	2	15	18	21	22	24	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	19	19	22	24	25	35	41

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, B-lymphocyte count decreased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	63	51	47	39	39	33	28	27	13	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	62	64

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Bilirubin conjugated increased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	53	49	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Blood alkaline phosphatase increased



Patients at risk											
Rituximab + GemOx	33	26	14	12	8	7	5	1	NE	NE	NE
Glofitamab + GemOx	68	57	45	41	34	31	28	23	22	9	3
Patients censored											
Rituximab + GemOx	0	2	14	16	20	21	23	27	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	24	24	27	32	33	46	52

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Blood bilirubin increased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	63	51	47	40	40	34	29	28	13	4	1
Patients censored												
Rituximab + GemOx	0	2	15	18	22	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	52	61	64

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Blood cholesterol increased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Blood creatinine increased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	18	22	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Blood fibrinogen decreased



Patients at risk											
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE
Glofitamab + GemOx	68	64	51	47	39	39	33	28	26	12	2
Patients censored											
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	62

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Blood glucose increased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	41	35	30	29	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Blood immunoglobulin G decreased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Blood immunoglobulin M decreased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Blood lactate dehydrogenase increased



Patients at risk											
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE
Glofitamab + GemOx	68	61	48	44	35	35	31	27	26	11	2
Patients censored											
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	30	34	35	49	58

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, C-reactive protein increased



Patients at risk											
Rituximab + GemOx	33	30	17	14	10	9	7	1	NE	NE	NE
Glofitamab + GemOx	68	60	47	44	36	35	30	23	22	8	2
Patients censored											
Rituximab + GemOx	0	2	15	17	21	22	24	30	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	25	25	30	35	36	50	56

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Fibrin D dimer increased



Patients at risk												
Rituximab + GemOx	33	29	16	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	64	52	48	40	40	35	30	29	14	4	1
Patients censored												
Rituximab + GemOx	0	2	15	17	21	22	24	30	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	52	62	65

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Gamma-glutamyltransferase increased



Patients at risk											
Rituximab + GemOx	33	28	15	13	8	7	5	NE	NE	NE	NE
Glofitamab + GemOx	68	57	46	41	33	31	28	23	22	8	2
Patients censored											
Rituximab + GemOx	0	2	15	17	21	22	24	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	28	33	34	48	54

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Globulins decreased



Patients at risk											
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	14	3
Patients censored											
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Hepatic enzyme increased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Hepatitis B surface antigen positive



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	41	41	35	30	29	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Interferon gamma level increased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Interleukin level increased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Intraocular pressure increased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	53	49	41	41	35	30	29	14	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Laboratory test abnormal



Patients at risk											
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	14	3
Patients censored											
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Lipase increased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	63	50	46	38	37	31	26	25	12	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	25	25	31	36	37	50	59	61

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Liver function test abnormal



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Lymphocyte count decreased



Patients at risk											
Rituximab + GemOx	33	30	17	14	10	9	7	1	NE	NE	NE
Glofitamab + GemOx	68	47	35	30	23	23	20	17	16	4	2
Patients censored											
Rituximab + GemOx	0	2	14	17	21	22	24	30	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	23	23	26	29	30	42	44

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Lymphocyte count increased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Natural killer cell count decreased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	63	51	47	40	40	34	29	27	13	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	51	60	62

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Neutrophil count decreased



Patients at risk											
Rituximab + GemOx	33	29	16	12	10	9	7	1	NE	NE	NE
Glofitamab + GemOx	68	52	39	30	28	26	22	17	16	5	2
Patients censored											
Rituximab + GemOx	0	2	15	17	19	20	22	28	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	20	20	23	26	27	38	41

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Neutrophil count increased



Patients at risk												
Rituximab + GemOx	33	30	16	13	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	64	52	47	39	39	33	28	27	13	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	22	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	61	64

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Platelet count decreased



Patients at risk											
Rituximab + GemOx	33	21	12	10	8	6	5	1	NE	NE	NE
Glofitamab + GemOx	68	38	29	23	19	19	17	14	13	4	2
Patients censored											
Rituximab + GemOx	0	2	11	13	15	16	17	21	NE	NE	NE
Glofitamab + GemOx	0	2	10	14	18	18	20	22	23	32	34

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Platelet count increased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Procalcitonin increased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Protein total decreased



Patients at risk											
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE
Glofitamab + GemOx	68	65	53	48	40	40	34	29	28	13	2
Patients censored											
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Serum ferritin increased



Patients at risk												
Rituximab + GemOx	33	27	15	13	9	8	6	1	NE	NE	NE	NE
Glofitamab + GemOx	68	55	44	40	32	32	28	23	22	8	3	1
Patients censored												
Rituximab + GemOx	0	1	13	15	19	20	22	27	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	29	34	35	49	54	56

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, T-lymphocyte count decreased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, T-lymphocyte count increased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	64	52	48	40	40	34	29	28	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	62	65

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Urinary occult blood positive



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	41	35	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Weight decreased



Patients at risk											
Rituximab + GemOx	33	29	17	13	9	8	6	1	NE	NE	NE
Glofitamab + GemOx	68	64	52	46	39	38	32	27	26	12	3
Patients censored											
Rituximab + GemOx	0	2	14	17	21	22	24	29	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	24	24	29	34	35	49	58

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, White blood cell count decreased



Patients at risk											
Rituximab + GemOx	33	29	16	14	10	9	7	1	NE	NE	NE
Glofitamab + GemOx	68	49	36	31	27	26	23	19	17	4	2
Patients censored											
Rituximab + GemOx	0	2	15	17	21	22	24	30	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	21	21	24	28	29	42	44

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, White blood cell count increased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	63	51	46	38	38	33	28	27	13	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	51	60	63

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, All



Patients at risk											
Rituximab + GemOx	33	20	9	8	5	5	5	1	NE	NE	NE
Glofitamab + GemOx	68	35	25	21	18	18	14	12	11	3	2
Patients censored											
Rituximab + GemOx	0	1	10	11	13	13	13	17	NE	NE	NE
Glofitamab + GemOx	0	1	8	8	9	9	13	14	15	23	24

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Decreased appetite



Patients at risk												
Rituximab + GemOx	33	25	13	11	7	6	6	1	NE	NE	NE	NE
Glofitamab + GemOx	68	56	42	35	29	29	24	21	20	9	4	1
Patients censored												
Rituximab + GemOx	0	2	13	15	18	19	19	24	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	20	20	25	28	29	40	45	48

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Electrolyte imbalance



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypercalcaemia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	49	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypercholesterolaemia



Patients at risk											
Rituximab + GemOx	33	30	17	14	10	9	7	1	NE	NE	NE
Glofitamab + GemOx	68	61	49	43	35	35	29	24	23	9	2
Patients censored											
Rituximab + GemOx	0	1	14	16	20	21	23	29	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	30	35	36	50	57

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hyperglycaemia



Patients at risk												
Rituximab + GemOx	33	29	15	13	9	8	6	1	NE	NE	NE	NE
Glofitamab + GemOx	68	60	47	42	35	35	29	24	23	10	4	1
Patients censored												
Rituximab + GemOx	0	1	14	16	20	21	23	28	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	24	24	29	34	35	48	54	57

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hyperkalaemia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	29	28	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	51	62	65

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypermagnesaemia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	53	49	41	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	18	22	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hyperphosphataemia



Patients at risk												
Rituximab + GemOx	33	30	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	63	51	46	37	37	32	27	26	11	3	1
Patients censored												
Rituximab + GemOx	0	1	14	16	20	21	23	29	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	30	35	36	51	59	61

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypertriglyceridaemia



Patients at risk											
Rituximab + GemOx	33	29	17	14	10	9	7	1	NE	NE	NE
Glofitamab + GemOx	68	58	46	41	33	33	28	23	22	8	2
Patients censored											
Rituximab + GemOx	0	2	14	16	20	21	23	29	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	30	35	36	50	56

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hyperuricaemia



Patients at risk											
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE
Glofitamab + GemOx	68	63	50	43	36	36	32	27	26	11	3
Patients censored											
Rituximab + GemOx	0	2	16	18	22	23	25	31	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	29	33	34	49	57

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypoalbuminaemia



Patients at risk												
Rituximab + GemOx	33	30	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	62	50	46	39	39	31	27	26	11	3	1
Patients censored												
Rituximab + GemOx	0	1	14	16	20	21	23	29	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	35	36	51	59	61

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypocalcaemia



Patients at risk												
Rituximab + GemOx	33	30	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	63	51	48	41	41	35	30	29	14	3	1
Patients censored												
Rituximab + GemOx	0	2	15	18	22	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	24	24	30	35	36	51	62	64

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypoglycaemia



Patients at risk												
Rituximab + GemOx	33	31	17	14	9	8	6	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	53	49	41	40	34	30	29	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	36	37	52	62	65

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypokalaemia



Patients at risk												
Rituximab + GemOx	33	30	15	12	9	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	54	44	43	37	37	31	29	28	13	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	22	22	24	30	NE	NE	NE	NE
Glofitamab + GemOx	0	1	10	10	14	14	20	22	23	38	48	50

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypomagnesaemia



Patients at risk												
Rituximab + GemOx	33	29	15	12	8	8	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	63	51	47	39	39	33	27	26	13	4	1
Patients censored												
Rituximab + GemOx	0	1	15	18	22	22	23	29	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	25	25	31	36	37	50	59	62

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hyponatraemia



Patients at risk												
Rituximab + GemOx	33	31	17	13	9	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	61	50	46	40	39	33	29	28	13	3	1
Patients censored												
Rituximab + GemOx	0	2	16	18	22	22	24	30	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	15	20	20	26	30	31	45	55	57

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypophosphataemia



Patients at risk												
Rituximab + GemOx	33	30	16	13	9	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	61	50	47	40	40	34	29	28	14	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	1	12	15	22	22	28	33	34	48	59	61

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypoproteinaemia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	52	48	41	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	30	35	36	51	62	65

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Malnutrition



Patients at risk												
Rituximab + GemOx	33	30	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	14	4	1
Patients censored												
Rituximab + GemOx	0	2	15	18	22	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Steroid diabetes



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Tumour lysis syndrome



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Musculoskeletal and connective tissue disorders, All



Patients at risk											
Rituximab + GemOx	33	29	13	10	7	6	5	1	NE	NE	NE
Glofitamab + GemOx	68	62	49	42	34	34	29	24	24	14	3
Patients censored											
Rituximab + GemOx	0	2	15	18	21	22	23	27	NE	NE	NE
Glofitamab + GemOx	0	1	12	16	24	24	29	34	34	44	55

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Musculoskeletal and connective tissue disorders, Arthralgia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	48	40	40	34	29	28	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	51	62	65

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Musculoskeletal and connective tissue disorders, Back pain



Patients at risk												
Rituximab + GemOx	33	30	15	12	8	7	5	1	NE	NE	NE	NE
Glofitamab + GemOx	68	64	52	47	39	39	33	28	28	15	4	1
Patients censored												
Rituximab + GemOx	0	2	15	18	22	23	25	29	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	37	50	61	64

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Musculoskeletal and connective tissue disorders, Bone pain



Patients at risk												
Rituximab + GemOx	33	31	16	13	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	22	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Musculoskeletal and connective tissue disorders, Groin pain



Patients at risk												
Rituximab + GemOx	33	30	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	15	18	22	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Musculoskeletal and connective tissue disorders, Intervertebral disc degeneration



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	53	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Musculoskeletal and connective tissue disorders, Muscle atrophy



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	49	41	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Musculoskeletal and connective tissue disorders, Muscular weakness



Patients at risk											
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	14	3
Patients censored											
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Musculoskeletal and connective tissue disorders, Myalgia



Patients at risk												
Rituximab + GemOx	33	30	16	13	9	8	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Musculoskeletal and connective tissue disorders, Pain in extremity



Patients at risk											
Rituximab + GemOx	33	31	16	13	9	8	6	1	NE	NE	NE
Glofitamab + GemOx	68	66	53	48	40	40	34	29	28	14	3
Patients censored											
Rituximab + GemOx	0	2	16	19	23	24	26	31	NE	NE	NE
Glofitamab + GemOx	0	1	12	16	24	24	30	35	36	50	61

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Neoplasms benign, malignant and unspecified (incl cysts and polyps), All



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	64	54	50	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	11	15	23	23	29	34	35	49	60	63

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Neoplasms benign, malignant and unspecified (incl cysts and polyps), Squamous cell carcinoma



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Neoplasms benign, malignant and unspecified (incl cysts and polyps), Tumour flare



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Neoplasms benign, malignant and unspecified (incl cysts and polyps), Tumour pain



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Neoplasms benign, malignant and unspecified (incl cysts and polyps), Tumour ulceration



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, All



Patients at risk											
Rituximab + GemOx	33	25	11	8	6	5	4	1	NE	NE	NE
Glofitamab + GemOx	68	52	37	32	26	24	18	14	13	7	2
Patients censored											
Rituximab + GemOx	0	2	15	18	20	21	22	25	NE	NE	NE
Glofitamab + GemOx	0	1	13	17	22	22	24	27	27	33	38

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Brain fog



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Cerebral haemorrhage



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Dizziness



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	62	50	46	38	38	33	29	29	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	35	35	49	59	62

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Dysgeusia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Headache



Patients at risk												
Rituximab + GemOx	33	31	15	12	9	8	6	1	NE	NE	NE	NE
Glofitamab + GemOx	68	63	49	45	38	37	33	29	29	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	22	23	25	30	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	29	33	33	48	58	61

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Hypoaesthesia



Patients at risk											
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE
Glofitamab + GemOx	68	66	53	49	41	40	32	27	25	12	3
Patients censored											
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	51	60

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Hypotonia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Loss of consciousness



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Neuropathy peripheral



Patients at risk												
Rituximab + GemOx	33	29	15	12	9	8	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	52	48	40	40	34	29	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	22	23	24	30	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	37	51	62	65

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Paraesthesia



Patients at risk												
Rituximab + GemOx	33	29	15	12	8	7	5	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	52	48	41	40	34	29	28	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	30	NE	NE	NE	NE
Glofitamab + GemOx	0	1	13	17	24	24	30	35	36	49	60	63

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Peripheral motor neuropathy



Patients at risk												
Rituximab + GemOx	33	30	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	15	18	22	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Peripheral sensory neuropathy



Patients at risk												
Rituximab + GemOx	33	30	16	13	8	7	5	1	NE	NE	NE	NE
Glofitamab + GemOx	68	62	50	45	36	33	28	22	21	11	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	30	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	47	55	57

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Peroneal nerve palsy



Patients at risk												
Rituximab + GemOx	33	30	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	15	18	22	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Polyneuropathy



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	41	34	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	35	36	50	61	64

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Taste disorder



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Product issues, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	25	25	31	35	36	51	62	65

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Product issues, Device breakage



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Product issues, Device occlusion



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	49	41	41	35	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Psychiatric disorders, All



Patients at risk												
Rituximab + GemOx	33	28	15	13	9	8	6	1	NE	NE	NE	NE
Glofitamab + GemOx	68	58	46	44	38	37	32	27	26	13	4	1
Patients censored												
Rituximab + GemOx	0	1	14	16	20	21	23	28	NE	NE	NE	NE
Glofitamab + GemOx	0	2	12	14	20	20	24	29	30	43	52	55

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Psychiatric disorders, Anxiety



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	15	18	22	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Psychiatric disorders, Confusional state



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	63	51	48	40	40	35	30	29	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	25	25	30	35	36	51	61	64

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Psychiatric disorders, Delirium



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Psychiatric disorders, Depression



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	53	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Psychiatric disorders, Insomnia



Patients at risk												
Rituximab + GemOx	33	28	15	13	9	8	6	1	NE	NE	NE	NE
Glofitamab + GemOx	68	62	50	47	40	39	34	29	28	14	4	1
Patients censored												
Rituximab + GemOx	0	1	14	16	20	21	23	28	NE	NE	NE	NE
Glofitamab + GemOx	0	2	12	15	22	22	26	31	32	46	56	59

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Psychiatric disorders, Panic attack



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Psychiatric disorders, Restlessness



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Renal and urinary disorders, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	64	54	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	12	16	24	24	30	34	35	49	60	63

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Renal and urinary disorders, Haematuria



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	49	41	41	35	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Renal and urinary disorders, Nocturia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Renal and urinary disorders, Renal failure



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Renal and urinary disorders, Urinary retention



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Reproductive system and breast disorders, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Reproductive system and breast disorders, Benign prostatic hyperplasia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, All



Patients at risk											
Rituximab + GemOx	33	27	14	10	6	6	5	1	NE	NE	NE
Glofitamab + GemOx	68	54	43	41	32	31	26	21	20	11	3
Patients censored											
Rituximab + GemOx	0	2	14	17	21	21	22	26	NE	NE	NE
Glofitamab + GemOx	0	2	11	13	21	21	26	30	31	39	47

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Cough



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	64	52	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	16	24	24	30	35	36	50	61	64

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Dysphonia



Patients at risk												
Rituximab + GemOx	33	30	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	15	18	22	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Dyspnoea



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	6	1	NE	NE	NE	NE
Glofitamab + GemOx	68	60	50	47	39	38	32	27	26	13	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	12	15	23	23	29	34	35	46	55	58

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Dyspnoea exertional



Patients at risk												
Rituximab + GemOx	33	30	16	13	9	8	6	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Epistaxis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Haemoptysis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Hiccups



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	64	52	48	40	40	34	29	28	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	51	62	65

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Hypoxia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Nasal congestion



Patients at risk												
Rituximab + GemOx	33	31	16	13	9	8	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Oropharyngeal pain



Patients at risk												
Rituximab + GemOx	33	30	16	13	9	8	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	15	18	22	23	24	30	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Pleural effusion



Patients at risk												
Rituximab + GemOx	33	30	16	13	9	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Pneumonitis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Pneumothorax



Patients at risk												
Rituximab + GemOx	33	31	17	14	9	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Productive cough



Patients at risk												
Rituximab + GemOx	33	30	16	13	9	8	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	52	48	39	39	34	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	15	18	22	23	24	30	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	35	36	50	61	64

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Respiratory disorder



Patients at risk											
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	30	29	14	3
Patients censored											
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Rhinorrhoea



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	53	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Sleep apnoea syndrome



Patients at risk												
Rituximab + GemOx	33	31	17	13	9	8	6	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Skin and subcutaneous tissue disorders, All



Patients at risk												
Rituximab + GemOx	33	29	14	11	8	7	6	1	NE	NE	NE	NE
Glofitamab + GemOx	68	52	41	37	30	29	24	21	20	12	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	22	23	23	28	NE	NE	NE	NE
Glofitamab + GemOx	0	2	12	16	23	23	28	31	32	40	49	51

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Skin and subcutaneous tissue disorders, Alopecia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	64	52	48	39	39	33	29	28	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	36	37	51	61	64

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Skin and subcutaneous tissue disorders, Dry skin



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Skin and subcutaneous tissue disorders, Erythema



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Skin and subcutaneous tissue disorders, Pruritus



Patients at risk												
Rituximab + GemOx	33	30	15	12	9	8	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	63	52	48	40	39	34	29	28	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	22	23	24	30	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	30	35	36	49	60	63

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Skin and subcutaneous tissue disorders, Rash



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	6	1	NE	NE	NE	NE
Glofitamab + GemOx	68	59	47	43	36	36	30	25	24	13	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	24	24	30	35	36	47	57	59

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Skin and subcutaneous tissue disorders, Rash pruritic



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Skin and subcutaneous tissue disorders, Urticaria



Patients at risk												
Rituximab + GemOx	33	30	16	13	9	8	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, All



Patients at risk												
Rituximab + GemOx	33	30	15	12	7	7	5	1	NE	NE	NE	NE
Glofitamab + GemOx	68	61	48	45	39	38	32	28	26	13	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	23	25	29	NE	NE	NE	NE
Glofitamab + GemOx	0	2	11	14	20	20	25	29	30	43	52	55

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, Deep vein thrombosis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, Haematoma



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	53	49	41	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, Hot flush



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, Hypertension



Patients at risk												
Rituximab + GemOx	33	30	16	13	8	8	6	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	42	42	36	31	29	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	23	25	30	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	24	24	30	35	36	51	61	64

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, Hypotension



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	41	35	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	35	36	51	62	65

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, Lymphoedema



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, Orthostatic hypotension



Patients at risk												
Rituximab + GemOx	33	31	16	13	9	8	6	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, Phlebitis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, Superficial vein thrombosis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	52	48	40	40	34	29	28	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	62	65

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, Thrombophlebitis



Patients at risk												
Rituximab + GemOx	33	30	16	13	9	8	6	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, Thrombosis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AE_3Lp_16FEB2024_41944.pdf
24AUG2024 4:00

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

All

			GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx				
			Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio			
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
Blood and lymphatic system disorders		n/a	112	100,0	32	28,6	80	71,4	55	100,0	11	20,0	44	80,0	0,4015	1,346	0,671	2,700	
Blood and lymphatic system disorders	Anaemia	n/a	112	100,0	12	10,7	100	89,3	55	100,0	6	10,9	49	89,1	0,8137	0,888	0,331	2,382	
Blood and lymphatic system disorders	Cytopenia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Blood and lymphatic system disorders	Febrile neutropenia	n/a	112	100,0	2	1,8	110	98,2	55	100,0	1	1,8	54	98,2	0,9690	0,953	0,086	10,510	
Blood and lymphatic system disorders	Lymphopenia	n/a	112	100,0	2	1,8	110	98,2	55	100,0	1	1,8	54	98,2	0,9942	0,991	0,089	10,983	
Blood and lymphatic system disorders	Myelosuppression	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1536	0,000	0,000	NE	
Blood and lymphatic system disorders	Neutropenia	n/a	112	100,0	15	13,4	97	86,6	55	100,0	3	5,5	52	94,5	0,6160	1,386	0,384	5,000	
Blood and lymphatic system disorders	Thrombocytopenia	n/a	112	100,0	9	8,0	103	92,0	55	100,0	2	3,6	53	96,4	0,3406	2,079	0,446	9,682	
Cardiac disorders		n/a	112	100,0	5	4,5	107	95,5	55	100,0	1	1,8	54	98,2	0,5181	2,010	0,232	17,409	
Cardiac disorders	Atrial fibrillation	n/a	112	100,0	3	2,7	109	97,3	55	100,0	0	0,0	55	100,0	0,2753	>1000.000	0,000	NE	
Cardiac disorders	Cardiac failure	n/a	112	100,0	1	0,9	111	99,1	55	100,0	1	1,8	54	98,2	0,4506	0,354	0,021	5,888	
Cardiac disorders	Myocardial infarction	n/a	112	100,0	1	0,9	111	99,1	55	100,0	1	1,8	54	98,2	0,6123	0,496	0,031	7,923	
Endocrine disorders		n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Endocrine disorders	Adrenal insufficiency	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Gastrointestinal disorders		n/a	112	100,0	11	9,8	101	90,2	55	100,0	0	0,0	55	100,0	0,0306	>1000.000	0,000	NE	
Gastrointestinal disorders	Abdominal pain	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Gastrointestinal disorders	Ascites	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	1,0000	NE	NE	NE	
Gastrointestinal disorders	Diarrhoea	n/a	112	100,0	4	3,6	108	96,4	55	100,0	0	0,0	55	100,0	0,1582	>1000.000	0,000	NE	
Gastrointestinal disorders	Enterocolitis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6287	>1000.000	0,000	NE	
Gastrointestinal disorders	Intestinal obstruction	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5403	>1000.000	0,000	NE	
Gastrointestinal disorders	Large intestine perforation	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	
Gastrointestinal disorders	Nausea	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	
Gastrointestinal disorders	Pancreatitis acute	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
General disorders and administration site conditions		n/a	112	100,0	7	6,3	105	93,8	55	100,0	3	5,5	52	94,5	0,9762	0,979	0,251	3,817	
General disorders and administration site conditions	Asthenia	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1449	0,000	0,000	NE	
General disorders and administration site conditions	Fatigue	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,4466	>1000.000	0,000	NE	
General disorders and administration site conditions	General physical health deterioration	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1554	0,000	0,000	NE	
General disorders and administration site conditions	Multiple organ dysfunction syndrome	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4969	>1000.000	0,000	NE	
General disorders and administration site conditions	Oedema peripheral	n/a	112	100,0	1	0,9	111	99,1	55	100,0	1	1,8	54	98,2	0,5078	0,403	0,025	6,525	
General disorders and administration site conditions	Pain	n/a	112	100,0	3	2,7	109	97,3	55	100,0	0	0,0	55	100,0	0,2454	>1000.000	0,000	NE	

General disorders and administration site conditions	Pyrexia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	
Hepatobiliary disorders		n/a	112	100,0	2	1,8	110	98,2	55	100,0	2	3,6	53	96,4	0,1896	0,241	0,025	2,372	
Hepatobiliary disorders	Cholecystitis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,8638	>1000.000	0,000	NE	
Hepatobiliary disorders	Cholelithiasis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	1	1,8	54	98,2	0,1171	0,073	0,002	3,002	
Hepatobiliary disorders	Cholestasis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	
Hepatobiliary disorders	Hepatic cytolysis	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1554	0,000	0,000	NE	
Immune system disorders		n/a	112	100,0	3	2,7	109	97,3	55	100,0	0	0,0	55	100,0	0,2214	>1000.000	0,000	NE	
Immune system disorders	Cytokine release syndrome	n/a	112	100,0	3	2,7	109	97,3	55	100,0	0	0,0	55	100,0	0,2214	>1000.000	0,000	NE	
Infections and infestations		n/a	112	100,0	28	25,0	84	75,0	55	100,0	9	16,4	46	83,6	0,8411	0,923	0,423	2,016	
Infections and infestations	Biliary tract infection	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5721	>1000.000	0,000	NE	
Infections and infestations	COVID-19	n/a	112	100,0	4	3,6	108	96,4	55	100,0	2	3,6	53	96,4	0,7731	0,778	0,140	4,313	
Infections and infestations	COVID-19 pneumonia	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,6192	>1000.000	0,000	NE	
Infections and infestations	Candida infection	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Infections and infestations	Cytomegalovirus infection reactivation	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1573	0,000	0,000	NE	
Infections and infestations	Cytomegalovirus viraemia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	1,0000	NE	NE	NE	
Infections and infestations	Enterococcal sepsis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6287	>1000.000	0,000	NE	
Infections and infestations	Escherichia bacteraemia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	NE	NE	NE	NE	
Infections and infestations	Escherichia infection	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1495	0,000	0,000	NE	
Infections and infestations	Herpes zoster	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	NE	NE	NE	NE	
Infections and infestations	Infection	n/a	112	100,0	0	0,0	112	100,0	55	100,0	2	3,6	53	96,4	0,0308	0,000	0,000	NE	
Infections and infestations	Listeriosis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4857	>1000.000	0,000	NE	
Infections and infestations	Lower respiratory tract infection	n/a	112	100,0	2	1,8	110	98,2	55	100,0	1	1,8	54	98,2	0,8617	0,807	0,071	9,105	
Infections and infestations	Meningitis aseptic	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Infections and infestations	Pneumocystis jirovecii pneumonia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	1,0000	NE	NE	NE	
Infections and infestations	Pneumonia	n/a	112	100,0	9	8,0	103	92,0	55	100,0	2	3,6	53	96,4	0,8082	1,219	0,246	6,031	
Infections and infestations	Pneumonia bacterial	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1007	0,000	0,000	NE	
Infections and infestations	Sepsis	n/a	112	100,0	3	2,7	109	97,3	55	100,0	0	0,0	55	100,0	0,3571	>1000.000	0,000	NE	
Infections and infestations	Septic shock	n/a	112	100,0	2	1,8	110	98,2	55	100,0	1	1,8	54	98,2	0,9901	0,985	0,089	10,862	
Infections and infestations	Skin infection	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5721	>1000.000	0,000	NE	
Infections and infestations	Splenic abscess	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,0718	0,000	0,000	NE	
Infections and infestations	Streptococcal sepsis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	
Infections and infestations	Ureteritis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6242	>1000.000	0,000	NE	
Infections and infestations	Urinary tract infection	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,4311	>1000.000	0,000	NE	
Infections and infestations	Urosepsis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5403	>1000.000	0,000	NE	
Injury, poisoning and procedural complications		n/a	112	100,0	6	5,4	106	94,6	55	100,0	0	0,0	55	100,0	0,1315	>1000.000	0,000	NE	
Injury, poisoning and procedural complications	Fall	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,8371	>1000.000	0,000	NE	
Injury, poisoning and procedural complications	Femur fracture	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5403	>1000.000	0,000	NE	

Injury, poisoning and procedural complications	Hip fracture	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,8371	>1000.000	0,000	NE	
Injury, poisoning and procedural complications	Infusion related reaction	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3202	>1000.000	0,000	NE	
Injury, poisoning and procedural complications	Road traffic accident	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5403	>1000.000	0,000	NE	
Injury, poisoning and procedural complications	Splenic rupture	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Injury, poisoning and procedural complications	Subdural haematoma	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5518	>1000.000	0,000	NE	
Injury, poisoning and procedural complications	Tibia fracture	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5403	>1000.000	0,000	NE	
Investigations		n/a	112	100,0	36	32,1	76	67,9	55	100,0	11	20,0	44	80,0	0,2993	1,437	0,722	2,862	
Investigations	Alanine aminotransferase abnormal	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	
Investigations	Alanine aminotransferase increased	n/a	112	100,0	4	3,6	108	96,4	55	100,0	2	3,6	53	96,4	0,9721	0,970	0,177	5,305	
Investigations	Amylase increased	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1475	0,000	0,000	NE	
Investigations	Aspartate aminotransferase abnormal	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	
Investigations	Aspartate aminotransferase increased	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3218	>1000.000	0,000	NE	
Investigations	Gamma-glutamyltransferase abnormal	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6310	>1000.000	0,000	NE	
Investigations	Gamma-glutamyltransferase increased	n/a	112	100,0	0	0,0	112	100,0	55	100,0	2	3,6	53	96,4	0,0420	0,000	0,000	NE	
Investigations	Lipase increased	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1475	0,000	0,000	NE	
Investigations	Lymphocyte count decreased	n/a	112	100,0	9	8,0	103	92,0	55	100,0	1	1,8	54	98,2	0,1149	4,553	0,575	36,035	
Investigations	Neutrophil count decreased	n/a	112	100,0	21	18,8	91	81,3	55	100,0	6	10,9	49	89,1	0,6249	1,260	0,498	3,192	
Investigations	Platelet count decreased	n/a	112	100,0	13	11,6	99	88,4	55	100,0	5	9,1	50	90,9	0,8127	1,134	0,401	3,207	
Investigations	Weight decreased	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4878	>1000.000	0,000	NE	
Investigations	White blood cell count decreased	n/a	112	100,0	6	5,4	106	94,6	55	100,0	4	7,3	51	92,7	0,6161	0,723	0,202	2,583	
Metabolism and nutrition disorders		n/a	112	100,0	11	9,8	101	90,2	55	100,0	4	7,3	51	92,7	0,6477	1,305	0,415	4,106	
Metabolism and nutrition disorders	Decreased appetite	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4878	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Dehydration	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4878	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Diabetic metabolic decompensation	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Hypercalcaemia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Hyperglycaemia	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1495	0,000	0,000	NE	
Metabolism and nutrition disorders	Hypertriglyceridaemia	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3268	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Hypocalcaemia	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1573	0,000	0,000	NE	
Metabolism and nutrition disorders	Hypokalaemia	n/a	112	100,0	3	2,7	109	97,3	55	100,0	0	0,0	55	100,0	0,2211	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Hypomagnesaemia	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1536	0,000	0,000	NE	
Metabolism and nutrition disorders	Hypophosphataemia	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3268	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Tumour lysis syndrome	n/a	112	100,0	2	1,8	110	98,2	55	100,0	3	5,5	52	94,5	0,1871	0,319	0,053	1,911	
Musculoskeletal and connective tissue disorders		n/a	112	100,0	3	2,7	109	97,3	55	100,0	1	1,8	54	98,2	0,7788	1,382	0,143	13,313	

Musculoskeletal and connective tissue disorders	Arthralgia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5424	>1000.000	0,000	NE	
Musculoskeletal and connective tissue disorders	Back pain	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3184	>1000.000	0,000	NE	
Musculoskeletal and connective tissue disorders	Pain in extremity	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1536	0,000	0,000	NE	
Nervous system disorders		n/a	112	100,0	4	3,6	108	96,4	55	100,0	0	0,0	55	100,0	0,2497	>1000.000	0,000	NE	
Nervous system disorders	Extrapyramidal disorder	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6310	>1000.000	0,000	NE	
Nervous system disorders	Peripheral sensory neuropathy	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3955	>1000.000	0,000	NE	
Nervous system disorders	Syncope	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5460	>1000.000	0,000	NE	
Psychiatric disorders		n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,4878	>1000.000	0,000	NE	
Psychiatric disorders	Confusional state	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	NE	NE	NE	NE	
Psychiatric disorders	Delirium	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4878	>1000.000	0,000	NE	
Renal and urinary disorders		n/a	112	100,0	3	2,7	109	97,3	55	100,0	0	0,0	55	100,0	0,2327	>1000.000	0,000	NE	
Renal and urinary disorders	Acute kidney injury	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3219	>1000.000	0,000	NE	
Renal and urinary disorders	Bladder perforation	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5077	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders		n/a	112	100,0	5	4,5	107	95,5	55	100,0	1	1,8	54	98,2	0,7438	1,441	0,159	13,082	
Respiratory, thoracic and mediastinal disorders	Acute respiratory distress syndrome	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6109	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1554	0,000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Aspiration	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4948	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Epistaxis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5460	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Pneumonitis	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,6242	>1000.000	0,000	NE	
Skin and subcutaneous tissue disorders		n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	
Skin and subcutaneous tissue disorders	Rash	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	
Vascular disorders		n/a	112	100,0	3	2,7	109	97,3	55	100,0	2	3,6	53	96,4	0,6567	0,667	0,111	4,015	
Vascular disorders	Embolism	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5658	>1000.000	0,000	NE	
Vascular disorders	Hypertension	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1536	0,000	0,000	NE	
Vascular disorders	Hypotension	n/a	112	100,0	2	1,8	110	98,2	55	100,0	1	1,8	54	98,2	0,8567	0,800	0,071	9,011	
Vascular disorders	Orthostatic hypotension	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte_soc.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_soc_SE_AEGE3_2L_16FEB2024_41944.xls
28FEB2025 12:23

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

All

			GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx				
			Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio			
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
Blood and lymphatic system disorders		n/a	68	100,0	29	42,6	39	57,4	33	100,0	5	15,2	28	84,8	0,0215	2,931	1,123	7,653	
Blood and lymphatic system disorders	Anaemia	n/a	68	100,0	17	25,0	51	75,0	33	100,0	2	6,1	31	93,9	0,0386	4,200	0,960	18,378	
Blood and lymphatic system disorders	Febrile neutropenia	n/a	68	100,0	4	5,9	64	94,1	33	100,0	0	0,0	33	100,0	0,1621	>1000.000	0,000	NE	
Blood and lymphatic system disorders	Leukopenia	n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0,0	33	100,0	0,3227	>1000.000	0,000	NE	
Blood and lymphatic system disorders	Lymphopenia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Blood and lymphatic system disorders	Myelosuppression	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Blood and lymphatic system disorders	Neutropenia	n/a	68	100,0	10	14,7	58	85,3	33	100,0	3	9,1	30	90,9	0,7606	1,224	0,333	4,506	
Blood and lymphatic system disorders	Thrombocytopenia	n/a	68	100,0	10	14,7	58	85,3	33	100,0	4	12,1	29	87,9	0,8859	1,089	0,338	3,508	
Cardiac disorders		n/a	68	100,0	3	4,4	65	95,6	33	100,0	1	3,0	32	97,0	0,8398	1,264	0,130	12,304	
Cardiac disorders	Atrial fibrillation	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4931	>1000.000	0,000	NE	
Cardiac disorders	Cardiac arrest	n/a	68	100,0	1	1,5	67	98,5	33	100,0	1	3,0	32	97,0	0,4358	0,345	0,021	5,664	
Cardiac disorders	Cardiac failure	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Cardiac disorders	Cardiac failure congestive	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Cardiac disorders	Coronary artery stenosis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Eye disorders		n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5973	>1000.000	0,000	NE	
Eye disorders	Necrotising retinitis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5973	>1000.000	0,000	NE	
Gastrointestinal disorders		n/a	68	100,0	10	14,7	58	85,3	33	100,0	0	0,0	33	100,0	0,0428	>1000.000	0,000	NE	
Gastrointestinal disorders	Abdominal pain	n/a	68	100,0	3	4,4	65	95,6	33	100,0	0	0,0	33	100,0	0,2217	>1000.000	0,000	NE	
Gastrointestinal disorders	Colitis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6256	>1000.000	0,000	NE	
Gastrointestinal disorders	Diarrhoea	n/a	68	100,0	3	4,4	65	95,6	33	100,0	0	0,0	33	100,0	0,2732	>1000.000	0,000	NE	
Gastrointestinal disorders	Enteritis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6256	>1000.000	0,000	NE	
Gastrointestinal disorders	Gastric ulcer	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	NE	NE	NE	NE	
Gastrointestinal disorders	Pancreatitis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Gastrointestinal disorders	Tooth loss	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6256	>1000.000	0,000	NE	
Gastrointestinal disorders	Vomiting	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5716	>1000.000	0,000	NE	
General disorders and administration site conditions		n/a	68	100,0	5	7,4	63	92,6	33	100,0	2	6,1	31	93,9	0,9013	1,110	0,214	5,752	
General disorders and administration site conditions	Asthenia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5151	>1000.000	0,000	NE	
General disorders and administration site conditions	Chest pain	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
General disorders and administration site conditions	Fatigue	n/a	68	100,0	1	1,5	67	98,5	33	100,0	1	3,0	32	97,0	0,5972	0,481	0,030	7,698	
General disorders and administration site conditions	General physical health deterioration	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5747	>1000.000	0,000	NE	
General disorders and administration site conditions	Localised oedema	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	

General disorders and administration site conditions	Multiple organ dysfunction syndrome	n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,1445	0,000	0,000	NE	
General disorders and administration site conditions	Non-cardiac chest pain	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
General disorders and administration site conditions	Systemic inflammatory response syndrome	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Immune system disorders		n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Immune system disorders	Cytokine release syndrome	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Infections and infestations		n/a	68	100,0	14	20,6	54	79,4	33	100,0	2	6,1	31	93,9	0,3265	2,091	0,464	9,425	
Infections and infestations	COVID-19	n/a	68	100,0	4	5,9	64	94,1	33	100,0	0	0,0	33	100,0	0,2955	>1000.000	0,000	NE	
Infections and infestations	COVID-19 pneumonia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5754	>1000.000	0,000	NE	
Infections and infestations	Cellulitis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Infections and infestations	Klebsiella bacteraemia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5973	>1000.000	0,000	NE	
Infections and infestations	Lower respiratory tract infection	n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0,0	33	100,0	0,5877	>1000.000	0,000	NE	
Infections and infestations	Neutropenic sepsis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5754	>1000.000	0,000	NE	
Infections and infestations	Pneumonia	n/a	68	100,0	3	4,4	65	95,6	33	100,0	2	6,1	31	93,9	0,3503	0,420	0,064	2,736	
Infections and infestations	Respiratory tract infection	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5289	>1000.000	0,000	NE	
Infections and infestations	Sepsis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Infections and infestations	Urinary tract infection	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6088	>1000.000	0,000	NE	
Investigations		n/a	68	100,0	31	45,6	37	54,4	33	100,0	9	27,3	24	72,7	0,1581	1,724	0,803	3,703	
Investigations	Alanine aminotransferase increased	n/a	68	100,0	1	1,5	67	98,5	33	100,0	1	3,0	32	97,0	0,4828	0,382	0,023	6,224	
Investigations	Aspartate aminotransferase increased	n/a	68	100,0	4	5,9	64	94,1	33	100,0	0	0,0	33	100,0	0,3083	>1000.000	0,000	NE	
Investigations	Blood alkaline phosphatase increased	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	NE	NE	NE	NE	
Investigations	Blood glucose increased	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6256	>1000.000	0,000	NE	
Investigations	C-reactive protein increased	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5151	>1000.000	0,000	NE	
Investigations	Gamma-glutamyltransferase increased	n/a	68	100,0	3	4,4	65	95,6	33	100,0	0	0,0	33	100,0	0,3200	>1000.000	0,000	NE	
Investigations	Lipase increased	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5151	>1000.000	0,000	NE	
Investigations	Lymphocyte count decreased	n/a	68	100,0	9	13,2	59	86,8	33	100,0	1	3,0	32	97,0	0,1109	4,650	0,584	37,050	
Investigations	Neutrophil count decreased	n/a	68	100,0	17	25,0	51	75,0	33	100,0	4	12,1	29	87,9	0,4460	1,534	0,506	4,650	
Investigations	Platelet count decreased	n/a	68	100,0	18	26,5	50	73,5	33	100,0	4	12,1	29	87,9	0,1766	2,109	0,698	6,373	
Investigations	Weight decreased	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6434	>1000.000	0,000	NE	
Investigations	White blood cell count decreased	n/a	68	100,0	10	14,7	58	85,3	33	100,0	2	6,1	31	93,9	0,2529	2,380	0,515	11,006	
Metabolism and nutrition disorders		n/a	68	100,0	10	14,7	58	85,3	33	100,0	1	3,0	32	97,0	0,1042	4,708	0,600	36,928	
Metabolism and nutrition disorders	Decreased appetite	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6101	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Hyperglycaemia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Hypermagnesaemia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5289	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Hypertriglyceridaemia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	

Metabolism and nutrition disorders	Hyperuricaemia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Hypocalcaemia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4931	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Hypokalaemia	n/a	68	100,0	2	2,9	66	97,1	33	100,0	1	3,0	32	97,0	0,8489	0,791	0,070	8,884	
Metabolism and nutrition disorders	Hyponatraemia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4795	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Hypophosphataemia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4931	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Steroid diabetes	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Tumour lysis syndrome	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Musculoskeletal and connective tissue disorders		n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Musculoskeletal and connective tissue disorders	Back pain	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Nervous system disorders		n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6101	>1000.000	0,000	NE	
Nervous system disorders	Cerebral haemorrhage	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6101	>1000.000	0,000	NE	
Product issues		n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5675	>1000.000	0,000	NE	
Product issues	Device occlusion	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5675	>1000.000	0,000	NE	
Psychiatric disorders		n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Psychiatric disorders	Insomnia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Renal and urinary disorders		n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0,0	33	100,0	0,3266	>1000.000	0,000	NE	
Renal and urinary disorders	Renal failure	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4931	>1000.000	0,000	NE	
Renal and urinary disorders	Urinary retention	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Reproductive system and breast disorders		n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Reproductive system and breast disorders	Benign prostatic hyperplasia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders		n/a	68	100,0	3	4,4	65	95,6	33	100,0	1	3,0	32	97,0	0,8826	0,837	0,079	8,870	
Respiratory, thoracic and mediastinal disorders	Dyspnoea	n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0,0	33	100,0	0,3969	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Pleural effusion	n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,1512	0,000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Pneumonitis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Pneumothorax	n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,0507	0,000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Respiratory disorder	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,8055	>1000.000	0,000	NE	
Vascular disorders		n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,0507	0,000	0,000	NE	
Vascular disorders	Hypertension	n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,0507	0,000	0,000	NE	

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, All



Patients at risk												
Rituximab + GemOx	55	47	35	24	17	16	14	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	86	76	73	66	60	55	46	43	26	5	1
Patients censored												
Rituximab + GemOx	0	2	13	20	27	28	30	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	11	13	19	23	26	35	37	54	75	79

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Anaemia



Patients at risk												
Rituximab + GemOx	55	49	36	26	18	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	99	89	86	79	74	70	60	57	37	7	1
Patients censored												
Rituximab + GemOx	0	3	15	23	31	32	34	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	13	16	23	27	30	40	43	63	93	99

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Cytopenia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	6	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Febrile neutropenia



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	96	93	84	77	74	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	45	48	71	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Lymphopenia



Patients at risk												
Rituximab + GemOx	55	51	38	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	95	93	84	77	74	64	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	17	26	33	36	46	48	71	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Myelosuppression



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	2	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Neutropenia



Patients at risk												
Rituximab + GemOx	55	51	38	28	19	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	104	92	88	79	71	66	54	49	30	6	1
Patients censored												
Rituximab + GemOx	0	3	16	24	33	35	37	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	32	35	45	48	67	91	96

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Thrombocytopenia



Patients at risk												
Rituximab + GemOx	55	52	39	28	20	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	102	91	88	79	72	68	58	55	34	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	33	35	37	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	13	16	25	32	35	45	48	69	96	102

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, All



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	95	92	83	75	72	62	59	37	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	35	45	48	70	100	106

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Atrial fibrillation



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	95	92	83	76	72	62	59	37	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	102	108

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Cardiac failure



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	77	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Myocardial infarction



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Endocrine disorders, All



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Endocrine disorders, Adrenal insufficiency



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, All



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	102	93	90	81	74	70	60	57	36	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	2	11	13	22	29	32	41	44	65	94	100

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Abdominal pain



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Ascites



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Diarrhoea



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	104	95	92	83	76	73	63	60	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	13	16	25	32	35	45	48	69	101	107

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Enterocolitis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	74	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Intestinal obstruction



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Large intestine perforation



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Nausea



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Pancreatitis acute



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, All



Patients at risk												
Rituximab + GemOx	55	50	37	28	19	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	92	84	77	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	35	37	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	12	14	22	28	30	40	43	66	98	104

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Asthenia



Patients at risk												
Rituximab + GemOx	55	52	38	29	20	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Fatigue



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	35	45	48	71	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, General physical health deterioration



Patients at risk												
Rituximab + GemOx	55	51	38	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Multiple organ dysfunction syndrome



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Oedema peripheral



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Pain



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	16	24	31	34	44	47	70	102	108

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Pyrexia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Hepatobiliary disorders, All



Patients at risk												
Rituximab + GemOx	55	51	38	28	19	16	14	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	63	60	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Hepatobiliary disorders, Cholecystitis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Hepatobiliary disorders, Cholelithiasis



Patients at risk												
Rituximab + GemOx	55	52	39	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Hepatobiliary disorders, Cholestasis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Hepatobiliary disorders, Hepatic cytolysis



Patients at risk												
Rituximab + GemOx	55	51	38	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Immune system disorders, All



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	13	16	25	32	35	45	48	71	102	108

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Immune system disorders, Cytokine release syndrome



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	13	16	25	32	35	45	48	71	102	108

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, All



Patients at risk											
Rituximab + GemOx	55	48	37	27	19	16	14	NE	NE	NE	NE
Glofitamab + GemOx	112	103	95	88	77	71	67	58	52	30	7
Patients censored											
Rituximab + GemOx	0	3	12	20	27	30	32	NE	NE	NE	NE
Glofitamab + GemOx	0	1	8	11	19	22	23	31	34	55	78

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Biliary tract infection



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, COVID-19



Patients at risk												
Rituximab + GemOx	55	51	39	29	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	97	94	84	77	73	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	32	35	37	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	13	16	25	32	35	43	46	69	101	107

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, COVID-19 pneumonia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	84	78	75	65	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	72	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Candida infection



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Cytomegalovirus infection reactivation



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Cytomegalovirus viraemia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Enterococcal sepsis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Escherichia bacteraemia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Escherichia infection



Patients at risk												
Rituximab + GemOx	55	52	38	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Herpes zoster



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Infection



Patients at risk												
Rituximab + GemOx	55	51	39	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Listeriosis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Lower respiratory tract infection



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	32	35	45	48	71	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Meningitis aseptic



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Pneumocystis jirovecii pneumonia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Pneumonia



Patients at risk											
Rituximab + GemOx	55	51	38	29	20	17	15	NE	NE	NE	NE
Glofitamab + GemOx	112	106	96	90	82	75	72	61	57	35	7
Patients censored											
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	25	31	34	44	47	69	97

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Pneumonia bacterial



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Sepsis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	32	35	45	48	71	102	108

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Septic shock



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	16	25	32	35	45	48	71	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Skin infection



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	84	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Splenic abscess



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Streptococcal sepsis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Ureteritis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Urinary tract infection



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	76	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	36	46	49	72	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Urosepsis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, All



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	95	90	81	74	71	61	58	35	6	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	45	48	71	100	105

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Fall



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Femur fracture



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	74	64	61	38	6	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Hip fracture



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Infusion related reaction



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	95	92	83	76	73	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	49	72	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Road traffic accident



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	74	64	61	38	6	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Splenic rupture



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Subdural haematoma



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Tibia fracture



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	74	64	61	38	6	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Investigations, All



Patients at risk											
Rituximab + GemOx	55	47	35	25	16	14	13	NE	NE	NE	NE
Glofitamab + GemOx	112	85	75	72	66	59	55	46	44	22	5
Patients censored											
Rituximab + GemOx	0	1	12	19	28	30	31	NE	NE	NE	NE
Glofitamab + GemOx	0	4	11	12	17	22	24	31	33	54	71

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Alanine aminotransferase abnormal



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Alanine aminotransferase increased



Patients at risk												
Rituximab + GemOx	55	50	37	28	19	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	104	94	91	83	77	74	64	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	25	31	34	44	46	69	101	107

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Amylase increased



Patients at risk												
Rituximab + GemOx	55	52	38	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Aspartate aminotransferase abnormal



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Aspartate aminotransferase increased



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	95	92	83	77	74	64	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	48	71	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Gamma-glutamyltransferase abnormal



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Gamma-glutamyltransferase increased



Patients at risk												
Rituximab + GemOx	55	50	38	29	20	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	35	37	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Lipase increased



Patients at risk												
Rituximab + GemOx	55	52	38	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Lymphocyte count decreased



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	99	88	85	79	72	69	60	58	35	7	1
Patients censored												
Rituximab + GemOx	0	3	16	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	24	31	34	43	45	68	96	102

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Neutrophil count decreased



Patients at risk											
Rituximab + GemOx	55	51	38	28	18	15	14	NE	NE	NE	NE
Glofitamab + GemOx	112	99	87	82	75	66	62	51	49	27	5
Patients censored											
Rituximab + GemOx	0	1	14	22	31	34	35	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	24	30	33	41	43	64	86

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Platelet count decreased



Patients at risk												
Rituximab + GemOx	55	51	39	29	20	16	14	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	99	90	86	77	71	68	59	57	35	7	1
Patients censored												
Rituximab + GemOx	0	1	13	22	31	34	36	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	12	15	23	29	31	40	42	64	92	98

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Weight decreased



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, White blood cell count decreased



Patients at risk												
Rituximab + GemOx	55	51	38	29	20	17	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	102	92	90	82	76	73	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	1	14	22	31	34	35	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	16	24	30	33	42	45	68	99	105

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, All



Patients at risk												
Rituximab + GemOx	55	48	37	29	20	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	100	90	88	79	72	69	59	57	35	6	1
Patients censored												
Rituximab + GemOx	0	3	14	22	31	33	35	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	11	13	22	29	32	42	44	66	95	100

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Decreased appetite



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	6	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Dehydration



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Diabetic metabolic decompensation



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypercalcaemia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hyperglycaemia



Patients at risk												
Rituximab + GemOx	55	51	38	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypertriglyceridaemia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	95	92	83	76	73	63	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	49	72	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypocalcaemia



Patients at risk												
Rituximab + GemOx	55	51	38	29	20	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypokalaemia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	105	95	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	16	25	32	35	45	48	71	102	108

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypomagnesaemia



Patients at risk												
Rituximab + GemOx	55	51	38	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypophosphataemia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	72	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Tumour lysis syndrome



Patients at risk												
Rituximab + GemOx	55	49	38	29	20	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	14	23	32	34	36	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	13	16	25	32	35	45	48	71	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Musculoskeletal and connective tissue disorders, All



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	95	91	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	25	32	35	45	48	71	102	108

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Musculoskeletal and connective tissue disorders, Arthralgia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Musculoskeletal and connective tissue disorders, Back pain



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	95	92	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	33	36	46	49	72	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Musculoskeletal and connective tissue disorders, Pain in extremity



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, All



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	92	83	77	72	62	59	37	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	71	101	107

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Extrapyramidal disorder



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Peripheral sensory neuropathy



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	73	63	60	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Syncope



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Psychiatric disorders, All



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Psychiatric disorders, Confusional state



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Psychiatric disorders, Delirium



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Renal and urinary disorders, All



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	95	92	83	76	73	63	60	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	71	102	108

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Renal and urinary disorders, Acute kidney injury



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	96	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	71	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Renal and urinary disorders, Bladder perforation



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, All



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	92	83	77	74	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	32	34	43	46	68	100	106

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Acute respiratory distress syndrome



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	84	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Acute respiratory failure



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Aspiration



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Epistaxis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Pneumonitis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	74	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	49	71	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Skin and subcutaneous tissue disorders, All



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Skin and subcutaneous tissue disorders, Rash



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, All



Patients at risk												
Rituximab + GemOx	55	50	38	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	96	92	83	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	32	35	45	48	70	102	108

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, Embolism



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, Hypertension



Patients at risk												
Rituximab + GemOx	55	51	38	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, Hypotension



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	83	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	71	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_2L_16FEB2024_41944.pdf
24AUG2024 4:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, Orthostatic hypotension



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, All



Patients at risk												
Rituximab + GemOx	33	26	13	10	8	8	6	1	NE	NE	NE	NE
Glofitamab + GemOx	68	42	35	34	29	29	26	24	23	11	1	1
Patients censored												
Rituximab + GemOx	0	2	15	18	20	20	22	27	NE	NE	NE	NE
Glofitamab + GemOx	0	1	7	8	11	11	14	16	17	28	38	38

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 5:33

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Anaemia



Patients at risk												
Rituximab + GemOx	33	29	16	13	9	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	51	41	40	36	36	32	28	27	13	3	1
Patients censored												
Rituximab + GemOx	0	2	15	18	22	22	24	30	NE	NE	NE	NE
Glofitamab + GemOx	0	2	11	12	16	16	20	24	25	38	48	50

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Febrile neutropenia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	63	53	49	41	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	1	11	15	23	23	28	33	34	49	60	63

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 5:33

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Leukopenia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	64	52	49	41	41	35	30	29	14	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	25	25	31	36	37	52	63	65

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Lymphopenia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Myelosuppression



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Neutropenia



Patients at risk												
Rituximab + GemOx	33	28	14	11	9	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	62	51	46	36	34	30	28	27	13	2	1
Patients censored												
Rituximab + GemOx	0	2	16	19	21	21	23	29	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	16	24	24	28	30	31	45	56	57

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 5:33

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Thrombocytopenia



Patients at risk												
Rituximab + GemOx	33	29	14	10	8	8	6	1	NE	NE	NE	NE
Glofitamab + GemOx	68	59	48	45	37	37	32	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	21	21	23	28	NE	NE	NE	NE
Glofitamab + GemOx	0	1	12	14	21	21	26	28	29	43	54	57

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 5:33

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	9	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	64	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	11	15	23	23	29	34	35	50	61	64

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Atrial fibrillation



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Cardiac arrest



Patients at risk												
Rituximab + GemOx	33	31	17	14	9	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Cardiac failure



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Cardiac failure congestive



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 5:33

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Coronary artery stenosis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Eye disorders, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	41	41	35	30	29	14	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Eye disorders, Necrotising retinitis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	41	41	35	30	29	14	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	61	50	48	39	37	32	28	27	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	12	13	21	21	26	30	31	44	54	57

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Abdominal pain



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	63	52	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	16	24	24	30	35	36	50	61	64

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Colitis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Diarrhoea



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	52	50	41	41	35	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	16	24	24	30	34	35	50	61	64

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 5:33

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Enteritis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 5:33

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Gastric ulcer



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	37	32	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Pancreatitis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Tooth loss



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	41	35	30	29	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 5:33

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Vomiting



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, All



Patients at risk												
Rituximab + GemOx	33	30	16	13	9	8	6	1	NE	NE	NE	NE
Glofitamab + GemOx	68	63	51	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	15	18	22	23	25	30	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	14	22	22	28	33	34	48	59	62

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 5:33

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Asthenia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	53	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 5:33

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Chest pain



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 5:33

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Fatigue



Patients at risk												
Rituximab + GemOx	33	30	16	13	9	8	6	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 5:33

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, General physical health deterioration



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 5:33

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Localised oedema



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 5:33

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Multiple organ dysfunction syndrome



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	15	18	22	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Non-cardiac chest pain



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 5:33

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Systemic inflammatory response syndrome



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 5:33

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Immune system disorders, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Immune system disorders, Cytokine release syndrome



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, All



Patients at risk											
Rituximab + GemOx	33	31	17	13	9	9	7	1	NE	NE	NE
Glofitamab + GemOx	68	64	52	49	39	38	33	28	26	14	3
Patients censored											
Rituximab + GemOx	0	2	15	18	22	22	24	30	NE	NE	NE
Glofitamab + GemOx	0	1	10	12	20	20	24	27	28	40	51

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, COVID-19



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	53	50	42	42	36	31	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	16	24	24	29	34	35	49	60	63

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, COVID-19 pneumonia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	55	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Cellulitis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	1	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 5:33

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Klebsiella bacteraemia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	41	41	35	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 5:33

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Lower respiratory tract infection



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	41	36	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	51	62	65

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Neutropenic sepsis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	55	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 5:33

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Pneumonia



Patients at risk											
Rituximab + GemOx	33	31	17	13	9	9	7	1	NE	NE	NE
Glofitamab + GemOx	68	65	54	49	41	41	35	29	28	14	3
Patients censored											
Rituximab + GemOx	0	2	15	18	22	22	24	30	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	51	62

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 5:33

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Respiratory tract infection



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	53	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 5:33

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Sepsis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 5:33

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Urinary tract infection



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	41	41	35	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 5:33

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Investigations, All



Patients at risk											
Rituximab + GemOx	33	24	13	9	7	6	4	1	NE	NE	NE
Glofitamab + GemOx	68	45	32	26	23	22	19	15	14	5	2
Patients censored											
Rituximab + GemOx	0	2	13	15	17	18	20	23	NE	NE	NE
Glofitamab + GemOx	0	2	12	14	16	16	19	22	23	32	35

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 5:33

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Alanine aminotransferase increased



Patients at risk												
Rituximab + GemOx	33	30	16	13	9	8	6	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Aspartate aminotransferase increased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	42	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	24	24	30	35	36	49	60	63

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Blood alkaline phosphatase increased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Blood glucose increased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	41	35	30	29	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, C-reactive protein increased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	53	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 5:33

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Gamma-glutamyltransferase increased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	40	39	34	29	28	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	51	61	64

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Lipase increased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	53	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Lymphocyte count decreased



Patients at risk												
Rituximab + GemOx	33	30	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	57	45	41	36	36	30	25	24	10	3	1
Patients censored												
Rituximab + GemOx	0	2	15	18	22	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	23	23	29	34	35	49	56	58

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 5:33

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Neutrophil count decreased



Patients at risk											
Rituximab + GemOx	33	29	16	12	10	9	7	1	NE	NE	NE
Glofitamab + GemOx	68	59	46	38	34	32	28	21	20	8	3
Patients censored											
Rituximab + GemOx	0	2	15	17	19	20	22	28	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	22	22	26	30	31	43	48

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 5:33

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Platelet count decreased



Patients at risk												
Rituximab + GemOx	33	27	14	12	8	7	5	1	NE	NE	NE	NE
Glofitamab + GemOx	68	52	42	37	31	31	27	23	22	10	3	1
Patients censored												
Rituximab + GemOx	0	2	15	17	21	22	24	28	NE	NE	NE	NE
Glofitamab + GemOx	0	2	12	16	20	20	24	28	29	40	47	49

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Weight decreased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, White blood cell count decreased



Patients at risk											
Rituximab + GemOx	33	29	16	14	10	9	7	1	NE	NE	NE
Glofitamab + GemOx	68	58	46	42	37	35	31	27	26	12	2
Patients censored											
Rituximab + GemOx	0	2	15	17	21	22	24	30	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	23	23	27	31	32	46	56

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, All



Patients at risk												
Rituximab + GemOx	33	31	16	13	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	58	48	44	35	35	30	27	26	12	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	22	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	12	16	23	23	28	31	32	46	55	57

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Decreased appetite



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	41	41	35	30	29	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hyperglycaemia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypermagnesaemia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	53	49	41	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypertriglyceridaemia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hyperuricaemia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 5:33

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypocalcaemia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	14	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 5:33

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypokalaemia



Patients at risk												
Rituximab + GemOx	33	31	16	13	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	40	40	34	30	29	14	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	22	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	36	37	52	63	65

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hyponatraemia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypophosphataemia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Steroid diabetes



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Tumour lysis syndrome



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Musculoskeletal and connective tissue disorders, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Musculoskeletal and connective tissue disorders, Back pain



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Cerebral haemorrhage



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 5:33

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Product issues, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	49	41	41	35	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Product issues, Device occlusion



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	49	41	41	35	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 5:33

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Psychiatric disorders, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 5:33

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Psychiatric disorders, Insomnia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Renal and urinary disorders, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	64	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	12	16	24	24	30	35	36	51	62	65

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Renal and urinary disorders, Renal failure



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 5:33

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Renal and urinary disorders, Urinary retention



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 5:33

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Reproductive system and breast disorders, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Reproductive system and breast disorders, Benign prostatic hyperplasia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, All



Patients at risk											
Rituximab + GemOx	33	30	16	13	9	9	7	1	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	41	35	29	28	14	3
Patients censored											
Rituximab + GemOx	0	2	16	19	23	23	25	31	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	51	62

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 5:33

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Dyspnoea



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	51	62	65

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Pleural effusion



Patients at risk												
Rituximab + GemOx	33	30	16	13	9	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Pneumonitis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 5:33

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Pneumothorax



Patients at risk												
Rituximab + GemOx	33	31	17	14	9	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 5:33

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Respiratory disorder



Patients at risk											
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	30	29	14	3
Patients censored											
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	9	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 5:33

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3-5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, Hypertension



Patients at risk												
Rituximab + GemOx	33	31	17	14	9	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGE3_3Lp_16FEB2024_41944.pdf
24AUG2024 5:33

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

All

			GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx				
			Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio			
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
Blood and lymphatic system disorders		n/a	112	100,0	27	24,1	85	75,9	55	100,0	10	18,2	45	81,8	0,5196	1,271	0,611	2,643	
Blood and lymphatic system disorders	Anaemia	n/a	112	100,0	12	10,7	100	89,3	55	100,0	6	10,9	49	89,1	0,8137	0,888	0,331	2,382	
Blood and lymphatic system disorders	Cytopenia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Blood and lymphatic system disorders	Febrile neutropenia	n/a	112	100,0	2	1,8	110	98,2	55	100,0	1	1,8	54	98,2	0,9690	0,953	0,086	10,510	
Blood and lymphatic system disorders	Lymphopenia	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1554	0,000	0,000	NE	
Blood and lymphatic system disorders	Neutropenia	n/a	112	100,0	11	9,8	101	90,2	55	100,0	3	5,5	52	94,5	0,8808	1,106	0,296	4,132	
Blood and lymphatic system disorders	Thrombocytopenia	n/a	112	100,0	9	8,0	103	92,0	55	100,0	2	3,6	53	96,4	0,3406	2,079	0,446	9,682	
Cardiac disorders		n/a	112	100,0	5	4,5	107	95,5	55	100,0	1	1,8	54	98,2	0,5181	2,010	0,232	17,409	
Cardiac disorders	Atrial fibrillation	n/a	112	100,0	3	2,7	109	97,3	55	100,0	0	0,0	55	100,0	0,2753	>1000.000	0,000	NE	
Cardiac disorders	Cardiac failure	n/a	112	100,0	1	0,9	111	99,1	55	100,0	1	1,8	54	98,2	0,4506	0,354	0,021	5,888	
Cardiac disorders	Myocardial infarction	n/a	112	100,0	1	0,9	111	99,1	55	100,0	1	1,8	54	98,2	0,6123	0,496	0,031	7,923	
Endocrine disorders		n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Endocrine disorders	Adrenal insufficiency	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Gastrointestinal disorders		n/a	112	100,0	9	8,0	103	92,0	55	100,0	0	0,0	55	100,0	0,0562	>1000.000	0,000	NE	
Gastrointestinal disorders	Abdominal pain	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Gastrointestinal disorders	Ascites	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	1,0000	NE	NE	NE	
Gastrointestinal disorders	Diarrhoea	n/a	112	100,0	4	3,6	108	96,4	55	100,0	0	0,0	55	100,0	0,1582	>1000.000	0,000	NE	
Gastrointestinal disorders	Enterocolitis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6287	>1000.000	0,000	NE	
Gastrointestinal disorders	Intestinal obstruction	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5403	>1000.000	0,000	NE	
Gastrointestinal disorders	Nausea	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	
General disorders and administration site conditions		n/a	112	100,0	6	5,4	106	94,6	55	100,0	3	5,5	52	94,5	0,7932	0,830	0,206	3,350	
General disorders and administration site conditions	Asthenia	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1449	0,000	0,000	NE	
General disorders and administration site conditions	Fatigue	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,4466	>1000.000	0,000	NE	
General disorders and administration site conditions	General physical health deterioration	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1554	0,000	0,000	NE	
General disorders and administration site conditions	Oedema peripheral	n/a	112	100,0	1	0,9	111	99,1	55	100,0	1	1,8	54	98,2	0,5078	0,403	0,025	6,525	
General disorders and administration site conditions	Pain	n/a	112	100,0	3	2,7	109	97,3	55	100,0	0	0,0	55	100,0	0,2454	>1000.000	0,000	NE	
General disorders and administration site conditions	Pyrexia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	
Hepatobiliary disorders		n/a	112	100,0	2	1,8	110	98,2	55	100,0	2	3,6	53	96,4	0,1896	0,241	0,025	2,372	
Hepatobiliary disorders	Cholecystitis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,8638	>1000.000	0,000	NE	
Hepatobiliary disorders	Cholelithiasis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	1	1,8	54	98,2	0,1171	0,073	0,002	3,002	
Hepatobiliary disorders	Cholestasis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	

Hepatobiliary disorders	Hepatic cytolysis	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1554	0,000	0,000	NE	
Immune system disorders		n/a	112	100,0	3	2,7	109	97,3	55	100,0	0	0,0	55	100,0	0,2214	>1000.000	0,000	NE	
Immune system disorders	Cytokine release syndrome	n/a	112	100,0	3	2,7	109	97,3	55	100,0	0	0,0	55	100,0	0,2214	>1000.000	0,000	NE	
Infections and infestations		n/a	112	100,0	24	21,4	88	78,6	55	100,0	7	12,7	48	87,3	0,8885	0,939	0,390	2,262	
Infections and infestations	Biliary tract infection	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5721	>1000.000	0,000	NE	
Infections and infestations	COVID-19	n/a	112	100,0	2	1,8	110	98,2	55	100,0	1	1,8	54	98,2	0,6617	0,588	0,053	6,531	
Infections and infestations	COVID-19 pneumonia	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,6192	>1000.000	0,000	NE	
Infections and infestations	Candida infection	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Infections and infestations	Cytomegalovirus infection reactivation	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1573	0,000	0,000	NE	
Infections and infestations	Cytomegalovirus viraemia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	1,0000	NE	NE	NE	
Infections and infestations	Enterococcal sepsis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6287	>1000.000	0,000	NE	
Infections and infestations	Escherichia bacteraemia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	NE	NE	NE	NE	
Infections and infestations	Escherichia infection	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1495	0,000	0,000	NE	
Infections and infestations	Herpes zoster	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	NE	NE	NE	NE	
Infections and infestations	Infection	n/a	112	100,0	0	0,0	112	100,0	55	100,0	2	3,6	53	96,4	0,0308	0,000	0,000	NE	
Infections and infestations	Listeriosis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4857	>1000.000	0,000	NE	
Infections and infestations	Lower respiratory tract infection	n/a	112	100,0	2	1,8	110	98,2	55	100,0	1	1,8	54	98,2	0,8617	0,807	0,071	9,105	
Infections and infestations	Meningitis aseptic	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Infections and infestations	Pneumocystis jirovecii pneumonia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	1,0000	NE	NE	NE	
Infections and infestations	Pneumonia	n/a	112	100,0	8	7,1	104	92,9	55	100,0	1	1,8	54	98,2	0,5098	2,029	0,237	17,352	
Infections and infestations	Sepsis	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,4743	>1000.000	0,000	NE	
Infections and infestations	Skin infection	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5721	>1000.000	0,000	NE	
Infections and infestations	Splenic abscess	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,0718	0,000	0,000	NE	
Infections and infestations	Ureteritis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6242	>1000.000	0,000	NE	
Infections and infestations	Urinary tract infection	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,4311	>1000.000	0,000	NE	
Infections and infestations	Urosepsis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5403	>1000.000	0,000	NE	
Injury, poisoning and procedural complications		n/a	112	100,0	5	4,5	107	95,5	55	100,0	0	0,0	55	100,0	0,1832	>1000.000	0,000	NE	
Injury, poisoning and procedural complications	Fall	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,8371	>1000.000	0,000	NE	
Injury, poisoning and procedural complications	Femur fracture	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5403	>1000.000	0,000	NE	
Injury, poisoning and procedural complications	Hip fracture	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,8371	>1000.000	0,000	NE	
Injury, poisoning and procedural complications	Infusion related reaction	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3202	>1000.000	0,000	NE	
Injury, poisoning and procedural complications	Road traffic accident	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5403	>1000.000	0,000	NE	
Injury, poisoning and procedural complications	Subdural haematoma	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5518	>1000.000	0,000	NE	
Injury, poisoning and procedural complications	Tibia fracture	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5403	>1000.000	0,000	NE	
Investigations		n/a	112	100,0	30	26,8	82	73,2	55	100,0	10	18,2	45	81,8	0,5765	1,233	0,591	2,574	
Investigations	Alanine aminotransferase abnormal	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	

Investigations	Alanine aminotransferase increased	n/a	112	100,0	4	3,6	108	96,4	55	100,0	2	3,6	53	96,4	0,9721	0,970	0,177	5,305	
Investigations	Amylase increased	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1475	0,000	0,000	NE	
Investigations	Aspartate aminotransferase abnormal	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	
Investigations	Aspartate aminotransferase increased	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3218	>1000.000	0,000	NE	
Investigations	Gamma-glutamyltransferase abnormal	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6310	>1000.000	0,000	NE	
Investigations	Gamma-glutamyltransferase increased	n/a	112	100,0	0	0,0	112	100,0	55	100,0	2	3,6	53	96,4	0,0420	0,000	0,000	NE	
Investigations	Lipase increased	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1475	0,000	0,000	NE	
Investigations	Lymphocyte count decreased	n/a	112	100,0	7	6,3	105	93,8	55	100,0	1	1,8	54	98,2	0,2138	3,486	0,428	28,418	
Investigations	Neutrophil count decreased	n/a	112	100,0	18	16,1	94	83,9	55	100,0	3	5,5	52	94,5	0,2875	1,948	0,558	6,808	
Investigations	Platelet count decreased	n/a	112	100,0	9	8,0	103	92,0	55	100,0	4	7,3	51	92,7	0,9521	0,964	0,294	3,163	
Investigations	Weight decreased	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4878	>1000.000	0,000	NE	
Investigations	White blood cell count decreased	n/a	112	100,0	6	5,4	106	94,6	55	100,0	2	3,6	53	96,4	0,6750	1,407	0,283	7,007	
Metabolism and nutrition disorders		n/a	112	100,0	10	8,9	102	91,1	55	100,0	4	7,3	51	92,7	0,7781	1,181	0,370	3,773	
Metabolism and nutrition disorders	Decreased appetite	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4878	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Dehydration	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4878	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Diabetic metabolic decompensation	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Hyperglycaemia	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1495	0,000	0,000	NE	
Metabolism and nutrition disorders	Hypertriglyceridaemia	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3268	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Hypocalcaemia	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1573	0,000	0,000	NE	
Metabolism and nutrition disorders	Hypokalaemia	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3195	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Hypomagnesaemia	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1536	0,000	0,000	NE	
Metabolism and nutrition disorders	Hypophosphataemia	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3268	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Tumour lysis syndrome	n/a	112	100,0	2	1,8	110	98,2	55	100,0	3	5,5	52	94,5	0,1871	0,319	0,053	1,911	
Musculoskeletal and connective tissue disorders		n/a	112	100,0	3	2,7	109	97,3	55	100,0	1	1,8	54	98,2	0,7788	1,382	0,143	13,313	
Musculoskeletal and connective tissue disorders	Arthralgia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5424	>1000.000	0,000	NE	
Musculoskeletal and connective tissue disorders	Back pain	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3184	>1000.000	0,000	NE	
Musculoskeletal and connective tissue disorders	Pain in extremity	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1536	0,000	0,000	NE	
Nervous system disorders		n/a	112	100,0	4	3,6	108	96,4	55	100,0	0	0,0	55	100,0	0,2497	>1000.000	0,000	NE	
Nervous system disorders	Extrapyramidal disorder	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6310	>1000.000	0,000	NE	
Nervous system disorders	Peripheral sensory neuropathy	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3955	>1000.000	0,000	NE	
Nervous system disorders	Syncope	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5460	>1000.000	0,000	NE	
Psychiatric disorders		n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,4878	>1000.000	0,000	NE	
Psychiatric disorders	Confusional state	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	NE	NE	NE	NE	
Psychiatric disorders	Delirium	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4878	>1000.000	0,000	NE	

Renal and urinary disorders		n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3363	>1000.000	0,000	NE	
Renal and urinary disorders	Acute kidney injury	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4878	>1000.000	0,000	NE	
Renal and urinary disorders	Bladder perforation	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5077	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders		n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3613	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Aspiration	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4948	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Epistaxis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5460	>1000.000	0,000	NE	
Skin and subcutaneous tissue disorders		n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	
Skin and subcutaneous tissue disorders	Rash	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	
Vascular disorders		n/a	112	100,0	3	2,7	109	97,3	55	100,0	2	3,6	53	96,4	0,6567	0,667	0,111	4,015	
Vascular disorders	Embolism	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5658	>1000.000	0,000	NE	
Vascular disorders	Hypertension	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1536	0,000	0,000	NE	
Vascular disorders	Hypotension	n/a	112	100,0	2	1,8	110	98,2	55	100,0	1	1,8	54	98,2	0,8567	0,800	0,071	9,011	
Vascular disorders	Orthostatic hypotension	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte_soc.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_soc_SE_AEGR3_2L_16FEB2024_41944.xls
28FEB2025 12:31

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

All

			GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
			Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
Blood and lymphatic system disorders		n/a	68	100,0	25	36,8	43	63,2	33	100,0	3	9,1	30	90,9	0,0128	4,131	1,233	13,842
Blood and lymphatic system disorders	Anaemia	n/a	68	100,0	17	25,0	51	75,0	33	100,0	1	3,0	32	97,0	0,0126	8,551	1,130	64,710
Blood and lymphatic system disorders	Febrile neutropenia	n/a	68	100,0	3	4,4	65	95,6	33	100,0	0	0,0	33	100,0	0,2290	>1000.000	0,000	NE
Blood and lymphatic system disorders	Leukopenia	n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0,0	33	100,0	0,3227	>1000.000	0,000	NE
Blood and lymphatic system disorders	Neutropenia	n/a	68	100,0	8	11,8	60	88,2	33	100,0	2	6,1	31	93,9	0,6982	1,365	0,282	6,613
Blood and lymphatic system disorders	Thrombocytopenia	n/a	68	100,0	6	8,8	62	91,2	33	100,0	2	6,1	31	93,9	0,7118	1,352	0,272	6,729
Cardiac disorders		n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0,0	33	100,0	0,3227	>1000.000	0,000	NE
Cardiac disorders	Atrial fibrillation	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4931	>1000.000	0,000	NE
Cardiac disorders	Cardiac failure	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE
Cardiac disorders	Cardiac failure congestive	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE
Cardiac disorders	Coronary artery stenosis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE
Gastrointestinal disorders		n/a	68	100,0	10	14,7	58	85,3	33	100,0	0	0,0	33	100,0	0,0428	>1000.000	0,000	NE
Gastrointestinal disorders	Abdominal pain	n/a	68	100,0	3	4,4	65	95,6	33	100,0	0	0,0	33	100,0	0,2217	>1000.000	0,000	NE
Gastrointestinal disorders	Colitis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6256	>1000.000	0,000	NE
Gastrointestinal disorders	Diarrhoea	n/a	68	100,0	3	4,4	65	95,6	33	100,0	0	0,0	33	100,0	0,2732	>1000.000	0,000	NE
Gastrointestinal disorders	Enteritis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6256	>1000.000	0,000	NE
Gastrointestinal disorders	Gastric ulcer	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	NE	NE	NE	NE
Gastrointestinal disorders	Pancreatitis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE
Gastrointestinal disorders	Tooth loss	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6256	>1000.000	0,000	NE
Gastrointestinal disorders	Vomiting	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5716	>1000.000	0,000	NE
General disorders and administration site conditions		n/a	68	100,0	5	7,4	63	92,6	33	100,0	1	3,0	32	97,0	0,4607	2,203	0,256	18,963
General disorders and administration site conditions	Asthenia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5151	>1000.000	0,000	NE
General disorders and administration site conditions	Chest pain	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE
General disorders and administration site conditions	Fatigue	n/a	68	100,0	1	1,5	67	98,5	33	100,0	1	3,0	32	97,0	0,5972	0,481	0,030	7,698
General disorders and administration site conditions	General physical health deterioration	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5747	>1000.000	0,000	NE
General disorders and administration site conditions	Localised oedema	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE
General disorders and administration site conditions	Non-cardiac chest pain	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE
General disorders and administration site conditions	Systemic inflammatory response syndrome	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE
Immune system disorders		n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE

Immune system disorders	Cytokine release syndrome	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Infections and infestations		n/a	68	100,0	11	16,2	57	83,8	33	100,0	1	3,0	32	97,0	0,2316	3,292	0,417	26,001	
Infections and infestations	COVID-19	n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0,0	33	100,0	0,4133	>1000.000	0,000	NE	
Infections and infestations	COVID-19 pneumonia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5754	>1000.000	0,000	NE	
Infections and infestations	Cellulitis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Infections and infestations	Klebsiella bacteraemia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5973	>1000.000	0,000	NE	
Infections and infestations	Lower respiratory tract infection	n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0,0	33	100,0	0,5877	>1000.000	0,000	NE	
Infections and infestations	Pneumonia	n/a	68	100,0	3	4,4	65	95,6	33	100,0	1	3,0	32	97,0	0,8474	0,795	0,076	8,290	
Infections and infestations	Sepsis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Infections and infestations	Urinary tract infection	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6088	>1000.000	0,000	NE	
Investigations		n/a	68	100,0	26	38,2	42	61,8	33	100,0	7	21,2	26	78,8	0,2014	1,732	0,739	4,062	
Investigations	Alanine aminotransferase increased	n/a	68	100,0	1	1,5	67	98,5	33	100,0	1	3,0	32	97,0	0,4828	0,382	0,023	6,224	
Investigations	Aspartate aminotransferase increased	n/a	68	100,0	4	5,9	64	94,1	33	100,0	0	0,0	33	100,0	0,3083	>1000.000	0,000	NE	
Investigations	Blood alkaline phosphatase increased	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	NE	NE	NE	NE	
Investigations	Blood glucose increased	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6256	>1000.000	0,000	NE	
Investigations	Gamma-glutamyltransferase increased	n/a	68	100,0	3	4,4	65	95,6	33	100,0	0	0,0	33	100,0	0,3200	>1000.000	0,000	NE	
Investigations	Lipase increased	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5151	>1000.000	0,000	NE	
Investigations	Lymphocyte count decreased	n/a	68	100,0	6	8,8	62	91,2	33	100,0	0	0,0	33	100,0	0,0823	>1000.000	0,000	NE	
Investigations	Neutrophil count decreased	n/a	68	100,0	13	19,1	55	80,9	33	100,0	3	9,1	30	90,9	0,4809	1,572	0,442	5,594	
Investigations	Platelet count decreased	n/a	68	100,0	9	13,2	59	86,8	33	100,0	3	9,1	30	90,9	0,6892	1,310	0,347	4,947	
Investigations	Weight decreased	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6434	>1000.000	0,000	NE	
Investigations	White blood cell count decreased	n/a	68	100,0	9	13,2	59	86,8	33	100,0	2	6,1	31	93,9	0,3622	2,023	0,431	9,494	
Metabolism and nutrition disorders		n/a	68	100,0	8	11,8	60	88,2	33	100,0	1	3,0	32	97,0	0,1974	3,600	0,448	28,902	
Metabolism and nutrition disorders	Decreased appetite	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6101	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Hyperglycaemia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Hypermagnesaemia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5289	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Hypertriglyceridaemia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Hypokalaemia	n/a	68	100,0	2	2,9	66	97,1	33	100,0	1	3,0	32	97,0	0,8489	0,791	0,070	8,884	
Metabolism and nutrition disorders	Hypophosphataemia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4931	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Steroid diabetes	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Tumour lysis syndrome	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Musculoskeletal and connective tissue disorders		n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Musculoskeletal and connective tissue disorders	Back pain	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Product issues		n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5675	>1000.000	0,000	NE	

Product issues	Device occlusion	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5675	>1000.000	0,000	NE	
Psychiatric disorders		n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Psychiatric disorders	Insomnia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Renal and urinary disorders		n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0,0	33	100,0	0,3266	>1000.000	0,000	NE	
Renal and urinary disorders	Renal failure	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4931	>1000.000	0,000	NE	
Renal and urinary disorders	Urinary retention	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Reproductive system and breast disorders		n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Reproductive system and breast disorders	Benign prostatic hyperplasia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders		n/a	68	100,0	3	4,4	65	95,6	33	100,0	1	3,0	32	97,0	0,8826	0,837	0,079	8,870	
Respiratory, thoracic and mediastinal disorders	Dyspnoea	n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0,0	33	100,0	0,3969	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Pleural effusion	n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,1512	0,000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Pneumonitis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Respiratory disorder	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,8055	>1000.000	0,000	NE	
Vascular disorders		n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,0507	0,000	0,000	NE	
Vascular disorders	Hypertension	n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,0507	0,000	0,000	NE	

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte_soc.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_soc_SE_AEGR3_3Lp_16FEB2024_41944.xls
28FEB2025 12:38

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, All



Patients at risk												
Rituximab + GemOx	55	47	35	24	17	16	14	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	89	79	75	67	61	57	48	45	27	5	1
Patients censored												
Rituximab + GemOx	0	3	14	21	28	29	31	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	11	14	21	25	28	37	40	58	80	84

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Anaemia



Patients at risk												
Rituximab + GemOx	55	49	36	26	18	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	99	89	86	79	74	70	60	57	37	7	1
Patients censored												
Rituximab + GemOx	0	3	15	23	31	32	34	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	13	16	23	27	30	40	43	63	93	99

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Cytopenia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	6	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Febrile neutropenia



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	96	93	84	77	74	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	45	48	71	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Lymphopenia



Patients at risk												
Rituximab + GemOx	55	51	38	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Neutropenia



Patients at risk												
Rituximab + GemOx	55	51	38	28	19	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	105	93	89	79	71	67	56	52	32	6	1
Patients censored												
Rituximab + GemOx	0	3	16	24	33	35	37	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	69	95	100

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Thrombocytopenia



Patients at risk												
Rituximab + GemOx	55	52	39	28	20	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	102	91	88	79	72	68	58	55	34	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	33	35	37	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	13	16	25	32	35	45	48	69	96	102

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, All



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	95	92	83	75	72	62	59	37	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	35	45	48	70	100	106

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Atrial fibrillation



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	95	92	83	76	72	62	59	37	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	102	108

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Cardiac failure



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	77	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Myocardial infarction



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Endocrine disorders, All



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Endocrine disorders, Adrenal insufficiency



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, All



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	102	93	90	81	74	70	60	57	36	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	13	15	24	31	34	43	46	67	96	102

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Abdominal pain



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Ascites



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Diarrhoea



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	104	95	92	83	76	73	63	60	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	13	16	25	32	35	45	48	69	101	107

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Enterocolitis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	74	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Intestinal obstruction



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Nausea



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, All



Patients at risk												
Rituximab + GemOx	55	50	37	28	19	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	92	84	77	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	35	37	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	13	15	23	29	31	41	44	67	99	105

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Asthenia



Patients at risk												
Rituximab + GemOx	55	52	38	29	20	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Fatigue



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	35	45	48	71	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, General physical health deterioration



Patients at risk												
Rituximab + GemOx	55	51	38	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Oedema peripheral



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Pain



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	16	24	31	34	44	47	70	102	108

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Pyrexia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Hepatobiliary disorders, All



Patients at risk												
Rituximab + GemOx	55	51	38	28	19	16	14	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	63	60	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Hepatobiliary disorders, Cholecystitis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Hepatobiliary disorders, Cholelithiasis



Patients at risk												
Rituximab + GemOx	55	52	39	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Hepatobiliary disorders, Cholestasis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Hepatobiliary disorders, Hepatic cytolysis



Patients at risk												
Rituximab + GemOx	55	51	38	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Immune system disorders, All



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	13	16	25	32	35	45	48	71	102	108

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Immune system disorders, Cytokine release syndrome



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	13	16	25	32	35	45	48	71	102	108

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, All



Patients at risk											
Rituximab + GemOx	55	49	37	27	19	16	14	NE	NE	NE	NE
Glofitamab + GemOx	112	105	95	89	77	71	67	58	52	30	7
Patients censored											
Rituximab + GemOx	0	3	13	22	29	32	34	NE	NE	NE	NE
Glofitamab + GemOx	0	2	11	14	23	26	27	35	38	59	82

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Biliary tract infection



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, COVID-19



Patients at risk												
Rituximab + GemOx	55	52	39	29	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	84	77	73	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	45	48	71	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, COVID-19 pneumonia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	84	78	75	65	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	72	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Candida infection



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Cytomegalovirus infection reactivation



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Cytomegalovirus viraemia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Enterococcal sepsis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Escherichia bacteraemia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Escherichia infection



Patients at risk												
Rituximab + GemOx	55	52	38	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Herpes zoster



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Infection



Patients at risk												
Rituximab + GemOx	55	51	39	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Listeriosis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Lower respiratory tract infection



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	32	35	45	48	71	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Meningitis aseptic



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Pneumocystis jirovecii pneumonia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Pneumonia



Patients at risk											
Rituximab + GemOx	55	52	38	29	20	17	15	NE	NE	NE	NE
Glofitamab + GemOx	112	106	96	91	82	75	72	61	57	35	7
Patients censored											
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	32	35	45	48	70	98

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Sepsis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	72	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Skin infection



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	84	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Splenic abscess



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Ureteritis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Urinary tract infection



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	76	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	36	46	49	72	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Urosepsis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, All



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	95	90	81	74	71	61	58	35	6	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	49	72	101	106

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Fall



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Femur fracture



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	74	64	61	38	6	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Hip fracture



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Infusion related reaction



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	95	92	83	76	73	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	49	72	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Road traffic accident



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	74	64	61	38	6	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Subdural haematoma



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Tibia fracture



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	74	64	61	38	6	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Investigations, All



Patients at risk											
Rituximab + GemOx	55	47	35	25	16	14	13	NE	NE	NE	NE
Glofitamab + GemOx	112	89	78	75	70	63	59	50	47	24	6
Patients censored											
Rituximab + GemOx	0	2	13	20	29	31	32	NE	NE	NE	NE
Glofitamab + GemOx	0	4	13	14	19	24	27	34	36	58	76

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Alanine aminotransferase abnormal



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Alanine aminotransferase increased



Patients at risk												
Rituximab + GemOx	55	50	37	28	19	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	104	94	91	83	77	74	64	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	25	31	34	44	46	69	101	107

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Amylase increased



Patients at risk												
Rituximab + GemOx	55	52	38	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Aspartate aminotransferase abnormal



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Aspartate aminotransferase increased



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	95	92	83	77	74	64	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	48	71	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Gamma-glutamyltransferase abnormal



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Gamma-glutamyltransferase increased



Patients at risk												
Rituximab + GemOx	55	50	38	29	20	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	35	37	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Lipase increased



Patients at risk												
Rituximab + GemOx	55	52	38	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Lymphocyte count decreased



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	101	90	87	81	74	71	62	59	36	7	1
Patients censored												
Rituximab + GemOx	0	3	16	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	24	31	34	43	46	69	98	104

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Neutrophil count decreased



Patients at risk											
Rituximab + GemOx	55	52	39	28	18	15	14	NE	NE	NE	NE
Glofitamab + GemOx	112	100	89	84	77	69	66	55	52	29	6
Patients censored											
Rituximab + GemOx	0	3	16	25	34	37	38	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	24	30	33	41	43	65	88

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Platelet count decreased



Patients at risk												
Rituximab + GemOx	55	51	39	29	20	16	14	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	102	91	87	79	73	69	60	57	35	7	1
Patients censored												
Rituximab + GemOx	0	2	14	23	32	35	37	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	25	31	34	43	46	68	96	102

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Weight decreased



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, White blood cell count decreased



Patients at risk												
Rituximab + GemOx	55	51	38	29	20	17	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	103	93	90	82	76	73	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	24	33	36	37	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	16	24	30	33	42	45	68	99	105

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, All



Patients at risk												
Rituximab + GemOx	55	48	37	29	20	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	101	91	89	80	73	70	60	58	36	6	1
Patients censored												
Rituximab + GemOx	0	3	14	22	31	33	35	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	11	13	22	29	32	42	44	66	96	101

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Decreased appetite



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	6	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Dehydration



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Diabetic metabolic decompensation



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hyperglycaemia



Patients at risk												
Rituximab + GemOx	55	51	38	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypertriglyceridaemia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	95	92	83	76	73	63	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	49	72	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypocalcaemia



Patients at risk												
Rituximab + GemOx	55	51	38	29	20	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypokalaemia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	96	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	16	25	32	35	45	48	71	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypomagnesaemia



Patients at risk												
Rituximab + GemOx	55	51	38	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypophosphataemia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	72	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Tumour lysis syndrome



Patients at risk												
Rituximab + GemOx	55	49	38	29	20	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	14	23	32	34	36	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	13	16	25	32	35	45	48	71	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Musculoskeletal and connective tissue disorders, All



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	95	91	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	25	32	35	45	48	71	102	108

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Musculoskeletal and connective tissue disorders, Arthralgia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Musculoskeletal and connective tissue disorders, Back pain



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	95	92	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	33	36	46	49	72	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Musculoskeletal and connective tissue disorders, Pain in extremity



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, All



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	92	83	77	72	62	59	37	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	71	101	107

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Extrapyramidal disorder



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Peripheral sensory neuropathy



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	73	63	60	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Syncope



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Psychiatric disorders, All



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Psychiatric disorders, Confusional state



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Psychiatric disorders, Delirium



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Renal and urinary disorders, All



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	95	92	83	76	73	63	60	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Renal and urinary disorders, Acute kidney injury



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Renal and urinary disorders, Bladder perforation



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, All



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	92	84	77	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	33	35	45	48	71	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Aspiration



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Epistaxis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Skin and subcutaneous tissue disorders, All



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Skin and subcutaneous tissue disorders, Rash



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, All



Patients at risk												
Rituximab + GemOx	55	50	38	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	96	92	83	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	32	35	45	48	70	102	108

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, Embolism



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, Hypertension



Patients at risk												
Rituximab + GemOx	55	51	38	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, Hypotension



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	83	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	71	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, Orthostatic hypotension



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_2L_16FEB2024_41944.pdf
24AUG2024 5:41

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, All



Patients at risk												
Rituximab + GemOx	33	28	14	11	8	8	6	1	NE	NE	NE	NE
Glofitamab + GemOx	68	45	36	35	32	32	28	25	24	11	1	1
Patients censored												
Rituximab + GemOx	0	2	16	19	22	22	24	29	NE	NE	NE	NE
Glofitamab + GemOx	0	1	9	10	13	13	17	19	20	32	42	42

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_3Lp_16FEB2024_41944.pdf
24AUG2024 6:11

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Anaemia



Patients at risk												
Rituximab + GemOx	33	30	16	13	9	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	51	41	40	36	36	32	28	27	13	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	11	12	16	16	20	24	25	38	48	50

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Febrile neutropenia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	64	53	49	41	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	1	12	16	24	24	29	34	35	50	61	64

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_3Lp_16FEB2024_41944.pdf
24AUG2024 6:11

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Leukopenia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	64	52	49	41	41	35	30	29	14	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	25	25	31	36	37	52	63	65

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Neutropenia



Patients at risk												
Rituximab + GemOx	33	29	15	12	9	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	63	52	47	38	37	32	28	27	13	2	1
Patients censored												
Rituximab + GemOx	0	2	16	19	22	22	24	30	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	16	24	24	29	32	33	47	58	59

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_3Lp_16FEB2024_41944.pdf
24AUG2024 6:11

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Thrombocytopenia



Patients at risk												
Rituximab + GemOx	33	30	15	12	9	8	6	1	NE	NE	NE	NE
Glofitamab + GemOx	68	61	49	45	38	38	32	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	22	23	25	30	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	24	24	30	32	33	47	58	61

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_3Lp_16FEB2024_41944.pdf
24AUG2024 6:11

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	64	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	12	16	24	24	30	35	36	51	62	65

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Atrial fibrillation



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_3Lp_16FEB2024_41944.pdf
24AUG2024 6:11

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Cardiac failure



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Cardiac failure congestive



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_3Lp_16FEB2024_41944.pdf
24AUG2024 6:11

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Coronary artery stenosis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	61	50	48	39	37	32	28	27	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	12	13	21	21	26	30	31	44	54	57

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Abdominal pain



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	63	52	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	16	24	24	30	35	36	50	61	64

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Colitis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Diarrhoea



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	52	50	41	41	35	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	16	24	24	30	34	35	50	61	64

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_3Lp_16FEB2024_41944.pdf
24AUG2024 6:11

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Enteritis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Gastric ulcer



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	37	32	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Pancreatitis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_3Lp_16FEB2024_41944.pdf
24AUG2024 6:11

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Tooth loss



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	41	35	30	29	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Vomiting



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, All



Patients at risk												
Rituximab + GemOx	33	30	16	13	9	8	6	1	NE	NE	NE	NE
Glofitamab + GemOx	68	63	51	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	14	22	22	28	33	34	48	59	62

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_3Lp_16FEB2024_41944.pdf
24AUG2024 6:11

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Asthenia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	53	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Chest pain



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Fatigue



Patients at risk												
Rituximab + GemOx	33	30	16	13	9	8	6	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_3Lp_16FEB2024_41944.pdf
24AUG2024 6:11

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, General physical health deterioration



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_3Lp_16FEB2024_41944.pdf
24AUG2024 6:11

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Localised oedema



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_3Lp_16FEB2024_41944.pdf
24AUG2024 6:11

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Non-cardiac chest pain



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_3Lp_16FEB2024_41944.pdf
24AUG2024 6:11

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Systemic inflammatory response syndrome



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Immune system disorders, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Immune system disorders, Cytokine release syndrome



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_3Lp_16FEB2024_41944.pdf
24AUG2024 6:11

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, All



Patients at risk											
Rituximab + GemOx	33	31	17	13	9	9	7	1	NE	NE	NE
Glofitamab + GemOx	68	64	54	49	39	38	33	28	27	14	3
Patients censored											
Rituximab + GemOx	0	2	16	19	23	23	25	31	NE	NE	NE
Glofitamab + GemOx	0	1	10	14	22	22	26	29	30	43	54

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, COVID-19



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	30	35	36	51	62	65

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, COVID-19 pneumonia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	55	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Cellulitis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	1	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_3Lp_16FEB2024_41944.pdf
24AUG2024 6:11

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Klebsiella bacteraemia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	41	41	35	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Lower respiratory tract infection



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	41	36	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	51	62	65

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Pneumonia



Patients at risk											
Rituximab + GemOx	33	31	17	13	9	9	7	1	NE	NE	NE
Glofitamab + GemOx	68	65	54	49	41	41	35	29	28	14	3
Patients censored											
Rituximab + GemOx	0	2	16	19	23	23	25	31	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	51	62

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_3Lp_16FEB2024_41944.pdf
24AUG2024 6:11

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Sepsis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_3Lp_16FEB2024_41944.pdf
24AUG2024 6:11

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Urinary tract infection



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	41	41	35	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_3Lp_16FEB2024_41944.pdf
24AUG2024 6:11

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Investigations, All



Patients at risk											
Rituximab + GemOx	33	26	14	10	8	7	5	1	NE	NE	NE
Glofitamab + GemOx	68	51	37	30	27	24	21	17	16	6	2
Patients censored											
Rituximab + GemOx	0	2	14	16	18	19	21	25	NE	NE	NE
Glofitamab + GemOx	0	2	13	16	18	18	21	25	26	36	40

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Alanine aminotransferase increased



Patients at risk												
Rituximab + GemOx	33	30	16	13	9	8	6	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Aspartate aminotransferase increased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	42	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	24	24	30	35	36	49	60	63

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Blood alkaline phosphatase increased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Blood glucose increased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	41	35	30	29	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Gamma-glutamyltransferase increased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	40	39	34	29	28	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	51	61	64

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Lipase increased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	53	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Lymphocyte count decreased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	60	48	44	38	38	32	27	26	12	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	24	24	30	35	36	50	58	61

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_3Lp_16FEB2024_41944.pdf
24AUG2024 6:11

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Neutrophil count decreased



Patients at risk											
Rituximab + GemOx	33	30	16	12	10	9	7	1	NE	NE	NE
Glofitamab + GemOx	68	61	48	40	35	33	29	24	23	10	3
Patients censored											
Rituximab + GemOx	0	2	16	18	20	21	23	29	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	23	23	27	31	32	45	52

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Platelet count decreased



Patients at risk												
Rituximab + GemOx	33	28	15	13	9	8	6	1	NE	NE	NE	NE
Glofitamab + GemOx	68	60	49	44	36	36	32	27	26	13	4	1
Patients censored												
Rituximab + GemOx	0	2	15	17	21	22	24	29	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	23	23	27	32	33	46	55	58

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_3Lp_16FEB2024_41944.pdf
24AUG2024 6:11

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Weight decreased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_3Lp_16FEB2024_41944.pdf
24AUG2024 6:11

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, White blood cell count decreased



Patients at risk											
Rituximab + GemOx	33	29	16	14	10	9	7	1	NE	NE	NE
Glofitamab + GemOx	68	60	47	43	37	35	31	27	26	12	2
Patients censored											
Rituximab + GemOx	0	2	15	17	21	22	24	30	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	24	24	28	32	33	47	57

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, All



Patients at risk												
Rituximab + GemOx	33	31	16	13	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	60	49	45	36	36	31	27	26	12	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	22	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	24	24	29	33	34	48	57	59

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Decreased appetite



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	41	41	35	30	29	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hyperglycaemia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypermagnesaemia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	53	49	41	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypertriglyceridaemia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypokalaemia



Patients at risk												
Rituximab + GemOx	33	31	16	13	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	40	40	34	30	29	14	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	22	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	36	37	52	63	65

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypophosphataemia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Steroid diabetes



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_3Lp_16FEB2024_41944.pdf
24AUG2024 6:11

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Tumour lysis syndrome



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_3Lp_16FEB2024_41944.pdf
24AUG2024 6:11

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Musculoskeletal and connective tissue disorders, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Musculoskeletal and connective tissue disorders, Back pain



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Product issues, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	49	41	41	35	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_3Lp_16FEB2024_41944.pdf
24AUG2024 6:11

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Product issues, Device occlusion



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	49	41	41	35	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_3Lp_16FEB2024_41944.pdf
24AUG2024 6:11

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Psychiatric disorders, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Psychiatric disorders, Insomnia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_3Lp_16FEB2024_41944.pdf
24AUG2024 6:11

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Renal and urinary disorders, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	64	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	12	16	24	24	30	35	36	51	62	65

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_3Lp_16FEB2024_41944.pdf
24AUG2024 6:11

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Renal and urinary disorders, Renal failure



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_3Lp_16FEB2024_41944.pdf
24AUG2024 6:11

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Renal and urinary disorders, Urinary retention



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_3Lp_16FEB2024_41944.pdf
24AUG2024 6:11

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Reproductive system and breast disorders, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Reproductive system and breast disorders, Benign prostatic hyperplasia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_3Lp_16FEB2024_41944.pdf
24AUG2024 6:11

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, All



Patients at risk											
Rituximab + GemOx	33	30	16	13	9	9	7	1	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	41	35	29	28	14	3
Patients censored											
Rituximab + GemOx	0	2	16	19	23	23	25	31	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	51	62

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Dyspnoea



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	51	62	65

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Pleural effusion



Patients at risk												
Rituximab + GemOx	33	30	16	13	9	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Pneumonitis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Respiratory disorder



Patients at risk											
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	30	29	14	3
Patients censored											
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_3Lp_16FEB2024_41944.pdf
24AUG2024 6:11

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	9	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR3_3Lp_16FEB2024_41944.pdf
24AUG2024 6:11

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, Hypertension



Patients at risk												
Rituximab + GemOx	33	31	17	14	9	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

All

			GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
			Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
Blood and lymphatic system disorders		n/a	112	100,0	10	8,9	102	91,1	55	100,0	1	1,8	54	98,2	0,3055	2,891	0,347	24,114
Blood and lymphatic system disorders	Lymphopenia	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3202	>1000.000	0,000	NE
Blood and lymphatic system disorders	Myelosuppression	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1536	0,000	0,000	NE
Blood and lymphatic system disorders	Neutropenia	n/a	112	100,0	7	6,3	105	93,8	55	100,0	0	0,0	55	100,0	0,2532	>1000.000	0,000	NE
Blood and lymphatic system disorders	Thrombocytopenia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE
Gastrointestinal disorders		n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3195	>1000.000	0,000	NE
Gastrointestinal disorders	Large intestine perforation	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE
Gastrointestinal disorders	Pancreatitis acute	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE
Infections and infestations		n/a	112	100,0	2	1,8	110	98,2	55	100,0	2	3,6	53	96,4	0,4114	0,448	0,063	3,202
Infections and infestations	COVID-19	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1573	0,000	0,000	NE
Infections and infestations	Pneumonia	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1554	0,000	0,000	NE
Infections and infestations	Sepsis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5617	>1000.000	0,000	NE
Infections and infestations	Septic shock	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1536	0,000	0,000	NE
Infections and infestations	Streptococcal sepsis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE
Injury, poisoning and procedural complications		n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE
Injury, poisoning and procedural complications	Splenic rupture	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE
Investigations		n/a	112	100,0	12	10,7	100	89,3	55	100,0	3	5,5	52	94,5	0,4385	1,650	0,459	5,933
Investigations	Lymphocyte count decreased	n/a	112	100,0	3	2,7	109	97,3	55	100,0	0	0,0	55	100,0	0,2211	>1000.000	0,000	NE
Investigations	Neutrophil count decreased	n/a	112	100,0	5	4,5	107	95,5	55	100,0	3	5,5	52	94,5	0,4567	0,573	0,130	2,524
Investigations	Platelet count decreased	n/a	112	100,0	6	5,4	106	94,6	55	100,0	1	1,8	54	98,2	0,3926	2,452	0,293	20,522
Investigations	White blood cell count decreased	n/a	112	100,0	2	1,8	110	98,2	55	100,0	2	3,6	53	96,4	0,4653	0,489	0,069	3,480
Metabolism and nutrition disorders		n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3184	>1000.000	0,000	NE
Metabolism and nutrition disorders	Hypercalcaemia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE
Metabolism and nutrition disorders	Hypokalaemia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE
Renal and urinary disorders		n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE
Renal and urinary disorders	Acute kidney injury	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE
Respiratory, thoracic and mediastinal disorders		n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1554	0,000	0,000	NE

Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1554	0,000	0,000	NE	

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte_soc.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_soc_SE_AEGR4_2L_16FEB2024_41944.xls
28FEB2025 12:41

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

All

			GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx				
			Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio			
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
Blood and lymphatic system disorders		n/a	68	100,0	11	16,2	57	83,8	33	100,0	3	9,1	30	90,9	0,5186	1,523	0,420	5,521	
Blood and lymphatic system disorders	Anaemia	n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,1512	0,000	0,000	NE	
Blood and lymphatic system disorders	Febrile neutropenia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Blood and lymphatic system disorders	Lymphopenia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Blood and lymphatic system disorders	Myelosuppression	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Blood and lymphatic system disorders	Neutropenia	n/a	68	100,0	4	5,9	64	94,1	33	100,0	1	3,0	32	97,0	0,7519	1,424	0,157	12,905	
Blood and lymphatic system disorders	Thrombocytopenia	n/a	68	100,0	5	7,4	63	92,6	33	100,0	2	6,1	31	93,9	0,9498	1,055	0,202	5,505	
Cardiac disorders		n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,0507	0,000	0,000	NE	
Cardiac disorders	Cardiac arrest	n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,0507	0,000	0,000	NE	
Eye disorders		n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5973	>1000.000	0,000	NE	
Eye disorders	Necrotising retinitis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5973	>1000.000	0,000	NE	
Investigations		n/a	68	100,0	15	22,1	53	77,9	33	100,0	3	9,1	30	90,9	0,2045	2,219	0,628	7,844	
Investigations	C-reactive protein increased	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5151	>1000.000	0,000	NE	
Investigations	Lymphocyte count decreased	n/a	68	100,0	4	5,9	64	94,1	33	100,0	1	3,0	32	97,0	0,5337	1,981	0,221	17,781	
Investigations	Neutrophil count decreased	n/a	68	100,0	6	8,8	62	91,2	33	100,0	1	3,0	32	97,0	0,5318	1,970	0,226	17,152	
Investigations	Platelet count decreased	n/a	68	100,0	10	14,7	58	85,3	33	100,0	1	3,0	32	97,0	0,1245	4,429	0,557	35,244	
Investigations	White blood cell count decreased	n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0,0	33	100,0	0,3227	>1000.000	0,000	NE	
Metabolism and nutrition disorders		n/a	68	100,0	3	4,4	65	95,6	33	100,0	0	0,0	33	100,0	0,2242	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Hyperuricaemia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Hypocalcaemia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4931	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Hyponatraemia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4795	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders		n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,0507	0,000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Pneumothorax	n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,0507	0,000	0,000	NE	

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte_soc.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_soc_SE_AEGR4_3Lp_16FEB2024_41944.xls
28FEB2025 12:47

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, All



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	103	92	90	82	75	71	59	55	36	7	1
Patients censored												
Rituximab + GemOx	0	2	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	17	25	32	35	45	47	66	95	101

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR4_2L_16FEB2024_41944.pdf
24AUG2024 6:17

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Lymphopenia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	95	93	84	77	74	64	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	17	26	33	36	46	48	71	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Myelosuppression



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	2	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR4_2L_16FEB2024_41944.pdf
24AUG2024 6:17

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Neutropenia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	95	92	84	77	73	61	56	36	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	33	36	46	49	69	98	104

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR4_2L_16FEB2024_41944.pdf
24AUG2024 6:17

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Thrombocytopenia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR4_2L_16FEB2024_41944.pdf
24AUG2024 6:17

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, All



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	16	25	32	35	45	48	71	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Large intestine perforation



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR4_2L_16FEB2024_41944.pdf
24AUG2024 6:17

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Pancreatitis acute



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, All



Patients at risk												
Rituximab + GemOx	55	50	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	14	23	32	35	37	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	25	32	35	45	48	71	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, COVID-19



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR4_2L_16FEB2024_41944.pdf
24AUG2024 6:17

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Pneumonia



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Sepsis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Septic shock



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR4_2L_16FEB2024_41944.pdf
24AUG2024 6:17

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Streptococcal sepsis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, All



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR4_2L_16FEB2024_41944.pdf
24AUG2024 6:17

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Splenic rupture



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, All



Patients at risk												
Rituximab + GemOx	55	51	38	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	101	92	89	80	72	69	58	56	34	6	1
Patients censored												
Rituximab + GemOx	0	1	14	22	31	34	36	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	12	15	23	30	32	42	44	66	94	99

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Lymphocyte count decreased



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	105	94	91	83	76	73	63	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	33	36	46	48	71	102	108

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR4_2L_16FEB2024_41944.pdf
24AUG2024 6:17

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Neutrophil count decreased



Patients at risk												
Rituximab + GemOx	55	51	38	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	95	92	83	75	71	60	57	35	6	1
Patients censored												
Rituximab + GemOx	0	1	14	22	31	34	36	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	101	106

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Platelet count decreased



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	105	96	92	83	75	73	63	61	38	7	1
Patients censored												
Rituximab + GemOx	0	2	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	13	16	24	31	33	43	45	68	99	105

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, White blood cell count decreased



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	96	93	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	1	14	23	32	35	37	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	25	32	35	45	48	71	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR4_2L_16FEB2024_41944.pdf
24AUG2024 6:17

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, All



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypercalcaemia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypokalaemia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR4_2L_16FEB2024_41944.pdf
24AUG2024 6:17

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Renal and urinary disorders, All



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Renal and urinary disorders, Acute kidney injury



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, All



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Acute respiratory failure



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR4_2L_16FEB2024_41944.pdf
24AUG2024 6:17

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, All



Patients at risk												
Rituximab + GemOx	33	29	16	12	9	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	60	50	46	37	36	32	28	27	13	2	1
Patients censored												
Rituximab + GemOx	0	2	15	18	21	21	23	29	NE	NE	NE	NE
Glofitamab + GemOx	0	1	11	14	21	21	25	29	30	44	55	56

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR4_3Lp_16FEB2024_41944.pdf
24AUG2024 6:23

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Anaemia



Patients at risk												
Rituximab + GemOx	33	30	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	15	18	22	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR4_3Lp_16FEB2024_41944.pdf
24AUG2024 6:23

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Febrile neutropenia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR4_3Lp_16FEB2024_41944.pdf
24AUG2024 6:23

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Lymphopenia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Myelosuppression



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR4_3Lp_16FEB2024_41944.pdf
24AUG2024 6:23

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Neutropenia



Patients at risk												
Rituximab + GemOx	33	30	16	13	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	48	39	38	33	29	28	13	2	1
Patients censored												
Rituximab + GemOx	0	2	16	19	22	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	35	36	51	62	63

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Thrombocytopenia



Patients at risk												
Rituximab + GemOx	33	30	16	12	9	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	63	52	49	40	40	35	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	22	22	24	30	NE	NE	NE	NE
Glofitamab + GemOx	0	1	12	15	23	23	28	32	33	48	59	62

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR4_3Lp_16FEB2024_41944.pdf
24AUG2024 6:23

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	9	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Cardiac arrest



Patients at risk												
Rituximab + GemOx	33	31	17	14	9	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR4_3Lp_16FEB2024_41944.pdf
24AUG2024 6:23

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Eye disorders, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	41	41	35	30	29	14	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR4_3Lp_16FEB2024_41944.pdf
24AUG2024 6:23

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Eye disorders, Necrotising retinitis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	41	41	35	30	29	14	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR4_3Lp_16FEB2024_41944.pdf
24AUG2024 6:23

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Investigations, All



Patients at risk												
Rituximab + GemOx	33	28	16	13	9	8	6	1	NE	NE	NE	NE
Glofitamab + GemOx	68	55	43	39	34	34	28	22	21	10	3	1
Patients censored												
Rituximab + GemOx	0	2	14	17	21	22	24	29	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	16	21	21	27	31	32	43	50	52

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR4_3Lp_16FEB2024_41944.pdf
24AUG2024 6:23

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, C-reactive protein increased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	53	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR4_3Lp_16FEB2024_41944.pdf
24AUG2024 6:23

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Lymphocyte count decreased



Patients at risk												
Rituximab + GemOx	33	30	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	62	50	46	40	40	34	29	28	13	3	1
Patients censored												
Rituximab + GemOx	0	2	15	18	22	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	24	24	30	35	36	51	61	63

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR4_3Lp_16FEB2024_41944.pdf
24AUG2024 6:23

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Neutrophil count decreased



Patients at risk												
Rituximab + GemOx	33	30	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	63	51	46	39	39	33	26	25	12	4	1
Patients censored												
Rituximab + GemOx	0	2	15	18	22	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	50	58	61

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR4_3Lp_16FEB2024_41944.pdf
24AUG2024 6:23

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Platelet count decreased



Patients at risk												
Rituximab + GemOx	33	30	16	13	9	8	6	1	NE	NE	NE	NE
Glofitamab + GemOx	68	58	47	43	36	36	30	26	25	12	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	23	23	29	33	34	46	55	57

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR4_3Lp_16FEB2024_41944.pdf
24AUG2024 6:23

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, White blood cell count decreased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	64	52	48	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	24	24	30	35	36	51	62	65

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR4_3Lp_16FEB2024_41944.pdf
24AUG2024 6:23

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	63	52	48	40	40	34	30	29	14	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	35	36	51	62	64

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR4_3Lp_16FEB2024_41944.pdf
24AUG2024 6:23

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hyperuricaemia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR4_3Lp_16FEB2024_41944.pdf
24AUG2024 6:23

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypocalcaemia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	14	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR4_3Lp_16FEB2024_41944.pdf
24AUG2024 6:23

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hyponatraemia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR4_3Lp_16FEB2024_41944.pdf
24AUG2024 6:23

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	9	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR4_3Lp_16FEB2024_41944.pdf
24AUG2024 6:23

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 4 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Pneumothorax



Patients at risk												
Rituximab + GemOx	33	31	17	14	9	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

All

			GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx				
			Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio			
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
General disorders and administration site conditions		n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4969	>1000.000	0,000	NE	
General disorders and administration site conditions	Multiple organ dysfunction syndrome	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4969	>1000.000	0,000	NE	
Infections and infestations		n/a	112	100,0	5	4,5	107	95,5	55	100,0	1	1,8	54	98,2	0,4501	2,241	0,261	19,261	
Infections and infestations	COVID-19	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3184	>1000.000	0,000	NE	
Infections and infestations	Pneumonia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5658	>1000.000	0,000	NE	
Infections and infestations	Pneumonia bacterial	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1007	0,000	0,000	NE	
Infections and infestations	Septic shock	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3195	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders		n/a	112	100,0	3	2,7	109	97,3	55	100,0	0	0,0	55	100,0	0,4800	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Acute respiratory distress syndrome	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6109	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Pneumonitis	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,6242	>1000.000	0,000	NE	

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte_soc.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_soc_SE_AEGR5_2L_16FEB2024_41944.xls
28FEB2025 12:50

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

All

			GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx				
			Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio			
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
Cardiac disorders		n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5002	>1000.000	0,000	NE	
Cardiac disorders	Cardiac arrest	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5002	>1000.000	0,000	NE	
General disorders and administration site conditions		n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,1445	0,000	0,000	NE	
General disorders and administration site conditions	Multiple organ dysfunction syndrome	n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,1445	0,000	0,000	NE	
Infections and infestations		n/a	68	100,0	4	5,9	64	94,1	33	100,0	2	6,1	31	93,9	0,5009	0,549	0,093	3,225	
Infections and infestations	COVID-19	n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0,0	33	100,0	0,5143	>1000.000	0,000	NE	
Infections and infestations	Neutropenic sepsis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5754	>1000.000	0,000	NE	
Infections and infestations	Pneumonia	n/a	68	100,0	0	0,0	68	100,0	33	100,0	2	6,1	31	93,9	0,0144	0,000	0,000	NE	
Infections and infestations	Respiratory tract infection	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5289	>1000.000	0,000	NE	
Nervous system disorders		n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6101	>1000.000	0,000	NE	
Nervous system disorders	Cerebral haemorrhage	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6101	>1000.000	0,000	NE	

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte_soc.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_soc_SE_AEGR5_3Lp_16FEB2024_41944.xls
28FEB2025 12:56

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, All



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR5_2L_16FEB2024_41944.pdf
24AUG2024 6:25

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Multiple organ dysfunction syndrome



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR5_2L_16FEB2024_41944.pdf
24AUG2024 6:25

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, All



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	97	93	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	2	11	14	22	29	32	42	45	68	100	106

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR5_2L_16FEB2024_41944.pdf
24AUG2024 6:25

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, COVID-19



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	13	16	25	32	35	45	48	71	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Pneumonia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Pneumonia bacterial



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Septic shock



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	16	25	32	35	45	48	71	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR5_2L_16FEB2024_41944.pdf
24AUG2024 6:25

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, All



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	84	78	74	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	45	48	70	102	108

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Acute respiratory distress syndrome



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	84	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first grade 5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Pneumonitis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	74	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	49	71	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR5_3Lp_16FEB2024_41944.pdf
24AUG2024 6:30

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Cardiac arrest



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR5_3Lp_16FEB2024_41944.pdf
24AUG2024 6:30

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	15	18	22	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR5_3Lp_16FEB2024_41944.pdf
24AUG2024 6:30

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Multiple organ dysfunction syndrome



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	15	18	22	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	9	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	53	50	42	42	36	31	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	15	18	22	22	24	30	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	15	23	23	29	34	35	49	60	63

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, COVID-19



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	53	50	42	42	36	31	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	25	25	31	36	37	51	62	65

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Neutropenic sepsis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	55	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Pneumonia



Patients at risk												
Rituximab + GemOx	33	31	17	14	9	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	15	18	22	22	24	30	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Respiratory tract infection



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	53	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_AEGR5_3Lp_16FEB2024_41944.pdf
24AUG2024 6:30

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first grade 5 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Cerebral haemorrhage



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

All

			GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx				
			Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio			
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	
Blood and lymphatic system disorders		n/a	112	100,0	2	1,8	110	98,2	55	100,0	3	5,5	52	94,5	0,0813	0,199	0,027	1,445	
Blood and lymphatic system disorders	Anaemia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	1	1,8	54	98,2	0,2136	0,145	0,005	3,876	
Blood and lymphatic system disorders	Febrile neutropenia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	1	1,8	54	98,2	0,5921	0,477	0,030	7,624	
Blood and lymphatic system disorders	Myelosuppression	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1536	0,000	0,000	NE	
Cardiac disorders		n/a	112	100,0	6	5,4	106	94,6	55	100,0	1	1,8	54	98,2	0,4913	2,092	0,244	17,918	
Cardiac disorders	Atrial fibrillation	n/a	112	100,0	3	2,7	109	97,3	55	100,0	0	0,0	55	100,0	0,3741	>1000.000	0,000	NE	
Cardiac disorders	Atrial flutter	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4969	>1000.000	0,000	NE	
Cardiac disorders	Cardiac failure	n/a	112	100,0	1	0,9	111	99,1	55	100,0	1	1,8	54	98,2	0,4506	0,354	0,021	5,888	
Cardiac disorders	Myocardial infarction	n/a	112	100,0	1	0,9	111	99,1	55	100,0	1	1,8	54	98,2	0,6123	0,496	0,031	7,923	
Eye disorders		n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	NE	NE	NE	NE	
Eye disorders	Vitritis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	NE	NE	NE	NE	
Gastrointestinal disorders		n/a	112	100,0	10	8,9	102	91,1	55	100,0	0	0,0	55	100,0	0,0651	>1000.000	0,000	NE	
Gastrointestinal disorders	Abdominal pain	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4795	>1000.000	0,000	NE	
Gastrointestinal disorders	Ascites	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	1,0000	NE	NE	NE	
Gastrointestinal disorders	Diarrhoea	n/a	112	100,0	4	3,6	108	96,4	55	100,0	0	0,0	55	100,0	0,2220	>1000.000	0,000	NE	
Gastrointestinal disorders	Enterocolitis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6287	>1000.000	0,000	NE	
Gastrointestinal disorders	Intestinal obstruction	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5403	>1000.000	0,000	NE	
Gastrointestinal disorders	Large intestine perforation	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	
Gastrointestinal disorders	Pancreatitis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5952	>1000.000	0,000	NE	
Gastrointestinal disorders	Pancreatitis acute	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
General disorders and administration site conditions		n/a	112	100,0	8	7,1	104	92,9	55	100,0	2	3,6	53	96,4	0,5800	1,553	0,322	7,480	
General disorders and administration site conditions	Asthenia	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1449	0,000	0,000	NE	
General disorders and administration site conditions	Fatigue	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6171	>1000.000	0,000	NE	
General disorders and administration site conditions	General physical health deterioration	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1554	0,000	0,000	NE	
General disorders and administration site conditions	Multiple organ dysfunction syndrome	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4969	>1000.000	0,000	NE	
General disorders and administration site conditions	Pyrexia	n/a	112	100,0	7	6,3	105	93,8	55	100,0	0	0,0	55	100,0	0,1049	>1000.000	0,000	NE	
Hepatobiliary disorders		n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,4727	>1000.000	0,000	NE	
Hepatobiliary disorders	Cholelithiasis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,8638	>1000.000	0,000	NE	
Hepatobiliary disorders	Hepatic cytolysis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	
Immune system disorders		n/a	112	100,0	26	23,2	86	76,8	55	100,0	0	0,0	55	100,0	0,0002	>1000.000	0,000	NE	
Immune system disorders	Cytokine release syndrome	n/a	112	100,0	26	23,2	86	76,8	55	100,0	0	0,0	55	100,0	0,0002	>1000.000	0,000	NE	

Infections and infestations		n/a	112	100,0	32	28,6	80	71,4	55	100,0	9	16,4	46	83,6	0,8759	1,063	0,494	2,289	
Infections and infestations	Bacteraemia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5403	>1000.000	0,000	NE	
Infections and infestations	Biliary tract infection	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Infections and infestations	COVID-19	n/a	112	100,0	5	4,5	107	95,5	55	100,0	2	3,6	53	96,4	0,9729	0,972	0,186	5,066	
Infections and infestations	COVID-19 pneumonia	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,6192	>1000.000	0,000	NE	
Infections and infestations	Candida infection	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Infections and infestations	Cytomegalovirus viraemia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	1,0000	NE	NE	NE	
Infections and infestations	Escherichia bacteraemia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	NE	NE	NE	NE	
Infections and infestations	Escherichia infection	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1495	0,000	0,000	NE	
Infections and infestations	Escherichia pyelonephritis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4857	>1000.000	0,000	NE	
Infections and infestations	Infection	n/a	112	100,0	0	0,0	112	100,0	55	100,0	2	3,6	53	96,4	0,0308	0,000	0,000	NE	
Infections and infestations	Listeriosis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4857	>1000.000	0,000	NE	
Infections and infestations	Lower respiratory tract infection	n/a	112	100,0	4	3,6	108	96,4	55	100,0	1	1,8	54	98,2	0,9469	1,081	0,110	10,651	
Infections and infestations	Meningitis aseptic	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Infections and infestations	Pneumocystis jirovecii pneumonia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	1,0000	NE	NE	NE	
Infections and infestations	Pneumonia	n/a	112	100,0	9	8,0	103	92,0	55	100,0	2	3,6	53	96,4	0,8082	1,219	0,246	6,031	
Infections and infestations	Pneumonia bacterial	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1007	0,000	0,000	NE	
Infections and infestations	Sepsis	n/a	112	100,0	3	2,7	109	97,3	55	100,0	0	0,0	55	100,0	0,3571	>1000.000	0,000	NE	
Infections and infestations	Septic shock	n/a	112	100,0	2	1,8	110	98,2	55	100,0	1	1,8	54	98,2	0,9901	0,985	0,089	10,862	
Infections and infestations	Splenic abscess	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,0718	0,000	0,000	NE	
Infections and infestations	Streptococcal sepsis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	
Infections and infestations	Ureteritis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6242	>1000.000	0,000	NE	
Infections and infestations	Urinary tract infection	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5460	>1000.000	0,000	NE	
Infections and infestations	Urosepsis	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5403	>1000.000	0,000	NE	
Injury, poisoning and procedural complications		n/a	112	100,0	5	4,5	107	95,5	55	100,0	0	0,0	55	100,0	0,1838	>1000.000	0,000	NE	
Injury, poisoning and procedural complications	Femur fracture	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5403	>1000.000	0,000	NE	
Injury, poisoning and procedural complications	Hip fracture	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,8371	>1000.000	0,000	NE	
Injury, poisoning and procedural complications	Infusion related reaction	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	
Injury, poisoning and procedural complications	Road traffic accident	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5403	>1000.000	0,000	NE	
Injury, poisoning and procedural complications	Splenic rupture	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Injury, poisoning and procedural complications	Subdural haematoma	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5518	>1000.000	0,000	NE	
Injury, poisoning and procedural complications	Tibia fracture	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5403	>1000.000	0,000	NE	
Investigations		n/a	112	100,0	5	4,5	107	95,5	55	100,0	1	1,8	54	98,2	0,5811	1,830	0,207	16,181	
Investigations	Alanine aminotransferase increased	n/a	112	100,0	1	0,9	111	99,1	55	100,0	1	1,8	54	98,2	0,5438	0,433	0,027	6,972	
Investigations	Aspartate aminotransferase increased	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Investigations	Liver function test abnormal	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5460	>1000.000	0,000	NE	

Investigations	Neutrophil count decreased	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,8124	>1000.000	0,000	NE	
Investigations	Platelet count decreased	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4878	>1000.000	0,000	NE	
Investigations	Weight decreased	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4878	>1000.000	0,000	NE	
Metabolism and nutrition disorders		n/a	112	100,0	4	3,6	108	96,4	55	100,0	1	1,8	54	98,2	0,5398	1,960	0,219	17,532	
Metabolism and nutrition disorders	Dehydration	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4878	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Hypercalcaemia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Hypokalaemia	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Tumour lysis syndrome	n/a	112	100,0	1	0,9	111	99,1	55	100,0	1	1,8	54	98,2	0,6050	0,489	0,031	7,813	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6128	>1000.000	0,000	NE	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6128	>1000.000	0,000	NE	
Nervous system disorders		n/a	112	100,0	3	2,7	109	97,3	55	100,0	0	0,0	55	100,0	0,2699	>1000.000	0,000	NE	
Nervous system disorders	Extrapyramidal disorder	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6310	>1000.000	0,000	NE	
Nervous system disorders	Immune effector cell-associated neurotoxicity syndrome	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Nervous system disorders	Syncope	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4834	>1000.000	0,000	NE	
Psychiatric disorders		n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,4878	>1000.000	0,000	NE	
Psychiatric disorders	Confusional state	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	NE	NE	NE	NE	
Psychiatric disorders	Delirium	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4878	>1000.000	0,000	NE	
Renal and urinary disorders		n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3339	>1000.000	0,000	NE	
Renal and urinary disorders	Acute kidney injury	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4815	>1000.000	0,000	NE	
Renal and urinary disorders	Bladder perforation	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,5077	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders		n/a	112	100,0	4	3,6	108	96,4	55	100,0	1	1,8	54	98,2	0,9540	1,070	0,109	10,515	
Respiratory, thoracic and mediastinal disorders	Acute respiratory distress syndrome	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,6109	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	n/a	112	100,0	0	0,0	112	100,0	55	100,0	1	1,8	54	98,2	0,1554	0,000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Aspiration	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0,0	55	100,0	0,4948	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Pneumonitis	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,6242	>1000.000	0,000	NE	
Vascular disorders		n/a	112	100,0	3	2,7	109	97,3	55	100,0	1	1,8	54	98,2	0,8352	1,272	0,131	12,391	
Vascular disorders	Hypotension	n/a	112	100,0	1	0,9	111	99,1	55	100,0	1	1,8	54	98,2	0,5997	0,484	0,030	7,735	
Vascular disorders	Orthostatic hypotension	n/a	112	100,0	2	1,8	110	98,2	55	100,0	0	0,0	55	100,0	0,3868	>1000.000	0,000	NE	

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

All

			GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
			Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
Blood and lymphatic system disorders		n/a	68	100,0	9	13,2	59	86,8	33	100,0	1	3,0	32	97,0	0,1616	3,938	0,496	31,243
Blood and lymphatic system disorders	Anaemia	n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,1512	0,000	0,000	NE
Blood and lymphatic system disorders	Febrile neutropenia	n/a	68	100,0	4	5,9	64	94,1	33	100,0	0	0,0	33	100,0	0,1621	>1000.000	0,000	NE
Blood and lymphatic system disorders	Myelosuppression	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE
Blood and lymphatic system disorders	Neutropenia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5973	>1000.000	0,000	NE
Blood and lymphatic system disorders	Thrombocytopenia	n/a	68	100,0	4	5,9	64	94,1	33	100,0	0	0,0	33	100,0	0,2108	>1000.000	0,000	NE
Cardiac disorders		n/a	68	100,0	2	2,9	66	97,1	33	100,0	1	3,0	32	97,0	0,8466	0,788	0,070	8,859
Cardiac disorders	Cardiac arrest	n/a	68	100,0	1	1,5	67	98,5	33	100,0	1	3,0	32	97,0	0,4358	0,345	0,021	5,664
Cardiac disorders	Cardiac failure congestive	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE
Eye disorders		n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5973	>1000.000	0,000	NE
Eye disorders	Necrotising retinitis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5973	>1000.000	0,000	NE
Gastrointestinal disorders		n/a	68	100,0	7	10,3	61	89,7	33	100,0	0	0,0	33	100,0	0,0918	>1000.000	0,000	NE
Gastrointestinal disorders	Abdominal pain	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4795	>1000.000	0,000	NE
Gastrointestinal disorders	Colitis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6256	>1000.000	0,000	NE
Gastrointestinal disorders	Diarrhoea	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4931	>1000.000	0,000	NE
Gastrointestinal disorders	Enteritis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6256	>1000.000	0,000	NE
Gastrointestinal disorders	Gastric ulcer	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	NE	NE	NE	NE
Gastrointestinal disorders	Nausea	n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0,0	33	100,0	0,3824	>1000.000	0,000	NE
Gastrointestinal disorders	Pancreatitis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE
Gastrointestinal disorders	Vomiting	n/a	68	100,0	3	4,4	65	95,6	33	100,0	0	0,0	33	100,0	0,2936	>1000.000	0,000	NE
General disorders and administration site conditions		n/a	68	100,0	4	5,9	64	94,1	33	100,0	2	6,1	31	93,9	0,5775	0,608	0,104	3,557
General disorders and administration site conditions	Multiple organ dysfunction syndrome	n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,1445	0,000	0,000	NE
General disorders and administration site conditions	Pyrexia	n/a	68	100,0	4	5,9	64	94,1	33	100,0	1	3,0	32	97,0	0,9045	1,148	0,121	10,926
Immune system disorders		n/a	68	100,0	9	13,2	59	86,8	33	100,0	0	0,0	33	100,0	0,0304	>1000.000	0,000	NE
Immune system disorders	Cytokine release syndrome	n/a	68	100,0	9	13,2	59	86,8	33	100,0	0	0,0	33	100,0	0,0304	>1000.000	0,000	NE
Infections and infestations		n/a	68	100,0	14	20,6	54	79,4	33	100,0	2	6,1	31	93,9	0,3283	2,086	0,463	9,404
Infections and infestations	Acinetobacter bacteraemia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6088	>1000.000	0,000	NE
Infections and infestations	COVID-19	n/a	68	100,0	4	5,9	64	94,1	33	100,0	0	0,0	33	100,0	0,2955	>1000.000	0,000	NE
Infections and infestations	COVID-19 pneumonia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5754	>1000.000	0,000	NE
Infections and infestations	Cellulitis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE
Infections and infestations	Klebsiella bacteraemia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5973	>1000.000	0,000	NE

Infections and infestations	Lower respiratory tract infection	n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0,0	33	100,0	0,5877	>1000.000	0,000	NE	
Infections and infestations	Neutropenic sepsis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5754	>1000.000	0,000	NE	
Infections and infestations	Pneumonia	n/a	68	100,0	3	4,4	65	95,6	33	100,0	2	6,1	31	93,9	0,3503	0,420	0,064	2,736	
Infections and infestations	Respiratory tract infection	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5289	>1000.000	0,000	NE	
Infections and infestations	Sepsis	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Investigations		n/a	68	100,0	6	8,8	62	91,2	33	100,0	0	0,0	33	100,0	0,1382	>1000.000	0,000	NE	
Investigations	Aspartate aminotransferase increased	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6394	>1000.000	0,000	NE	
Investigations	Neutrophil count decreased	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5675	>1000.000	0,000	NE	
Investigations	Platelet count decreased	n/a	68	100,0	5	7,4	63	92,6	33	100,0	0	0,0	33	100,0	0,1617	>1000.000	0,000	NE	
Investigations	White blood cell count decreased	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5675	>1000.000	0,000	NE	
Metabolism and nutrition disorders		n/a	68	100,0	4	5,9	64	94,1	33	100,0	0	0,0	33	100,0	0,1823	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Hypokalaemia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5967	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Hyponatraemia	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4795	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Steroid diabetes	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Metabolism and nutrition disorders	Tumour lysis syndrome	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Tumour flare	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Nervous system disorders		n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6101	>1000.000	0,000	NE	
Nervous system disorders	Cerebral haemorrhage	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,6101	>1000.000	0,000	NE	
Product issues		n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5675	>1000.000	0,000	NE	
Product issues	Device occlusion	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5675	>1000.000	0,000	NE	
Renal and urinary disorders		n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5675	>1000.000	0,000	NE	
Renal and urinary disorders	Haematuria	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,5675	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders		n/a	68	100,0	1	1,5	67	98,5	33	100,0	1	3,0	32	97,0	0,5933	0,478	0,030	7,641	
Respiratory, thoracic and mediastinal disorders	Dyspnoea	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0,0	33	100,0	0,4860	>1000.000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Pleural effusion	n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,1512	0,000	0,000	NE	
Respiratory, thoracic and mediastinal disorders	Pneumothorax	n/a	68	100,0	0	0,0	68	100,0	33	100,0	1	3,0	32	97,0	0,0507	0,000	0,000	NE	

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte_soc.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_soc_SE_SAE_3Lp_16FEB2024_41944.xls
28FEB2025 13:04

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, All



Patients at risk												
Rituximab + GemOx	55	50	38	29	20	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	97	94	85	79	76	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	2	14	23	32	34	36	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	32	35	45	48	71	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Anaemia



Patients at risk												
Rituximab + GemOx	55	51	38	29	20	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	79	76	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Febrile neutropenia



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Myelosuppression



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	2	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, All



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	95	92	83	75	72	61	58	35	6	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	35	45	48	71	100	105

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Atrial fibrillation



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	73	62	59	36	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	102	108

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Atrial flutter



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	64	61	38	6	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Cardiac failure



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	77	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Myocardial infarction



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Eye disorders, All



Patients at risk																		
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	40	8	2	1	1	1	1	1	1
Patients censored																		
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110	111	111	111	111	111	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Eye disorders, Vitritis



Patients at risk																		
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	40	8	2	1	1	1	1	1	1
Patients censored																		
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110	111	111	111	111	111	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, All



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	105	96	93	83	77	73	63	60	37	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	2	11	13	22	28	31	40	43	65	95	101

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Abdominal pain



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Ascites



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Diarrhoea



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	105	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	13	16	25	32	35	45	48	70	101	107

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Enterocolitis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	74	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Intestinal obstruction



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Large intestine perforation



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Pancreatitis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	84	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Pancreatitis acute



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, All



Patients at risk												
Rituximab + GemOx	55	51	37	28	19	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	94	90	81	73	71	61	58	35	6	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	13	16	25	32	34	43	46	69	98	103

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Asthenia



Patients at risk												
Rituximab + GemOx	55	52	38	29	20	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Fatigue



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	77	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, General physical health deterioration



Patients at risk												
Rituximab + GemOx	55	51	38	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Multiple organ dysfunction syndrome



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Pyrexia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	94	90	81	73	71	61	58	35	6	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	35	44	47	70	99	104

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Hepatobiliary disorders, All



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	63	60	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Hepatobiliary disorders, Cholelithiasis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Hepatobiliary disorders, Hepatic cytolysis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Immune system disorders, All



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	85	76	73	64	59	58	49	49	31	6	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	12	15	23	27	28	37	37	55	80	85

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Immune system disorders, Cytokine release syndrome



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	85	76	73	64	59	58	49	49	31	6	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	12	15	23	27	28	37	37	55	80	85

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, All



Patients at risk													
Rituximab + GemOx	55	48	37	27	19	16	14	NE	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	103	94	85	75	70	65	57	50	30	7	1	1
Patients censored													
Rituximab + GemOx	0	3	12	20	27	30	32	NE	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	1	8	11	18	20	22	29	32	52	75	80	80

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Bacteraemia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Biliary tract infection



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, COVID-19



Patients at risk												
Rituximab + GemOx	55	51	39	29	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	97	93	83	77	73	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	32	35	37	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	13	16	25	31	34	42	45	68	100	106

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, COVID-19 pneumonia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	84	78	75	65	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	72	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Candida infection



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Cytomegalovirus viraemia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Escherichia bacteraemia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Escherichia infection



Patients at risk												
Rituximab + GemOx	55	52	38	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Escherichia pyelonephritis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Infection



Patients at risk												
Rituximab + GemOx	55	51	39	29	20	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Listeriosis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Lower respiratory tract infection



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	74	64	60	37	6	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	32	35	45	48	71	102	107

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Meningitis aseptic



Patients at risk													
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	97	94	85	78	75	65	62	40	8	2	1
Patients censored													
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	71	103	109	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Pneumocystis jirovecii pneumonia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Pneumonia



Patients at risk											
Rituximab + GemOx	55	51	38	29	20	17	15	NE	NE	NE	NE
Glofitamab + GemOx	112	106	96	90	82	75	72	62	58	36	7
Patients censored											
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	25	31	34	43	46	68	97

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Pneumonia bacterial



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Sepsis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	26	32	35	45	48	71	102	108

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Septic shock



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	16	25	32	35	45	48	71	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Splenic abscess



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Streptococcal sepsis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Ureteritis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Urinary tract infection



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Urosepsis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, All



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	91	82	75	72	61	58	35	6	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	72	101	106

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Femur fracture



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	74	64	61	38	6	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Hip fracture



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Infusion related reaction



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Road traffic accident



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	74	64	61	38	6	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Splenic rupture



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Subdural haematoma



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Injury, poisoning and procedural complications, Tibia fracture



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	74	64	61	38	6	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Investigations, All



Patients at risk												
Rituximab + GemOx	55	52	39	29	20	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	105	95	92	83	76	73	62	60	37	6	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	16	25	32	35	45	47	70	101	106

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Alanine aminotransferase increased



Patients at risk												
Rituximab + GemOx	55	52	39	29	20	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Aspartate aminotransferase increased



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Liver function test abnormal



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	93	84	77	74	64	61	38	6	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Neutrophil count decreased



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Platelet count decreased



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Weight decreased



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, All



Patients at risk												
Rituximab + GemOx	55	51	38	29	20	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	104	95	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	13	15	24	31	34	44	47	69	101	107

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Dehydration



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypercalcaemia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypokalaemia



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Tumour lysis syndrome



Patients at risk												
Rituximab + GemOx	55	51	38	29	20	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Neoplasms benign, malignant and unspecified (incl cysts and polyps), All



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Neoplasms benign, malignant and unspecified (incl cysts and polyps), Squamous cell carcinoma



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, All



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	73	63	60	37	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	72	102	108

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Extrapyramidal disorder



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Immune effector cell-associated neurotoxicity syndrome



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Syncope



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Psychiatric disorders, All



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Psychiatric disorders, Confusional state



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Psychiatric disorders, Delirium



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Renal and urinary disorders, All



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Renal and urinary disorders, Acute kidney injury



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Renal and urinary disorders, Bladder perforation



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, All



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	83	77	74	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	35	44	47	69	101	107

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Acute respiratory distress syndrome



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	84	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Acute respiratory failure



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Aspiration



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	96	93	84	77	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Pneumonitis



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	74	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	49	71	103	109

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, All



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	96	93	83	76	73	63	60	38	6	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	71	103	108

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, Hypotension



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Vascular disorders, Orthostatic hypotension



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	97	94	84	77	74	64	61	38	6	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	104	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_2L_16FEB2024_41944.pdf
24AUG2024 6:32

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, All



Patients at risk												
Rituximab + GemOx	33	30	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	61	52	47	38	38	34	30	29	14	3	1
Patients censored												
Rituximab + GemOx	0	2	15	18	22	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	1	10	14	21	21	25	29	30	45	56	58

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_3Lp_16FEB2024_41944.pdf
24AUG2024 6:46

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Anaemia



Patients at risk												
Rituximab + GemOx	33	30	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	15	18	22	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Febrile neutropenia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	63	53	49	41	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	1	11	15	23	23	28	33	34	49	60	63

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_3Lp_16FEB2024_41944.pdf
24AUG2024 6:46

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Myelosuppression



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_3Lp_16FEB2024_41944.pdf
24AUG2024 6:46

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Neutropenia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	41	41	35	30	29	14	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Blood and lymphatic system disorders, Thrombocytopenia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	49	40	40	35	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	1	12	16	24	24	29	33	34	49	60	63

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_3Lp_16FEB2024_41944.pdf
24AUG2024 6:46

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	9	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	12	16	24	24	30	35	36	51	62	65

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_3Lp_16FEB2024_41944.pdf
24AUG2024 6:46

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Cardiac arrest



Patients at risk												
Rituximab + GemOx	33	31	17	14	9	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Cardiac disorders, Cardiac failure congestive



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Eye disorders, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	41	41	35	30	29	14	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Eye disorders, Necrotising retinitis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	41	41	35	30	29	14	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_3Lp_16FEB2024_41944.pdf
24AUG2024 6:46

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	63	51	47	40	39	34	29	28	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	15	22	22	27	32	33	46	57	60

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Abdominal pain



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_3Lp_16FEB2024_41944.pdf
24AUG2024 6:46

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Colitis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_3Lp_16FEB2024_41944.pdf
24AUG2024 6:46

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Diarrhoea



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Enteritis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Gastric ulcer



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	37	32	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Nausea



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	53	48	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	51	62	65

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Pancreatitis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Gastrointestinal disorders, Vomiting



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	53	47	40	40	34	29	28	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	50	61	64

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	9	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	64	52	48	41	40	36	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	15	18	22	22	24	30	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	29	34	35	49	60	63

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_3Lp_16FEB2024_41944.pdf
24AUG2024 6:46

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Multiple organ dysfunction syndrome



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	15	18	22	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

General disorders and administration site conditions, Pyrexia



Patients at risk												
Rituximab + GemOx	33	31	17	14	9	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	64	52	48	41	40	36	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	29	34	35	49	60	63

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Immune system disorders, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	57	46	44	36	36	31	27	26	12	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	15	23	23	28	32	33	47	56	58

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Immune system disorders, Cytokine release syndrome



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	57	46	44	36	36	31	27	26	12	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	15	23	23	28	32	33	47	56	58

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_3Lp_16FEB2024_41944.pdf
24AUG2024 6:46

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, All



Patients at risk											
Rituximab + GemOx	33	31	17	13	9	9	7	1	NE	NE	NE
Glofitamab + GemOx	68	64	52	49	39	38	34	28	26	14	3
Patients censored											
Rituximab + GemOx	0	2	15	18	22	22	24	30	NE	NE	NE
Glofitamab + GemOx	0	1	10	12	20	20	23	27	28	40	51

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_3Lp_16FEB2024_41944.pdf
24AUG2024 6:46

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Acinetobacter bacteraemia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	41	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_3Lp_16FEB2024_41944.pdf
24AUG2024 6:46

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, COVID-19



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	53	50	42	42	36	31	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	16	24	24	29	34	35	49	60	63

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_3Lp_16FEB2024_41944.pdf
24AUG2024 6:46

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, COVID-19 pneumonia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	55	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Cellulitis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	1	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_3Lp_16FEB2024_41944.pdf
24AUG2024 6:46

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Klebsiella bacteraemia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	41	41	35	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_3Lp_16FEB2024_41944.pdf
24AUG2024 6:46

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Lower respiratory tract infection



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	41	36	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	51	62	65

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Neutropenic sepsis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	55	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Pneumonia



Patients at risk											
Rituximab + GemOx	33	31	17	13	9	9	7	1	NE	NE	NE
Glofitamab + GemOx	68	65	54	49	41	41	35	29	28	14	3
Patients censored											
Rituximab + GemOx	0	2	15	18	22	22	24	30	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	51	62

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_3Lp_16FEB2024_41944.pdf
24AUG2024 6:46

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Respiratory tract infection



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	53	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Infections and infestations, Sepsis



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	64	52	46	38	38	32	29	28	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	30	33	34	48	58	61

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Aspartate aminotransferase increased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	35	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_3Lp_16FEB2024_41944.pdf
24AUG2024 6:46

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Neutrophil count decreased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	49	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_3Lp_16FEB2024_41944.pdf
24AUG2024 6:46

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, Platelet count decreased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	64	52	46	38	38	33	29	28	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	30	34	35	49	59	62

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Investigations, White blood cell count decreased



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	49	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	63	52	48	40	40	34	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	24	24	30	34	35	49	60	63

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_3Lp_16FEB2024_41944.pdf
24AUG2024 6:46

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hypokalaemia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	41	41	35	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_3Lp_16FEB2024_41944.pdf
24AUG2024 6:46

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Hyponatraemia



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_3Lp_16FEB2024_41944.pdf
24AUG2024 6:46

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Steroid diabetes



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_3Lp_16FEB2024_41944.pdf
24AUG2024 6:46

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Metabolism and nutrition disorders, Tumour lysis syndrome



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_3Lp_16FEB2024_41944.pdf
24AUG2024 6:46

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Neoplasms benign, malignant and unspecified (incl cysts and polyps), All



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Neoplasms benign, malignant and unspecified (incl cysts and polyps), Tumour flare



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_3Lp_16FEB2024_41944.pdf
24AUG2024 6:46

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Nervous system disorders, Cerebral haemorrhage



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Product issues, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	49	41	41	35	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_3Lp_16FEB2024_41944.pdf
24AUG2024 6:46

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Product issues, Device occlusion



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	49	41	41	35	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Renal and urinary disorders, All



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	49	41	41	35	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Renal and urinary disorders, Haematuria



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	49	41	41	35	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_3Lp_16FEB2024_41944.pdf
24AUG2024 6:46

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, All



Patients at risk												
Rituximab + GemOx	33	30	16	13	9	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Dyspnoea



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km_socpt.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_socpt_SE_SAE_3Lp_16FEB2024_41944.pdf
24AUG2024 6:46

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Pleural effusion



Patients at risk												
Rituximab + GemOx	33	30	16	13	9	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first serious adverse event
MODEL: Unstratified Analysis
STUDY: GO41944

Respiratory, thoracic and mediastinal disorders, Pneumothorax



Patients at risk												
Rituximab + GemOx	33	31	17	14	9	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

POPULATION: Safety evaluable population (2L)
ENDPOINT: AEs leading to treatment discontinuation
MODEL: Unstratified analysis
STUDY: GO41944
Dichotomous Analysis (Safety)

All

			Glofitamab + GemOx (N=112)				Rituximab + GemOx (N=55)			
			Patients		Patients with Event		Patients		Patients with Event	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%
Blood and lymphatic system disorders		n/a	112	100,0	1	0,9	55	100,0	1	1,8
Blood and lymphatic system disorders	Neutropenia	n/a	112	100,0	1	0,9	55	100,0	0	0,0
Blood and lymphatic system disorders	Thrombocytopenia	n/a	112	100,0	0	0,0	55	100,0	1	1,8
Cardiac disorders		n/a	112	100,0	1	0,9	55	100,0	0	0,0
Cardiac disorders	Myocardial infarction	n/a	112	100,0	1	0,9	55	100,0	0	0,0
General disorders and administration site conditions		n/a	112	100,0	1	0,9	55	100,0	0	0,0
General disorders and administration site conditions	Multiple organ dysfunction syndrome	n/a	112	100,0	1	0,9	55	100,0	0	0,0
Immune system disorders		n/a	112	100,0	1	0,9	55	100,0	0	0,0
Immune system disorders	Cytokine release syndrome	n/a	112	100,0	1	0,9	55	100,0	0	0,0
Infections and infestations		n/a	112	100,0	17	15,2	55	100,0	6	10,9
Infections and infestations	COVID-19	n/a	112	100,0	11	9,8	55	100,0	5	9,1
Infections and infestations	COVID-19 pneumonia	n/a	112	100,0	1	0,9	55	100,0	0	0,0
Infections and infestations	Herpes zoster	n/a	112	100,0	1	0,9	55	100,0	0	0,0
Infections and infestations	Pneumonia	n/a	112	100,0	1	0,9	55	100,0	0	0,0
Infections and infestations	Pneumonia bacterial	n/a	112	100,0	0	0,0	55	100,0	1	1,8
Infections and infestations	Sepsis	n/a	112	100,0	1	0,9	55	100,0	0	0,0
Infections and infestations	Septic shock	n/a	112	100,0	2	1,8	55	100,0	0	0,0
Investigations		n/a	112	100,0	3	2,7	55	100,0	0	0,0
Investigations	Neutrophil count decreased	n/a	112	100,0	2	1,8	55	100,0	0	0,0
Investigations	SARS-CoV-2 test positive	n/a	112	100,0	1	0,9	55	100,0	0	0,0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		n/a	112	100,0	1	0,9	55	100,0	0	0,0

Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Squamous cell carcinoma	n/a	112	100,0	1	0,9	55	100,0	0	0,0
Nervous system disorders		n/a	112	100,0	4	3,6	55	100,0	0	0,0
Nervous system disorders	Peripheral sensory neuropathy	n/a	112	100,0	4	3,6	55	100,0	0	0,0
Respiratory, thoracic and mediastinal disorders		n/a	112	100,0	3	2,7	55	100,0	0	0,0
Respiratory, thoracic and mediastinal disorders	Acute respiratory distress syndrome	n/a	112	100,0	1	0,9	55	100,0	0	0,0
Respiratory, thoracic and mediastinal disorders	Pneumonitis	n/a	112	100,0	2	1,8	55	100,0	0	0,0

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_socdesc.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_socdesc_SE_DAE_2L_16FEB2024_41944.xls
05DEC2024 22:49

POPULATION: Safety evaluable population (3L+)
ENDPOINT: AEs leading to treatment discontinuation
MODEL: Unstratified analysis
STUDY: GO41944
Dichotomous Analysis (Safety)

All

			Glofitamab + GemOx (N=68)				Rituximab + GemOx (N=33)			
			Patients		Patients with Event		Patients		Patients with Event	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%
Blood and lymphatic system disorders		n/a	68	100,0	1	1,5	33	100,0	0	0,0
Blood and lymphatic system disorders	Thrombocytopenia	n/a	68	100,0	1	1,5	33	100,0	0	0,0
Cardiac disorders		n/a	68	100,0	2	2,9	33	100,0	0	0,0
Cardiac disorders	Cardiac arrest	n/a	68	100,0	1	1,5	33	100,0	0	0,0
Cardiac disorders	Cardiac failure congestive	n/a	68	100,0	1	1,5	33	100,0	0	0,0
Gastrointestinal disorders		n/a	68	100,0	2	2,9	33	100,0	0	0,0
Gastrointestinal disorders	Colitis	n/a	68	100,0	1	1,5	33	100,0	0	0,0
Gastrointestinal disorders	Enteritis	n/a	68	100,0	1	1,5	33	100,0	0	0,0
Gastrointestinal disorders	Pancreatitis	n/a	68	100,0	1	1,5	33	100,0	0	0,0
General disorders and administration site conditions		n/a	68	100,0	1	1,5	33	100,0	1	3,0
General disorders and administration site conditions	Multiple organ dysfunction syndrome	n/a	68	100,0	0	0,0	33	100,0	1	3,0
General disorders and administration site conditions	Pyrexia	n/a	68	100,0	1	1,5	33	100,0	0	0,0
Infections and infestations		n/a	68	100,0	10	14,7	33	100,0	2	6,1
Infections and infestations	COVID-19	n/a	68	100,0	9	13,2	33	100,0	0	0,0
Infections and infestations	Pneumonia	n/a	68	100,0	0	0,0	33	100,0	2	6,1
Infections and infestations	Respiratory tract infection	n/a	68	100,0	1	1,5	33	100,0	0	0,0
Investigations		n/a	68	100,0	2	2,9	33	100,0	1	3,0
Investigations	Alanine aminotransferase increased	n/a	68	100,0	1	1,5	33	100,0	0	0,0
Investigations	Aspartate aminotransferase increased	n/a	68	100,0	1	1,5	33	100,0	0	0,0
Investigations	Neutrophil count decreased	n/a	68	100,0	1	1,5	33	100,0	0	0,0
Investigations	Platelet count decreased	n/a	68	100,0	1	1,5	33	100,0	1	3,0
Nervous system disorders		n/a	68	100,0	1	1,5	33	100,0	0	0,0
Nervous system disorders	Cerebral haemorrhage	n/a	68	100,0	1	1,5	33	100,0	0	0,0

Vascular disorders		n/a	68	100,0	1	1,5	33	100,0	0	0,0
Vascular disorders	Thrombosis	n/a	68	100,0	1	1,5	33	100,0	0	0,0

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_socdesc.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_socdesc_SE_DAE_3Lp_16FEB2024_41944.xls
05DEC2024 22:53

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Grade >=2 CRS adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	15	13,4	97	86,6	55	100,0	0	0	55	100,0	0,0067	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AESI03_2L_16FEB2024_41944.xls
06DEC2024 2:09

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Grade >=2 CRS adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	7	10,3	61	89,7	33	100,0	0	0	33	100,0	0,0583	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AESI03_3Lp_16FEB2024_41944.xls
06DEC2024 5:54

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Grade >=2 CRS adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	97	88	85	76	72	69	59	58	36	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	2	11	14	22	26	28	38	39	61	90	96

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AESI03_2L_16FEB2024_41944.pdf
24AUG2024 18:41

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Grade >=2 CRS adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	59	48	46	38	38	32	27	26	13	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	15	23	23	29	34	35	48	58	60

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AESI03_3Lp_16FEB2024_41944.pdf
24AUG2024 22:03

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Grade >= 2 neurologic adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	34	30,4	78	69,6	55	100,0	7	12,7	48	87,3	0,1164	1,92	0,84	4,38

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AESI04_2L_16FEB2024_41944.xls
06DEC2024 2:15

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Grade >= 2 neurologic adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	20	29,4	48	70,6	33	100,0	4	12,1	29	87,9	0,5401	1,41	0,47	4,26

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AESI04_3Lp_16FEB2024_41944.xls
06DEC2024 5:59

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Grade >= 2 neurologic adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk											
Rituximab + GemOx	55	49	36	26	18	15	13	NE	NE	NE	NE
Glofitamab + GemOx	112	92	80	74	64	58	53	44	42	26	6
Patients censored											
Rituximab + GemOx	0	3	15	23	31	33	35	NE	NE	NE	NE
Glofitamab + GemOx	0	3	12	14	22	26	29	37	39	53	73

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AESI04_2L_16FEB2024_41944.pdf
24AUG2024 18:48

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Grade >= 2 neurologic adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk											
Rituximab + GemOx	33	29	16	13	9	8	6	1	NE	NE	NE
Glofitamab + GemOx	68	62	50	46	39	34	29	24	22	11	3
Patients censored											
Rituximab + GemOx	0	1	14	16	20	21	23	28	NE	NE	NE
Glofitamab + GemOx	0	1	11	14	20	20	23	27	28	38	46

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AESI04_3Lp_16FEB2024_41944.pdf
24AUG2024 22:11

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Any suspected HLH adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	0	0	112	100,0	55	100,0	0	0	55	100,0	NE	NE	NE	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AESI05_2L_16FEB2024_41944.xls
06DEC2024 2:21

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Any suspected HLH adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	0	0	68	100,0	33	100,0	0	0	33	100,0	NE	NE	NE	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AESI05_3Lp_16FEB2024_41944.xls
06DEC2024 6:06

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Any suspected HLH adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AESI05_2L_16FEB2024_41944.pdf
24AUG2024 18:55

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Any suspected HLH adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AESI05_3Lp_16FEB2024_41944.pdf
24AUG2024 22:18

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Febrile neutropenia (minimum Grade 3 by definition) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	2	1,8	110	98,2	55	100,0	1	1,8	54	98,2	0,9690	0,95	0,09	10,51

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AESI07_2L_16FEB2024_41944.xls
06DEC2024 2:34

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Febrile neutropenia (minimum Grade 3 by definition) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	4	5,9	64	94,1	33	100,0	0	0	33	100,0	0,1621	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AESI07_3Lp_16FEB2024_41944.xls
06DEC2024 6:19

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Febrile neutropenia (minimum Grade 3 by definition) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	96	93	84	77	74	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	45	48	71	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AESI07_2L_16FEB2024_41944.pdf
24AUG2024 19:08

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Febrile neutropenia (minimum Grade 3 by definition) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	63	53	49	41	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	1	11	15	23	23	28	33	34	49	60	63

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AESI07_3Lp_16FEB2024_41944.pdf
24AUG2024 22:33

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Grade >= 2 AST, ALT, or total bilirubin elevation adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	17	15,2	95	84,8	55	100,0	5	9,1	50	90,9	0,3191	1,66	0,61	4,52

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AESI08_2L_16FEB2024_41944.xls
06DEC2024 2:40

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Grade >= 2 AST, ALT, or total bilirubin elevation adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	7	10,3	61	89,7	33	100,0	2	6,1	31	93,9	0,6478	1,44	0,30	7,06

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AESI08_3Lp_16FEB2024_41944.xls
06DEC2024 6:26

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Grade >= 2 AST, ALT, or total bilirubin elevation adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	47	35	27	18	16	14	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	95	84	79	71	66	63	53	52	31	5	1
Patients censored												
Rituximab + GemOx	0	3	15	23	32	34	36	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	13	16	24	29	32	42	43	64	90	94

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AESI08_2L_16FEB2024_41944.pdf
24AUG2024 19:14

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Grade >= 2 AST, ALT, or total bilirubin elevation adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	29	15	12	8	7	5	NE	NE	NE	NE	NE
Glofitamab + GemOx	68	62	50	45	38	37	31	27	26	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	24	24	30	34	35	46	57	60

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AESI08_3Lp_16FEB2024_41944.pdf
24AUG2024 22:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Any grade disseminated intravascular coagulation (minimum Grade 2 by definition) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	0	0	112	100,0	55	100,0	0	0	55	100,0	NE	NE	NE	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AESI09_2L_16FEB2024_41944.xls
06DEC2024 2:46

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Any grade disseminated intravascular coagulation (minimum Grade 2 by definition) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	0	0	68	100,0	33	100,0	0	0	33	100,0	NE	NE	NE	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AESI09_3Lp_16FEB2024_41944.xls
06DEC2024 6:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Any grade disseminated intravascular coagulation (minimum Grade 2 by definition) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AESI09_2L_16FEB2024_41944.pdf
24AUG2024 19:21

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Any grade disseminated intravascular coagulation (minimum Grade 2 by definition) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AESI09_3Lp_16FEB2024_41944.pdf
24AUG2024 22:46

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Grade >=2 tumor flare (e.g., manifestation of signs/symptoms associated with an increase in size of known nodal or extranodal lesions by clinical or radiographic assessment) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0	55	100,0	0,4834	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AESI10_2L_16FEB2024_41944.xls
06DEC2024 2:51

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Grade >=2 tumor flare (e.g., manifestation of signs/symptoms associated with an increase in size of known nodal or extranodal lesions by clinical or radiographic assessment) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	0	0	68	100,0	33	100,0	1	3,0	32	97,0	0,1512	0,00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AESI10_3Lp_16FEB2024_41944.xls
06DEC2024 6:37

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Grade >=2 tumor flare (e.g., manifestation of signs/symptoms associated with an increase in size of known nodal or extranodal lesions by clinical or radiographic assessment) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AESI10_2L_16FEB2024_41944.pdf
24AUG2024 19:27

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Grade >=2 tumor flare (e.g., manifestation of signs/symptoms associated with an increase in size of known nodal or extranodal lesions by clinical or radiographic assessment) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	30	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	15	18	22	23	25	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AESI10_3Lp_16FEB2024_41944.pdf
24AUG2024 22:53

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Any grade pneumonitis, interstitial lung disease, acute respiratory distress syndrome, pulmonary fibrosis, organizing pneumonia, and/or pulmonary toxicity (excluding pneumonia of infectious etiology) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	3	2,7	109	97,3	55	100,0	0	0	55	100,0	0,4800	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AESI11_2L_16FEB2024_41944.xls
06DEC2024 2:57

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Any grade pneumonitis, interstitial lung disease, acute respiratory distress syndrome, pulmonary fibrosis, organizing pneumonia, and/or pulmonary toxicity (excluding pneumonia of infectious etiology) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0	33	100,0	0,4860	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AESI11_3Lp_16FEB2024_41944.xls
06DEC2024 6:44

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Any grade pneumonitis, interstitial lung disease, acute respiratory distress syndrome, pulmonary fibrosis, organizing pneumonia, and/or pulmonary toxicity (excluding pneumonia of infectious etiology) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	84	78	74	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	45	48	70	102	108

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AESI11_2L_16FEB2024_41944.pdf
24AUG2024 19:34

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Any grade pneumonitis, interstitial lung disease, acute respiratory distress syndrome, pulmonary fibrosis, organizing pneumonia, and/or pulmonary toxicity (excluding pneumonia of infectious etiology) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AESI11_3Lp_16FEB2024_41944.pdf
24AUG2024 23:01

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Colitis of any grade (excluding infectious etiology) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	3	2,7	109	97,3	55	100,0	0	0	55	100,0	0,4742	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AESI12_2L_16FEB2024_41944.xls
06DEC2024 3:03

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Colitis of any grade (excluding infectious etiology) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0	33	100,0	0,6256	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AESI12_3Lp_16FEB2024_41944.xls
06DEC2024 6:51

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Colitis of any grade (excluding infectious etiology) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	36	45	48	71	102	108

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AESI12_2L_16FEB2024_41944.pdf
24AUG2024 19:41

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Colitis of any grade (excluding infectious etiology) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AESI12_3Lp_16FEB2024_41944.pdf
24AUG2024 23:08

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Grade >=2 CRS Grade >=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	3	2,7	109	97,3	55	100,0	0	0	55	100,0	0,2214	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_35AESI03_2L_16FEB2024_41944.xls
06DEC2024 2:11

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Grade >=2 CRS Grade >=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0	33	100,0	0,4860	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_35AESI03_3Lp_16FEB2024_41944.xls
06DEC2024 5:56

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Grade >=2 CRS Grade >=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	13	16	25	32	35	45	48	71	102	108

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_35AESI03_2L_16FEB2024_41944.pdf
24AUG2024 18:43

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Grade >=2 CRS Grade >=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	41	41	35	30	29	14	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_35AESI03_3Lp_16FEB2024_41944.pdf
24AUG2024 22:06

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Grade >= 2 neurologic adverse events Grade >=3
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	10	8,9	102	91,1	55	100,0	0	0	55	100,0	0,0737	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_35AESI04_2L_16FEB2024_41944.xls
06DEC2024 2:17

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Grade >= 2 neurologic adverse events Grade >=3
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	2	2,9	66	97,1	33	100,0	0	0	33	100,0	0,3895	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_35AESI04_3Lp_16FEB2024_41944.xls
06DEC2024 6:01

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Grade >= 2 neurologic adverse events Grade >=3
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	105	95	90	81	75	70	61	58	36	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	13	16	25	31	34	43	46	67	96	102

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_35AESI04_2L_16FEB2024_41944.pdf
24AUG2024 18:51

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Grade >= 2 neurologic adverse events Grade >=3
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	24	24	30	35	36	51	62	65

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_35AESI04_3Lp_16FEB2024_41944.pdf
24AUG2024 22:13

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Any suspected HLH Grade >=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	0	0	112	100,0	55	100,0	0	0	55	100,0	NE	NE	NE	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_35AESI05_2L_16FEB2024_41944.xls
06DEC2024 2:24

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Any suspected HLH Grade >=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	0	0	68	100,0	33	100,0	0	0	33	100,0	NE	NE	NE	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_35AESI05_3Lp_16FEB2024_41944.xls
06DEC2024 6:08

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Any suspected HLH Grade >=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_35AESI05_2L_16FEB2024_41944.pdf
24AUG2024 18:57

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Any suspected HLH Grade >=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_35AESI05_3Lp_16FEB2024_41944.pdf
24AUG2024 22:21

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Febrile neutropenia (minimum Grade 3 by definition) Grade>=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	2	1,8	110	98,2	55	100,0	1	1,8	54	98,2	0,9690	0,95	0,09	10,51

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_35AESI07_2L_16FEB2024_41944.xls
06DEC2024 2:36

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Febrile neutropenia (minimum Grade 3 by definition) Grade>=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	4	5,9	64	94,1	33	100,0	0	0	33	100,0	0,1621	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_35AESI07_3Lp_16FEB2024_41944.xls
06DEC2024 6:21

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Febrile neutropenia (minimum Grade 3 by definition) Grade>=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	96	93	84	77	74	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	45	48	71	103	109

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_35AESI07_2L_16FEB2024_41944.pdf
24AUG2024 19:10

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Febrile neutropenia (minimum Grade 3 by definition) Grade>=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	63	53	49	41	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	1	11	15	23	23	28	33	34	49	60	63

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_35AESI07_3Lp_16FEB2024_41944.pdf
24AUG2024 22:35

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Grade >= 2 AST, ALT, or total bilirubin elevation Grade>=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	5	4,5	107	95,5	55	100,0	2	3,6	53	96,4	0,8243	1,20	0,23	6,21

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_35AESI08_2L_16FEB2024_41944.xls
06DEC2024 2:42

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Grade >= 2 AST, ALT, or total bilirubin elevation Grade>=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	4	5,9	64	94,1	33	100,0	1	3,0	32	97,0	0,7573	1,41	0,15	12,92

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_35AESI08_3Lp_16FEB2024_41944.xls
06DEC2024 6:28

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Grade >= 2 AST, ALT, or total bilirubin elevation Grade>=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	50	37	28	19	17	15	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	104	94	91	83	77	74	64	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	13	16	24	30	33	43	45	68	100	106

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_35AESI08_2L_16FEB2024_41944.pdf
24AUG2024 19:16

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Grade >= 2 AST, ALT, or total bilirubin elevation Grade>=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	30	16	13	9	8	6	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	48	41	40	34	29	28	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	31	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	17	24	24	30	35	36	49	60	63

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_35AESI08_3Lp_16FEB2024_41944.pdf
24AUG2024 22:42

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Any grade disseminated intravascular coagulation (minimum Grade 2 by definition) Grade>=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	0	0	112	100,0	55	100,0	0	0	55	100,0	NE	NE	NE	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_35AESI09_2L_16FEB2024_41944.xls
06DEC2024 2:48

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Any grade disseminated intravascular coagulation (minimum Grade 2 by definition) Grade>=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	0	0	68	100,0	33	100,0	0	0	33	100,0	NE	NE	NE	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_35AESI09_3Lp_16FEB2024_41944.xls
06DEC2024 6:34

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Any grade disseminated intravascular coagulation (minimum Grade 2 by definition) Grade>=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_35AESI09_2L_16FEB2024_41944.pdf
24AUG2024 19:23

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Any grade disseminated intravascular coagulation (minimum Grade 2 by definition) Grade>=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_35AESI09_3Lp_16FEB2024_41944.pdf
24AUG2024 22:49

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Grade >=2 tumor flare (e.g., manifestation of signs/symptoms associated with an increase in size of known nodal or extranodal lesions by clinical or radiographic assessment) Grade>=3 adverse events
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0	55	100,0	0,4834	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_35AESI10_2L_16FEB2024_41944.xls
06DEC2024 2:53

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Grade >=2 tumor flare (e.g., manifestation of signs/symptoms associated with an increase in size of known nodal or extranodal lesions by clinical or radiographic assessment) Grade>=3 adverse events
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	0	0	68	100,0	33	100,0	0	0	33	100,0	NE	NE	NE	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_35AESI10_3Lp_16FEB2024_41944.xls
06DEC2024 6:40

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Grade >=2 tumor flare (e.g., manifestation of signs/symptoms associated with an increase in size of known nodal or extranodal lesions by clinical or radiographic assessment) Grade>=3 adverse events
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_35AESI10_2L_16FEB2024_41944.pdf
24AUG2024 19:29

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Grade >=2 tumor flare (e.g., manifestation of signs/symptoms associated with an increase in size of known nodal or extranodal lesions by clinical or radiographic assessment) Grade>=3 adverse events
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_35AESI10_3Lp_16FEB2024_41944.pdf
24AUG2024 22:56

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Any grade pneumonitis, interstitial lung disease, acute respiratory distress syndrome, pulmonary fibrosis, organizing pneumonia, and/or pulmonary toxicity (excluding pneumonia of infectious etiology) Grade>=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	3	2,7	109	97,3	55	100,0	0	0	55	100,0	0,4800	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_35AESI11_2L_16FEB2024_41944.xls
06DEC2024 2:59

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Any grade pneumonitis, interstitial lung disease, acute respiratory distress syndrome, pulmonary fibrosis, organizing pneumonia, and/or pulmonary toxicity (excluding pneumonia of infectious etiology) Grade>=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0	33	100,0	0,4860	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_35AESI11_3Lp_16FEB2024_41944.xls
06DEC2024 6:47

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Any grade pneumonitis, interstitial lung disease, acute respiratory distress syndrome, pulmonary fibrosis, organizing pneumonia, and/or pulmonary toxicity (excluding pneumonia of infectious etiology) Grade>=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	84	78	74	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	45	48	70	102	108

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_35AESI11_2L_16FEB2024_41944.pdf
24AUG2024 19:36

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Any grade pneumonitis, interstitial lung disease, acute respiratory distress syndrome, pulmonary fibrosis, organizing pneumonia, and/or pulmonary toxicity (excluding pneumonia of infectious etiology) Grade>=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_35AESI11_3Lp_16FEB2024_41944.pdf
24AUG2024 23:03

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Colitis of any grade (excluding infectious etiology) Grade>=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0	55	100,0	0,6287	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_35AESI12_2L_16FEB2024_41944.xls
06DEC2024 3:05

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Colitis of any grade (excluding infectious etiology) Grade>=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0	33	100,0	0,6256	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_35AESI12_3Lp_16FEB2024_41944.xls
06DEC2024 6:53

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Colitis of any grade (excluding infectious etiology) Grade>=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	74	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_35AESI12_2L_16FEB2024_41944.pdf
24AUG2024 19:43

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Colitis of any grade (excluding infectious etiology) Grade>=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_35AESI12_3Lp_16FEB2024_41944.pdf
24AUG2024 23:10

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Serious Grade >=2 CRS adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	13	11,6	99	88,4	55	100,0	0	0	55	100,0	0,0125	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_SAESI03_2L_16FEB2024_41944.xls
06DEC2024 2:13

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Serious Grade >=2 CRS adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	5	7,4	63	92,6	33	100,0	0	0	33	100,0	0,1124	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_SAESI03_3Lp_16FEB2024_41944.xls
06DEC2024 5:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Serious Grade >=2 CRS adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	98	89	86	76	72	69	59	58	36	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	12	15	24	28	30	40	41	63	92	98

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_SAESI03_2L_16FEB2024_41944.pdf
24AUG2024 18:46

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Serious Grade >=2 CRS adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	61	50	48	40	40	34	29	28	13	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	15	23	23	29	34	35	50	60	62

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_SAESI03_3Lp_16FEB2024_41944.pdf
24AUG2024 22:08

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Serious Grade >= 2 neurologic adverse events
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	10	8,9	102	91,1	55	100,0	0	0	55	100,0	0,0669	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_SAESI04_2L_16FEB2024_41944.xls
06DEC2024 2:19

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Serious Grade >= 2 neurologic adverse events
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0	33	100,0	0,6101	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_SAESI04_3Lp_16FEB2024_41944.xls
06DEC2024 6:04

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Serious Grade >= 2 neurologic adverse events
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk													
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	105	95	91	81	74	70	61	58	36	7	2	1
Patients censored													
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	3	12	15	24	31	34	43	46	68	97	102	102

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_SAESI04_2L_16FEB2024_41944.pdf
24AUG2024 18:53

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Serious Grade >= 2 neurologic adverse events
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_SAESI04_3Lp_16FEB2024_41944.pdf
24AUG2024 22:15

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Serious Any suspected HLH adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	0	0	112	100,0	55	100,0	0	0	55	100,0	NE	NE	NE	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_SAESI05_2L_16FEB2024_41944.xls
06DEC2024 2:26

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Serious Any suspected HLH adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	0	0	68	100,0	33	100,0	0	0	33	100,0	NE	NE	NE	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_SAESI05_3Lp_16FEB2024_41944.xls
06DEC2024 6:10

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Serious Any suspected HLH adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_SAESI05_2L_16FEB2024_41944.pdf
24AUG2024 18:59

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Serious Any suspected HLH adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_SAESI05_3Lp_16FEB2024_41944.pdf
24AUG2024 22:23

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Serious Febrile neutropenia (minimum Grade 3 by definition) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	1	0,9	111	99,1	55	100,0	1	1,8	54	98,2	0,5921	0,48	0,03	7,62

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_SAESI07_2L_16FEB2024_41944.xls
06DEC2024 2:38

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Serious Febrile neutropenia (minimum Grade 3 by definition) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	4	5,9	64	94,1	33	100,0	0	0	33	100,0	0,1621	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_SAESI07_3Lp_16FEB2024_41944.xls
06DEC2024 6:23

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Serious Febrile neutropenia (minimum Grade 3 by definition) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	51	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	15	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_SAESI07_2L_16FEB2024_41944.pdf
24AUG2024 19:12

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Serious Febrile neutropenia (minimum Grade 3 by definition) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	63	53	49	41	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	1	11	15	23	23	28	33	34	49	60	63

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_SAESI07_3Lp_16FEB2024_41944.pdf
24AUG2024 22:37

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Serious Grade >= 2 AST, ALT, or total bilirubin elevation adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	4	3,6	108	96,4	55	100,0	1	1,8	54	98,2	0,6093	1,76	0,20	15,79

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_SAESI08_2L_16FEB2024_41944.xls
06DEC2024 2:44

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Serious Grade >= 2 AST, ALT, or total bilirubin elevation adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0	33	100,0	0,6394	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_SAESI08_3Lp_16FEB2024_41944.xls
06DEC2024 6:30

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Serious Grade >= 2 AST, ALT, or total bilirubin elevation adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	52	39	29	20	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	95	91	82	75	72	62	60	38	6	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	48	70	102	107

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_SAESI08_2L_16FEB2024_41944.pdf
24AUG2024 19:19

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Serious Grade >= 2 AST, ALT, or total bilirubin elevation adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	35	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_SAESI08_3Lp_16FEB2024_41944.pdf
24AUG2024 22:44

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Serious Any grade disseminated intravascular coagulation (minimum Grade 2 by definition) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	0	0	112	100,0	55	100,0	0	0	55	100,0	NE	NE	NE	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_SAESI09_2L_16FEB2024_41944.xls
06DEC2024 2:50

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Serious Any grade disseminated intravascular coagulation (minimum Grade 2 by definition) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	0	0	68	100,0	33	100,0	0	0	33	100,0	NE	NE	NE	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_SAESI09_3Lp_16FEB2024_41944.xls
06DEC2024 6:36

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Serious Any grade disseminated intravascular coagulation (minimum Grade 2 by definition) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_SAESI09_2L_16FEB2024_41944.pdf
24AUG2024 19:25

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Serious Any grade disseminated intravascular coagulation (minimum Grade 2 by definition) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_SAESI09_3Lp_16FEB2024_41944.pdf
24AUG2024 22:51

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Serious Grade >=2 tumor flare (e.g., manifestation of signs/symptoms associated with an increase in size of known nodal or extranodal lesions by clinical or radiographic assessment) adverse events
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	0	0	112	100,0	55	100,0	0	0	55	100,0	NE	NE	NE	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_SAESI10_2L_16FEB2024_41944.xls
06DEC2024 2:55

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Serious Grade >=2 tumor flare (e.g., manifestation of signs/symptoms associated with an increase in size of known nodal or extranodal lesions by clinical or radiographic assessment) adverse events
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	0	0	68	100,0	33	100,0	0	0	33	100,0	NE	NE	NE	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_SAESI10_3Lp_16FEB2024_41944.xls
06DEC2024 6:42

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Serious Grade >=2 tumor flare (e.g., manifestation of signs/symptoms associated with an increase in size of known nodal or extranodal lesions by clinical or radiographic assessment) adverse events
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_SAESI10_2L_16FEB2024_41944.pdf
24AUG2024 19:31

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Serious Grade >=2 tumor flare (e.g., manifestation of signs/symptoms associated with an increase in size of known nodal or extranodal lesions by clinical or radiographic assessment) adverse events
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_SAESI10_3Lp_16FEB2024_41944.pdf
24AUG2024 22:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Serious Any grade pneumonitis, interstitial lung disease, acute respiratory distress syndrome, pulmonary fibrosis, organizing pneumonia, and/or pulmonary toxicity (excluding pneumonia of infectious etiology) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	3	2,7	109	97,3	55	100,0	0	0	55	100,0	0,4800	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_SAESI11_2L_16FEB2024_41944.xls
06DEC2024 3:01

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Serious Any grade pneumonitis, interstitial lung disease, acute respiratory distress syndrome, pulmonary fibrosis, organizing pneumonia, and/or pulmonary toxicity (excluding pneumonia of infectious etiology) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	0	0	68	100,0	33	100,0	0	0	33	100,0	NE	NE	NE	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_SAESI11_3Lp_16FEB2024_41944.xls
06DEC2024 6:49

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Serious Any grade pneumonitis, interstitial lung disease, acute respiratory distress syndrome, pulmonary fibrosis, organizing pneumonia, and/or pulmonary toxicity (excluding pneumonia of infectious etiology) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	84	78	74	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	33	36	45	48	70	102	108

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_SAESI11_2L_16FEB2024_41944.pdf
24AUG2024 19:39

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Serious Any grade pneumonitis, interstitial lung disease, acute respiratory distress syndrome, pulmonary fibrosis, organizing pneumonia, and/or pulmonary toxicity (excluding pneumonia of infectious etiology) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_SAESI11_3Lp_16FEB2024_41944.pdf
24AUG2024 23:06

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Serious Colitis of any grade (excluding infectious etiology) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0	55	100,0	0,6287	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_SAESI12_2L_16FEB2024_41944.xls
06DEC2024 3:07

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Serious Colitis of any grade (excluding infectious etiology) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0	33	100,0	0,6256	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_SAESI12_3Lp_16FEB2024_41944.xls
06DEC2024 6:55

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Serious Colitis of any grade (excluding infectious etiology) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	74	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_SAESI12_2L_16FEB2024_41944.pdf
24AUG2024 19:46

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Serious Colitis of any grade (excluding infectious etiology) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	41	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_SAESI12_3Lp_16FEB2024_41944.pdf
24AUG2024 23:13

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Secondary malignancies adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	4	3,6	108	96,4	55	100,0	1	1,8	54	98,2	0,6089	1,76	0,19	15,96

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AESI13_2L_16FEB2024_41944.xls
06DEC2024 3:09

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Secondary malignancies adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	4	5,9	64	94,1	33	100,0	0	0	33	100,0	0,1946	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AESI13_3Lp_16FEB2024_41944.xls
06DEC2024 6:56

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Secondary malignancies adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	51	38	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	105	96	93	84	76	73	63	60	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	24	33	36	38	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	13	16	25	32	35	45	48	69	101	107

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AESI13_2L_16FEB2024_41944.pdf
24AUG2024 19:48

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Secondary malignancies adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	64	54	50	41	41	35	30	29	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	11	15	23	23	29	34	35	49	60	63

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AESI13_3Lp_16FEB2024_41944.pdf
24AUG2024 23:15

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Secondary malignancies Grade>=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	0	0	112	100,0	55	100,0	0	0	55	100,0	NE	NE	NE	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_35AESI13_2L_16FEB2024_41944.xls
06DEC2024 3:11

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Secondary malignancies Grade>=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	0	0	68	100,0	33	100,0	0	0	33	100,0	NE	NE	NE	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_35AESI13_3Lp_16FEB2024_41944.xls
06DEC2024 6:58

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Secondary malignancies Grade>=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_35AESI13_2L_16FEB2024_41944.pdf
24AUG2024 19:50

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Secondary malignancies Grade>=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_35AESI13_3Lp_16FEB2024_41944.pdf
24AUG2024 23:17

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Serious infections Grade>=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	26	23,2	86	76,8	55	100,0	9	16,4	46	83,6	0,8262	0,92	0,42	2,00

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_35AESI14_2L_16FEB2024_41944.xls
06DEC2024 3:18

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Serious infections Grade>=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	13	19,1	55	80,9	33	100,0	2	6,1	31	93,9	0,3793	1,95	0,43	8,89

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_35AESI14_3Lp_16FEB2024_41944.xls
06DEC2024 7:04

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Serious infections Grade>=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk											
Rituximab + GemOx	55	48	37	27	19	16	14	NE	NE	NE	NE
Glofitamab + GemOx	112	103	95	88	76	71	67	59	53	31	7
Patients censored											
Rituximab + GemOx	0	3	12	20	27	30	32	NE	NE	NE	NE
Glofitamab + GemOx	0	1	8	11	19	21	23	31	34	56	80

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_35AESI14_2L_16FEB2024_41944.pdf
24AUG2024 19:56

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Serious infections Grade>=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk											
Rituximab + GemOx	33	31	17	13	9	9	7	1	NE	NE	NE
Glofitamab + GemOx	68	64	52	49	40	39	34	28	26	14	3
Patients censored											
Rituximab + GemOx	0	2	15	18	22	22	24	30	NE	NE	NE
Glofitamab + GemOx	0	1	10	12	20	20	24	28	29	41	52

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_35AESI14_3Lp_16FEB2024_41944.pdf
24AUG2024 23:24

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Serious neutropenia Grade>=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0	55	100,0	0,8124	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_35AESI15_2L_16FEB2024_41944.xls
06DEC2024 3:22

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Serious neutropenia Grade>=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	3	4,4	65	95,6	33	100,0	0	0	33	100,0	0,3376	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_35AESI15_3Lp_16FEB2024_41944.xls
06DEC2024 7:09

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Serious neutropenia Grade>=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_35AESI15_2L_16FEB2024_41944.pdf
24AUG2024 20:01

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Serious neutropenia Grade>=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	55	49	41	41	35	30	29	14	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	24	24	30	35	36	51	62	64

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_35AESI15_3Lp_16FEB2024_41944.pdf
24AUG2024 23:29

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Serious IRRs Grade>=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0	55	100,0	0,4834	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_35AESI16_2L_16FEB2024_41944.xls
06DEC2024 3:26

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Serious IRRs Grade>=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	0	0	68	100,0	33	100,0	0	0	33	100,0	NE	NE	NE	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_35AESI16_3Lp_16FEB2024_41944.xls
06DEC2024 7:13

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Serious IRRs Grade>=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_35AESI16_2L_16FEB2024_41944.pdf
24AUG2024 20:05

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Serious IRRs Grade>=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_35AESI16_3Lp_16FEB2024_41944.pdf
24AUG2024 23:35

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Serious Secondary malignancies adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0	55	100,0	0,6128	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_SAESI13_2L_16FEB2024_41944.xls
06DEC2024 3:13

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Serious Secondary malignancies adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0	33	100,0	0,4860	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_SAESI13_3Lp_16FEB2024_41944.xls
06DEC2024 7:00

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Serious Secondary malignancies adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	77	74	64	61	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_SAESI13_2L_16FEB2024_41944.pdf
24AUG2024 19:52

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Serious Secondary malignancies adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	65	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	25	25	31	36	37	52	63	66

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_SAESI13_3Lp_16FEB2024_41944.pdf
24AUG2024 23:20

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Serious infections adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	32	28,6	80	71,4	55	100,0	9	16,4	46	83,6	0,8759	1,06	0,49	2,29

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AESI14_2L_16FEB2024_41944.xls
06DEC2024 3:16

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Serious infections adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	14	20,6	54	79,4	33	100,0	2	6,1	31	93,9	0,3283	2,09	0,46	9,40

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AESI14_3Lp_16FEB2024_41944.xls
06DEC2024 7:02

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Serious infections adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk													
Rituximab + GemOx	55	48	37	27	19	16	14	NE	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	103	94	85	75	70	65	57	50	30	7	1	1
Patients censored													
Rituximab + GemOx	0	3	12	20	27	30	32	NE	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	1	8	11	18	20	22	29	32	52	75	80	80

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AESI14_2L_16FEB2024_41944.pdf
24AUG2024 19:54

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Serious infections adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk											
Rituximab + GemOx	33	31	17	13	9	9	7	1	NE	NE	NE
Glofitamab + GemOx	68	64	52	49	39	38	34	28	26	14	3
Patients censored											
Rituximab + GemOx	0	2	15	18	22	22	24	30	NE	NE	NE
Glofitamab + GemOx	0	1	10	12	20	20	23	27	28	40	51

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AESI14_3Lp_16FEB2024_41944.pdf
24AUG2024 23:22

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Serious neutropenia adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0	55	100,0	0,8124	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AESI15_2L_16FEB2024_41944.xls
06DEC2024 3:20

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Serious neutropenia adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	3	4,4	65	95,6	33	100,0	0	0	33	100,0	0,3376	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AESI15_3Lp_16FEB2024_41944.xls
06DEC2024 7:07

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Serious neutropenia adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AESI15_2L_16FEB2024_41944.pdf
24AUG2024 19:59

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Serious neutropenia adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	55	49	41	41	35	30	29	14	3	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	13	17	24	24	30	35	36	51	62	64

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AESI15_3Lp_16FEB2024_41944.pdf
24AUG2024 23:27

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Serious IRRs adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0	55	100,0	0,4834	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AESI16_2L_16FEB2024_41944.xls
06DEC2024 3:24

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Serious IRRs adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	0	0	68	100,0	33	100,0	0	0	33	100,0	NE	NE	NE	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AESI16_3Lp_16FEB2024_41944.xls
06DEC2024 7:11

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Serious IRRs adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	96	93	84	77	74	64	61	38	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AESI16_2L_16FEB2024_41944.pdf
24AUG2024 20:03

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Serious IRRs adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AESI16_3Lp_16FEB2024_41944.pdf
24AUG2024 23:32

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first TLS adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	2	1,8	110	98,2	55	100,0	3	5,5	52	94,5	0,1871	0,32	0,05	1,91

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AESI06_2L_16FEB2024_41944.xls
05MAR2025 21:47

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first TLS adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0	33	100,0	0,4860	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AESI06_3Lp_16FEB2024_41944.xls
05MAR2025 22:09

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first TLS adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk													
Rituximab + GemOx	55	49	38	29	20	18	16	NE	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	97	94	85	78	75	65	62	39	7	1	NE
Patients censored													
Rituximab + GemOx	0	3	14	23	32	34	36	NE	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	13	16	25	32	35	45	48	71	103	109	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AESI06_2L_16FEB2024_41944.pdf
05MAR2025 22:20

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first TLS adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk													
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	42	42	36	31	30	15	4	1	NE
Patients censored													
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	52	63	66	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AESI06_3Lp_16FEB2024_41944.pdf
05MAR2025 22:41

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Grade>=3 TLS adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	2	1,8	110	98,2	55	100,0	3	5,5	52	94,5	0,1871	0,32	0,05	1,91

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_35AESI06_2L_16FEB2024_41944.xls
05MAR2025 21:51

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Grade>=3 TLS adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0	33	100,0	0,4860	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_35AESI06_3Lp_16FEB2024_41944.xls
05MAR2025 22:13

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Grade>=3 TLS adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk													
Rituximab + GemOx	55	49	38	29	20	18	16	NE	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	106	97	94	85	78	75	65	62	39	7	1	NE
Patients censored													
Rituximab + GemOx	0	3	14	23	32	34	36	NE	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	13	16	25	32	35	45	48	71	103	109	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_35AESI06_2L_16FEB2024_41944.pdf
05MAR2025 22:23

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Grade>=3 TLS adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk													
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	42	42	36	31	30	15	4	1	NE
Patients censored													
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	52	63	66	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_35AESI06_3Lp_16FEB2024_41944.pdf
05MAR2025 22:45

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Serious TLS adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	1	0,9	111	99,1	55	100,0	1	1,8	54	98,2	0,6050	0,49	0,03	7,81

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_SAESI06_2L_16FEB2024_41944.xls
05MAR2025 21:55

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Serious TLS adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	1	1,5	67	98,5	33	100,0	0	0	33	100,0	0,4860	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_SAESI06_3Lp_16FEB2024_41944.xls
05MAR2025 22:17

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Serious TLS adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk													
Rituximab + GemOx	55	51	38	29	20	18	16	NE	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	107	97	94	85	78	75	65	62	39	7	1	NE
Patients censored													
Rituximab + GemOx	0	3	16	25	34	36	38	NE	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	14	17	26	33	36	46	49	72	104	110	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_SAESI06_2L_16FEB2024_41944.pdf
05MAR2025 22:27

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Serious TLS adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk													
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE	NE
Glofitamab + GemOx	68	65	53	49	42	42	36	31	30	15	4	1	NE
Patients censored													
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	25	25	31	36	37	52	63	66	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_SAESI06_3Lp_16FEB2024_41944.pdf
05MAR2025 22:48

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Drug-induced liver injury (DILI) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	1	0,9	111	99,1	55	100,0	0	0	55	100,0	0,5403	>1000.00	0,00	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AESI01_2L_16FEB2024_41944.xls
06DEC2024 1:51

DILI event reported via eCRF. Case could not be confirmed by a medical evaluation

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Drug-induced liver injury (DILI) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	0	0	68	100,0	33	100,0	0	0	33	100,0	NE	NE	NE	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AESI01_3Lp_16FEB2024_41944.xls
06DEC2024 5:43

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Drug-induced liver injury (DILI) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	17	26	33	36	46	49	72	104	110

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AESI01_2L_16FEB2024_41944.pdf
24AUG2024 18:27

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Drug-induced liver injury (DILI) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AESI01_3Lp_16FEB2024_41944.pdf
24AUG2024 21:50

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Drug-induced liver injury (DILI) Grade >=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	0	0	112	100,0	55	100,0	0	0	55	100,0	NE	NE	NE	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_35AESI01_2L_16FEB2024_41944.xls
06DEC2024 1:55

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Drug-induced liver injury (DILI) Grade >=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	0	0	68	100,0	33	100,0	0	0	33	100,0	NE	NE	NE	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_35AESI01_3Lp_16FEB2024_41944.xls
06DEC2024 5:45

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Drug-induced liver injury (DILI) Grade >=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_35AESI01_2L_16FEB2024_41944.pdf
24AUG2024 18:29

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Drug-induced liver injury (DILI) Grade >=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_35AESI01_3Lp_16FEB2024_41944.pdf
24AUG2024 21:52

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Serious Drug-induced liver injury (DILI) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	0	0	112	100,0	55	100,0	0	0	55	100,0	NE	NE	NE	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_SAESI01_2L_16FEB2024_41944.xls
06DEC2024 1:59

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Serious Drug-induced liver injury (DILI) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	0	0	68	100,0	33	100,0	0	0	33	100,0	NE	NE	NE	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_SAESI01_3Lp_16FEB2024_41944.xls
06DEC2024 5:47

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Serious Drug-induced liver injury (DILI) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_SAESI01_2L_16FEB2024_41944.pdf
24AUG2024 18:31

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Serious Drug-induced liver injury (DILI) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_SAESI01_3Lp_16FEB2024_41944.pdf
24AUG2024 21:54

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Suspected transmission of an infectious agent by the study treatment (STIAMP) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	0	0	112	100,0	55	100,0	0	0	55	100,0	NE	NE	NE	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AESI02_2L_16FEB2024_41944.xls
06DEC2024 2:01

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Suspected transmission of an infectious agent by the study treatment (STIAMP) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	0	0	68	100,0	33	100,0	0	0	33	100,0	NE	NE	NE	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_AESI02_3Lp_16FEB2024_41944.xls
06DEC2024 5:49

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Suspected transmission of an infectious agent by the study treatment (STIAMP) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AESI02_2L_16FEB2024_41944.pdf
24AUG2024 18:34

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Suspected transmission of an infectious agent by the study treatment (STIAMP) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_AESI02_3Lp_16FEB2024_41944.pdf
24AUG2024 21:57

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Suspected transmission of an infectious agent by the study treatment (STIAMP) Grade >=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	0	0	112	100,0	55	100,0	0	0	55	100,0	NE	NE	NE	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_35AESI02_2L_16FEB2024_41944.xls
06DEC2024 2:04

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Suspected transmission of an infectious agent by the study treatment (STIAMP) Grade >=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	0	0	68	100,0	33	100,0	0	0	33	100,0	NE	NE	NE	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_35AESI02_3Lp_16FEB2024_41944.xls
06DEC2024 5:50

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Suspected transmission of an infectious agent by the study treatment (STIAMP) Grade >=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_35AESI02_2L_16FEB2024_41944.pdf
24AUG2024 18:36

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Suspected transmission of an infectious agent by the study treatment (STIAMP) Grade >=3 adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_35AESI02_3Lp_16FEB2024_41944.pdf
24AUG2024 21:59

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Serious Suspected transmission of an infectious agent by the study treatment (STIAMP) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=112)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=55)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	112	100,0	0	0	112	100,0	55	100,0	0	0	55	100,0	NE	NE	NE	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_SAESI02_2L_16FEB2024_41944.xls
06DEC2024 2:07

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Serious Suspected transmission of an infectious agent by the study treatment (STIAMP) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944
Time to Event Analysis (Safety)

		GLOFITAMAB + GEMCITABINE PLUS OXALIPLATIN (N=68)						RITUXIMAB + GEMCITABINE PLUS OXALIPLATIN (N=33)						Glofitamab + GemOx vs. Rituximab + GemOx			
		Patients		Patients with Event		Censored		Patients		Patients with Event		Censored		log-rank	Hazard Ratio		
Name	Level	n	%	n	%	n	%	n	%	n	%	n	%	p-value	Hazard Ratio	95% Lower CL	95% Upper CL
All	n/a	68	100,0	0	0	68	100,0	33	100,0	0	0	33	100,0	NE	NE	NE	NE

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_tte.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_tte_SE_SAESI02_3Lp_16FEB2024_41944.xls
06DEC2024 5:52

POPULATION: Safety evaluable population (2L)
ENDPOINT: Time to first Serious Suspected transmission of an infectious agent by the study treatment (STIAMP) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	55	52	39	30	21	18	16	NE	NE	NE	NE	NE
Glofitamab + GemOx	112	108	97	94	85	78	75	65	62	39	7	1
Patients censored												
Rituximab + GemOx	0	3	16	25	34	37	39	NE	NE	NE	NE	NE
Glofitamab + GemOx	0	4	15	18	27	34	37	47	50	73	105	111

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_SAESI02_2L_16FEB2024_41944.pdf
24AUG2024 18:38

POPULATION: Safety evaluable population (3L+)
ENDPOINT: Time to first Serious Suspected transmission of an infectious agent by the study treatment (STIAMP) adverse event
MODEL: Unstratified Analysis
STUDY: GO41944



Patients at risk												
Rituximab + GemOx	33	31	17	14	10	9	7	1	NE	NE	NE	NE
Glofitamab + GemOx	68	66	54	50	42	42	36	31	30	15	4	1
Patients censored												
Rituximab + GemOx	0	2	16	19	23	24	26	32	NE	NE	NE	NE
Glofitamab + GemOx	0	2	14	18	26	26	32	37	38	53	64	67

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/g_ae_km.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/g_ae_km_SE_SAESI02_3Lp_16FEB2024_41944.pdf
24AUG2024 22:01

POPULATION: Safety evaluable population (2L)
ENDPOINT: All Patients
MODEL: --
STUDY: GO41944
Outcome of Adverse Events

	Glofitamab + GemOx (N=112)															Rituximab + GemOx (N=55)													
	Total	RECOVERED/RESOLVED		RECOVERED/RESOLVED WITH SEQUELAE		NOT RECOVERED/NOT RESOLVED		FATAL		RECOVERING/RESOLVING		UNKNOWN		MISSING		Total	RECOVERED/RESOLVED		RECOVERED/RESOLVED WITH SEQUELAE		NOT RECOVERED/NOT RESOLVED		FATAL		RECOVERING/RESOLVING		UNKNOWN		MISSING	
Category of Adverse Events	n	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Any AEs																														
All	1981	1628	82,2	18	0,9	322	16,3	9	0,5	0	0,0	4	0,2	0	0,0	590	451	76,4	4	0,7	117	19,8	1	0,2	0	0,0	17	2,9	0	0,0
Grade 1	1238	1024	82,7	8	0,6	203	16,4	0	0,0	0	0,0	3	0,2	0	0,0	371	289	77,9	2	0,5	71	19,1	0	0,0	0	0,0	9	2,4	0	0,0
Grade 2	480	380	79,2	5	1,0	94	19,6	0	0,0	0	0,0	1	0,2	0	0,0	145	107	73,8	0	0,0	32	22,1	0	0,0	0	0,0	6	4,1	0	0,0
Grade 3	210	185	88,1	5	2,4	20	9,5	0	0,0	0	0,0	0	0,0	0	0,0	62	46	74,2	2	3,2	12	19,4	0	0,0	0	0,0	2	3,2	0	0,0
Grade 4	39	34	87,2	0	0,0	5	12,8	0	0,0	0	0,0	0	0,0	0	0,0	11	9	81,8	0	0,0	2	18,2	0	0,0	0	0,0	0	0,0	0	0,0
Grade 5	9	0	0,0	0	0,0	0	0,0	9	100,0	0	0,0	0	0,0	0	0,0	1	0	0,0	0	0,0	0	0,0	1	100,0	0	0,0	0	0,0	0	0,0
Missing	5	5	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Any SAEs																														
All	140	110	78,6	4	2,9	17	12,1	9	6,4	0	0,0	0	0,0	0	0,0	24	17	70,8	1	4,2	5	20,8	1	4,2	0	0,0	0	0,0	0	0,0
Grade 1	26	23	88,5	1	3,8	2	7,7	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 2	34	31	91,2	0	0,0	3	8,8	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 3	62	51	82,3	3	4,8	8	12,9	0	0,0	0	0,0	0	0,0	0	0,0	18	14	77,8	1	5,6	3	16,7	0	0,0	0	0,0	0	0,0	0	0,0
Grade 4	9	5	55,6	0	0,0	4	44,4	0	0,0	0	0,0	0	0,0	0	0,0	5	3	60,0	0	0,0	2	40,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 5	9	0	0,0	0	0,0	0	0,0	9	100,0	0	0,0	0	0,0	0	0,0	1	0	0,0	0	0,0	0	0,0	1	100,0	0	0,0	0	0,0	0	0,0
Any AESI																														
All	145	100	69,0	1	0,7	35	24,1	9	6,2	0	0,0	0	0,0	0	0,0	34	23	67,6	1	2,9	8	23,5	1	2,9	0	0,0	1	2,9	0	0,0
Grade 1	4	2	50,0	0	0,0	2	50,0	0	0,0	0	0,0	0	0,0	0	0,0	1	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 2	78	54	69,2	1	1,3	23	29,5	0	0,0	0	0,0	0	0,0	0	0,0	15	9	60,0	0	0,0	5	33,3	0	0,0	0	0,0	1	6,7	0	0,0
Grade 3	51	42	82,4	0	0,0	9	17,6	0	0,0	0	0,0	0	0,0	0	0,0	14	12	85,7	1	7,1	1	7,1	0	0,0	0	0,0	0	0,0	0	0,0
Grade 4	3	2	66,7	0	0,0	1	33,3	0	0,0	0	0,0	0	0,0	0	0,0	3	1	33,3	0	0,0	2	66,7	0	0,0	0	0,0	0	0,0	0	0,0
Grade 5	9	0	0,0	0	0,0	0	0,0	9	100,0	0	0,0	0	0,0	0	0,0	1	0	0,0	0	0,0	0	0,0	1	100,0	0	0,0	0	0,0	0	0,0

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_resolved.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_resolved_SE_2L_16FEB2024_41944.xls
11MAR2025 17:41

POPULATION: Safety evaluable population (3L+)
ENDPOINT: All Patients
MODEL: --
STUDY: GO41944
Outcome of Adverse Events

	Glofitamab + GemOx (N=68)															Rituximab + GemOx (N=33)													
	Total	RECOVERED/RESOLVED		RECOVERED/RESOLVED WITH SEQUELAE		NOT RECOVERED/NOT RESOLVED		FATAL		RECOVERING/RESOLVING		UNKNOWN		MISSING		Total	RECOVERED/RESOLVED		RECOVERED/RESOLVED WITH SEQUELAE		NOT RECOVERED/NOT RESOLVED		FATAL		RECOVERING/RESOLVING		UNKNOWN		MISSING	
Category of Adverse Events	n	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Any AEs																														
All	1371	1111	81,0	12	0,9	226	16,5	6	0,4	0	0,0	16	1,2	0	0,0	278	198	71,2	2	0,7	66	23,7	3	1,1	0	0,0	9	3,2	0	0,0
Grade 1	831	708	85,2	3	0,4	113	13,6	0	0,0	0	0,0	7	0,8	0	0,0	168	123	73,2	0	0,0	38	22,6	0	0,0	0	0,0	7	4,2	0	0,0
Grade 2	306	235	76,8	2	0,7	63	20,6	0	0,0	0	0,0	6	2,0	0	0,0	75	48	64,0	1	1,3	24	32,0	0	0,0	0	0,0	2	2,7	0	0,0
Grade 3	175	129	73,7	6	3,4	39	22,3	0	0,0	0	0,0	1	0,6	0	0,0	22	18	81,8	1	4,5	3	13,6	0	0,0	0	0,0	0	0,0	0	0,0
Grade 4	51	38	74,5	1	2,0	11	21,6	0	0,0	0	0,0	1	2,0	0	0,0	10	9	90,0	0	0,0	1	10,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 5	6	0	0,0	0	0,0	0	0,0	6	100,0	0	0,0	0	0,0	0	0,0	3	0	0,0	0	0,0	0	0,0	3	100,0	0	0,0	0	0,0	0	0,0
Missing	2	1	50,0	0	0,0	0	0,0	0	0,0	0	0,0	1	50,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Any SAEs																														
All	75	49	65,3	3	4,0	15	20,0	6	8,0	0	0,0	2	2,7	0	0,0	11	4	36,4	1	9,1	3	27,3	3	27,3	0	0,0	0	0,0	0	0,0
Grade 1	10	10	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	1	0	0,0	0	0,0	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 2	14	12	85,7	0	0,0	0	0,0	0	0,0	0	0,0	2	14,3	0	0,0	1	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 3	30	17	56,7	3	10,0	10	33,3	0	0,0	0	0,0	0	0,0	0	0,0	3	1	33,3	1	33,3	1	33,3	0	0,0	0	0,0	0	0,0	0	0,0
Grade 4	15	10	66,7	0	0,0	5	33,3	0	0,0	0	0,0	0	0,0	0	0,0	3	2	66,7	0	0,0	1	33,3	0	0,0	0	0,0	0	0,0	0	0,0
Grade 5	6	0	0,0	0	0,0	0	0,0	6	100,0	0	0,0	0	0,0	0	0,0	3	0	0,0	0	0,0	0	0,0	3	100,0	0	0,0	0	0,0	0	0,0
Any AESI																														
All	73	45	61,6	2	2,7	20	27,4	5	6,8	0	0,0	1	1,4	0	0,0	12	6	50,0	0	0,0	4	33,3	2	16,7	0	0,0	0	0,0	0	0,0
Grade 1	3	3	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 2	36	23	63,9	0	0,0	12	33,3	0	0,0	0	0,0	1	2,8	0	0,0	8	4	50,0	0	0,0	4	50,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 3	25	15	60,0	2	8,0	8	32,0	0	0,0	0	0,0	0	0,0	0	0,0	2	2	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 4	4	4	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 5	5	0	0,0	0	0,0	0	0,0	5	100,0	0	0,0	0	0,0	0	0,0	2	0	0,0	0	0,0	0	0,0	2	100,0	0	0,0	0	0,0	0	0,0

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_resolved.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_resolved_SE_3Lp_16FEB2024_41944.xls
11MAR2025 17:52

POPULATION: Safety evaluable population (2L)
ENDPOINT: All Patients
MODEL: --
STUDY: GO41944
Outcome of Adverse Events of Special Interest

	Glofitamab + GemOx (N=112)															Rituximab + GemOx (N=55)													
	Total	RECOVERED/RESOLVED		RECOVERED/RESOLVED WITH SEQUELAE		NOT RECOVERED/NOT RESOLVED		FATAL		RECOVERING/RESOLVING		UNKNOWN		MISSING		Total	RECOVERED/RESOLVED		RECOVERED/RESOLVED WITH SEQUELAE		NOT RECOVERED/NOT RESOLVED		FATAL		RECOVERING/RESOLVING		UNKNOWN		MISSING	
Category of Adverse Events	n	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Drug-induced liver injury (DILI)																														
All	1	0	0,0	0	0,0	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 1	1	0	0,0	0	0,0	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Serious Drug-induced liver injury (DILI)																														
All	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Suspected transmission of an infectious agent by the study treatment (STIAMP)																														
All	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Serious Suspected transmission of an infectious agent by the study treatment (STIAMP)																														
All	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade >=2 CRS																														
All	17	17	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 2	14	14	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 3	3	3	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Serious Grade >=2 CRS																														
All	14	14	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 2	12	12	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 3	2	2	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade >=2 Neurologic																														
All	48	29	60,4	1	2,1	18	37,5	0	0,0	0	0,0	0	0,0	0	0,0	9	4	44,4	0	0,0	4	44,4	0	0,0	0	0,0	1	11,1	0	0,0
Grade 2	38	21	55,3	1	2,6	16	42,1	0	0,0	0	0,0	0	0,0	0	0,0	9	4	44,4	0	0,0	4	44,4	0	0,0	0	0,0	1	11,1	0	0,0
Grade 3	10	8	80,0	0	0,0	2	20,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Serious Grade >=2 Neurologic																														
All	10	9	90,0	0	0,0	1	10,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 2	4	3	75,0	0	0,0	1	25,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 3	6	6	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Suspected HLH																														
All	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Serious Suspected HLH																														
All	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
TLS																														
All	3	3	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	3	3	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 3	3	3	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	3	3	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Serious TLS																														
All	1	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	1	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 3	1	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	1	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Febrile Neutropenia (minimum Grade 3 by definition)																														
All	2	2	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	1	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 3	2	2	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	1	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Serious Febrile Neutropenia (minimum Grade 3 by definition)																														
All	1	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	1	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 3	1	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	1	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade >= 2 AST, ALT, or total bilirubin elevation																														
All	23	18	78,3	0	0,0	4	17,4	1	4,3	0	0,0	0	0,0	0	0,0	9	8	88,9	0	0,0	1	11,1	0	0,0	0	0,0	0	0,0	0	0,0
Grade 2	16	13	81,3	0	0,0	3	18,8	0	0,0	0	0,0	0	0,0	0	0,0	6	5	83,3	0	0,0	1	16,7	0	0,0	0	0,0	0	0,0	0	0,0
Grade 3	6	5	83,3	0	0,0	1	16,7	0	0,0	0	0,0	0	0,0	0	0,0	3	3	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 5	1	0	0,0	0	0,0	0	0,0	1	100,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Serious Grade >= 2 AST, ALT, or total bilirubin elevation																														
All	5	4	80,0	0	0,0	0	0,0	1	20,0	0	0,0	0	0,0	0	0,0	1	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 2	2	2	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 3	2	2	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	1	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 5	1	0	0,0	0	0,0	0	0,0	1	100,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Disseminated Intravascular Coagulation (minimum Grade 2 by definition)																														
All	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Serious Disseminated Intravascular Coagulation (minimum Grade 2 by definition)																														
All	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade >=2 Tumor Flare																														
All	1	0	0,0	0	0,0	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 3	1	0	0,0	0	0,0	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Serious Grade >=2 Tumor Flare																														
All	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Pneumonitis or ILD																														
All	3	0	0,0	0	0,0	0	0,0	3	100,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 5	3	0	0,0	0	0,0	0	0,0	3	100,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Serious Pneumonitis or ILD																														
All	3	0	0,0	0	0,0	0	0,0	3	100,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 5	3	0	0,0	0	0,0	0	0,0	3	100,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Colitis of any grade (excluding infectious etiology)																														
All	3	0	0,0	0	0,0	3	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 2	2	0	0,0	0	0,0	2	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 3	1	0	0,0	0	0,0	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Serious Colitis of any grade (excluding infectious etiology)																														

All	1	0	0,0	0	0,0	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 3	1	0	0,0	0	0,0	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Secondary Malignancies																																
All	4	2	50,0	0	0,0	2	50,0	0	0,0	0	0,0	0	0,0	0	0,0	1	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 1	2	2	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	1	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 2	2	0	0,0	0	0,0	2	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Serious Secondary Malignancies																																
All	1	0	0,0	0	0,0	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 2	1	0	0,0	0	0,0	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Serious Infections																																
All	41	28	68,3	0	0,0	7	17,1	6	14,6	0	0,0	0	0,0	0	0,0	11	6	54,5	1	9,1	3	27,3	1	9,1	0	0,0	0	0,0	0	0,0	0	0,0
Grade 1	1	0	0,0	0	0,0	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 2	7	6	85,7	0	0,0	1	14,3	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 3	25	21	84,0	0	0,0	4	16,0	0	0,0	0	0,0	0	0,0	0	0,0	7	5	71,4	1	14,3	1	14,3	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 4	2	1	50,0	0	0,0	1	50,0	0	0,0	0	0,0	0	0,0	0	0,0	3	1	33,3	0	0,0	2	66,7	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 5	6	0	0,0	0	0,0	0	0,0	6	100,0	0	0,0	0	0,0	0	0,0	1	0	0,0	0	0,0	0	0,0	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0
Serious Neutropenia																																
All	1	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 4	1	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Serious IRRs																																
All	1	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 3	1	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_resolved.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_resolved_SE_AESI_2L_16FEB2024_41944.xls
11MAR2025 17:26

POPULATION: Safety evaluable population (3L+)
ENDPOINT: All Patients
MODEL: --
STUDY: GO41944
Outcome of Adverse Events of Special Interest

	Glofitamab + GemOx (N=68)																Rituximab + GemOx (N=33)															
	Total	RECOVERED/RESOLVED		RECOVERED/RESOLVED WITH SEQUELAE		NOT RECOVERED/NOT RESOLVED		FATAL		RECOVERING/RESOLVING		UNKNOWN		MISSING		Total	RECOVERED/RESOLVED		RECOVERED/RESOLVED WITH SEQUELAE		NOT RECOVERED/NOT RESOLVED		FATAL		RECOVERING/RESOLVING		UNKNOWN		MISSING		
Category of Adverse Events	n	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	n	%	n	%	n	%	n	%	n	%	n	%	n	%		
Drug-induced liver injury (DILI)																																
All	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Serious Drug-induced liver injury (DILI)																																
All	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Suspected transmission of an infectious agent by the study treatment (STIAMP)																																
All	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Serious Suspected transmission of an infectious agent by the study treatment (STIAMP)																																
All	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Grade >=2 CRS																																
All	7	7	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Grade 2	6	6	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Grade 3	1	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Serious Grade >=2 CRS																																
All	5	5	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Grade 2	4	4	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Grade 3	1	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Grade >=2 Neurologic																																
All	23	10	43,5	0	0,0	11	47,8	1	4,3	0	0,0	1	4,3	0	0,0	5	1	20,0	0	0,0	4	80,0	0	0,0	0	0,0	0	0,0	0	0,0		
Grade 2	21	10	47,6	0	0,0	10	47,6	0	0,0	0	0,0	1	4,8	0	0,0	5	1	20,0	0	0,0	4	80,0	0	0,0	0	0,0	0	0,0	0	0,0		
Grade 3	1	0	0,0	0	0,0	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Grade 5	1	0	0,0	0	0,0	0	0,0	1	100,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Serious Grade >=2 Neurologic																																
All	1	0	0,0	0	0,0	0	0,0	1	100,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Grade 5	1	0	0,0	0	0,0	0	0,0	1	100,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Suspected HLH																																
All	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Serious Suspected HLH																																
All	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
TLS																																
All	1	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Grade 3	1	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Serious TLS																																
All	1	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Grade 3	1	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Febrile Neutropenia (minimum Grade 3 by definition)																																
All	5	5	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Grade 3	4	4	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Grade 4	1	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Serious Febrile Neutropenia (minimum Grade 3 by definition)																																
All	5	5	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Grade 3	4	4	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Grade 4	1	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Grade >= 2 AST, ALT, or total bilirubin elevation																																
All	12	10	83,3	0	0,0	2	16,7	0	0,0	0	0,0	0	0,0	0	0,0	3	3	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Grade 2	7	6	85,7	0	0,0	1	14,3	0	0,0	0	0,0	0	0,0	0	0,0	2	2	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Grade 3	5	4	80,0	0	0,0	1	20,0	0	0,0	0	0,0	0	0,0	0	0,0	1	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Serious Grade >= 2 AST, ALT, or total bilirubin elevation																																
All	1	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Grade 2	1	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Disseminated Intravascular Coagulation (minimum Grade 2 by definition)																																
All	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Serious Disseminated Intravascular Coagulation (minimum Grade 2 by definition)																																
All	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Grade >=2 Tumor Flare																																
All	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	1	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Grade 2	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	1	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Serious Grade >=2 Tumor Flare																																
All	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Pneumonitis or ILD																																
All	1	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Grade 3	1	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Serious Pneumonitis or ILD																																
All	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Colitis of any grade (excluding infectious etiology)																																
All	2	0	0,0	2	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Grade 3	2	0	0,0	2	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Serious Colitis of any grade (excluding infectious etiology)																																
All	2	0	0,0	2	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Grade 3	2	0	0,0	2	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0		
Secondary Malignancies																																

All	4	3	75,0	0	0,0	1	25,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 1	3	3	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 2	1	0	0,0	0	0,0	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Serious Secondary Malignancies																																		
All	1	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 1	1	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Serious Infections																																		
All	16	6	37,5	0	0,0	6	37,5	4	25,0	0	0,0	0	0,0	0	0,0	3	1	33,3	0	0,0	0	0,0	2	66,7	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 2	1	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 3	11	5	45,5	0	0,0	6	54,5	0	0,0	0	0,0	0	0,0	0	0,0	1	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 5	4	0	0,0	0	0,0	0	0,0	4	100,0	0	0,0	0	0,0	0	0,0	2	0	0,0	0	0,0	0	0,0	2	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Serious Neutropenia																																		
All	4	3	75,0	0	0,0	0	0,0	1	25,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 4	3	3	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Grade 5	1	0	0,0	0	0,0	0	0,0	1	100,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Serious IRRs																																		
All	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0

Clinical cut-off: 16FEB2024

Program: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_BASE/prod/program/t_ae_resolved.sas
Output: root/clinical_studies/RO7082859/CDT30295/GO41944/data_analysis/ACE_Follow_Up_Analysis_2024/prod/output/t_ae_resolved_SE_AESI_3Lp_16FEB2024_41944.xls
11MAR2025 17:36